anandamide profile

anandamide : An N-acylethanolamine 20:4 resulting from the formal condensation of carboxy group of arachidonic acid with the amino group of ethanolamine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	5281969
CHEMBL ID	15848
CHEBI ID	2700
SCHEMBL ID	43143
MeSH ID	M0211180

Synonym
BRD-K42352790-001-03-8
gtpl2364
(5z,8z,11z,14z)-n-(2-hydroxyethyl)icosa-5,8,11,14-tetraenamide
arachidonyl ethanolamide
n-arachidonoylethanolamine
(all-z)-n-(2-hydroxyethyl)-5,8,11,14-eicosatetraenamide
CHEBI:2700 ,
n-(2-hydroxyethyl)anachidonamide
(5z,8z,11z,14z)-n-(2-hydroxyethyl)-5,8,11,14-eicosatetraenamide
n-arachidonoyl-2-hydroxyethylamide
n-(5z,8z,11z,14z-icosatetraenoyl)-ethanolamide
chembl15848 ,
arachidonoylethanolamide (aea)
bdbm22988
[14c]anandamide
[3h]anandamide
n-(2-hydroxyethyl)-5,8,11,14-eicosatetraenamide (all-z)-
IDI1_034003
LMFA08040001
arachidonoylethanolamide
anandamide(20:4, n-6)
anandamide (20:4, n-6)
n-arachidonoyl ethanolamine
arachidonoyl-ea
BSPBIO_001533
SMP2_000328
arachidonoyl ethanolamide
arachidonic acid n-(hydroxyethyl)amide
5,8,11,14-eicosatetraenamide, n-(2-hydroxyethyl)-, (5z,8z,11z,14z)-
5,8,11,14-eicosatetraenoylethanolamide
anandamide (20.4, n-6)
5,8,11,14-eicosatetraenamide, n-(2-hydroxyethyl)-, (all-z)-
(5z,8z,11z,14z)- n-(2-hydroxyethyl)- 5,8,11,14-eicosatetraenamide
anandamide
n-(5z,8z,11z,14z-eicosatetraenoyl)-ethanolamine
arachidonylethanolamide
94421-68-8
AEA ,
NCGC00161195-06
NCGC00161195-05
NCGC00161195-04
NCGC00161195-03
NCGC00161195-07
annh
HMS1989M15
L000111
BML2-B09
HMS1791M15
HMS1361M15
AKOS015951333
unii-ur5g69tjkh
ur5g69tjkh ,
anandamide [mi]
CCG-208077
SCHEMBL43143
n-arachidonoylaminoethan-2-ol
n-(2-hydroxyethyl)-5z,8z,11z,14z-eicosatetraenamide
anandamide (in tocrisolvetrade mark 100)
HMS3649B09
HMS3402M15
n-(2-hydroxyethyl)-5,8,11,14-eicosatetraenamide (all-z)
nae(20:4)
Q410228
SR-01000946635-1
sr-01000946635
DTXSID301017453
924894-98-4
aea-d8
e7y ,
BA166586

Excerpt	Reference	Relevance
"Anandamide (AEA) is a primary endocannabinoid which exhibits immunomodulatory effects through mixed cannabinoid receptor agonism."	( Nano-encapsulated anandamide reduces inflammatory cytokines in vitro and lesion severity in a murine model of cutaneous lupus erythematosus. Chalmers, S; Draganski, A; Friedman, A; Friedman, J; Garcia, S; McCormick, ET; Nussbaum, D; Putterman, C; Zahn, J, 2023)	1.97
"Anandamide is an endocannabinoid that contributes to certain aspects of social behavior, like play and reward, by binding to cannabinoid receptor type 1 (CB1). "	( Effects of systemic endocannabinoid manipulation on social and exploratory behavior in prairie voles (Microtus ochrogaster). Bales, KL; Simmons, TC; Singh, ALK, 2021)	2.06
"Anandamide is an endocannabinoid derived from arachidonic acid-containing membrane lipids and has numerous biological functions. "	( The rise and fall of anandamide: processes that control synthesis, degradation, and storage. Biringer, RG, 2021)	2.38
"Anandamide (AEA) is a ubiquitous lipid that exerts neurotransmitter functions but also controls important biological functions such as proliferation, survival, or programmed cell death. "	( Ceramide binding to anandamide increases its half-life and potentiates its cytotoxicity in human neuroblastoma cells. Chahinian, H; Di Scala, C; Fantini, J; Garmy, N; Mazzarino, M; Varini, K; Yahi, N, 2017)	2.22
"Anandamide is a lipid neurotransmitter derived from arachidonic acid, a polyunsaturated fatty acid. "	( Anandamide Revisited: How Cholesterol and Ceramides Control Receptor-Dependent and Receptor-Independent Signal Transmission Pathways of a Lipid Neurotransmitter. Barrantes, FJ; Chahinian, H; Di Scala, C; Fantini, J; Yahi, N, 2018)	3.37
"Anandamide is a lipid mediator that acts as an endogenous ligand of CB1 receptors. "	( Brain activity of anandamide: a rewarding bliss? Fadda, P; Fratta, W; Masia, P; Satta, V; Scherma, M; Tanda, G, 2019)	2.29
"Anandamide is a ligand of the endocannabinoid system. "	( Cerebrospinal fluid anandamide levels, cannabis use and psychotic-like symptoms. Brandner, B; Chatten, K; Curran, HV; Gulati, S; Leweke, FM; Manocha, A; Morgan, CJ; Page, E; Schaefer, C, 2013)	2.16
"Anandamide (AEA) is an endocannabinoid that is inactivated by cellular uptake followed by intracellular hydrolysis by fatty acid amide hydrolase (FAAH)."	( Role of FAAH-like anandamide transporter in anandamide inactivation. Deutsch, DG; Elmes, MW; Glaser, ST; Kaczocha, M; Leung, K, 2013)	1.45
"Anandamide is an endocannabinoid that regulates multiple physiological functions by pharmacological actions, in a manner similar to marijuana. "	( The endocannabinoid anandamide inhibits voltage-gated sodium channels Nav1.2, Nav1.6, Nav1.7, and Nav1.8 in Xenopus oocytes. Horishita, T; Okura, D; Sata, T; Sudo, Y; Ueno, S; Uezono, Y; Yanagihara, N, 2014)	2.17
"Anandamide is an endocannabinoid involved in several physiological functions including neuroprotection. "	( Normal aging in rats and pathological aging in human Alzheimer's disease decrease FAAH activity: modulation by cannabinoid agonists. de Ceballos, ML; Giusto, NM; Martín-Moreno, AM; Pascual, AC; Pasquaré, SJ, 2014)	1.85
"Anandamide (AEA) is an endocannabinoid present in human plasma that is associated with several physiological functions and disease states. "	( High-throughput salting-out assisted liquid-liquid extraction with acetonitrile for the determination of anandamide in plasma of hemodialysis patients with liquid chromatography tandem mass spectrometry. Cheng, L; Mao, W; Xiong, X; Zhang, L, 2015)	2.07
"Anandamide (AEA) is an endocannabinoid (EC) that modulates multiple functions in the CNS and that is released in areas of injury, exerting putative neuroprotective actions. "	( Endocannabinoids regulate the activity of astrocytic hemichannels and the microglial response against an injury: In vivo studies. Cravatt, BF; Hillard, CJ; Koester, EC; Moreno, M; Pazos, MR; Romero, J; Tolón, RM; Vázquez, C, 2015)	1.86
"Anandamide is a lipid mediator involved in reproductive physiology."	( Sperm Release From the Oviductal Epithelium Depends on Ca(2+) Influx Upon Activation of CB1 and TRPV1 by Anandamide. Alonso, CA; Castellano, L; Franchi, AM; Gervasi, MG; Llados, C; Osycka-Salut, C; Perez-Martinez, S; Sanchez, T; Villalón, M, 2016)	1.37
"Anandamide (AEA) is an endogenous ligand for the cannabinoid receptors CB1 and CB2."	( Role of the endocannabinoid system in the mechanisms involved in the LPS-induced preterm labor. Aisemberg, J; Bariani, MV; Burdet, J; Cella, M; Domínguez Rubio, AP; Franchi, AM, 2015)	1.14
"Anandamide is an endocannabinoid known to participate in reproductive processes. "	( 17beta-oestradiol and progesterone regulate anandamide synthesis in the rat uterus. Billi, S; Cervini, M; Farina, MG; Franchi, AM; Ribeiro, ML; Sordelli, MS; Vercelli, CA, 2009)	2.06
"Anandamide is a lipid neurotransmitter which belongs to a class of molecules termed the endocannabinoids involved in multiple physiological functions. "	( The insertion and transport of anandamide in synthetic lipid membranes are both cholesterol-dependent. Chahinian, H; Di Pasquale, E; Fantini, J; Sanchez, P, 2009)	2.08
"Anandamide is a bioactive lipid binding to cannabinoid receptors. "	( Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. Giuffrida, A; Hellmich, M; Klosterkötter, J; Koethe, D; Leweke, FM; Piomelli, D; Ruhrmann, S; Schreiber, D; Schultze-Lutter, F, 2009)	3.24
"Anandamide (AEA) is a member of an endogenous class of lipid mediators, known as endocannabinoids, which are involved in various biological processes. "	( Regulation of gene transcription and keratinocyte differentiation by anandamide. Maccarrone, M; Malaponti, M; Oddi, S; Pasquariello, N, 2009)	2.03
"Anandamide (AEA) is an endogenous agonist of type 1 cannabinoid receptors (CB1R) that, along with metabolic enzymes of AEA and congeners, compose the "endocannabinoid system." Here we report the biochemical, morphological, and functional characterization of the endocannabinoid system in human neuroblastoma SH-SY5Y cells that are an experimental model for neuronal cell damage and death, as well as for major human neurodegenerative disorders. "	( Characterization of the endocannabinoid system in human neuronal cells and proteomic analysis of anandamide-induced apoptosis. Amadio, D; Barcaroli, D; Catanzaro, G; Federici, G; Finazzi Agrò, A; Maccarrone, M; Marzano, V; Oddi, S; Pasquariello, N; Urbani, A, 2009)	2.01
"Anandamide (AEA) is an endogenous lipid mediator that exerts several effects in the brain as well as in peripheral tissues. "	( Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors. Battistini, L; Bernardi, G; Borsellino, G; Catanzaro, G; Cencioni, MT; Chiurchiù, V; Maccarrone, M, 2010)	3.25
"Anandamide (AEA) is an endogenous agonist for cannabinoid receptor CB1-R and seems to be involved in the control of cancer growth. "	( Effects of anandamide on polyamine levels and cell growth in human colon cancer cells. Bifulco, M; Caruso, MG; Laezza, C; Linsalata, M; Messa, C; Notarnicola, M; Orlando, A; Santoro, A; Tutino, V, 2010)	2.19
"Anandamide (AEA) is an endogenous agonist for the cannabinoid receptor 2 (CB2) which is expressed in osteoblasts. "	( Eicosapentaenoic acid decreases expression of anandamide synthesis enzyme and cannabinoid receptor 2 in osteoblast-like cells. Hannon, K; Hutchins, HL; Li, Y; Watkins, BA, 2011)	2.07
"Anandamide is an arachidonic acid-derived endogenous cannabinoid that regulates normal physiological functions and pathophysiological responses within the central nervous system and in the periphery. "	( Anandamide oxidation by wild-type and polymorphically expressed CYP2B6 and CYP2D6. Hollenberg, PF; Snider, NT; Sridar, C, 2011)	3.25
"Anandamide is an endocannabinoid that has antiarrhythmic effects through inhibition of L-type Ca(2+) channels in cardiomyocytes. "	( Effects of anandamide on potassium channels in rat ventricular myocytes: a suppression of I(to) and augmentation of K(ATP) channels. Li, DP; Li, Q; Ma, HJ; Shi, M; Song, SL; Zhang, Y, 2012)	2.21
"Anandamide is a lipid mediator that participates in the regulation of several female and male reproductive functions."	( Anandamide induces sperm release from oviductal epithelia through nitric oxide pathway in bovines. Cella, M; Franchi, AM; Gervasi, MG; Osycka-Salut, C; Pereyra, E; Perez-Martinez, S; Ribeiro, ML, 2012)	2.54
"Anandamide (AEA) is a lipid mediator that participates in the regulation of several reproductive functions. "	( Differential expression of endocannabinoid system in normal and preeclamptic placentas: effects on nitric oxide synthesis. Abán, C; Cella, M; Damiano, A; Farina, MG; Franchi, AM; Leguizamón, GF, 2013)	1.83
"Anandamide acts as a full vanilloid receptor agonist in many bioassay systems, but it is a weak activator of primary afferents in the airways. "	( Mechanisms underlying tissue selectivity of anandamide and other vanilloid receptor agonists. Adner, M; Andersson, DA; Högestätt, ED; Zygmunt, PM, 2002)	2.02
"Anandamide is a neuroimmunoregulatory molecule that triggers apoptosis in a number of cell types including PC12 cells. "	( ASK1-p38 MAPK/JNK signaling cascade mediates anandamide-induced PC12 cell death. Biswas, KK; Hahiguchi, T; Kitajima, I; Kracht, M; Lee, KY; Maruyama, I; Sarker, KP; Yamakuchi, M, 2003)	2.02
"Anandamide (ANA) is an endogenous lipid which acts as a cannabinoid receptor ligand and with potent anticarcinogenic activity in several cancer cell types."	( Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor receptor down-regulation and ceramide production. Bailly, C; Hénichart, JP; Mimeault, M; Pommery, N; Wattez, N, 2003)	2.02
"Anandamide is a prominent member of the endocannabinoids, a group of diffusible lipid molecules which influences neuronal excitability. "	( Sodium channel inhibition by anandamide and synthetic cannabimimetics in brain. Coyne, L; David, LS; Errington, AC; Lees, G; Liao, C; Nicholson, RA; Singh, G; Zheng, J, 2003)	2.05
"Anandamide is an endogenous ligand for cannabinoid receptor and its protein-mediated transport across cellular membranes has been demonstrated in cells derived from brain as well as in cells of the immune system. "	( Uptake and metabolism of [3H]anandamide by rabbit platelets. Lack of transporter? Fasia, L; Karava, V; Siafaka-Kapadai, A, 2003)	2.05
"Anandamide (AEA) is an endogenous cannabinoid ligand acting predominantly on the cannabinoid 1 (CB(1)) receptor, but it is also an agonist on the capsaicin VR(1)/TRPV(1) receptor. "	( Inhibitory effect of anandamide on resiniferatoxin-induced sensory neuropeptide release in vivo and neuropathic hyperalgesia in the rat. Bölcskei, K; Helyes, Z; Németh, J; Pintér, E; Szolcsányi, J; Thán, M, 2003)	2.08
"Anandamide amidase is an enzyme that metabolizes anandamide into arachadonic acid and ethanolamine."	( Behavioral effects of inhibition of cannabinoid metabolism: The amidase inhibitor AM374 enhances the suppression of lever pressing produced by exogenously administered anandamide. Aberman, JE; Arizzi, MN; Betz, A; Cervone, KM; Lin, S; Liu, Q; Makriyannis, A; Salamone, JD, 2004)	1.24
"Anandamide is an endocannabinoid that evokes hypotension by interaction with peripheral cannabinoid CB1 receptors and with the perivascular transient receptor potential vanilloid type 1 protein (TRPV1). "	( Increased anandamide induced relaxation in mesenteric arteries of cirrhotic rats: role of cannabinoid and vanilloid receptors. Arroyo, V; Briones, AM; Campistol, JM; Cejudo-Martín, P; Crespo, M; Domenicali, M; Fernández-Varo, G; Jiménez, W; Morales-Ruiz, M; Rodés, J; Ros, J; Vila, E, 2005)	2.17
"Anandamide is an endogenous cannabinoid ligand, and its levels are spatiotemporally regulated in the uterus during early pregnancy, showing lower levels in the receptive uterus and at the implantation site."	( N-acylphosphatidylethanolamine-hydrolyzing phospholipase D is an important determinant of uterine anandamide levels during implantation. Das, SK; Dey, SK; Guo, Y; Kingsley, PJ; Marnett, LJ; Okamoto, Y; Schmid, HH; Ueda, N; Wang, H, 2005)	1.27
"Anandamide is an endogenous lipidic cannabinoid (CB) characterized by potent vasodilator activity acting mainly through the activation of CB receptors, located on the vessel walls, and the vanilloid receptor 1, located on sensory peptidergic nerve endings within the external layers of vessel walls."	( Evolving the concept of regulation of vascular tone in humans. Taddei, S, 2005)	1.05
"Anandamide is an endogenous ligand for brain cannabinoid CB(1) receptors, but its behavioral effects are difficult to measure due to rapid inactivation. "	( The endogenous cannabinoid anandamide produces delta-9-tetrahydrocannabinol-like discriminative and neurochemical effects that are enhanced by inhibition of fatty acid amide hydrolase but not by inhibition of anandamide transport. Goldberg, SR; Justinova, Z; Makriyannis, A; Piomelli, D; Solinas, M; Tanda, G; Vadivel, SK; Wertheim, CE; Yasar, S, 2007)	2.08
"Anandamide (AEA) is a lipid molecule belonging to the family of endocannabinoids. "	( Anandamide protects from low serum-induced apoptosis via its degradation to ethanolamine. Juknat, A; Klin, Y; Matas, D; Pietr, M; Vogel, Z, 2007)	3.23
"Anandamide is an endogenous agonist for cannabinoid receptors and produces analgesia by acting at these receptors in several sites in the brain and peripheral nervous system. "	( Methanandamide activation of a novel current in mouse trigeminal ganglion sensory neurons in vitro. Connor, M; Roberts, LA; Ross, HR, 2008)	2.35
"Anandamide is an endogenous signaling lipid that binds to and activates cannabinoid receptors in the brain and peripheral tissues. "	( Identification of biosynthetic precursors for the endocannabinoid anandamide in the rat brain. Ahmed, F; Astarita, G; Piomelli, D, 2008)	2.03
"Anandamide is a lipid messenger that carries out a wide variety of biological functions. "	( Evidence for the intracellular accumulation of anandamide in adiposomes. Dainese, E; De Simone, C; Fezza, F; Finazzi-Agrò, A; Maccarrone, M; Oddi, S; Pasquariello, N; Rapino, C, 2008)	2.05
"Anandamide (AEA) is an endogenous ligand of cannabinoid receptors and a well characterized mediator of many physiological processes including inflammation, pain, and appetite. "	( Anandamide biosynthesis catalyzed by the phosphodiesterase GDE1 and detection of glycerophospho-N-acyl ethanolamine precursors in mouse brain. Cravatt, BF; Simon, GM, 2008)	3.23
"Anandamide is a potential target for medications aimed at relieving SUD in schizophrenia."	( Endogenous cannabinoids in patients with schizophrenia and substance use disorder during quetiapine therapy. Astarita, G; Bouchard, RH; Demers, MF; Gendron, A; Kouassi, E; Lipp, O; Piomelli, D; Potvin, S; Roy, MA; Stip, E, 2008)	1.07
"Anandamide (AN) is an arachidonic acid congener, found in the brain, that binds to the cannabinoid receptor and elicits cannabinoid-like pharmacological activity. "	( Microsomal cytochrome P450-mediated liver and brain anandamide metabolism. Bornheim, LM; Chen, B; Correia, MA; Kim, KY, 1995)	1.98
"Anandamide is an endogenous ligand for delta 9-tetrahydrocannabinol (THC) receptors. "	( The MAP kinase signal transduction pathway is activated by the endogenous cannabinoid anandamide. Burstein, SH; Campbell, D; Davis, RJ; Subramanian, A; Wartmann, M, 1995)	1.96
"Anandamide is an endogenous ligand for central cannabinoid receptors and is released after neuronal depolarization. "	( Regulation of a neuronal form of focal adhesion kinase by anandamide. Burgaya, F; de Franciscis, V; Derkinderen, P; Gelman, M; Girault, JA; Le Bert, M; Siciliano, JC; Toutant, M, 1996)	1.98
"Anandamide is an endogenous ligand for cannabinoid receptors. "	( Enzymes for anandamide biosynthesis and metabolism. Kurahashi, Y; Tokunaga, T; Ueda, N; Yamamoto, K; Yamamoto, S, 1996)	2.12
"Anandamide appears to be a novel and synergistic growth stimulator for hematopoietic cells."	( Anandamide, a natural ligand for the peripheral cannabinoid receptor is a novel synergistic growth factor for hematopoietic cells. Delwel, R; Hol, S; Löwenberg, B; Mancham, S; Mayen, A; Ploemacher, R; Valk, P; Vankan, Y; Verbakel, S, 1997)	2.46
"Anandamide is an putative endogenous cannabinoid ligand that produces pharmacological effects similar to those of Delta9-tetrahydrocannabinol, the principle psychoactive constituent in marijuana. "	( The effect of the enzyme inhibitor phenylmethylsulfonyl fluoride on the pharmacological effect of anandamide in the mouse model of cannabimimetic activity. Compton, DR; Martin, BR, 1997)	1.96
"Anandamide is an endogenous ligand of cannabinoid receptors that induces pharmacological responses in animals similar to those of cannabinoids such as delta9-tetrahydrocannabinol (THC). "	( Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission. Bickler, PE; Bornheim, LM; Gray, AT; Hampson, AJ; Hansen, BM; Leonoudakis, DJ; Scanziani, M; Yost, CS, 1998)	2.09
"Anandamide is an endogenous cannabinoid receptor agonist with similar pharmacological effects as D9-tetrahydrocannabinol, the major psychoactive compound in marijuana. "	( Anandamide inhibition of recombinant AMPA receptor subunits in Xenopus oocytes is increased by forskolin and 8-bromo-cyclic AMP. Akinshola, BE; Ogunseitan, AB; Onaivi, ES; Taylor, RE, 1999)	3.19
"Anandamide is an endogenous compound that acts as an agonist at cannabinoid receptors. "	( The cellular uptake of anandamide is coupled to its breakdown by fatty-acid amide hydrolase. Abumrad, N; Deutsch, DG; Glaser, ST; Hillard, CJ; Howell, JM; Kunz, JS; Puffenbarger, RA, 2001)	2.06
"Anandamide is a lipid that binds to cannabinoid receptors and mimics the psychoactive effects of the drug."	( Marijuana and chocolate. James, JS, 1996)	1.02
"Anandamide (ANA) is an endogenous ligand for the cannabinoid receptors Cb1 and Cb2 that is able to synergistically stimulate the proliferation of hematopoietic growth factor-dependent blood cells in serum-free culture. "	( Enhancement of erythropoietin-stimulated cell proliferation by Anandamide correlates with increased activation of the mitogen-activated protein kinases ERK1 and ERK2. Delwel, R; Löwenberg, B; Valk, P; Verbakel, S; von Lindern, M, 2000)	1.99

Excerpt	Reference	Relevance
"Anandamide has a very short biological half-life as they are extensively metabolized by fatty acid amide hydrolase enzyme (FAAH)."	( Novel topical anandamide formulation for alleviating peripheral neuropathic pain. Doerksen, RJ; Narasimha Murthy, S; Pandey, P; Police, A; Rangappa, S; Shankar, VK, 2023)	1.99
"Anandamide has been identified in porcine brain as an endogenous cannabinoid receptor ligand and is believed to be a counterpart to the psychoactive component of marijuana, delta 9-tetrahydrocannabinol (delta 9-THC). "	( Anandamide, an endogenous cannabinoid, inhibits Shaker-related voltage-gated K+ channels. Poling, JS; Rogawski, MA; Salem, N; Vicini, S, 1996)	3.18
"Anandamide has a very short biological half-life as they are extensively metabolized by fatty acid amide hydrolase enzyme (FAAH)."	( Novel topical anandamide formulation for alleviating peripheral neuropathic pain. Doerksen, RJ; Narasimha Murthy, S; Pandey, P; Police, A; Rangappa, S; Shankar, VK, 2023)	1.99
"Anandamide has also been implicated in blood pressure regulation."	( Decreased circulating anandamide levels in preeclampsia. Fügedi, G; Molvarec, A; Rigó, J; Stenczer, B; Szabó, E; Walentin, S, 2015)	1.45
"Anandamide (AEA) has been reported to have pleiotropic effects on reproduction, but the mechanism by which it exerts these effects is unclear. "	( Dual effect of anandamide on rat placenta nitric oxide synthesis. Cella, M; Cervini, M; Farina, MG; Franchi, AM; Guadagnoli, T; Leguizamón, GF; Ribeiro, ML; Sordelli, MS, 2008)	2.14
"Anandamide has been characterized as both an endocannabinoid and endovanilloid. "	( Excitation of cutaneous C nociceptors by intraplantar administration of anandamide. Brink, TS; Potenzieri, C; Simone, DA, 2009)	2.03
"Anandamide has been shown to act through both the cannabinoid receptor 1 (CB1) and the vanilloid receptor 1 (VR1)."	( The actions of anandamide on rat superficial medullary dorsal horn neurons in vitro. Christie, MJ; Jennings, EA; Roberts, LA; Vaughan, CW, 2003)	1.39
"Anandamide has vasodilator activity, and the binding to albumin may mediate its transport in aqueous compartments."	( Binding of anandamide to bovine serum albumin. Bojesen, IN; Hansen, HS, 2003)	1.43
"Anandamide has been shown previously to inhibit trigeminovascular neurons and prevent vasodilation, through an action at CB(1) receptors."	( Anandamide acts as a vasodilator of dural blood vessels in vivo by activating TRPV1 receptors. Akerman, S; Goadsby, PJ; Kaube, H, 2004)	2.49
"As anandamide has been implicated in the vasodilated state in advanced cirrhosis, the study investigated whether the mesenteric bed from cirrhotic rats has an altered and selective vasodilator response to anandamide."	( Increased anandamide induced relaxation in mesenteric arteries of cirrhotic rats: role of cannabinoid and vanilloid receptors. Arroyo, V; Briones, AM; Campistol, JM; Cejudo-Martín, P; Crespo, M; Domenicali, M; Fernández-Varo, G; Jiménez, W; Morales-Ruiz, M; Rodés, J; Ros, J; Vila, E, 2005)	1.24
"Anandamide (AEA) uptake has been described over the last decade to occur by facilitated diffusion, but a protein has yet to be isolated. "	( Anandamide transport: a critical review. Deutsch, DG; Glaser, ST; Kaczocha, M, 2005)	3.21
"Anandamide has been shown to directly modulate various ion channels, such as alpha7-nicotinic acetylcholine receptors, T-type Ca2+ channels, voltage-gated and background K+-channels and Transient Receptor Potential Vanilloid type 1 (TRPV1) channels."	( Anandamide as an intracellular messenger regulating ion channel activity. Di Marzo, V; van der Stelt, M, 2005)	2.49
"Anandamide, has been reported to have pleiotropic effects on human reproduction and in experimental animal models."	( The role of the endocannabinoid system in gametogenesis, implantation and early pregnancy. Ang, C; Bell, SC; Konje, JC; Taylor, AH, )	0.85
"Anandamide has never been isolated from human brain or peripheral tissues and its role in human physiology has not been examined."	( Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. Axelrod, J; Becker, GW; Briley, EM; Felder, CC; Koppel, GA; Nguyen, DN; Nielsen, A; Palkovits, M; Paul, SM; Priller, J; Richardson, JM; Riggin, RM, 1996)	1.25
"Anandamides have been observed to lower intraocular pressure in the rabbit eye, preceded by a period of hypertension. "	( Effects of topical alpha-substituted anandamides on intraocular pressure in normotensive rabbits. Jarho, P; Järvinen, K; Järvinen, T; Mahadevan, V; Pate, DW; Urtti, A, 1997)	2.01
"Anandamide (AEA) has vasodilator activity, which can be terminated by cellular re-uptake and degradation. "	( Anandamide uptake by human endothelial cells and its regulation by nitric oxide. Bari, M; Bisogno, T; Di Marzo, V; Finazzi-Agrò, A; Lorenzon, T; Maccarrone, M, 2000)	3.19

Excerpt	Reference	Relevance
"Anandamide plays a very important role in the carcinogenesis and development of colorectal cancer."	( [Anandamide inhibits the growth of colorectal cancer cells through CB1 and lipid rafts]. Liao, YS; Wang, P; Wu, J; Zhang, H, 2011)	2
"Anandamide was found to cause mitochondrial damage of the B-type neurons of trigeminal ganglia similar to what has been described for capsaicin."	( Neonatal anandamide treatment results in prolonged mitochondrial damage in the vanilloid receptor type 1-immunoreactive B-type neurons of the rat trigeminal ganglion. Czéh, G; Seress, L; Szoke, E; Szolcsányi, J, 2002)	1.45
"Anandamide was able to inhibit dural blood vessel dilation brought about by electrical stimulation by 50%, calcitonin gene-related peptide (CGRP) by 30%, capsaicin by 45%, and nitric oxide by 40%."	( Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascular-mediated nociception. Akerman, S; Goadsby, PJ; Kaube, H, 2004)	2.49
"The anandamide-induced increase in PPP was found concomitantly with a significant increase in TXB(2) and Cys-LT production in the perfusate."	( Roles of anandamide in the hepatic microcirculation in cirrhotic rats. Hou, MC; Huang, YT; Lee, FY; Lee, SD; Lee, TY; Lin, HC; Wang, YW; Yang, YY, 2006)	1.23
"Anandamide can activate potassium (K(+)) channels to induce an endothelium-dependent vasorelaxation in normal rat mesenteric arteries. "	( Role of Ca2+-dependent potassium channels in in vitro anandamide-mediated mesenteric vasorelaxation in rats with biliary cirrhosis. Hou, MC; Huang, YT; Lee, FY; Lee, SD; Lee, TY; Lin, HC; Wang, YW; Yang, YY, 2007)	2.03
"Anandamide was shown to inhibit competitively the specific binding of [3H]CP55940 to synaptosomal membranes."	( N-arachidonoylethanolamine (anandamide), an endogenous cannabinoid receptor ligand, and related lipid molecules in the nervous tissues. Kondo, S; Nakane, S; Sugiura, T; Sukagawa, A; Tonegawa, T; Waku, K; Yamashita, A, 1996)	1.31
"2. Anandamide induced an increase in Ca2+ in endothelial cells which, in contrast to histamine, developed slowly and was transient."	( Anandamide-induced mobilization of cytosolic Ca2+ in endothelial cells. Graier, WF; Holzmann, S; Kostner, GM; Mombouli, JV; Schaeffer, G, 1999)	2.26

Excerpt	Reference	Relevance
"The anandamide-treated group showed a significant decrease in seizure scores, while no change was shown in seizure scores in the capsazepine- and AM251-treated groups compared with the control group."	( The Role of the Possible Receptors and Intracellular Pathways in Protective Effect of Exogenous Anandamide in Kindling Model of Epilepsy. Khaksar, S; Naderi, N; Salimi, M; Zeinoddini, H, 2022)	1.42
"The anandamide treatment resulted in cell cycle redistribution of gastric cancer cells."	( Simulation of Swanson's literature-based discovery: anandamide treatment inhibits growth of gastric cancer cells in vitro and in silico. Dong, W; Hu, Y; Liu, Y; Mou, Q; Wang, J; Zhu, W, 2014)	1.13
"Anandamide levels in untreated patients were more than doubled as compared to controls."	( Dynamic changes of anandamide in the cerebrospinal fluid of Parkinson's disease patients. Bari, M; Bernardi, G; Fezza, F; Galati, S; Maccarrone, M; Moschella, V; Pisani, A; Pisani, V; Stanzione, P, 2010)	1.41
"Anandamide treatment resulted in an increase in the phosphorylation of sphingosine kinase-1 within the CA."	( Interaction between anandamide and sphingosine-1-phosphate in mediating vasorelaxation in rat coronary artery. Brett, RR; Kane, KA; Kennedy, S; Mair, KM; Pyne, NJ; Pyne, S; Robinson, E, 2010)	1.41
"Anandamide treatment suppressed both apo A-I mRNA and apo A-I gene promoter activity in both cell lines."	( Inhibition of apolipoprotein A-I gene expression by obesity-associated endocannabinoids. Haas, MJ; Mazza, AD; Mooradian, AD; Wong, NC, 2012)	1.1
"Anandamide treatment resulted in the activation of p38 mitogen-activated protein kinase (MAPK), c-Jun N-terminal kinase (JNK), and p44/42 MAPK in apoptosing cells."	( ASK1-p38 MAPK/JNK signaling cascade mediates anandamide-induced PC12 cell death. Biswas, KK; Hahiguchi, T; Kitajima, I; Kracht, M; Lee, KY; Maruyama, I; Sarker, KP; Yamakuchi, M, 2003)	1.3
"This anandamide pretreatment completely blocked capsaicin-induced arteriolar constriction (response decreased to 1 +/- 0.6%), and this inhibition was reversed by a protein phosphatase-2B inhibitor (cyclosporin-A; 100 nM, 5 min) treatment (constriction, 31 +/- 1%)."	( Phosphorylation-dependent desensitization by anandamide of vanilloid receptor-1 (TRPV1) function in rat skeletal muscle arterioles and in Chinese hamster ovary cells expressing TRPV1. Bagi, Z; Blumberg, PM; Edes, I; Kedei, N; Lizanecz, E; Papp, Z; Pásztor, ET; Tóth, A, 2006)	1.05
"Anandamide treatment blunted the rise in blood pressure without affecting the increase in splanchnic nerve discharge."	( Mechanism of the hypotensive action of anandamide in anesthetized rats. Guyenet, PG; Huangfu, D; Kunos, G; Lake, KD; Varga, K, 1996)	1.28
"3. Anandamide pretreatment slightly reduced the mobilization of Ca2+ from intracellular stores that was evoked by histamine."	( Anandamide-induced mobilization of cytosolic Ca2+ in endothelial cells. Graier, WF; Holzmann, S; Kostner, GM; Mombouli, JV; Schaeffer, G, 1999)	2.26
"Anandamide-treated mice consumed 44% more food (P<0.05) during 1 week of 2.5-h feeding each day."	( Low dose anandamide affects food intake, cognitive function, neurotransmitter and corticosterone levels in diet-restricted mice. Avraham, Y; Berry, EM; Hao, S; Mechoulam, R, 2000)	1.45
"Rats treated with anandamide earlier in development took longer to learn the task, suggesting that anandamide exerts a harmful effect on cognition in developing rats."	( Exposure to anandamide on young rats causes deficits in learning, temporal perception and induces changes in NMDA receptor expression. Aguilera-Reyes, U; Buenrostro-Jauregui, M; Galicia-Castillo, O; García-Salcedo, V; Hernández-Guerrero, C; Martínez-Castro, N; Sanchez-Castillo, H, 2023)	1.61

Excerpt	Reference	Relevance
" Cisplatin produces a cumulative toxic effect on peripheral nerves, and 30-40% of cancer patients receiving this agent experience pain."	( Cannabinoid type-1 receptor reduces pain and neurotoxicity produced by chemotherapy. Harding-Rose, C; Khasabov, S; Khasabova, IA; Paz, J; Seybold, VS; Simone, DA, 2012)	0.38
" These findings support a neuroprotective and modulatory role of cannabinoids in the early toxic events elicited by agents inducing excitotoxic processes."	( Cannabinoid receptor agonists reduce the short-term mitochondrial dysfunction and oxidative stress linked to excitotoxicity in the rat brain. Castellanos, P; Colín-González, AL; Paz-Loyola, AL; Pinzón, E; Rangel-López, E; Santamaría, A; Serratos, IN; Souza, DO; Torres, I; Wajner, M, 2015)	0.42
" This study aimed to determine specific associations between genetic variants of fatty acid amide hydrolase (FAAH) and postoperative central opioid adverse effects in children undergoing tonsillectomy."	( Novel associations between FAAH genetic variants and postoperative central opioid-related adverse effects. Chidambaran, V; Kaufman, KM; Martin, LJ; Mavi, J; McAuliffe, J; Meller, J; Mersha, TB; Pilipenko, V; Sadhasivam, S; Zhang, X, 2015)	0.42

Excerpt	Reference	Relevance
" alone and in combination with at least one dose of rimonabant."	( Apparent affinity estimates of rimonabant in combination with anandamide and chemical analogs of anandamide in rhesus monkeys discriminating Delta9-tetrahydrocannabinol. McMahon, LR, 2009)	0.59
" Additional experiments examined these compounds in combination with morphine."	( Effects of alterations in cannabinoid signaling, alone and in combination with morphine, on pain-elicited and pain-suppressed behavior in mice. Dykstra, LA; Miller, LL; Picker, MJ; Schmidt, KT; Umberger, MD, 2012)	0.38
"A simple and reliable method was developed and validated to determine the endocannabinoids anandamide (AEA) and 2-arachidonoylglycerol (2-AG) in rat brain samples by micro salting-out assisted liquid-liquid extraction combined with ultra-high performance liquid chromatography tandem mass spectrometry (SALLLE/UHPLC-MS/MS)."	( A micro salting-out assisted liquid-liquid extraction combined with ultra-high performance liquid chromatography tandem mass spectrometry to determine anandamide and 2-arachidonoylglycerol in rat brain samples. Oliveira, IGC; Queiroz, MEC, 2020)	0.98

Excerpt	Reference	Relevance
" Clinical trials are now required, but are hindered by a paucity of cannabinoids of suitable bioavailability and therapeutic ratio."	( Cannabinoids and pain. Rice, AS, 2001)	0.31
" However, a large fraction of these n-3 PUFAs is present in the phospholipid (PL) fraction and may have high bioavailability and capacity to change the endocannabinoid profile."	( Intake of a Western diet containing cod instead of pork alters fatty acid composition in tissue phospholipids and attenuates obesity and hepatic lipid accumulation in mice. Fauske, KR; Fjære, E; Frøyland, L; Graff, IE; Kopecky, J; Kristiansen, K; Kuda, O; Liaset, B; Liisberg, U; Madsen, L; Myrmel, LS; Norberg, N, 2016)	0.43

Excerpt	Relevance	Reference
"We have recently described the dose-response effect of anandamide (AEA), the N-amide derivative of arachidonic acid that acts as an endogenous ligand for the cannabinoid receptor, on extrapyramidal function."	( Time-course of the effects of anandamide, the putative endogenous cannabinoid receptor ligand, on extrapyramidal function. de Miguel, R; Fernández-Ruiz, JJ; García-Palomero, E; Ramos, JA; Romero, J, 1995)	0.83
" Following training, substitution tests using a cumulative dosing procedure revealed that anandamide (0."	( (R)-methanandamide, but not anandamide, substitutes for delta 9-THC in a drug-discrimination procedure. Burkey, RT; Nation, JR, 1997)	0.95
" Therefore, in this study we determined the efficacy of these two N-acylethanolamides in the prevention of VVH in the same model, using a prophylactic dosing regimen."	( The endogenous cannabinoid anandamide, but not the CB2 ligand palmitoylethanolamide, prevents the viscero-visceral hyper-reflexia associated with inflammation of the rat urinary bladder. Jaggar, SI; Rice, AS; Sellaturay, S, 1998)	0.6
"3 and 1 mg/kg) produced rightward shifts in the Delta9-THC dose-response curve for Delta9-THC-appropriate responding and for (R)-methanandamide-appropriate responding (surmountable antagonism)."	( (R)-methanandamide and Delta 9-THC as discriminative stimuli in rats: tests with the cannabinoid antagonist SR-141716 and the endogenous ligand anandamide. Järbe, TU; Lamb, RJ; Lin, S; Makriyannis, A, 2001)	0.95
" Dose-response curves for coronary perfusion pressure (CPP) and LVDP were constructed to anandamide, R-(+)-methanandamide, palmitoylethanolamide (PEA) and JWH015 in isolated Langendorff-perfused rat hearts."	( Evidence of a novel site mediating anandamide-induced negative inotropic and coronary vasodilatator responses in rat isolated hearts. Ford, WR; Hiley, CR; Honan, SA; White, R, 2002)	0.81
" Lauroylethanolamide (C12:0) produced a leftward shift in the dose-response curve for AEA."	( 'Entourage' effects of N-acyl ethanolamines at human vanilloid receptors. Comparison of effects upon anandamide-induced vanilloid receptor activation and upon anandamide metabolism. Fowler, CJ; Jonsson, KO; Lambert, DM; Smart, D; Vandevoorde, S, 2002)	0.53
" In the present work, we tested in rats the dose-response effects of UCM707 in the open-field and hot-plate tests, and, in particular, we analyzed whether this compound enhanced the hypokinetic and/or the antinociceptive actions of anandamide at a subeffective dose, using these two in vivo assays."	( UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of anandamide. de Lago, E; Fernández-Ruiz, J; López-Rodríguez, ML; Ortega-Gutiérrez, S; Ramos, JA; Viso, A, 2002)	0.71
" 19 and 20 produced leftward shifts in the dose-response curve for AEA activation of Ca(2+) influx into hVR1-HEK293 cells."	( N-Morpholino- and N-diethyl-analogues of palmitoylethanolamide increase the sensitivity of transfected human vanilloid receptors to activation by anandamide without affecting fatty acid amidohydrolase activity. Fowler, CJ; Jonsson, KO; Lambert, DM; Smart, D; Vandevoorde, S, 2003)	0.52
" One group of three normal mice was not dosed (naïve) while another group of three normal mice received a bolus intravenous injection of 50 mg/kg of anandamide."	( Formation of prostamides from anandamide in FAAH knockout mice analyzed by HPLC with tandem mass spectrometry. Acheampong, A; Burk, R; Cravatt, BF; Ling, KH; Ni, J; Tang-Liu, DD; Weber, A; Woodward, D, 2004)	0.81
" Sativex is a sublingual spray on Cannabis extract basis, and is equipped with an electronic tool to facilitate accurate dosing and to prevent misuses."	( [A novel analgesics made from Cannabis]. Szendrei, K, 2004)	0.32
" Although the basis for this unique pharmacology has not as yet been determined, it is possible that regional specificity of cannabinoid CB1 receptor downregulation and endocannabinoid release induced by repeated dosing with Delta9-tetrahydrocannabinol may play a role."	( Task specificity of cross-tolerance between Delta9-tetrahydrocannabinol and anandamide analogs in mice. Dewey, WL; Razdan, RK; Smith, FL; Wiley, JL, 2005)	0.56
" Dose-response curve for a beta-adrenergic agonist isoproterenol was constructed in the presence and absence of a CB-1 antagonist AM251 (1 microM)."	( Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Baik, SK; Gaskari, SA; Lee, SS; Li, Y; Liu, H; Moezi, L, 2005)	0.33
"), given 60 min before the test, exhibited a dose-response anxiolytic effect evaluated in terms of increase in the percentage of total entries and time spent in the open and decrease of total entries and time spent in the closed arms."	( 5-HT1A receptors are involved in the anxiolytic effect of Delta9-tetrahydrocannabinol and AM 404, the anandamide transport inhibitor, in Sprague-Dawley rats. Braida, D; Limonta, V; Malabarba, L; Sala, M; Zani, A, 2007)	0.55
"05-5pmol) induced anxiolytic-like effects with bell-shaped dose-response curves, the higher doses being ineffective."	( Anxiolytic-like effect of cannabinoids injected into the rat dorsolateral periaqueductal gray. Aguiar, DC; Guimarães, FS; Moreira, FA, 2007)	0.34
"05); the dose-response curve was shifted to the left in the obese."	( Effects of cannabinoid receptors on skeletal muscle oxidative pathways. Cameron-Smith, D; Cavuoto, P; Hatzinikolas, G; McAinch, AJ; Wittert, GA, 2007)	0.34
" Both 8-Br-cAMP (100 microM) and forskolin (10 microM) right-shifted the dose-response curves for the TRPM8-mediated effect of icilin and menthol on intracellular Ca(2+)."	( Regulation of transient receptor potential channels of melastatin type 8 (TRPM8): effect of cAMP, cannabinoid CB(1) receptors and endovanilloids. De Petrocellis, L; Di Marzo, V; Moriello, AS; Orlando, P; Starowicz, K; Vivese, M, 2007)	0.34
" Our results indicate clearly a dose-response blockade of extinction induced by AM251 injected into the striatum but a facilitation of extinction when administered into the hippocampus."	( Impairment of endocannabinoids activity in the dorsolateral striatum delays extinction of behavior in a procedural memory task in rats. Méndez-Díaz, M; Montes-Rodriguez, CJ; Prospéro-García, O; Rueda-Orozco, PE; Soria-Gomez, E, 2008)	0.35
" Therefore, coadministration of AEA did not significantly shift the dose-response curve to EM-1."	( Antinociceptive interactions between anandamide and endomorphin-1 at the spinal level. Benedek, G; Horvath, G; Mecs, L; Tuboly, G, 2009)	0.63
" Several studies have described characteristic inverted U-shaped dose-response effects of drugs that modulate the endocannabinoid levels."	( Dose-response effects of systemic anandamide administration in mice sequentially submitted to the open field and elevated plus-maze tests. Ferraz-de-Paula, V; Palermo-Neto, J; Pinheiro, ML; Ribeiro, A, 2009)	0.63
" Intra-cerebral administration of cannabidiol, a phytocannabinoid, or anandamide, an endocannabinoid, into the dorsolateral portion of periaqueductal gray (dlPAG) promotes anxiolytic-like effects in several animal models of anxiety with bell-shaped dose-response curves."	( Evidence for a potential role for TRPV1 receptors in the dorsolateral periaqueductal gray in the attenuation of the anxiolytic effects of cannabinoids. Campos, AC; Guimarães, FS, 2009)	0.59
" FAAH(-/-) mice dosed subchronically with equi-active maximally effective doses of AEA or THC displayed greater rightward shifts in THC dose-effect curves for antinociception, catalepsy, and hypothermia than in AEA dose-effect curves."	( FAAH-/- mice display differential tolerance, dependence, and cannabinoid receptor adaptation after delta 9-tetrahydrocannabinol and anandamide administration. Abdullah, RA; Cravatt, BF; Falenski, KW; Lichtman, AH; Schlosburg, JE; Selley, DE; Sim-Selley, LJ; Smith, TH; Thorpe, AJ, 2010)	0.56
" A low dose of the selective adenosine A(2A) receptor antagonist MSX-3 (1 mg/kg) caused downward shifts of THC and anandamide dose-response curves."	( Reinforcing and neurochemical effects of cannabinoid CB1 receptor agonists, but not cocaine, are altered by an adenosine A2A receptor antagonist. Ferré, S; Franco, R; Goldberg, SR; Justinová, Z; Mascia, P; Müller, CE; Quarta, D; Redhi, GH; Stroik, J; Yasar, S, 2011)	0.58
"05-10 μg/mouse) produced antidepressant-like effect dose-dependently, whereas influenced the MBB in a biphasic manner (produced a U-shaped dose-response curve)."	( Involvement of endocannabinoids in antidepressant and anti-compulsive effect of fluoxetine in mice. Jain, NS; Manna, SS; Umathe, SN, 2011)	0.37
" This control, however, is probably complex, which may explain the usually bell-shaped dose-response curves observed with drugs that act on NO- or CB1-mediated neurotransmission."	( Fine-tuning of defensive behaviors in the dorsal periaqueductal gray by atypical neurotransmitters. Aguiar, DC; Casarotto, PC; Fogaça, MV; Gomes, FV; Guimarães, FS; Lisboa, SF; Moreira, FA, 2012)	0.38
"Effects of pre-treatment with a single dose, versus 4 day repeated dosing with the selective FAAH inhibitor, URB597 (i."	( Lack of effect of chronic pre-treatment with the FAAH inhibitor URB597 on inflammatory pain behaviour: evidence for plastic changes in the endocannabinoid system. Alexander, SP; Barrett, DA; Bennett, AJ; Burston, J; Chapman, V; Kendall, DA; Norris, LM; Okine, BN; Patel, A; Woodhams, S, 2012)	0.38
" Finally, activation of TRPV1 channels may help us to explain the antipsychotic effect and the bell-shaped dose-response curves commonly observed with CBD."	( Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Campos, AC; Del Bel, EA; Gomes, FV; Guimarães, FS; Moreira, FA, 2012)	0.38
" This exposure resulted in the accumulation of 2-AG and AEA in the forebrain of juvenile rats; however, even at the lowest dosage level used (1."	( Low level chlorpyrifos exposure increases anandamide accumulation in juvenile rat brain in the absence of brain cholinesterase inhibition. Carr, RL; Graves, CA; Mangum, LC; Nail, CA; Ross, MK, 2014)	0.67
" However, despite the accumulation of evidence about long-term cognitive damage due to cannabis use, it is difficult to find unequivocal results, arising from the existence of many variables such as large differences between cannabis users, frequency of use, dosage and endogenous brain compensation."	( [Short-and long-term effects of cannabinoids on memory, cognition and mental illness]. Bart, Y; Eliasi, Y; Livneh, I; Monovich, E; Sagie, S, 2013)	0.39
" Whether repeated dosing would achieve greater protection remains to be examined."	( Endocannabinoid degradation inhibition improves neurobehavioral function, blood-brain barrier integrity, and neuroinflammation following mild traumatic brain injury. Impastato, RA; Katz, PS; Molina, PE; Rogers, EK; Sulzer, JK; Teng, SX, 2015)	0.42
" Lethality was increased by AM251 with the higher dosage of PO, but no lethality was noted with either dosage of CPO, with or without AM251."	( The cannabinoid receptor antagonist AM251 increases paraoxon and chlorpyrifos oxon toxicity in rats. Liu, J; Pope, C, 2015)	0.42
"6 mg/kg) served as a discriminative stimulus in both genotypes, with similar THC dose-response curves between groups."	( Phenotypic assessment of THC discriminative stimulus properties in fatty acid amide hydrolase knockout and wildtype mice. Vann, RE; Walentiny, DM; Wiley, JL, 2015)	0.42
" To constitute morphine analgesic tolerance, a 3-day cumulative dosing regimen was used."	( The effects of endocannabinoid receptor agonist anandamide and antagonist rimonabant on opioid analgesia and tolerance in rats. Altun, A; Bagcivan, I; Durmus, N; Gursoy, S; Ozdemir, E; Yildirim, K, 2015)	0.67
"0mg/kg, but at a lower dosage (0."	( Decreased anxiety in juvenile rats following exposure to low levels of chlorpyrifos during development. Armstrong, NH; Buchanan, AT; Carr, RL; Eells, JB; Mohammed, AN; Nail, CA; Ross, MK, 2017)	0.46
" Dose-response curves had inverted U shapes, with peak response rates occurring at a dose of 10 μg/kg/injection."	( Self-administration of the anandamide transport inhibitor AM404 by squirrel monkeys. Goldberg, SR; Justinova, Z; Makriyannis, A; Redhi, GH; Scherma, M; Schindler, CW; Vadivel, SK, 2016)	0.73
" CPF inhibited ChE activity in spleen and liver (all dosages) and in brain (highest dosage only)."	( Inhibition of Endocannabinoid-Metabolizing Enzymes in Peripheral Tissues Following Developmental Chlorpyrifos Exposure in Rats. Alugubelly, N; Buntyn, RW; Carr, RL; Hybart, RL; Mohammed, AN; Nail, CA; Parker, GC; Ross, MK, )	0.13
" There are several limitations, such as poor oral bioavailability, side effects, low adherence to treatment, and high dosage frequency of formulations due to the short half-life of the active ingredients used, among others."	( Anandamide and endocannabinoid system: an attractive therapeutic approach for cardiovascular disease. Fuentes, LB; Kassuha, DE; Manucha, W; Martín Giménez, VM; Noriega, SE, 2018)	1.92
"Intra-DMH anandamide treatment yielded a U-shaped dose-response curve with no effect of the lowest (0."	( Opposing roles of dorsomedial hypothalamic CB1 and TRPV1 receptors in anandamide signaling during the panic-like response elicited in mice by Brazilian rainbow Boidae snakes. Coimbra, NC; Dos Anjos-Garcia, T, 2019)	1.15
" To further investigate the specificity of effects on partner preference, we repeated our URB597 dosing regimen on an additional group of females and tested their anxiety-related behavior in both an elevated-plus maze and a light/dark test."	( Effects of systemic endocannabinoid manipulation on social and exploratory behavior in prairie voles (Microtus ochrogaster). Bales, KL; Simmons, TC; Singh, ALK, 2021)	0.62

Role	Description
neurotransmitter	An endogenous compound that is used to transmit information across the synapse between a neuron and another cell.
vasodilator agent	A drug used to cause dilation of the blood vessels.
human blood serum metabolite	Any metabolite (endogenous or exogenous) found in human blood serum samples.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
endocannabinoid	A class of cannabinoids present in mammalian biological fluids and tissues that activate cannabinoid receptors.
N-acylethanolamine 20:4	A N-(long-chain-acyl)ethanolamine in which the acyl group contains 20 carbons and 4 double bonds.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
Metabolism	1496	1108
Metabolism of lipids	500	463
Fatty acid metabolism	113	203
Arachidonic acid metabolism	36	82
16p11.2 proximal deletion syndrome	0	39
anandamide degradation	1	6
Cannabinoid receptor signaling	0	20
Thermogenesis	0	18

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, Ferritin light chain	Equus caballus (horse)	Potency	28.1838	5.6234	17.2929	31.6228	AID485281
phosphopantetheinyl transferase	Bacillus subtilis	Potency	44.6684	0.1413	37.9142	100.0000	AID1490
aldehyde dehydrogenase 1 family, member A1	Homo sapiens (human)	Potency	10.0000	0.0112	12.4002	100.0000	AID1030
Bloom syndrome protein isoform 1	Homo sapiens (human)	Potency	35.4813	0.5406	17.6392	96.1227	AID2528
vitamin D3 receptor isoform VDRA	Homo sapiens (human)	Potency	70.7946	0.3548	28.0659	89.1251	AID504847
DNA polymerase kappa isoform 1	Homo sapiens (human)	Potency	39.8107	0.0316	22.3146	100.0000	AID588579
Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)	Potency	0.1413	0.3162	12.7657	31.6228	AID881
Histamine H2 receptor	Cavia porcellus (domestic guinea pig)	Potency	0.1413	0.0063	8.2350	39.8107	AID881
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Fatty-acid amide hydrolase 1	Homo sapiens (human)	IC50 (µMol)	3.7500	0.0002	0.5982	7.0000	AID1350521; AID346660
Fatty-acid amide hydrolase 1	Homo sapiens (human)	Ki	10.0000	0.0006	1.2747	6.0000	AID71609
Potassium channel subfamily K member 3	Homo sapiens (human)	IC50 (µMol)	3.0000	0.0070	0.8985	5.1000	AID1525557
Fatty acid-binding protein, liver	Mus musculus (house mouse)	Ki	0.1110	0.0210	0.3483	2.0000	AID1802031
Cannabinoid receptor 1	Rattus norvegicus (Norway rat)	Ki	0.6393	0.0002	0.5665	10.0000	AID1287160; AID238320; AID356564; AID49140; AID49141; AID49664; AID49667; AID49668; AID49671; AID49673; AID49674
Cannabinoid receptor 1	Homo sapiens (human)	Ki	0.1834	0.0001	0.5077	9.6000	AID1127497; AID1185844; AID1363876; AID1630814; AID1662648; AID1798961; AID238432; AID258587; AID262877; AID268443; AID282918; AID289135; AID346363; AID353802; AID415512; AID49299; AID49300; AID49301; AID49303; AID49304; AID49322; AID633479
Cannabinoid receptor 2	Homo sapiens (human)	Ki	0.2699	0.0000	0.4156	10.0000	AID1127570; AID1386799; AID1630815; AID1798961; AID258588; AID262878; AID268444; AID346364; AID353803; AID49842
Alpha-1A adrenergic receptor	Rattus norvegicus (Norway rat)	Ki	0.0720	0.0000	0.9650	10.0000	AID258587
Cannabinoid receptor 1	Mus musculus (house mouse)	Ki	1.8470	0.0006	0.7246	7.2000	AID48996; AID49469; AID49470
Cannabinoid receptor 2	Mus musculus (house mouse)	Ki	0.5260	0.0002	0.0797	0.7943	AID1386798; AID48996
Fatty-acid amide hydrolase 1	Rattus norvegicus (Norway rat)	IC50 (µMol)	11.7490	0.0005	1.3313	8.0000	AID420415
Fatty-acid amide hydrolase 1	Rattus norvegicus (Norway rat)	Ki	0.1800	0.0006	0.1619	2.0000	AID262878
Corticotropin-releasing factor receptor 2	Homo sapiens (human)	Ki	0.1680	0.1680	0.1680	0.1680	AID353803
Lanosterol 14-alpha demethylase	Homo sapiens (human)	IC50 (µMol)	200.0000	0.0500	1.4390	4.0000	AID322753
Potassium channel subfamily K member 2	Bos taurus (cattle)	IC50 (µMol)	1.0000	0.4300	2.5760	8.2000	AID1307729
Cannabinoid receptor 2	Rattus norvegicus (Norway rat)	Ki	0.5393	0.0200	0.2206	0.9120	AID49140; AID49141; AID49864
Transient receptor potential cation channel subfamily V member 2	Rattus norvegicus (Norway rat)	IC50 (µMol)	4.7800	0.0370	1.9345	8.6000	AID1400243; AID1400244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Glutamate receptor 1	Rattus norvegicus (Norway rat)	EC50 (µMol)	15.8489	0.0041	1.8963	8.7000	AID257800
Glutamate receptor 2	Rattus norvegicus (Norway rat)	EC50 (µMol)	15.8489	0.0041	1.6251	7.6000	AID257800
Glutamate receptor 3	Rattus norvegicus (Norway rat)	EC50 (µMol)	15.8489	0.0041	1.1706	3.5000	AID257800
Glutamate receptor 4	Rattus norvegicus (Norway rat)	EC50 (µMol)	15.8489	0.0041	1.1339	3.5000	AID257800
Cannabinoid receptor 1	Rattus norvegicus (Norway rat)	EC50 (µMol)	11.9039	0.0002	0.1921	1.9953	AID1386800; AID257800; AID49472
Fatty acid-binding protein 5	Mus musculus (house mouse)	Kd	0.1003	0.0421	0.0708	0.1003	AID1802827
Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)	EC50 (µMol)	0.3072	0.0005	1.0674	6.3096	AID1127515; AID1798962; AID262881; AID353804; AID725619
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Cannabinoid receptor 1	Homo sapiens (human)	Log Ki	0.0019	0.0003	0.0019	0.0036	AID49325
Cannabinoid receptor 2	Homo sapiens (human)	Log Ki	0.0026	0.0005	0.0020	0.0035	AID49851
Fatty-acid amide hydrolase 1	Rattus norvegicus (Norway rat)	Km	2.7800	2.3400	2.5600	2.7800	AID38666
Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)	Activity	1.0000	0.0100	3.5198	10.0000	AID500214
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
fatty acid catabolic process	Fatty-acid amide hydrolase 1	Homo sapiens (human)
arachidonic acid metabolic process	Fatty-acid amide hydrolase 1	Homo sapiens (human)
positive regulation of vasoconstriction	Fatty-acid amide hydrolase 1	Homo sapiens (human)
monoacylglycerol catabolic process	Fatty-acid amide hydrolase 1	Homo sapiens (human)
potassium ion transport	Potassium channel subfamily K member 3	Homo sapiens (human)
chemical synaptic transmission	Potassium channel subfamily K member 3	Homo sapiens (human)
response to xenobiotic stimulus	Potassium channel subfamily K member 3	Homo sapiens (human)
monoatomic ion transmembrane transport	Potassium channel subfamily K member 3	Homo sapiens (human)
negative regulation of cytosolic calcium ion concentration	Potassium channel subfamily K member 3	Homo sapiens (human)
regulation of resting membrane potential	Potassium channel subfamily K member 3	Homo sapiens (human)
cellular response to zinc ion	Potassium channel subfamily K member 3	Homo sapiens (human)
cellular response to hypoxia	Potassium channel subfamily K member 3	Homo sapiens (human)
cochlea development	Potassium channel subfamily K member 3	Homo sapiens (human)
potassium ion transmembrane transport	Potassium channel subfamily K member 3	Homo sapiens (human)
stabilization of membrane potential	Potassium channel subfamily K member 3	Homo sapiens (human)
lipid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
phospholipid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
apoptotic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of cell population proliferation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of macrophage derived foam cell differentiation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
arachidonic acid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of cell migration	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
prostate gland development	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
regulation of epithelial cell differentiation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of chemokine production	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathway	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of keratinocyte differentiation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of cell cycle	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of growth	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
hepoxilin biosynthetic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
endocannabinoid signaling pathway	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
cannabinoid biosynthetic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipoxin A4 biosynthetic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
linoleic acid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipid oxidation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipoxygenase pathway	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of acute inflammatory response to antigenic stimulus	Cannabinoid receptor 1	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Cannabinoid receptor 1	Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	Cannabinoid receptor 1	Homo sapiens (human)
spermatogenesis	Cannabinoid receptor 1	Homo sapiens (human)
axonal fasciculation	Cannabinoid receptor 1	Homo sapiens (human)
response to nutrient	Cannabinoid receptor 1	Homo sapiens (human)
memory	Cannabinoid receptor 1	Homo sapiens (human)
positive regulation of neuron projection development	Cannabinoid receptor 1	Homo sapiens (human)
negative regulation of serotonin secretion	Cannabinoid receptor 1	Homo sapiens (human)
positive regulation of fever generation	Cannabinoid receptor 1	Homo sapiens (human)
negative regulation of fatty acid beta-oxidation	Cannabinoid receptor 1	Homo sapiens (human)
regulation of synaptic transmission, GABAergic	Cannabinoid receptor 1	Homo sapiens (human)
response to lipopolysaccharide	Cannabinoid receptor 1	Homo sapiens (human)
negative regulation of mast cell activation	Cannabinoid receptor 1	Homo sapiens (human)
negative regulation of dopamine secretion	Cannabinoid receptor 1	Homo sapiens (human)
response to nicotine	Cannabinoid receptor 1	Homo sapiens (human)
cannabinoid signaling pathway	Cannabinoid receptor 1	Homo sapiens (human)
response to cocaine	Cannabinoid receptor 1	Homo sapiens (human)
glucose homeostasis	Cannabinoid receptor 1	Homo sapiens (human)
positive regulation of apoptotic process	Cannabinoid receptor 1	Homo sapiens (human)
response to ethanol	Cannabinoid receptor 1	Homo sapiens (human)
negative regulation of action potential	Cannabinoid receptor 1	Homo sapiens (human)
negative regulation of blood pressure	Cannabinoid receptor 1	Homo sapiens (human)
positive regulation of blood pressure	Cannabinoid receptor 1	Homo sapiens (human)
regulation of insulin secretion	Cannabinoid receptor 1	Homo sapiens (human)
regulation of synaptic transmission, glutamatergic	Cannabinoid receptor 1	Homo sapiens (human)
maternal process involved in female pregnancy	Cannabinoid receptor 1	Homo sapiens (human)
regulation of feeding behavior	Cannabinoid receptor 1	Homo sapiens (human)
regulation of penile erection	Cannabinoid receptor 1	Homo sapiens (human)
retrograde trans-synaptic signaling by endocannabinoid	Cannabinoid receptor 1	Homo sapiens (human)
regulation of presynaptic cytosolic calcium ion concentration	Cannabinoid receptor 1	Homo sapiens (human)
trans-synaptic signaling by endocannabinoid, modulating synaptic transmission	Cannabinoid receptor 1	Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathway	Cannabinoid receptor 1	Homo sapiens (human)
regulation of metabolic process	Cannabinoid receptor 1	Homo sapiens (human)
response to amphetamine	Cannabinoid receptor 2	Homo sapiens (human)
inflammatory response	Cannabinoid receptor 2	Homo sapiens (human)
immune response	Cannabinoid receptor 2	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Cannabinoid receptor 2	Homo sapiens (human)
leukocyte chemotaxis	Cannabinoid receptor 2	Homo sapiens (human)
negative regulation of synaptic transmission, GABAergic	Cannabinoid receptor 2	Homo sapiens (human)
response to lipopolysaccharide	Cannabinoid receptor 2	Homo sapiens (human)
negative regulation of mast cell activation	Cannabinoid receptor 2	Homo sapiens (human)
cannabinoid signaling pathway	Cannabinoid receptor 2	Homo sapiens (human)
negative regulation of action potential	Cannabinoid receptor 2	Homo sapiens (human)
regulation of metabolic process	Cannabinoid receptor 2	Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathway	Cannabinoid receptor 2	Homo sapiens (human)
cell surface receptor signaling pathway	Corticotropin-releasing factor receptor 2	Homo sapiens (human)
cellular response to corticotropin-releasing hormone stimulus	Corticotropin-releasing factor receptor 2	Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	Corticotropin-releasing factor receptor 2	Homo sapiens (human)
long-term synaptic potentiation	Corticotropin-releasing factor receptor 2	Homo sapiens (human)
steroid biosynthetic process	Lanosterol 14-alpha demethylase	Homo sapiens (human)
cholesterol biosynthetic process	Lanosterol 14-alpha demethylase	Homo sapiens (human)
sterol metabolic process	Lanosterol 14-alpha demethylase	Homo sapiens (human)
negative regulation of protein catabolic process	Lanosterol 14-alpha demethylase	Homo sapiens (human)
negative regulation of protein secretion	Lanosterol 14-alpha demethylase	Homo sapiens (human)
negative regulation of amyloid-beta clearance	Lanosterol 14-alpha demethylase	Homo sapiens (human)
thermoception	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
fever generation	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
microglial cell activation	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
diet induced thermogenesis	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
peptide secretion	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
negative regulation of systemic arterial blood pressure	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
lipid metabolic process	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
cell surface receptor signaling pathway	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
chemosensory behavior	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
negative regulation of heart rate	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
negative regulation of mitochondrial membrane potential	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
glutamate secretion	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
calcium-mediated signaling	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
cellular response to heat	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
positive regulation of apoptotic process	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
response to peptide hormone	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
positive regulation of nitric oxide biosynthetic process	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
behavioral response to pain	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
sensory perception of mechanical stimulus	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
detection of temperature stimulus involved in thermoception	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
detection of temperature stimulus involved in sensory perception of pain	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of pain	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
protein homotetramerization	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
excitatory postsynaptic potential	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
smooth muscle contraction involved in micturition	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
calcium ion transmembrane transport	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
cellular response to alkaloid	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
cellular response to ATP	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
cellular response to tumor necrosis factor	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
cellular response to acidic pH	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
cellular response to temperature stimulus	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
negative regulation of establishment of blood-brain barrier	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
calcium ion import across plasma membrane	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
response to capsazepine	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
cellular response to nerve growth factor stimulus	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
protein binding	Fatty-acid amide hydrolase 1	Homo sapiens (human)
phospholipid binding	Fatty-acid amide hydrolase 1	Homo sapiens (human)
fatty acid amide hydrolase activity	Fatty-acid amide hydrolase 1	Homo sapiens (human)
identical protein binding	Fatty-acid amide hydrolase 1	Homo sapiens (human)
acylglycerol lipase activity	Fatty-acid amide hydrolase 1	Homo sapiens (human)
amidase activity	Fatty-acid amide hydrolase 1	Homo sapiens (human)
monoatomic ion channel activity	Potassium channel subfamily K member 3	Homo sapiens (human)
open rectifier potassium channel activity	Potassium channel subfamily K member 3	Homo sapiens (human)
potassium channel activity	Potassium channel subfamily K member 3	Homo sapiens (human)
potassium ion leak channel activity	Potassium channel subfamily K member 3	Homo sapiens (human)
S100 protein binding	Potassium channel subfamily K member 3	Homo sapiens (human)
outward rectifier potassium channel activity	Potassium channel subfamily K member 3	Homo sapiens (human)
iron ion binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
calcium ion binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
protein binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipid binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
linoleate 13S-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
arachidonate 8(S)-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
arachidonate 15-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
linoleate 9S-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
cannabinoid receptor activity	Cannabinoid receptor 1	Homo sapiens (human)
protein binding	Cannabinoid receptor 1	Homo sapiens (human)
identical protein binding	Cannabinoid receptor 1	Homo sapiens (human)
G protein-coupled receptor activity	Cannabinoid receptor 1	Homo sapiens (human)
protein binding	Cannabinoid receptor 2	Homo sapiens (human)
cannabinoid receptor activity	Cannabinoid receptor 2	Homo sapiens (human)
protein binding	Corticotropin-releasing factor receptor 2	Homo sapiens (human)
peptide hormone binding	Corticotropin-releasing factor receptor 2	Homo sapiens (human)
corticotrophin-releasing factor receptor activity	Corticotropin-releasing factor receptor 2	Homo sapiens (human)
G protein-coupled peptide receptor activity	Corticotropin-releasing factor receptor 2	Homo sapiens (human)
corticotropin-releasing hormone receptor activity	Corticotropin-releasing factor receptor 2	Homo sapiens (human)
iron ion binding	Lanosterol 14-alpha demethylase	Homo sapiens (human)
sterol 14-demethylase activity	Lanosterol 14-alpha demethylase	Homo sapiens (human)
heme binding	Lanosterol 14-alpha demethylase	Homo sapiens (human)
oxidoreductase activity	Lanosterol 14-alpha demethylase	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Lanosterol 14-alpha demethylase	Homo sapiens (human)
transmembrane signaling receptor activity	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
extracellular ligand-gated monoatomic ion channel activity	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
voltage-gated calcium channel activity	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
calcium channel activity	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
protein binding	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
calmodulin binding	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
ATP binding	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
intracellularly gated calcium channel activity	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
chloride channel regulator activity	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
phosphatidylinositol binding	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
identical protein binding	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
metal ion binding	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
phosphoprotein binding	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
temperature-gated ion channel activity	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
endoplasmic reticulum membrane	Fatty-acid amide hydrolase 1	Homo sapiens (human)
cytoskeleton	Fatty-acid amide hydrolase 1	Homo sapiens (human)
organelle membrane	Fatty-acid amide hydrolase 1	Homo sapiens (human)
plasma membrane	Potassium channel subfamily K member 3	Homo sapiens (human)
synapse	Potassium channel subfamily K member 3	Homo sapiens (human)
plasma membrane	Potassium channel subfamily K member 3	Homo sapiens (human)
nucleus	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
cytosol	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
cytoskeleton	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
plasma membrane	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
adherens junction	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
focal adhesion	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
membrane	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
extracellular exosome	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
plasma membrane	Glutamate receptor 1	Rattus norvegicus (Norway rat)
plasma membrane	Glutamate receptor 2	Rattus norvegicus (Norway rat)
mitochondrial outer membrane	Cannabinoid receptor 1	Homo sapiens (human)
plasma membrane	Cannabinoid receptor 1	Homo sapiens (human)
actin cytoskeleton	Cannabinoid receptor 1	Homo sapiens (human)
growth cone	Cannabinoid receptor 1	Homo sapiens (human)
presynaptic membrane	Cannabinoid receptor 1	Homo sapiens (human)
membrane raft	Cannabinoid receptor 1	Homo sapiens (human)
glutamatergic synapse	Cannabinoid receptor 1	Homo sapiens (human)
GABA-ergic synapse	Cannabinoid receptor 1	Homo sapiens (human)
plasma membrane	Cannabinoid receptor 1	Homo sapiens (human)
cytoplasm	Cannabinoid receptor 1	Homo sapiens (human)
plasma membrane	Cannabinoid receptor 2	Homo sapiens (human)
dendrite	Cannabinoid receptor 2	Homo sapiens (human)
extrinsic component of cytoplasmic side of plasma membrane	Cannabinoid receptor 2	Homo sapiens (human)
perikaryon	Cannabinoid receptor 2	Homo sapiens (human)
endoplasmic reticulum	Cannabinoid receptor 2	Homo sapiens (human)
plasma membrane	Cannabinoid receptor 2	Homo sapiens (human)
cytoplasm	Cannabinoid receptor 2	Homo sapiens (human)
plasma membrane	Corticotropin-releasing factor receptor 2	Homo sapiens (human)
axon terminus	Corticotropin-releasing factor receptor 2	Homo sapiens (human)
plasma membrane	Corticotropin-releasing factor receptor 2	Homo sapiens (human)
dendrite	Corticotropin-releasing factor receptor 2	Homo sapiens (human)
endoplasmic reticulum membrane	Lanosterol 14-alpha demethylase	Homo sapiens (human)
membrane	Lanosterol 14-alpha demethylase	Homo sapiens (human)
plasma membrane	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
external side of plasma membrane	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
membrane	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
dendritic spine membrane	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
neuronal cell body	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
postsynaptic membrane	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
plasma membrane	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID1069535	AUC in rat plasma at 3 mg/kg, po by LC/MS/MS analysis	2014	Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4	Design, synthesis, and biological evaluation of a series of piperazine ureas as fatty acid amide hydrolase inhibitors.
AID1616997	Antiallergic activity in rat RBL2H3 cells assessed as inhibition of DNP-HSA-mediated degranulation by measuring decrease in beta-hexosaminidase activity preincubated for 30 mins followed by DNP-HSA stimulation and measured after 30 mins by 4-nitrophenyl 2	2019	Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21	Structure-Activity Relationships of Fish Oil Derivatives with Antiallergic Activity in Vitro and in Vivo.
AID109901	Effective concentration that causes twitch inhibition in a mouse vas deferens assay	1997	Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22	Synthesis and pharmacological comparison of dimethylheptyl and pentyl analogs of anandamide.
AID49857	Compound was evaluated for its binding affinity for mouse spleen Cannabinoid receptor 2	1996	Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22	Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand.
AID1386800	Agonist activity at rat CB1 receptor expressed in HEK293 cells assessed as inhibition of forskolin-induced cAMP accumulation incubated for 30 mins	2018	Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19	( R)- N-(1-Methyl-2-hydroxyethyl)-13-( S)-methyl-arachidonamide (AMG315): A Novel Chiral Potent Endocannabinoid Ligand with Stability to Metabolizing Enzymes.
AID238320	Binding affinity for cannabinoid receptor 1	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications.
AID1069545	Cmax in rat brain at 0.3 mg/kg, po by LC/MS/MS analysis	2014	Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4	Design, synthesis, and biological evaluation of a series of piperazine ureas as fatty acid amide hydrolase inhibitors.
AID49141	Binding affinity for the cannabinoid receptor in the presence of phenylmethanesulfonyl fluoride (PMSF) was determined in rat fore brain membranes	1994	Journal of medicinal chemistry, Jun-10, Volume: 37, Issue:12	(R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability.
AID1069538	Cmax in rat plasma at 3 mg/kg, po by LC/MS/MS analysis	2014	Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4	Design, synthesis, and biological evaluation of a series of piperazine ureas as fatty acid amide hydrolase inhibitors.
AID49476	Maximal response of cannabinoid receptor to compound was evaluated using [35S]GTP-gamma-S-binding studies	2004	Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12	Synthesis and CB1 receptor activities of novel arachidonyl alcohol derivatives.
AID49472	Cannabinoid receptor 1 dependent activity of compound was evaluated by using [35S]GTP-gamma-S-binding studies	2004	Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12	Synthesis and CB1 receptor activities of novel arachidonyl alcohol derivatives.
AID49332	Binding affinity towards Cannabinoid receptor 1 was determined using [3H]-CP- cannabinoid as radioligand with mouse brain membrane in the presence of PMSF	2003	Bioorganic & medicinal chemistry letters, Oct-06, Volume: 13, Issue:19	Arachidonylsulfonyl derivatives as cannabinoid CB1 receptor and fatty acid amide hydrolase inhibitors.
AID690265	Activity of human recombinant FAAH assessed as compound hydrolysis at 10'-5 M after 90 mins by HPLC/MS analysis	2011	Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19	SAR and LC/MS studies of β-lactamic inhibitors of human fatty acid amide hydrolase (hFAAH): evidence of a nonhydrolytic process.
AID353801	Agonist activity at CB1 receptor expressed in mouse brain membrane by [35S]GTPgammaS binding assay relative to WIN-55212-2	2009	Journal of medicinal chemistry, May-14, Volume: 52, Issue:9	Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes.
AID289135	Displacement of [3H]CP-55940 from human CB1 receptor expressed in HEK cells	2007	Bioorganic & medicinal chemistry, Aug-15, Volume: 15, Issue:16	Design, synthesis, binding, and molecular modeling studies of new potent ligands of cannabinoid receptors.
AID725619	Agonist activity at TRPV1 receptor (unknown origin)	2013	Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5	Novel acylethanolamide derivatives that modulate body weight through enhancement of hypothalamic pro-opiomelanocortin (POMC) and/or decreased neuropeptide Y (NPY).
AID679534	TP_TRANSPORTER: inhibition of PAH uptake (Anandamide: 100 uM) in OAT1-expressing HeLa cells	1999	The American journal of physiology, 02, Volume: 276, Issue:2	Cloning of the human kidney PAH transporter: narrow substrate specificity and regulation by protein kinase C.
AID690266	Activity of human recombinant FAAH assessed as compound hydrolysis at 10'-5 M after 90 mins by HPLC/MS analysis in presence of URB-597	2011	Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19	SAR and LC/MS studies of β-lactamic inhibitors of human fatty acid amide hydrolase (hFAAH): evidence of a nonhydrolytic process.
AID262877	Binding affinity to human recombinant CB1 receptor expressed in COS cells	2006	Journal of medicinal chemistry, Apr-06, Volume: 49, Issue:7	Oxyhomologues of anandamide and related endolipids: chemoselective synthesis and biological activity.
AID353800	Agonist activity at CB1 receptor expressed in mouse brain membrane by [35S]GTPgammaS binding assay	2009	Journal of medicinal chemistry, May-14, Volume: 52, Issue:9	Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes.
AID1069548	AUC in rat plasma at 0.03 mg/kg, po by LC/MS/MS analysis	2014	Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4	Design, synthesis, and biological evaluation of a series of piperazine ureas as fatty acid amide hydrolase inhibitors.
AID183630	Tested for percent immobility time in the ring test, expressed as % of control (p<0.01)	2001	Bioorganic & medicinal chemistry letters, Feb-26, Volume: 11, Issue:4	Synthesis and biological evaluation of novel amides of polyunsaturated fatty acids with dopamine.
AID268443	Displacement of [3H]CP-55-940 from human recombinant CB1 receptor in COS cells	2006	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 16, Issue:14	Synthesis of a potential photoactivatable anandamide analog.
AID38671	The compound was tested for hydrolysis by rat brain microsomal anandamide amidohydrolase (AAH) in the presence of OMe-delta8-THC (30 uM).	1999	Journal of medicinal chemistry, Mar-11, Volume: 42, Issue:5	Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase.
AID232844	Ratio of Vmax value and Km value of the compound.	1999	Journal of medicinal chemistry, Mar-11, Volume: 42, Issue:5	Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase.
AID196759	Inhibition of rat glial cell gap junction at the concentration of 50 uM	1999	Bioorganic & medicinal chemistry letters, Apr-19, Volume: 9, Issue:8	Arachidonic acid amide inhibitors of gap junction cell-cell communication.
AID195482	Tested for decrease in rectal temperature 10 min after ip injection	2001	Bioorganic & medicinal chemistry letters, Feb-26, Volume: 11, Issue:4	Synthesis and biological evaluation of novel amides of polyunsaturated fatty acids with dopamine.
AID49658	Binding affinity towards cannabinoid receptor 1 from rat forebrain membranes in the absence of phenylmethanesulfonylfluoride (PMSF) using 0.8 nM [3H]CP-55940 as radioligand	1998	Journal of medicinal chemistry, Dec-31, Volume: 41, Issue:27	Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability.
AID296285	Antinociceptive effect in rat at 10 mg/kg, iv by thermal escape test	2007	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12	Novel inhibitors of fatty acid amide hydrolase.
AID38683	V max value for hydrolysis by rat brain microsomal anandamide amidohydrolase (AAH).	1999	Journal of medicinal chemistry, Mar-11, Volume: 42, Issue:5	Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase.
AID356566	Activity at FAAH in mouse N18TG2 cell membranes	2003	Journal of natural products, Oct, Volume: 66, Issue:10	Semiplenamides A-G, fatty acid amides from a Papua New Guinea collection of the marine cyanobacterium Lyngbya semiplena.
AID49470	Binding affinity for Cannabinoid receptor 1 in presence of phenylmethylsulfonyl fluoride (PMSF)	1997	Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22	Potent anandamide analogs: the effect of changing the length and branching of the end pentyl chain.
AID49326	Ability to displace [3H]CP-55940 from the membranes prepared from HEK cell line with W4 64(256)A mutant Cannabinoid receptor 1; Not determined	2003	Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24	An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/inverse agonist binding region.
AID49666	Displacement of [3H]CP-55940 binding to Cannabinoid receptor 1 in rat brain membranes	1998	Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22	Derivation of a pharmacophore model for anandamide using constrained conformational searching and comparative molecular field analysis.
AID1287160	Displacement of [3H]CP55940 from CB1 receptor in Wistar rat brain incubated for 60 mins by radioactive filter binding assay	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	Tricyclic pyrazoles. Part 8. Synthesis, biological evaluation and modelling of tricyclic pyrazole carboxamides as potential CB2 receptor ligands with antagonist/inverse agonist properties.
AID114296	Antinociception as measured from the tail - flick response (TF), in mice	1997	Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22	Potent anandamide analogs: the effect of changing the length and branching of the end pentyl chain.
AID49301	Ability to displace [3H]CP-55940 from the membranes prepared from HEK cell line with W5 43(280)A mutant Cannabinoid receptor 1 at 5 uM	2003	Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24	An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/inverse agonist binding region.
AID49854	Binding affinity towards Cannabinoid receptor 2 from mouse spleen membranes using 0.8 nM [3H]CP-55940 as radioligand	1998	Journal of medicinal chemistry, Dec-31, Volume: 41, Issue:27	Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability.
AID71609	Inhibition of Fatty-acid amide hydrolase (FAAH) activity in human lymphoma U937 cell using [3H]AEA as substrate in the 0-25 uM conc	2002	Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17	Oxygenated metabolites of anandamide and 2-arachidonoylglycerol: conformational analysis and interaction with cannabinoid receptors, membrane transporter, and fatty acid amide hydrolase.
AID1350513	Induction of apoptosis in human MG63 cells at 12.5 by Annexin V-FITC/propidium iodide double staining based flow cytometry relative to control	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Antitumorigenic Properties of Omega-3 Endocannabinoid Epoxides.
AID38669	The compound was tested for hydrolysis by rat brain microsomal anandamide amidohydrolase (AAH) in the presence of CP-55244 (30 uM).	1999	Journal of medicinal chemistry, Mar-11, Volume: 42, Issue:5	Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase.
AID1363876	Binding affinity to CB1R (unknown origin)	2017	Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1	Therapeutic Potential of Fatty Acid Amide Hydrolase, Monoacylglycerol Lipase, and N-Acylethanolamine Acid Amidase Inhibitors.
AID143900	Inhibition of N-arachidonoylethanolamine transporter (AEA) activity in human lymphoma U937 cell using [3H]AEA as substrate in the 0-1000 nM conc.	2002	Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17	Oxygenated metabolites of anandamide and 2-arachidonoylglycerol: conformational analysis and interaction with cannabinoid receptors, membrane transporter, and fatty acid amide hydrolase.
AID1069547	Tmax in rat brain at 0.03 mg/kg, po by LC/MS/MS analysis	2014	Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4	Design, synthesis, and biological evaluation of a series of piperazine ureas as fatty acid amide hydrolase inhibitors.
AID415512	Binding affinity to human recombinant CB1 receptor expressed in african green monkey COS cells by radioligand binding assay	2009	Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8	New resorcinol-anandamide "hybrids" as potent cannabinoid receptor ligands endowed with antinociceptive activity in vivo.
AID1630815	Binding affinity to CB2 receptor (unknown origin)
AID49664	Displacement of [3H]CP-55940 from Cannabinoid receptor 1 of rat forebrain membranes	1996	Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22	Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand.
AID112196	The compound tested in vivo for hypothermia as changes in rectal temperature (RT)	1999	Journal of medicinal chemistry, Jun-03, Volume: 42, Issue:11	Unique analogues of anandamide: arachidonyl ethers and carbamates and norarachidonyl carbamates and ureas.
AID257800	Displacement of [35S]GTP-gamma-S from rat cerebellar CB1 receptor	2006	Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2	3D-QSAR studies on cannabinoid CB1 receptor agonists: G-protein activation as biological data.
AID49142	Binding affinity towards cannabinoid receptor using [3H]CP-55940 as radioligand in rat brain membrane	1997	Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22	Synthesis and pharmacological comparison of dimethylheptyl and pentyl analogs of anandamide.
AID546198	Antimicrobial activity against Hartmannella vermiformis assessed as growth inhibition at 10 ug/ml after 3 days by hemocytometer relative to control	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Endocannabinoids inhibit the growth of free-living amoebae.
AID1069544	Cmax in rat plasma at 0.3 mg/kg, po by LC/MS/MS analysis	2014	Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4	Design, synthesis, and biological evaluation of a series of piperazine ureas as fatty acid amide hydrolase inhibitors.
AID1386809	Antiallodynic activity in CD1 mouse model of CFA-induced inflammatory pain assessed as increase in CFA-reduced mechanical paw withdrawal threshold at 20 mg/kg, ip measured at 10 mins post injection	2018	Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19	( R)- N-(1-Methyl-2-hydroxyethyl)-13-( S)-methyl-arachidonamide (AMG315): A Novel Chiral Potent Endocannabinoid Ligand with Stability to Metabolizing Enzymes.
AID1069539	Cmax in rat brain at 3 mg/kg, po by LC/MS/MS analysis	2014	Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4	Design, synthesis, and biological evaluation of a series of piperazine ureas as fatty acid amide hydrolase inhibitors.
AID546188	Antimicrobial activity against Acanthamoeba castellanii assessed as growth inhibition at 10 ug/ml upto 3 days by hemocytometer	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Endocannabinoids inhibit the growth of free-living amoebae.
AID1386801	Agonist activity at rat CB1 receptor expressed in HEK293 cells assessed as inhibition of forskolin-induced cAMP accumulation incubated for 30 mins relative to 500 nM CP-55,940	2018	Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19	( R)- N-(1-Methyl-2-hydroxyethyl)-13-( S)-methyl-arachidonamide (AMG315): A Novel Chiral Potent Endocannabinoid Ligand with Stability to Metabolizing Enzymes.
AID49505	Binding affinity towards Cannabinoid receptor 1 in rat forebrain membranes using [3H]CP-55940 as radioligand	2003	Bioorganic & medicinal chemistry letters, Jun-16, Volume: 13, Issue:12	Hemisynthesis and preliminary evaluation of novel endocannabinoid analogues.
AID690268	Activity of mouse liver homogenate FAAH assessed as compound hydrolysis at 10'-5 M after 90 mins by HPLC/MS analysis in presence of PF-750	2011	Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19	SAR and LC/MS studies of β-lactamic inhibitors of human fatty acid amide hydrolase (hFAAH): evidence of a nonhydrolytic process.
AID1386810	Antiallodynic activity in CD1 mouse model of CFA-induced inflammatory pain assessed as increase in CFA-reduced mechanical paw withdrawal threshold at 20 mg/kg, ip measured at 30 mins post injection	2018	Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19	( R)- N-(1-Methyl-2-hydroxyethyl)-13-( S)-methyl-arachidonamide (AMG315): A Novel Chiral Potent Endocannabinoid Ligand with Stability to Metabolizing Enzymes.
AID49300	Ability to displace [3H]CP-55940 from the membranes prepared from HEK cell line with F3.36 (201)A mutant Cannabinoid receptor 1	2003	Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24	An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/inverse agonist binding region.
AID195483	Tested for decrease in rectal temperature 5 min after ip injection	2001	Bioorganic & medicinal chemistry letters, Feb-26, Volume: 11, Issue:4	Synthesis and biological evaluation of novel amides of polyunsaturated fatty acids with dopamine.
AID387641	Induction of platelet aggregation in New Zealand white rabbit ear vein plasma assessed as LDH activity at 0.36 mM	2008	Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18	Synthesis of all-trans anandamide: a substrate for fatty acid amide hydrolase with dual effects on rabbit platelet activation.
AID322753	Inhibition of human CYP51 expressed in Topp 3 cells by lanosterol demethylase assay	2007	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 35, Issue:3	Three-dimensional quantitative structure-activity relationship analysis of human CYP51 inhibitors.
AID38666	Km value for hydrolysis by rat brain microsomal anandamide amidohydrolase (AAH).	1999	Journal of medicinal chemistry, Mar-11, Volume: 42, Issue:5	Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase.
AID42890	Concentration required to displace 0.4 nM [3H]SR-141,716A from CB1 receptor in rat brain preparations in the presence of 0.1 mM phenylmethyl sulfonyl fluoride	2001	Bioorganic & medicinal chemistry letters, Feb-26, Volume: 11, Issue:4	Synthesis and biological evaluation of novel amides of polyunsaturated fatty acids with dopamine.
AID38678	The compound was tested for hydrolysis by rat brain microsomal anandamide amidohydrolase (AAH) in the presence of arachidonyl alcohol at concentration 100 uM	1999	Journal of medicinal chemistry, Mar-11, Volume: 42, Issue:5	Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase.
AID38681	The compound was tested for hydrolysis by rat brain microsomal anandamide amidohydrolase (AAH) in the presence of arachidonyl aldehyde at concentration 30 uM	1999	Journal of medicinal chemistry, Mar-11, Volume: 42, Issue:5	Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase.
AID112198	The compound tested in vivo for inhibition of spontaneous activity(SA)	1999	Journal of medicinal chemistry, Jun-03, Volume: 42, Issue:11	Unique analogues of anandamide: arachidonyl ethers and carbamates and norarachidonyl carbamates and ureas.
AID1069534	AUC in rat brain at 3 mg/kg, po by LC/MS/MS analysis	2014	Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4	Design, synthesis, and biological evaluation of a series of piperazine ureas as fatty acid amide hydrolase inhibitors.
AID49851	Binding affinity towards cloned human cannabinoid receptor 2	2000	Journal of medicinal chemistry, Jun-15, Volume: 43, Issue:12	A 3D-QSAR study on the structural requirements for binding to CB(1) and CB(2) cannabinoid receptors.
AID113697	Inhibition of ring immobility(RI) in mice was determined	1997	Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22	Synthesis and pharmacological comparison of dimethylheptyl and pentyl analogs of anandamide.
AID114230	Ring immobility (RI) in mice	1997	Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22	Potent anandamide analogs: the effect of changing the length and branching of the end pentyl chain.
AID1525557	Inhibition of human TASK1 expressed in African green monkey COS7 cells by whole cell patch clamp assay	2019	Journal of medicinal chemistry, 11-27, Volume: 62, Issue:22	TASK Channels Pharmacology: New Challenges in Drug Design.
AID346364	Displacement of [3H]CP-55-940 from human recombinant CB2 receptor expressed in COS cells	2009	Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4	Total synthesis of photoactivatable or fluorescent anandamide probes: novel bioactive compounds with angiogenic activity.
AID1069536	Tmax in rat brain at 3 mg/kg, po by LC/MS/MS analysis	2014	Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4	Design, synthesis, and biological evaluation of a series of piperazine ureas as fatty acid amide hydrolase inhibitors.
AID387645	Inhibition of FAAH in New Zealand white rabbit ear vein platelets assessed as [3H]anandamide hydrolysis at 1.5 uM	2008	Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18	Synthesis of all-trans anandamide: a substrate for fatty acid amide hydrolase with dual effects on rabbit platelet activation.
AID49671	The compound was tested for Ki value against rat whole brain P2 membrane preparation in absence of enzyme inhibitor PMSF	1999	Journal of medicinal chemistry, Jun-03, Volume: 42, Issue:11	Unique analogues of anandamide: arachidonyl ethers and carbamates and norarachidonyl carbamates and ureas.
AID38673	The compound was tested for hydrolysis by rat brain microsomal anandamide amidohydrolase (AAH) in the presence of WIN-55212-2 (30 uM).	1999	Journal of medicinal chemistry, Mar-11, Volume: 42, Issue:5	Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase.
AID1069541	Tmax in rat brain at 0.3 mg/kg, po by LC/MS/MS analysis	2014	Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4	Design, synthesis, and biological evaluation of a series of piperazine ureas as fatty acid amide hydrolase inhibitors.
AID1350512	Induction of apoptosis in human 143B cells at 12.5 by Annexin V-FITC/propidium iodide double staining based flow cytometry relative to control	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Antitumorigenic Properties of Omega-3 Endocannabinoid Epoxides.
AID113393	Maximal degree of inhibition of electrically evoked contractions in a mouse vas deferens assay	1997	Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22	Synthesis and pharmacological comparison of dimethylheptyl and pentyl analogs of anandamide.
AID49299	Ability to displace [3H]CP-55940 from the membranes prepared from HEK cell line with F3.25 (190)A mutant Cannabinoid receptor 1	2003	Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24	An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/inverse agonist binding region.
AID49842	Binding affinity to human CB2 cannabinoid receptor using [3H]CP-55940 in HEK293 EBNA transfected cells	2001	Journal of medicinal chemistry, Dec-20, Volume: 44, Issue:26	Design, synthesis and biological evaluation of novel arachidonic acid derivatives as highly potent and selective endocannabinoid transporter inhibitors.
AID546192	Antimicrobial activity against Hartmannella vermiformis assessed as growth inhibition at 2 ug/ml after 3 days by hemocytometer	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Endocannabinoids inhibit the growth of free-living amoebae.
AID218330	Binding affinity to vanilloid VR1 receptor using [3H]resiniferatoxin ([3H]-RTX) in rat spinal cord membranes	2001	Journal of medicinal chemistry, Dec-20, Volume: 44, Issue:26	Design, synthesis and biological evaluation of novel arachidonic acid derivatives as highly potent and selective endocannabinoid transporter inhibitors.
AID49667	Displacement of [3H]CP-55940 from rat forebrain membrane which expresses Cannabinoid receptor 1 in the presence of PMSF	2002	Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17	Oxygenated metabolites of anandamide and 2-arachidonoylglycerol: conformational analysis and interaction with cannabinoid receptors, membrane transporter, and fatty acid amide hydrolase.
AID49674	Tested for binding affinity to Cannabinoid receptor 1	1999	Journal of medicinal chemistry, Mar-11, Volume: 42, Issue:5	Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase.
AID282918	Displacement of [3H]CP-55940 from human CB1 receptor expressed in COS cells	2005	Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23	Design, synthesis, and binding studies of new potent ligands of cannabinoid receptors.
AID49325	Binding affinity towards cloned human Cannabinoid receptor 1	2000	Journal of medicinal chemistry, Jun-15, Volume: 43, Issue:12	A 3D-QSAR study on the structural requirements for binding to CB(1) and CB(2) cannabinoid receptors.
AID1069549	Cmax in rat brain at 0.03 mg/kg, po by LC/MS/MS analysis	2014	Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4	Design, synthesis, and biological evaluation of a series of piperazine ureas as fatty acid amide hydrolase inhibitors.
AID49331	Binding affinity towards Cannabinoid receptor 1 was determined using [3H]-CP- cannabinoid as radioligand with mouse brain membrane	2003	Bioorganic & medicinal chemistry letters, Oct-06, Volume: 13, Issue:19	Arachidonylsulfonyl derivatives as cannabinoid CB1 receptor and fatty acid amide hydrolase inhibitors.
AID49864	Displacement of [3H]CP-55940 from rat forebrain membrane which expresses Cannabinoid receptor 2 in the presence of PMSF	2002	Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17	Oxygenated metabolites of anandamide and 2-arachidonoylglycerol: conformational analysis and interaction with cannabinoid receptors, membrane transporter, and fatty acid amide hydrolase.
AID546203	Antimicrobial activity against Acanthamoeba castellanii assessed as decrease in viable cell concentration at 20 ug/ml after 3 days by hemocytometer	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Endocannabinoids inhibit the growth of free-living amoebae.
AID1069542	AUC in rat plasma at 0.3 mg/kg, po by LC/MS/MS analysis	2014	Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4	Design, synthesis, and biological evaluation of a series of piperazine ureas as fatty acid amide hydrolase inhibitors.
AID1069550	Tmax in rat plasma at 0.03 mg/kg, po by LC/MS/MS analysis	2014	Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4	Design, synthesis, and biological evaluation of a series of piperazine ureas as fatty acid amide hydrolase inhibitors.
AID387967	Antiproliferative activity against human WI38 cells at 10 uM after 48 hrs relative to control	2008	Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22	Acylamido analogs of endocannabinoids selectively inhibit cancer cell proliferation.
AID38672	The compound was tested for hydrolysis by rat brain microsomal anandamide amidohydrolase (AAH) in the presence of SR-141716A (30 uM).	1999	Journal of medicinal chemistry, Mar-11, Volume: 42, Issue:5	Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase.
AID1069551	Cmax in rat plasma at 0.03 mg/kg, po by LC/MS/MS analysis	2014	Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4	Design, synthesis, and biological evaluation of a series of piperazine ureas as fatty acid amide hydrolase inhibitors.
AID546189	Antimicrobial activity against Hartmannella vermiformis assessed as growth inhibition at 10 ug/ml upto 3 days by hemocytometer	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Endocannabinoids inhibit the growth of free-living amoebae.
AID48996	Ability to displace [3H]HU-243 binding to cannabinoid receptor in synaptosomal membrane	1993	Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20	Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor.
AID38679	The compound was tested for hydrolysis by rat brain microsomal anandamide amidohydrolase (AAH) in the presence of arachidonyl alcohol at concentration 30 uM	1999	Journal of medicinal chemistry, Mar-11, Volume: 42, Issue:5	Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase.
AID113712	Inhibition of tail flick response(TK) in mice was determined	1997	Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22	Synthesis and pharmacological comparison of dimethylheptyl and pentyl analogs of anandamide.
AID38680	The compound was tested for hydrolysis by rat brain microsomal anandamide amidohydrolase (AAH) in the presence of arachidonyl aldehyde at concentration 100 uM	1999	Journal of medicinal chemistry, Mar-11, Volume: 42, Issue:5	Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase.
AID49469	Binding affinity for Cannabinoid receptor 1 in absence of phenylmethylsulfonyl fluoride (PMSF)	1997	Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22	Potent anandamide analogs: the effect of changing the length and branching of the end pentyl chain.
AID690267	Activity of human recombinant FAAH assessed as compound hydrolysis at 10'-5 M after 90 mins by HPLC/MS analysis in presence of PF-750	2011	Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19	SAR and LC/MS studies of β-lactamic inhibitors of human fatty acid amide hydrolase (hFAAH): evidence of a nonhydrolytic process.
AID38675	The compound was tested for hydrolysis by rat brain microsomal anandamide amidohydrolase (AAH) in the presence of anandamine at concentration 30 uM	1999	Journal of medicinal chemistry, Mar-11, Volume: 42, Issue:5	Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase.
AID690264	Activity of mouse liver homogenate FAAH assessed as compound hydrolysis at 10'-5 M after 90 mins by HPLC/MS analysis in presence of URB-597	2011	Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19	SAR and LC/MS studies of β-lactamic inhibitors of human fatty acid amide hydrolase (hFAAH): evidence of a nonhydrolytic process.
AID1307729	Activation of bovine TREK1 expressed in AZT cells assessed as reduction in channel currents	2016	Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11	Perspectives on the Two-Pore Domain Potassium Channel TREK-1 (TWIK-Related K(+) Channel 1). A Novel Therapeutic Target?
AID15318	Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 10 (mg/kg) intravenous dose in 6 mice	1994	Journal of medicinal chemistry, Jun-10, Volume: 37, Issue:12	(R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability.
AID193980	Tested to induce analgesia in hot plate test, expressed as percent of latency time	2001	Bioorganic & medicinal chemistry letters, Feb-26, Volume: 11, Issue:4	Synthesis and biological evaluation of novel amides of polyunsaturated fatty acids with dopamine.
AID353802	Displacement of [3H]CP-55940 from human recombinant CB1 receptor expressed in HEK293 cell membrane	2009	Journal of medicinal chemistry, May-14, Volume: 52, Issue:9	Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes.
AID346660	Inhibition of FAAH	2008	Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23	Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors.
AID546191	Antimicrobial activity against Acanthamoeba castellanii assessed as growth inhibition at 2 ug/ml after 3 days by hemocytometer	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Endocannabinoids inhibit the growth of free-living amoebae.
AID238432	Binding affinity for human cannabinoid receptor 1	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications.
AID1069540	AUC in rat brain at 0.3 mg/kg, po by LC/MS/MS analysis	2014	Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4	Design, synthesis, and biological evaluation of a series of piperazine ureas as fatty acid amide hydrolase inhibitors.
AID1069537	Tmax in rat plasma at 3 mg/kg, po by LC/MS/MS analysis	2014	Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4	Design, synthesis, and biological evaluation of a series of piperazine ureas as fatty acid amide hydrolase inhibitors.
AID38677	The compound was tested for hydrolysis by rat brain microsomal anandamide amidohydrolase (AAH) in the presence of arachidonyl acid at concentration 30 uM	1999	Journal of medicinal chemistry, Mar-11, Volume: 42, Issue:5	Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase.
AID114200	Effective dose required to inhibit spontaneous locomotor activity in mice	1996	Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2	Structure-activity analysis of anandamide analogs: relationship to a cannabinoid pharmacophore.
AID22955	Mean difference between tail flick latency measured at -30 min and tail flick latency measured at 12 min calculated as percent maximum possible effect at 6.25 (mg/kg) intravenous dose in 6 mice	1994	Journal of medicinal chemistry, Jun-10, Volume: 37, Issue:12	(R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability.
AID1127506	Selectivity ratio of Ki for human CB2 receptor to Ki for human CB1 receptor	2013	Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21	Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.
AID1386802	Stability assessed as half life for rat FAAH-mediated compound hydrolysis by LC-MS/MS analysis	2018	Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19	( R)- N-(1-Methyl-2-hydroxyethyl)-13-( S)-methyl-arachidonamide (AMG315): A Novel Chiral Potent Endocannabinoid Ligand with Stability to Metabolizing Enzymes.
AID112195	The compound tested in vivo for antinociception as measured by tail flick response(TF)	1999	Journal of medicinal chemistry, Jun-03, Volume: 42, Issue:11	Unique analogues of anandamide: arachidonyl ethers and carbamates and norarachidonyl carbamates and ureas.
AID1069546	AUC in rat brain at 0.03 mg/kg, po by LC/MS/MS analysis	2014	Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4	Design, synthesis, and biological evaluation of a series of piperazine ureas as fatty acid amide hydrolase inhibitors.
AID262878	Binding affinity to human recombinant CB2 receptor expressed in COS cells	2006	Journal of medicinal chemistry, Apr-06, Volume: 49, Issue:7	Oxyhomologues of anandamide and related endolipids: chemoselective synthesis and biological activity.
AID1400244	Antagonist activity at recombinant rat TRPV2 expressed in HEK293 cells assessed as inhibition of CBD-induced Ca2+ levels preincubated for 5 mins followed by agonist addition by Fuo-4-AM based spectrofluorimetry	2018	Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18	Elongation of the Hydrophobic Chain as a Molecular Switch: Discovery of Capsaicin Derivatives and Endogenous Lipids as Potent Transient Receptor Potential Vanilloid Channel 2 Antagonists.
AID546199	Antimicrobial activity against Willaertia magna c2c Maky ATCC PTA-7824 assessed as growth inhibition at 10 ug/ml after 3 days by hemocytometer relative to control	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Endocannabinoids inhibit the growth of free-living amoebae.
AID238321	Binding affinity for cannabinoid receptor 2	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications.
AID49322	Compound was evaluated for its binding affinity towards Cannabinoid receptor 1 [Inactive form(R) of CB1 receptor]	2002	Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17	Conformational memories and the endocannabinoid binding site at the cannabinoid CB1 receptor.
AID353804	Agonist activity at human recombinant TRPV1 expressed in HEK293 cells assessed as increase in intracellular calcium level	2009	Journal of medicinal chemistry, May-14, Volume: 52, Issue:9	Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes.
AID19735	Mean number of squares entered(counts) over a 5 min period after placement in the center of a walled arena marked out in 16 squares of equal size at 6.25 (mg/kg) intravenous dose in 6 mice	1994	Journal of medicinal chemistry, Jun-10, Volume: 37, Issue:12	(R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability.
AID49303	Ability to displace [3H]CP-55940 from the membranes prepared from HEK cell line with W6 48(357)A mutant in Cannabinoid receptor 1	2003	Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24	An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/inverse agonist binding region.
AID38667	The compound was tested for hydrolysis by rat brain microsomal anandamide amidohydrolase (AAH) in the presence of (-)-11-OH-DMH-delta-8-THC (30 uM).	1999	Journal of medicinal chemistry, Mar-11, Volume: 42, Issue:5	Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase.
AID546190	Antimicrobial activity against Willaertia magna c2c Maky ATCC PTA-7824 assessed as growth inhibition at 10 ug/ml upto 3 days by hemocytometer	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Endocannabinoids inhibit the growth of free-living amoebae.
AID20507	Mean percentage time spend immobile on ring between 5 and 10 min at 6.25 (mg/kg) intravenous dose in 6 mice	1994	Journal of medicinal chemistry, Jun-10, Volume: 37, Issue:12	(R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability.
AID1386796	Displacement of [3H]CP-55,940 from CB1 receptor in rat brain membranes in absence of FAAH inhibitor PMSF by radioligand binding assay	2018	Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19	( R)- N-(1-Methyl-2-hydroxyethyl)-13-( S)-methyl-arachidonamide (AMG315): A Novel Chiral Potent Endocannabinoid Ligand with Stability to Metabolizing Enzymes.
AID100385	Evaluated for its growth enhancement or mitogenic activity using LNCaP prostate cultures	2000	Bioorganic & medicinal chemistry letters, Sep-04, Volume: 10, Issue:17	5-HETE congeners as modulators of cell proliferation.
AID19736	Mean number of squares entered(counts) over a 5 min period after placement in the center of a walled arena marked out in 16 squares of equal size at 10 (mg/kg) intravenous dose in 6 mice	1994	Journal of medicinal chemistry, Jun-10, Volume: 37, Issue:12	(R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability.
AID268444	Displacement of [3H]CP-55-940 from human recombinant CB2 receptor in COS cells	2006	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 16, Issue:14	Synthesis of a potential photoactivatable anandamide analog.
AID49503	Binding affinity to CB1 cannabinoid receptor using [3H]WIN-55212-2 in rat cerebellum membranes	2001	Journal of medicinal chemistry, Dec-20, Volume: 44, Issue:26	Design, synthesis and biological evaluation of novel arachidonic acid derivatives as highly potent and selective endocannabinoid transporter inhibitors.
AID293977	Induction of anti CD3-stimulated T-lymphocyte apoptosis after 48 hrs	2007	Bioorganic & medicinal chemistry, Mar-15, Volume: 15, Issue:6	Synthesis, pharmacological evaluation and electrochemical studies of novel 6-nitro-3,4-methylenedioxyphenyl-N-acylhydrazone derivatives: Discovery of LASSBio-881, a new ligand of cannabinoid receptors.
AID356567	Activity at AMT in rat RBL-2H3 cells	2003	Journal of natural products, Oct, Volume: 66, Issue:10	Semiplenamides A-G, fatty acid amides from a Papua New Guinea collection of the marine cyanobacterium Lyngbya semiplena.
AID1630814	Binding affinity to CB1 receptor (unknown origin)
AID387650	Inhibition of FAAH in New Zealand white rabbit ear vein platelet assessed as [3H]anandamide hydrolysis at 7.5 uM	2008	Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18	Synthesis of all-trans anandamide: a substrate for fatty acid amide hydrolase with dual effects on rabbit platelet activation.
AID1386799	Displacement of [3H]CP-55,940 from human CB2 receptor expressed in HEK293 cell membranes in absence of FAAH inhibitor PMSF by radioligand binding assay	2018	Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19	( R)- N-(1-Methyl-2-hydroxyethyl)-13-( S)-methyl-arachidonamide (AMG315): A Novel Chiral Potent Endocannabinoid Ligand with Stability to Metabolizing Enzymes.
AID38685	Tested for hydrolysis by rat brain microsomal anandamide amidohydrolase (AAH).	1999	Journal of medicinal chemistry, Mar-11, Volume: 42, Issue:5	Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase.
AID1386803	Stability assessed as half life for human FAAH-mediated compound hydrolysis by LC-MS/MS analysis	2018	Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19	( R)- N-(1-Methyl-2-hydroxyethyl)-13-( S)-methyl-arachidonamide (AMG315): A Novel Chiral Potent Endocannabinoid Ligand with Stability to Metabolizing Enzymes.
AID262879	Metabolic stability in rat brain membrane assessed by inhibition of AEA hydrolysis	2006	Journal of medicinal chemistry, Apr-06, Volume: 49, Issue:7	Oxyhomologues of anandamide and related endolipids: chemoselective synthesis and biological activity.
AID500214	Agonist activity at TRPV1	2005	Nature chemical biology, Jul, Volume: 1, Issue:2	Sensing with TRP channels.
AID20505	Mean percentage time spend immobile on ring between 5 and 10 min at 10 (mg/kg) intravenous dose in 6 mice	1994	Journal of medicinal chemistry, Jun-10, Volume: 37, Issue:12	(R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability.
AID49140	Binding affinity for the cannabinoid receptor in the absence of phenylmethanesulfonyl fluoride (PMSF) was determined in rat fore brain membranes	1994	Journal of medicinal chemistry, Jun-10, Volume: 37, Issue:12	(R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability.
AID546196	Antimicrobial activity against Willaertia magna c2c Maky ATCC PTA-7824 assessed as growth inhibition at 5 ug/ml after 3 days by hemocytometer	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Endocannabinoids inhibit the growth of free-living amoebae.
AID112348	Hypothermia as measured from changes in rectal (RT) in mice	1997	Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22	Potent anandamide analogs: the effect of changing the length and branching of the end pentyl chain.
AID356564	Displacement of [3H]SR141716A from CB1 receptor in CD rat brain membranes	2003	Journal of natural products, Oct, Volume: 66, Issue:10	Semiplenamides A-G, fatty acid amides from a Papua New Guinea collection of the marine cyanobacterium Lyngbya semiplena.
AID38674	The compound was tested for hydrolysis by rat brain microsomal anandamide amidohydrolase (AAH) in the presence of anandamine at concentration 100 uM	1999	Journal of medicinal chemistry, Mar-11, Volume: 42, Issue:5	Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase.
AID71618	Relative rate of fatty acid amide hydrolase hydrolysis of compound compared to that of oleamide.	2000	Bioorganic & medicinal chemistry letters, Dec-04, Volume: 10, Issue:23	Fatty acid amide hydrolase substrate specificity.
AID49668	In vitro binding affinity was determined against rat brain Cannabinoid receptor 1	1997	Journal of medicinal chemistry, Feb-28, Volume: 40, Issue:5	Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor.
AID15320	Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 6.25 (mg/kg) intravenous dose in 6 mice	1994	Journal of medicinal chemistry, Jun-10, Volume: 37, Issue:12	(R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability.
AID438799	Inhibition of FAAH in rat brain homogenates assessed as membrane bound [3H]anandamide level at 1 uM relative to control	2009	European journal of medicinal chemistry, Dec, Volume: 44, Issue:12	Synthesis and pharmacological evaluation of sulfamide-based analogues of anandamide.
AID1185844	Displacement of [3H]CP-55,940 from human recombinant CB1 receptor expressed in HEK293 cell membranes	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Structure-affinity relationships and pharmacological characterization of new alkyl-resorcinol cannabinoid receptor ligands: Identification of a dual cannabinoid receptor/TRPA1 channel agonist.
AID1350521	Inhibition of FAAH (unknown origin)	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Antitumorigenic Properties of Omega-3 Endocannabinoid Epoxides.
AID229798	Ratio of Ki at CB1 to Ki at CB2 receptors	2002	Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17	Oxygenated metabolites of anandamide and 2-arachidonoylglycerol: conformational analysis and interaction with cannabinoid receptors, membrane transporter, and fatty acid amide hydrolase.
AID112199	The compound tested in vivo for ring immobility (RI)	1999	Journal of medicinal chemistry, Jun-03, Volume: 42, Issue:11	Unique analogues of anandamide: arachidonyl ethers and carbamates and norarachidonyl carbamates and ureas.
AID546193	Antimicrobial activity against Willaertia magna c2c Maky ATCC PTA-7824 assessed as growth inhibition at 2 ug/ml after 3 days by hemocytometer	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Endocannabinoids inhibit the growth of free-living amoebae.
AID1662648	Displacement of [3H]-CP55940 from human recombinant CB1 receptor expressed in HEK cell membrane	2020	Bioorganic & medicinal chemistry, 06-01, Volume: 28, Issue:11	Synthetic bioactive olivetol-related amides: The influence of the phenolic group in cannabinoid receptor activity.
AID353803	Displacement of [3H]CP-55940 from human recombinant CB2 receptor expressed in HEK293 cell membrane	2009	Journal of medicinal chemistry, May-14, Volume: 52, Issue:9	Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes.
AID49673	The compound was tested for Ki value against rat whole brain P2 membrane preparation in presence of enzyme inhibitor PMSF.	1999	Journal of medicinal chemistry, Jun-03, Volume: 42, Issue:11	Unique analogues of anandamide: arachidonyl ethers and carbamates and norarachidonyl carbamates and ureas.
AID49473	Percentage affinity towards Cannabinoid receptor 1 using [3H]CP-55940 as radioligand in rat forebrain membranes	2003	Bioorganic & medicinal chemistry letters, Jun-16, Volume: 13, Issue:12	Hemisynthesis and preliminary evaluation of novel endocannabinoid analogues.
AID1127570	Binding affinity to human CB2 receptor in presence of serine protease inhibitor PMSF	2013	Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21	Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.
AID22953	Mean difference between tail flick latency measured at -30 min and tail flick latency measured at 12 min calculated as percent maximum possible effect at 10 (mg/kg) intravenous dose in 6 mice	1994	Journal of medicinal chemistry, Jun-10, Volume: 37, Issue:12	(R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability.
AID546202	Antimicrobial activity against Willaertia magna c2c Maky ATCC PTA-7824 after 3 days by hemocytometer	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Endocannabinoids inhibit the growth of free-living amoebae.
AID262880	Inhibition of AEA uptake in RBL2H3 cells	2006	Journal of medicinal chemistry, Apr-06, Volume: 49, Issue:7	Oxyhomologues of anandamide and related endolipids: chemoselective synthesis and biological activity.
AID420415	Inhibition of rat recombinant FAAH-mediated hydrolysis of [3H]AEA	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Synthesis, in vitro and in vivo evaluation, and radiolabeling of aryl anandamide analogues as candidate radioligands for in vivo imaging of fatty acid amide hydrolase in the brain.
AID546194	Antimicrobial activity against Acanthamoeba castellanii assessed as growth inhibition at 5 ug/ml after 3 days by hemocytometer	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Endocannabinoids inhibit the growth of free-living amoebae.
AID346363	Displacement of [3H]CP-55-940 from human recombinant CB1 receptor expressed in COS cells	2009	Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4	Total synthesis of photoactivatable or fluorescent anandamide probes: novel bioactive compounds with angiogenic activity.
AID71616	Binding affinity towards Fatty-acid amide hydrolase (FAAH) in rat forebrain membranes	2003	Bioorganic & medicinal chemistry letters, Jun-16, Volume: 13, Issue:12	Hemisynthesis and preliminary evaluation of novel endocannabinoid analogues.
AID258587	Displacement of [3H]CP-55940 from human recombinant CB1 receptor	2006	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 16, Issue:1	New metabolically stable fatty acid amide ligands of cannabinoid receptors: Synthesis and receptor affinity studies.
AID546197	Antimicrobial activity against Acanthamoeba castellanii assessed as growth inhibition at 10 ug/ml after 3 days by hemocytometer relative to control	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Endocannabinoids inhibit the growth of free-living amoebae.
AID1127497	Binding affinity to human CB1 receptor in presence of serine protease inhibitor PMSF	2013	Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21	Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.
AID546205	Antimicrobial activity against Willaertia magna c2c Maky ATCC PTA-7824 assessed as decrease in viable cell concentration at 20 ug/ml after 3 days by hemocytometer	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Endocannabinoids inhibit the growth of free-living amoebae.
AID49480	Binding affinity towards Cannabinoid receptor 1 was determined using [3H]-CP- cannabinoid as radioligand with rat brain membrane in the presence of PMSF	2003	Bioorganic & medicinal chemistry letters, Oct-06, Volume: 13, Issue:19	Arachidonylsulfonyl derivatives as cannabinoid CB1 receptor and fatty acid amide hydrolase inhibitors.
AID1350514	Induction of apoptosis in human HOS cells at 12.5 by Annexin V-FITC/propidium iodide double staining based flow cytometry relative to control	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Antitumorigenic Properties of Omega-3 Endocannabinoid Epoxides.
AID262882	Maximal agonist activity on human recombinant TRPV1-mediated enhancement of intracellular calcium concentration in HEK293 cells at 10 uM	2006	Journal of medicinal chemistry, Apr-06, Volume: 49, Issue:7	Oxyhomologues of anandamide and related endolipids: chemoselective synthesis and biological activity.
AID258588	Displacement of [3H]CP-55940 from human recombinant CB2 receptor	2006	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 16, Issue:1	New metabolically stable fatty acid amide ligands of cannabinoid receptors: Synthesis and receptor affinity studies.
AID690263	Activity of mouse liver homogenate FAAH assessed as compound hydrolysis at 10'-5 M after 90 mins by HPLC/MS analysis	2011	Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19	SAR and LC/MS studies of β-lactamic inhibitors of human fatty acid amide hydrolase (hFAAH): evidence of a nonhydrolytic process.
AID132852	Tested for potency towards inhibition of the twitch response in mouse vas deferens	1994	Journal of medicinal chemistry, Jun-10, Volume: 37, Issue:12	(R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability.
AID113711	Inhibition of spontaneous activity(SA) in mice was determined	1997	Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22	Synthesis and pharmacological comparison of dimethylheptyl and pentyl analogs of anandamide.
AID546201	Antimicrobial activity against Hartmannella vermiformis after 3 days by hemocytometer	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Endocannabinoids inhibit the growth of free-living amoebae.
AID546200	Antimicrobial activity against Acanthamoeba castellanii after 3 days by hemocytometer	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Endocannabinoids inhibit the growth of free-living amoebae.
AID114198	Effective dose required to increase tail-flick latency in mice	1996	Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2	Structure-activity analysis of anandamide analogs: relationship to a cannabinoid pharmacophore.
AID1069543	Tmax in rat plasma at 0.3 mg/kg, po by LC/MS/MS analysis	2014	Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4	Design, synthesis, and biological evaluation of a series of piperazine ureas as fatty acid amide hydrolase inhibitors.
AID1386798	Displacement of [3H]CP-55,940 from mouse CB2 receptor expressed in HEK293 cell membranes in absence of FAAH inhibitor PMSF by radioligand binding assay	2018	Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19	( R)- N-(1-Methyl-2-hydroxyethyl)-13-( S)-methyl-arachidonamide (AMG315): A Novel Chiral Potent Endocannabinoid Ligand with Stability to Metabolizing Enzymes.
AID49659	Binding affinity towards cannabinoid receptor 1 from rat forebrain membranes in the presence of phenylmethanesulfonylfluoride (PMSF) using 0.8 nM [3H]CP-55940 as radioligand	1998	Journal of medicinal chemistry, Dec-31, Volume: 41, Issue:27	Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability.
AID262881	Agonist activity on human recombinant TRPV1-mediated enhancement of intracellular calcium concentration in HEK293 cells	2006	Journal of medicinal chemistry, Apr-06, Volume: 49, Issue:7	Oxyhomologues of anandamide and related endolipids: chemoselective synthesis and biological activity.
AID633479	Displacement of [3H]CP55940 from human CB1 receptor expressed in human HEK293 cells in presence of 100 nM PMSF	2011	Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24	Resorcinol-sn-glycerol derivatives: novel 2-arachidonoylglycerol mimetics endowed with high affinity and selectivity for cannabinoid type 1 receptor.
AID49304	Ability to displace [3H]CP-55940 from the membranes prepared from HEK cell line with wild type Cannabinoid receptor 1	2003	Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24	An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/inverse agonist binding region.
AID546204	Antimicrobial activity against Hartmannella vermiformis assessed as decrease in viable cell concentration at 20 ug/ml after 3 days by hemocytometer	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Endocannabinoids inhibit the growth of free-living amoebae.
AID1400243	Antagonist activity at recombinant rat TRPV2 expressed in HEK293 cells assessed as inhibition of LPC-induced Ca2+ levels preincubated for 5 mins followed by agonist addition by Fuo-4-AM based spectrofluorimetry	2018	Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18	Elongation of the Hydrophobic Chain as a Molecular Switch: Discovery of Capsaicin Derivatives and Endogenous Lipids as Potent Transient Receptor Potential Vanilloid Channel 2 Antagonists.
AID1127515	Activation of human VR1 expressed in HEK293 cells assessed as stimulation of Ca2+ influx	2013	Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21	Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.
AID113708	Inhibition of spontaneous activity (SA) in mice	1997	Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22	Potent anandamide analogs: the effect of changing the length and branching of the end pentyl chain.
AID383278	Agonist activity at CB1 receptor in electrically-stimulated Swiss mouse vas deferens	2008	European journal of medicinal chemistry, Mar, Volume: 43, Issue:3	Synthesis and cannabinoid activity of 1-substituted-indole-3-oxadiazole derivatives: novel agonists for the CB1 receptor.
AID49143	Binding affinity towards cannabinoid receptor using [3H]SR-141,716A as radioligand in rat brain membrane	1997	Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22	Synthesis and pharmacological comparison of dimethylheptyl and pentyl analogs of anandamide.
AID387968	Antiproliferative activity against mouse RAW264.7 cells at 10 uM after 48 hrs relative to control	2008	Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22	Acylamido analogs of endocannabinoids selectively inhibit cancer cell proliferation.
AID38676	The compound was tested for hydrolysis by rat brain microsomal anandamide amidohydrolase (AAH) in the presence of arachidonyl acid at concentration 100 uM	1999	Journal of medicinal chemistry, Mar-11, Volume: 42, Issue:5	Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase.
AID113694	Inhibition of rectal temperature(RT) in mice was determined	1997	Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22	Synthesis and pharmacological comparison of dimethylheptyl and pentyl analogs of anandamide.
AID438793	Displacement of [3H]SR141716A from CB1 receptor in rat cerebellar membrane after 90 mins by scintillation counting	2009	European journal of medicinal chemistry, Dec, Volume: 44, Issue:12	Synthesis and pharmacological evaluation of sulfamide-based analogues of anandamide.
AID38670	The compound was tested for hydrolysis by rat brain microsomal anandamide amidohydrolase (AAH) in the presence of CP-55940 (30 uM).	1999	Journal of medicinal chemistry, Mar-11, Volume: 42, Issue:5	Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase.
AID196758	Tested for inhibition of rat glial cell gap junction at the concentration of 20 uM	1999	Bioorganic & medicinal chemistry letters, Apr-19, Volume: 9, Issue:8	Arachidonic acid amide inhibitors of gap junction cell-cell communication.
AID1626212	Binding affinity to PDEA modified AGP (unknown origin) at 40 uM by surface plasmon resonance method	2016	Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14	Chromenopyrazole, a Versatile Cannabinoid Scaffold with in Vivo Activity in a Model of Multiple Sclerosis.
AID293976	Induction of anti CD3-stimulated T-lymphocyte necrosis after 48 hrs	2007	Bioorganic & medicinal chemistry, Mar-15, Volume: 15, Issue:6	Synthesis, pharmacological evaluation and electrochemical studies of novel 6-nitro-3,4-methylenedioxyphenyl-N-acylhydrazone derivatives: Discovery of LASSBio-881, a new ligand of cannabinoid receptors.
AID1386797	Displacement of [3H]CP-55,940 from CB1 receptor in rat brain membranes in presence of FAAH inhibitor PMSF by radioligand binding assay	2018	Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19	( R)- N-(1-Methyl-2-hydroxyethyl)-13-( S)-methyl-arachidonamide (AMG315): A Novel Chiral Potent Endocannabinoid Ligand with Stability to Metabolizing Enzymes.
AID546195	Antimicrobial activity against Hartmannella vermiformis assessed as growth inhibition at 5 ug/ml after 3 days by hemocytometer	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Endocannabinoids inhibit the growth of free-living amoebae.
AID38668	The compound was tested for hydrolysis by rat brain microsomal anandamide amidohydrolase (AAH) in the presence of (-)-delta8-THC (30 uM).	1999	Journal of medicinal chemistry, Mar-11, Volume: 42, Issue:5	Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1346702	Human Cav3.3 (Voltage-gated calcium channels)	2001	The EMBO journal, Dec-17, Volume: 20, Issue:24	Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide.
AID1345070	Human GPR55 (GPR18, GPR55 and GPR119)	2007	British journal of pharmacology, Dec, Volume: 152, Issue:7	The orphan receptor GPR55 is a novel cannabinoid receptor.
AID1346669	Human K2P9.1 (Two P domain potassium channels)	2000	The Journal of biological chemistry, Jun-02, Volume: 275, Issue:22	TASK-3, a novel tandem pore domain acid-sensitive K+ channel. An extracellular histiding as pH sensor.
AID1346728	Human CB2 receptor (Cannabinoid receptors)	1995	Molecular pharmacology, Sep, Volume: 48, Issue:3	Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.
AID1346814	Human GPR18 (GPR18, GPR55 and GPR119)	2012	British journal of pharmacology, Apr, Volume: 165, Issue:8	Δ(9) -Tetrahydrocannabinol and N-arachidonyl glycine are full agonists at GPR18 receptors and induce migration in human endometrial HEC-1B cells.
AID1346728	Human CB2 receptor (Cannabinoid receptors)	1996	The Journal of pharmacology and experimental therapeutics, Sep, Volume: 278, Issue:3	Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands.
AID1346701	Human CB1 receptor (Cannabinoid receptors)	1996	The Journal of pharmacology and experimental therapeutics, Sep, Volume: 278, Issue:3	Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands.
AID1346728	Human CB2 receptor (Cannabinoid receptors)	1995	Biochemical pharmacology, Jun-29, Volume: 50, Issue:1	Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors.
AID1346720	Human Cav3.2 (Voltage-gated calcium channels)	2001	The EMBO journal, Dec-17, Volume: 20, Issue:24	Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide.
AID1346643	Rat TRPV1 (Transient Receptor Potential channels)	1999	Nature, Jul-29, Volume: 400, Issue:6743	Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide.
AID1346701	Human CB1 receptor (Cannabinoid receptors)	1995	Molecular pharmacology, Sep, Volume: 48, Issue:3	Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.
AID1346617	Human TRPV1 (Transient Receptor Potential channels)	2000	British journal of pharmacology, Jan, Volume: 129, Issue:2	The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1).
AID1346712	Human Kv1.2 (Voltage-gated potassium channels)	1996	Neuropharmacology, , Volume: 35, Issue:7	Anandamide, an endogenous cannabinoid, inhibits Shaker-related voltage-gated K+ channels.
AID1346602	Human K2P3.1 (Two P domain potassium channels)	2001	The EMBO journal, Jan-15, Volume: 20, Issue:1-2	The endocannabinoid anandamide is a direct and selective blocker of the background K(+) channel TASK-1.
AID1346719	Human Cav3.1 (Voltage-gated calcium channels)	2001	The EMBO journal, Dec-17, Volume: 20, Issue:24	Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide.
AID1802031	FABP1 Fluorescent Ligand Displacement Assay from Article 10.1021/acs.biochem.6b00446: \\FABP1: A Novel Hepatic Endocannabinoid and Cannabinoid Binding Protein.\\	2016	Biochemistry, 09-20, Volume: 55, Issue:37	FABP1: A Novel Hepatic Endocannabinoid and Cannabinoid Binding Protein.
AID1798962	TRPV1 Channel Activity Assay from Article 10.1021/jm900130m: \\Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes.\\	2009	Journal of medicinal chemistry, May-14, Volume: 52, Issue:9	Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes.
AID1798961	CB Receptor Radioligand Binding Assay (Ki) from Article 10.1021/jm900130m: \\Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes.\\	2009	Journal of medicinal chemistry, May-14, Volume: 52, Issue:9	Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes.
AID1802827	Fluorescence Competition Assay from Article 10.1074/jbc.M114.559062: \\Fatty acid-binding protein 5 (FABP5) regulates cognitive function both by decreasing anandamide levels and by activating the nuclear receptor peroxisome proliferator-activated receptor	2014	The Journal of biological chemistry, May-02, Volume: 289, Issue:18	Fatty acid-binding protein 5 (FABP5) regulates cognitive function both by decreasing anandamide levels and by activating the nuclear receptor peroxisome proliferator-activated receptor β/δ (PPARβ/δ) in the brain.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	322 (12.80)	18.2507
2000's	1121 (44.57)	29.6817
2010's	890 (35.39)	24.3611
2020's	182 (7.24)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	29 (1.13%)	5.53%
Reviews	311 (12.12%)	6.00%
Case Studies	5 (0.19%)	4.05%
Observational	2 (0.08%)	0.25%
Other	2,219 (86.48%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
alpha-ketoglutaric acid 2-oxoglutaric acid : An oxo dicarboxylic acid that consists of glutaric acid bearing an oxo substituent at position 2. It is an intermediate metabolite in Krebs cycle.	2	1	0	oxo dicarboxylic acid	fundamental metabolite
gamma-aminobutyric acid gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.. gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.	13.47	43	0	amino acid zwitterion; gamma-amino acid; monocarboxylic acid	human metabolite; neurotransmitter; Saccharomyces cerevisiae metabolite; signalling molecule
acetic acid Acetic Acid: Product of the oxidation of ethanol and of the destructive distillation of wood. It is used locally, occasionally internally, as a counterirritant and also as a reagent. (Stedman, 26th ed). acetic acid : A simple monocarboxylic acid containing two carbons.	2.07	1	0	monocarboxylic acid	antimicrobial food preservative; Daphnia magna metabolite; food acidity regulator; protic solvent
adenine [no description available]	2.74	3	0	6-aminopurines; purine nucleobase	Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
ammonium hydroxide azane : Saturated acyclic nitrogen hydrides having the general formula NnHn+2.	2.02	1	0	azane; gas molecular entity; mononuclear parent hydride	EC 3.5.1.4 (amidase) inhibitor; metabolite; mouse metabolite; neurotoxin; NMR chemical shift reference compound; nucleophilic reagent; refrigerant
carbamates [no description available]	13.42	151	0	amino-acid anion
chlorine chloride : A halide anion formed when chlorine picks up an electron to form an an anion.	2.72	3	0	halide anion; monoatomic chlorine	cofactor; Escherichia coli metabolite; human metabolite
hippuric acid hippuric acid: RN given refers to parent cpd; structure in Merck Index, 9th ed, #4591. N-benzoylglycine : An N-acylglycine in which the acyl group is specified as benzoyl.	2	1	0	N-acylglycine	human blood serum metabolite; uremic toxin
n(g),n(g')-dimethyl-l-arginine N,N-dimethylarginine: asymmetric dimethylarginine; do not confuse with N,N'-dimethylarginine	2.05	1	0	alpha-amino acid
3,4-dihydroxyphenylacetic acid 3,4-Dihydroxyphenylacetic Acid: A deaminated metabolite of LEVODOPA.. (3,4-dihydroxyphenyl)acetic acid : A dihydroxyphenylacetic acid having the two hydroxy substituents located at the 3- and 4-positions. It is a metabolite of dopamine.. dihydroxyphenylacetic acid : A dihydroxy monocarboxylic acid consisting of phenylacetic acid having two phenolic hydroxy substituents.	2.93	4	0	catechols; dihydroxyphenylacetic acid	human metabolite
lactic acid Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed). 2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.	2.95	4	0	2-hydroxy monocarboxylic acid	algal metabolite; Daphnia magna metabolite
dimethyl sulfoxide Dimethyl Sulfoxide: A highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect tissue during CRYOPRESERVATION. Dimethyl sulfoxide shows a range of pharmacological activity including analgesia and anti-inflammation.. dimethyl sulfoxide : A 2-carbon sulfoxide in which the sulfur atom has two methyl substituents.	2.42	2	0	sulfoxide; volatile organic compound	alkylating agent; antidote; Escherichia coli metabolite; geroprotector; MRI contrast agent; non-narcotic analgesic; polar aprotic solvent; radical scavenger
ethanolamine [no description available]	7.01	26	0	ethanolamines; primary alcohol; primary amine	Escherichia coli metabolite; human metabolite; mouse metabolite
formaldehyde paraform: polymerized formaldehyde; RN given refers to parent cpd; used in root canal therapy	5.43	14	0	aldehyde; one-carbon compound	allergen; carcinogenic agent; disinfectant; EC 3.5.1.4 (amidase) inhibitor; environmental contaminant; Escherichia coli metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
glutaric acid glutaric acid: RN given refers to parent cpd. glutaric acid : An alpha,omega-dicarboxylic acid that is a linear five-carbon dicarboxylic acid.	7.45	2	0	alpha,omega-dicarboxylic acid; dicarboxylic fatty acid	Daphnia magna metabolite; human metabolite
glycine [no description available]	5.29	16	0	alpha-amino acid; amino acid zwitterion; proteinogenic amino acid; serine family amino acid	EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor; fundamental metabolite; hepatoprotective agent; micronutrient; neurotransmitter; NMDA receptor agonist; nutraceutical
glycerol Moon: The natural satellite of the planet Earth. It includes the lunar cycles or phases, the lunar month, lunar landscapes, geography, and soil.	8.55	8	0	alditol; triol	algal metabolite; detergent; Escherichia coli metabolite; geroprotector; human metabolite; mouse metabolite; osmolyte; Saccharomyces cerevisiae metabolite; solvent
histamine [no description available]	2.73	3	0	aralkylamino compound; imidazoles	human metabolite; mouse metabolite; neurotransmitter
kynurenine Kynurenine: A metabolite of the essential amino acid tryptophan metabolized via the tryptophan-kynurenine pathway.. kynurenine : A ketone that is alanine in which one of the methyl hydrogens is substituted by a 2-aminobenzoyl group.	2.6	1	0	aromatic ketone; non-proteinogenic alpha-amino acid; substituted aniline	human metabolite
malonic acid malonic acid : An alpha,omega-dicarboxylic acid in which the two carboxy groups are separated by a single methylene group.. dicarboxylic acid : Any carboxylic acid containing two carboxy groups.	2.03	1	0	alpha,omega-dicarboxylic acid	human metabolite
methanol Methanol: A colorless, flammable liquid used in the manufacture of FORMALDEHYDE and ACETIC ACID, in chemical synthesis, antifreeze, and as a solvent. Ingestion of methanol is toxic and may cause blindness.. primary alcohol : A primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it.. methanol : The primary alcohol that is the simplest aliphatic alcohol, comprising a methyl and an alcohol group.	3.45	1	1	alkyl alcohol; one-carbon compound; primary alcohol; volatile organic compound	amphiprotic solvent; Escherichia coli metabolite; fuel; human metabolite; mouse metabolite; Mycoplasma genitalium metabolite
inositol Inositol: An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.. inositol : Any cyclohexane-1,2,3,4,5,6-hexol.. 1D-chiro-inositol : Belonging to the inositol family of compounds, D-chiro-inositol (DCI) is an isomer of glucose. It is an important secondary messenger in insulin signal transduction.. muco-inositol : An inositol that is cyclohexane-1,2,3,4,5,6-hexol having a (1R,2R,3r,4R,5S,6r)-configuration.	2.06	1	0	cyclitol; hexol
melatonin [no description available]	4	2	0	acetamides; tryptamines	anticonvulsant; central nervous system depressant; geroprotector; hormone; human metabolite; immunological adjuvant; mouse metabolite; radical scavenger
nickel Nickel: A trace element with the atomic symbol Ni, atomic number 28, and atomic weight 58.69. It is a cofactor of the enzyme UREASE.. nickel ion : A nickel atom having a net electric charge.. nickel atom : Chemical element (nickel group element atom) with atomic number 28.	2.01	1	0	metal allergen; nickel group element atom	epitope; micronutrient
nitrates Nitrates: Inorganic or organic salts and esters of nitric acid. These compounds contain the NO3- radical.	2.96	4	0	monovalent inorganic anion; nitrogen oxoanion; reactive nitrogen species
nitrites Nitrites: Salts of nitrous acid or compounds containing the group NO2-. The inorganic nitrites of the type MNO2 (where M=metal) are all insoluble, except the alkali nitrites. The organic nitrites may be isomeric, but not identical with the corresponding nitro compounds. (Grant & Hackh's Chemical Dictionary, 5th ed)	4.52	5	0	monovalent inorganic anion; nitrogen oxoanion; reactive nitrogen species	human metabolite
1-octanol 1-Octanol: A colorless, slightly viscous liquid used as a defoaming or wetting agent. It is also used as a solvent for protective coatings, waxes, and oils, and as a raw material for plasticizers. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed). octan-1-ol : An octanol carrying the hydroxy group at position 1.	2	1	0	octanol; primary alcohol	antifungal agent; bacterial metabolite; fuel additive; kairomone; plant metabolite
hexadecanal [no description available]	3.17	1	0	2,3-saturated fatty aldehyde; long-chain fatty aldehyde	human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
palmitic acid Palmitic Acid: A common saturated fatty acid found in fats and waxes including olive oil, palm oil, and body lipids.. hexadecanoic acid : A straight-chain, sixteen-carbon, saturated long-chain fatty acid.	2.17	1	0	long-chain fatty acid; straight-chain saturated fatty acid	algal metabolite; Daphnia magna metabolite; EC 1.1.1.189 (prostaglandin-E2 9-reductase) inhibitor; plant metabolite
phosphorylcholine Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.. phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.	2.03	1	0	phosphocholines	allergen; epitope; hapten; human metabolite; mouse metabolite
phthalic acid phthalic acid: RN given refers to parent cpd; structure in Merck Index, 9th ed, #7178. phthalic acid : A benzenedicarboxylic acid cosisting of two carboxy groups at ortho positions.	2.17	1	0	benzenedicarboxylic acid	human xenobiotic metabolite
quinolinic acid Quinolinic Acid: A metabolite of tryptophan with a possible role in neurodegenerative disorders. Elevated CSF levels of quinolinic acid are correlated with the severity of neuropsychological deficits in patients who have AIDS.. pyridinedicarboxylic acid : Any member of the class of pyridines carrying two carboxy groups.. quinolinic acid : A pyridinedicarboxylic acid that is pyridine substituted by carboxy groups at positions 2 and 3. It is a metabolite of tryptophan.	7.86	3	0	pyridinedicarboxylic acid	Escherichia coli metabolite; human metabolite; mouse metabolite; NMDA receptor agonist
taurine [no description available]	2.06	1	0	amino sulfonic acid; zwitterion	antioxidant; Escherichia coli metabolite; glycine receptor agonist; human metabolite; mouse metabolite; nutrient; radical scavenger; Saccharomyces cerevisiae metabolite
toluene methylbenzene : Any alkylbenzene that is benzene substituted with one or more methyl groups.	7.07	1	0	methylbenzene; toluenes; volatile organic compound	cholinergic antagonist; fuel additive; neurotoxin; non-polar solvent
urea pseudourea: clinical use; structure. isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.	8.15	5	0	isourea; monocarboxylic acid amide; one-carbon compound	Daphnia magna metabolite; Escherichia coli metabolite; fertilizer; flour treatment agent; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
vanillin Vanilla: A plant genus of the family ORCHIDACEAE that is the source of the familiar flavoring used in foods and medicines (FLAVORING AGENTS).	2.03	1	0	benzaldehydes; monomethoxybenzene; phenols	anti-inflammatory agent; anticonvulsant; antioxidant; flavouring agent; plant metabolite
2-amino-5-phosphonovalerate 2-Amino-5-phosphonovalerate: The D-enantiomer is a potent and specific antagonist of NMDA glutamate receptors (RECEPTORS, N-METHYL-D-ASPARTATE). The L form is inactive at NMDA receptors but may affect the AP4 (2-amino-4-phosphonobutyrate; APB) excitatory amino acid receptors.	2.43	2	0	non-proteinogenic alpha-amino acid	NMDA receptor antagonist
8-hydroxy-2-(di-n-propylamino)tetralin 8-Hydroxy-2-(di-n-propylamino)tetralin: A serotonin 1A-receptor agonist that is used experimentally to test the effects of serotonin.. 8-OH-DPAT : A tetralin substituted at positions 1 and 7 by hydroxy and dipropylamino groups respectively	2.74	3	0	phenols; tertiary amino compound; tetralins	serotonergic antagonist
alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid: An IBOTENIC ACID homolog and glutamate agonist. The compound is the defining agonist for the AMPA subtype of glutamate receptors (RECEPTORS, AMPA). It has been used as a radionuclide imaging agent but is more commonly used as an experimental tool in cell biological studies.	2.44	2	0	non-proteinogenic alpha-amino acid
sk&f 82958 [no description available]	2	1	0	benzazepine
4-iodo-2,5-dimethoxyphenylisopropylamine 4-iodo-2,5-dimethoxyphenylisopropylamine: RN given refers to unlabeled parent cpd without isomeric designation; a serotonin agonist. 2-(4-iodo-2,5-dimethoxyphenyl)-1-methylethylamine : An organoiodine compound that is amphetamine bearing two methoxy substituents at positions 2 and 5 as well as an iodo substituent at position 4.	2.02	1	0	amphetamines; dimethoxybenzene; organoiodine compound
ibotenic acid Ibotenic Acid: A neurotoxic isoxazole (similar to KAINIC ACID and MUSCIMOL) found in AMANITA mushrooms. It causes motor depression, ataxia, and changes in mood, perceptions and feelings, and is a potent excitatory amino acid agonist.	2.03	1	0	non-proteinogenic alpha-amino acid	neurotoxin
b 844-39 [no description available]	3.23	1	0	diarylmethane
octoclothepine octoclothepine: major tranquilizer with action similar to those of the phenothiazines; used in schizophrenic & manic psychoses; minor decriptor (77-86); on-line & INDEX MEDICUS search DIBENZOTHIEPINS (77-86); RN given refers to parent cpd without isomeric designation	3.31	1	0	dibenzothiepine
sk&f-38393 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine: A selective D1 dopamine receptor agonist used primarily as a research tool.. 1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol : A benzazepine that is 2,3,4,5-tetrahydro-3-benzazepine bearing a phenyl substituent at position 1 and two hydroxy substituents at positions 7 and 8.. SKF 38393 : A racemate comprising equimolar amounts of (R)- and (S)-SKF 38393	2.92	4	0	benzazepine; catechols; secondary amino compound
menthol Menthol: A monoterpene cyclohexanol produced from mint oils.	4.96	4	0	p-menthane monoterpenoid; secondary alcohol	volatile oil component
1-(3-chlorophenyl)biguanide 1-(3-chlorophenyl)biguanide: RN given refers to parent cp; a 5-HT3 receptor agonist	2.01	1	0	biguanides; monochlorobenzenes
1-anilino-8-naphthalenesulfonate 1-anilino-8-naphthalenesulfonate: RN given refers to parent cpd. 8-anilinonaphthalene-1-sulfonic acid : A naphthalenesulfonic acid that is naphthalene-1-sulfonic acid substituted by a phenylamino group at position 8.	2.95	4	0	aminonaphthalene; naphthalenesulfonic acid	fluorescent probe
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease.. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine : A tetrahydropyridine that is 1,2,3,6-tetrahydropyridine substituted by a methyl group at position 1 and a phenyl group at position 4.	2.03	1	0	methylpyridines; phenylpyridine; tetrahydropyridine	neurotoxin
1-oleoyl-2-acetoyl-sn-glycerol [no description available]	2.05	1	0
14,15-epoxy-5,8,11-eicosatrienoic acid 14,15-epoxy-5,8,11-eicosatrienoic acid: RN given refers to cpd without isomeric designation	2.73	3	0	long-chain fatty acid
17-octadecynoic acid octadec-17-ynoic acid : An acetylenic fatty acid that is octadecanoi acid (stearic acid) which has been doubly dehydrogenated at positions 17 and 18 to give the corresponding alkynoic acid.	2	1	0	acetylenic fatty acid; long-chain fatty acid; monounsaturated fatty acid; terminal acetylenic compound	EC 1.14.14.94 (leukotriene-B4 20-monooxygenase) inhibitor; EC 1.14.15.3 (alkane 1-monooxygenase) inhibitor; P450 inhibitor
1h-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one 1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one: structure given in first source; inhibits guanylyl cyclase. 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one : A member of the class of oxadiazoloquinoxalines that is 1H-[1,2,4]oxadiazolo[4,3-a]quinoxaline substituted at position 1 by an oxo group.	2.41	2	0	oxadiazoloquinoxaline	EC 4.6.1.2 (guanylate cyclase) inhibitor
2-methyl-5-ht 2-methyl-5-HT: M-receptor agonist	2.01	1	0	tryptamines	serotonergic agonist
2-aminoethoxydiphenyl borate 2-aminoethoxydiphenyl borate: is a novel membrane-penetrable modulator and transient receptor potential channel blocker; structure in first source; do not confuse with 2-APB cpd. 2-aminoethoxydiphenylborane : An organoboron compound that is diphenylborane in which the borane hydrogen is replaced by a 2-aminoethoxy group.	5.15	5	0	organoboron compound; primary amino compound	calcium channel blocker; IP3 receptor antagonist; potassium channel opener
n-methyl-3,4-methylenedioxyamphetamine N-Methyl-3,4-methylenedioxyamphetamine: An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy.. 3,4-methylenedioxymethamphetamine : A member of the class of benzodioxoles that is 1,3-benzodioxole substituted by a 2-(methylamino)propyl group at position 5.	3.56	1	1	amphetamines; benzodioxoles	neurotoxin
phaclofen phaclofen: peripheral & central baclofen & GABA antagonist; structure given in first source	1.98	1	0	organophosphate oxoanion; zwitterion
3-nitropropionic acid 3-nitropropionic acid: succinate dehydrogenase inactivator; biosynthesized by FABACEAE plants from ASPARAGINE. 3-nitropropanoic acid : A C-nitro compound that is propanoic acid in which one of the methyl hydrogens has been replaced by a nitro group.	2.03	1	0	C-nitro compound	antimycobacterial drug; EC 1.3.5.1 [succinate dehydrogenase (quinone)] inhibitor; mycotoxin; neurotoxin
4-aminopyridine [no description available]	2.94	4	0	aminopyridine; aromatic amine	avicide; orphan drug; potassium channel blocker
4-diphenylacetoxy-1,1-dimethylpiperidinium 4-diphenylacetoxy-1,1-dimethylpiperidinium: muscarinic receptor antagonist; RN given refers to parent cpd; do not confuse abbreviation 4-DAMP with a similar cpd which does not contain dimethyl groups. 4-DAMP(1+) : A quaternary ammonium salt obtained by formal methylation of the tertiary amino function of 4-diphenylacetoxy-N-methylpiperidine.	2.08	1	0	quaternary ammonium ion	cholinergic antagonist; muscarinic antagonist
5,8,11,14-eicosatetraynoic acid 5,8,11,14-Eicosatetraynoic Acid: A 20-carbon unsaturated fatty acid containing 4 alkyne bonds. It inhibits the enzymatic conversion of arachidonic acid to prostaglandins E(2) and F(2a).	2.41	2	0	long-chain fatty acid
5,8,11-eicosatriynoic acid 5,8,11-eicosatriynoic acid: a lipoxygenase inhibitor. 5,8,11-icosatriynoic acid : A C20 polyunsaturated fatty acid having three triple bonds in the 5-, 8- and 11-positions.	2	1	0	acetylenic fatty acid; icosanoid; long-chain fatty acid; polyunsaturated fatty acid	EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor
hydroxyindoleacetic acid (5-hydroxyindol-3-yl)acetic acid : A member of the class of indole-3-acetic acids that is indole-3-acetic acid substituted by a hydroxy group at C-5.	5.77	2	2	indole-3-acetic acids	drug metabolite; human metabolite; mouse metabolite
7-nitroindazole 7-nitroindazole: an inhibitor of nitric oxide synthase; exhibits anti-nociceptive activity without increasing blood pressure	2.11	1	0
8-(4-sulfophenyl)theophylline 8-(4-sulfophenyl)theophylline: adenosine antagonist	2	1	0
2,2'-azobis(2-amidinopropane) 2,2'-azobis(2-amidinopropane): water-soluble free-radical initiator	2.04	1	0	monoazo compound
acetaminophen Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.. paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.	9.24	5	0	acetamides; phenols	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; cyclooxygenase 3 inhibitor; environmental contaminant; ferroptosis inducer; geroprotector; hepatotoxic agent; human blood serum metabolite; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
tyrphostin 25 [no description available]	1.99	1	0	benzenetriol
am 251 AM 251: an analog of SR141716A; structure given in first source. AM-251 : A carbohydrazide obtained by formal condensation of the carboxy group of 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxylic acid with the amino group of 1-aminopiperidine. An antagonist at the CB1 cannabinoid receptor.	8.09	151	0	amidopiperidine; carbohydrazide; dichlorobenzene; organoiodine compound; pyrazoles	antidepressant; antineoplastic agent; apoptosis inducer; CB1 receptor antagonist
aminoglutethimide Aminoglutethimide: An aromatase inhibitor that is used in the treatment of advanced BREAST CANCER.. aminoglutethimide : A dicarboximide that is a six-membered cyclic compound having ethyl and 4-aminophenyl substituents at the 3-position.	2.01	1	0	dicarboximide; piperidones; substituted aniline	adrenergic agent; anticonvulsant; antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor
p-aminohippuric acid p-Aminohippuric Acid: The glycine amide of 4-aminobenzoic acid. Its sodium salt is used as a diagnostic aid to measure effective renal plasma flow (ERPF) and excretory capacity.. p-aminohippurate : A hippurate that is the conjugate base of p-aminohippuric acid, arising from deprotonation of the carboxy group.. p-aminohippuric acid : An N-acylglycine that is the 4-amino derivative of hippuric acid; used as a diagnostic agent in the measurement of renal plasma flow.	2	1	0	N-acylglycine	Daphnia magna metabolite
theophylline [no description available]	2	1	0	dimethylxanthine	adenosine receptor antagonist; anti-asthmatic drug; anti-inflammatory agent; bronchodilator agent; drug metabolite; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; fungal metabolite; human blood serum metabolite; immunomodulator; muscle relaxant; vasodilator agent
dan 2163 [no description available]	3.46	1	1	aromatic amide; aromatic amine; benzamides; pyrrolidines; sulfone	environmental contaminant; second generation antipsychotic; xenobiotic
amlodipine Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.. amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.	3.23	1	0	dihydropyridine; ethyl ester; methyl ester; monochlorobenzenes; primary amino compound	antihypertensive agent; calcium channel blocker; vasodilator agent
aspirin Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5). acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.. acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.	3.26	6	0	benzoic acids; phenyl acetates; salicylates	anticoagulant; antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; EC 1.1.1.188 (prostaglandin-F synthase) inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; plant activator; platelet aggregation inhibitor; prostaglandin antagonist; teratogenic agent
azasetron azasetron: a selective 5-HT3 receptor antagonist; structure given in first source;	2.01	1	0	benzoxazine
baclofen [no description available]	2.93	4	0	amino acid zwitterion; gamma-amino acid; monocarboxylic acid; monochlorobenzenes; primary amino compound	central nervous system depressant; GABA agonist; muscle relaxant
benzo(a)pyrene Benzo(a)pyrene: A potent mutagen and carcinogen. It is a public health concern because of its possible effects on industrial workers, as an environmental pollutant, an as a component of tobacco smoke.. benzo[a]pyrene : An ortho- and peri-fused polycyclic arene consisting of five fused benzene rings.	2.13	1	0	ortho- and peri-fused polycyclic arene	carcinogenic agent; mouse metabolite
bay h 4502 bifonazole : A racemate comprising equimolar amounts of R- and S-bifonazole. It is a broad spectrum antifungal drug used for the treatment of fungal skin and nail infections.. 1-[biphenyl-4-yl(phenyl)methyl]imidazole : A member of the class of imidazoles carrying an alpha-(biphenyl-4-yl)benzyl substituent at position 1.	2.03	1	0	biphenyls; imidazoles
bisindolylmaleimide i bisindolylmaleimide I: a bis(indolyl)maleimide	2.94	1	0
bithionol Bithionol: Halogenated anti-infective agent that is used against trematode and cestode infestations.. bithionol : An aryl sulfide that is diphenyl sulfide in which each phenyl group is substituted at position 2 by hydroxy and at positions 3 and 5 by chlorine. A fungicide and anthelmintic, it was used in various topical drug products for the treatment of liver flukes, but withdrawn after being shown to be a potent photosensitizer with the potential to cause serious skin disorders.	2.25	1	0	aryl sulfide; bridged diphenyl antifungal drug; bridged diphenyl fungicide; dichlorobenzene; organochlorine pesticide; polyphenol	antifungal agrochemical; antiplatyhelmintic drug
bupivacaine Bupivacaine: A widely used local anesthetic agent.. 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide : A piperidinecarboxamide obtained by formal condensation of the carboxy group of N-butylpipecolic acid with the amino group of 2,6-dimethylaniline.. bupivacaine : A racemate composed of equimolar amounts of dextrobupivacaine and levobupivacaine. Used (in the form of its hydrochloride hydrate) as a local anaesthetic.	4.06	4	0	aromatic amide; piperidinecarboxamide; tertiary amino compound
caffeine [no description available]	3.12	5	0	purine alkaloid; trimethylxanthine	adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic
verapamil Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.	7.41	2	0	aromatic ether; nitrile; polyether; tertiary amino compound
calmidazolium calmidazolium: powerful inhibitor of or red blood cell Ca++-ATPase & Ca++ transport into inside-out red blood cell vesicles; RN refers to chloride; structure in first source; an antagonist of calmodulin. calmidazolium : An imidazolium ion that is imidazolium cation substituted by a bis(4-chlorophenyl)methyl group at position 1 and a 2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl group at position 3. It acts as an antagonist of calmodulin, a calcium binding messenger protein.	1.99	1	0	imidazolium ion	apoptosis inducer; calmodulin antagonist
cannabinol Cannabinol: A physiologically inactive constituent of Cannabis sativa L.	4.35	6	0	dibenzopyran
carbamazepine Carbamazepine: A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.. carbamazepine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant.	7.06	1	0	dibenzoazepine; ureas	analgesic; anticonvulsant; antimanic drug; drug allergen; EC 3.5.1.98 (histone deacetylase) inhibitor; environmental contaminant; glutamate transporter activator; mitogen; non-narcotic analgesic; sodium channel blocker; xenobiotic
carvedilol [no description available]	3.23	1	0	carbazoles; secondary alcohol; secondary amino compound	alpha-adrenergic antagonist; antihypertensive agent; beta-adrenergic antagonist; cardiovascular drug; vasodilator agent
celecoxib [no description available]	2.5	2	0	organofluorine compound; pyrazoles; sulfonamide; toluenes	cyclooxygenase 2 inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug
chelerythrine chelerythrine : A benzophenanthridine alkaloid isolated from the root of Zanthoxylum simulans, Chelidonium majus L., and other Papaveraceae.	2	1	0	benzophenanthridine alkaloid; organic cation	antibacterial agent; antineoplastic agent; EC 2.7.11.13 (protein kinase C) inhibitor
chlorpromazine Chlorpromazine: The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.. chlorpromazine : A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety.	3.23	1	0	organochlorine compound; phenothiazines; tertiary amine	anticoronaviral agent; antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; phenothiazine antipsychotic drug
chlorpropamide Chlorpropamide: A sulfonylurea hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. (From Martindale, The Extra Pharmacopoeia, 30th ed, p277). chlorpropamide : An N-sulfonylurea that is urea in which a hydrogen attached to one of the nitrogens is substituted by 4-chlorobenzenesulfonyl group and a hydrogen attached to the other nitrogen is substituted by propyl group. Chlorpropamide is a hypoglycaemic agent used in the treatment of type 2 (non-insulin-dependent) diabetes mellitus not responding to dietary modification.	2.03	1	0	monochlorobenzenes; N-sulfonylurea	hypoglycemic agent; insulin secretagogue
chlorpyrifos Chlorpyrifos: An organothiophosphate cholinesterase inhibitor that is used as an insecticide and as an acaricide.. chlorpyrifos : An organic thiophosphate that is O,O-diethyl hydrogen phosphorothioate in which the hydrogen of the hydroxy group has been replaced by a 3,5,6-trichloropyridin-2-yl group.	8.46	7	0	chloropyridine; organic thiophosphate	acaricide; agrochemical; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; environmental contaminant; insecticide; xenobiotic
eucalyptol [no description available]	3.12	1	0
cirazoline cirazoline: posseses agonist properties at alpha-adrenoreceptor sites; RN given refers to parent cpd	2.01	1	0	aromatic ether
citalopram Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.. citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.. 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.	2.1	1	0	2-benzofurans; cyclic ether; nitrile; organofluorine compound; tertiary amino compound
clonidine Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.. clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.	2.71	3	0	clonidine; imidazoline
clotrimazole [no description available]	2.69	3	0	conazole antifungal drug; imidazole antifungal drug; imidazoles; monochlorobenzenes	antiinfective agent; environmental contaminant; xenobiotic
desipramine Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.. desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.	2.72	3	0	dibenzoazepine; secondary amino compound	adrenergic uptake inhibitor; alpha-adrenergic antagonist; antidepressant; cholinergic antagonist; drug allergen; EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; serotonin uptake inhibitor
nonivamide nonivamide: has effect on sensory neurons. nonivamide : A capsaicinoid that is the carboxamide resulting from the formal condensation of the amino group of 4-hydroxy-3-methoxybenzylamine with the carboxy group of nonanoic acid. It is the active ingredient in many pepper sprays.	2.44	2	0	capsaicinoid; phenols	lachrymator
amphetamine Amphetamine: A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.. 1-phenylpropan-2-amine : A primary amine that is isopropylamine in which a hydrogen attached to one of the methyl groups has been replaced by a phenyl group.. amphetamine : A racemate comprising equimolar amounts of (R)-amphetamine (also known as levamphetamine or levoamphetamine) and (S)-amphetamine (also known as dexamfetamine or dextroamphetamine.	7.73	3	0	primary amine
diazepam Diazepam: A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.. diazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a methyl group at position 1 and a phenyl group at position 5.	7.82	3	0	1,4-benzodiazepinone; organochlorine compound	anticonvulsant; anxiolytic drug; environmental contaminant; sedative; xenobiotic
diazinon Diazinon: A cholinesterase inhibitor that is used as an organothiophosphorus insecticide.. diazinon : A member of the class of pyrimidines that is pyrimidine carrying an isopropyl group at position 2, a methyl group at position 6 and a (diethoxyphosphorothioyl)oxy group at position 4.	2	1	0	organic thiophosphate; pyrimidines	acaricide; agrochemical; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; environmental contaminant; nematicide; xenobiotic
diclofenac Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.. diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.	3.55	2	0	amino acid; aromatic amine; dichlorobenzene; monocarboxylic acid; secondary amino compound	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
disulfiram [no description available]	3.25	1	0	organic disulfide; organosulfur acaricide	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor; EC 3.1.1.1 (carboxylesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 5.99.1.2 (DNA topoisomerase) inhibitor; ferroptosis inducer; fungicide; NF-kappaB inhibitor
valproic acid Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.. valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.	7.87	3	0	branched-chain fatty acid; branched-chain saturated fatty acid	anticonvulsant; antimanic drug; EC 3.5.1.98 (histone deacetylase) inhibitor; GABA agent; neuroprotective agent; psychotropic drug; teratogenic agent
2-amino-7-phosphonoheptanoic acid 2-amino-7-phosphonoheptanoic acid: (D)-isomer active as an antagonist of N-methyl-D-aspartate excitation of central neurons; (L)-isomer inactive; RN given refers to cpd without isomeric designation	2.08	1	0
thiorphan Thiorphan: A potent inhibitor of membrane metalloendopeptidase (ENKEPHALINASE). Thiorphan potentiates morphine-induced ANALGESIA and attenuates naloxone-precipitated withdrawal symptoms.	2	1	0	N-acyl-amino acid
doxapram Doxapram: A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225). doxapram : A member of the class of pyrrolidin-2-ones that is N-ethylpyrrolidin-2-one in which both of the hydrogens at the 3 position (adjacent to the carbonyl group) are substituted by phenyl groups, and one of the hydrogens at the 4 position is substituted by a 2-(morpholin-4-yl)ethyl group. A central and respiratory stimulant with a brief duration of action, it is used (generally as the hydrochloride or the hydrochloride hydrate) as a temporary treatment of acute respiratory failure, particularly when superimposed on chronic obstructive pulmonary disease, and of postoperative respiratory depression. It has also been used for treatment of postoperative shivering.	3.31	1	0	morpholines; pyrrolidin-2-ones	central nervous system stimulant
e 4031 E 4031: class III anti-arrhythmia agent; structure given in UD	2.01	1	0	sulfonamide
econazole Econazole: An imidazole derivative that is commonly used as a topical antifungal agent.. econazole : A racemate composed of equimolar amounts of (R)- and (S)-econazole. Used (as its nitrate salt) to treat skin infections such as athlete's foot, jock itch, ringworm and other fungal skin infections.. 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole : A member of the class of imidazoles that is 1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)ethanol in which the hydroxyl hydrogen is replaced by a 4-chlorobenzyl group.	2.03	1	0	dichlorobenzene; ether; imidazoles; monochlorobenzenes
9-(2-hydroxy-3-nonyl)adenine 9-(2-hydroxy-3-nonyl)adenine: specific inhibitor of adenosine deaminase	2.03	1	0
erythrosine Fluoresceins: A family of spiro(isobenzofuran-1(3H),9'-(9H)xanthen)-3-one derivatives. These are used as dyes, as indicators for various metals, and as fluorescent labels in immunoassays.	2.03	1	0
ether Ether: A mobile, very volatile, highly flammable liquid used as an inhalation anesthetic and as a solvent for waxes, fats, oils, perfumes, alkaloids, and gums. It is mildly irritating to skin and mucous membranes.. ether : An organooxygen compound with formula ROR, where R is not hydrogen.. diethyl ether : An ether in which the oxygen atom is linked to two ethyl groups.	3.31	1	0	ether; volatile organic compound	inhalation anaesthetic; non-polar solvent; refrigerant
eicosapentaenoic acid ethyl ester [no description available]	2	1	0
famotidine Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.	2.03	1	0	1,3-thiazoles; guanidines; sulfonamide	anti-ulcer drug; H2-receptor antagonist; P450 inhibitor
fenofibrate Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE	2.03	1	0	aromatic ether; chlorobenzophenone; isopropyl ester; monochlorobenzenes	antilipemic drug; environmental contaminant; geroprotector; xenobiotic
berotek Fenoterol: A synthetic adrenergic beta-2 agonist that is used as a bronchodilator and tocolytic.. fenoterol : A member of the class resorcinols that is 5-(1-hydroxyethyl)benzene-1,3-diol in which one of the methyl hydrogens is replaced by a 1-(4-hydroxyphenyl)propan-2-amino group. A beta2-adrenergic agonist, it is used (as the hydrobromide salt) as a bronchodilator in the management of reversible airway obstruction.	2.06	1	0	resorcinols; secondary alcohol; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; sympathomimetic agent; tocolytic agent
fexofenadine fexofenadine: a second generation antihistamine; metabolite of the antihistaminic drug terfenadine; structure in first source; RN refers to HCl. fexofenadine : A piperidine-based anti-histamine compound.	2.21	1	0	piperidines; tertiary amine	anti-allergic agent; H1-receptor antagonist
fluconazole Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.. fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.	2.03	1	0	conazole antifungal drug; difluorobenzene; tertiary alcohol; triazole antifungal drug	environmental contaminant; P450 inhibitor; xenobiotic
flufenamic acid Flufenamic Acid: An anthranilic acid derivative with analgesic, anti-inflammatory, and antipyretic properties. It is used in musculoskeletal and joint disorders and administered by mouth and topically. (From Martindale, The Extra Pharmacopoeia, 30th ed, p16). flufenamic acid : An aromatic amino acid consisting of anthranilic acid carrying an N-(trifluoromethyl)phenyl substituent. An analgesic and anti-inflammatory, it is used in rheumatic disorders.	3.62	2	0	aromatic amino acid; organofluorine compound	antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
fluphenazine [no description available]	3.23	1	0	N-alkylpiperazine; organofluorine compound; phenothiazines	anticoronaviral agent; dopaminergic antagonist; phenothiazine antipsychotic drug
fluorescite fluorescein (acid form) : A xanthene dye that is highly fluorescent and commonly used as a fluorescent tracer.	2	1	0	benzoic acids; cyclic ketone; hydroxy monocarboxylic acid; organic heterotricyclic compound; phenols; xanthene dye	fluorescent dye; radioopaque medium
fluoxetine Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.. fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.. N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.	4.1	4	0	(trifluoromethyl)benzenes; aromatic ether; secondary amino compound
flurbiprofen Flurbiprofen: An anti-inflammatory analgesic and antipyretic of the phenylalkynoic acid series. It has been shown to reduce bone resorption in periodontal disease by inhibiting CARBONIC ANHYDRASE.. flurbiprofen : A monocarboxylic acid that is a 2-fluoro-[1,1'-biphenyl-4-yl] moiety linked to C-2 of propionic acid. A non-steroidal anti-inflammatory, analgesic and antipyretic, it is used as a pre-operative anti-miotic as well as orally for arthritis or dental pain.	3.28	6	0	fluorobiphenyl; monocarboxylic acid	antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
flutamide Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.	2.21	1	0	(trifluoromethyl)benzenes; monocarboxylic acid amide	androgen antagonist; antineoplastic agent
fpl 64176 FPL 64176: an activator of L-type calcium channels; structure given in first source. FPL 64176 : 1H-Pyrrole substituted at C-2 and -5 by methyl groups, at C-3 by methoxycarbonyl and at C-4 by a 2-benzylbenzoyl group.	2.05	1	0	carboxylic ester; pyrroles	calcium channel agonist
furosemide Furosemide: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.. furosemide : A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure.	2.4	2	0	chlorobenzoic acid; furans; sulfonamide	environmental contaminant; loop diuretic; xenobiotic
gentamicin Gentamicins: A complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS.	2.48	2	0
glyburide Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide. glyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group.	4.38	6	0	monochlorobenzenes; N-sulfonylurea	anti-arrhythmia drug; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor; hypoglycemic agent
guanethidine Guanethidine: An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues.. guanethidine : A member of the class of guanidines in which one of the hydrogens of the amino group has been replaced by a 2-azocan-1-ylethyl group.. guanethidine sulfate : A organic sulfate salt composed of two molecules of guanethidine and one of sulfuric acid.	2.05	1	0	azocanes; guanidines	adrenergic antagonist; antihypertensive agent; sympatholytic agent
guanidine Guanidine: A strong organic base existing primarily as guanidium ions at physiological pH. It is found in the urine as a normal product of protein metabolism. It is also used in laboratory research as a protein denaturant. (From Martindale, the Extra Pharmacopoeia, 30th ed and Merck Index, 12th ed) It is also used in the treatment of myasthenia and as a fluorescent probe in HPLC.. guanidine : An aminocarboxamidine, the parent compound of the guanidines.	2	1	0	carboxamidine; guanidines; one-carbon compound
haloperidol Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279). haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.	3.91	3	0	aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol	antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist
halothane [no description available]	5.3	6	0	haloalkane; organobromine compound; organochlorine compound; organofluorine compound	inhalation anaesthetic
hexadecanesulfonyl fluoride AM 374: a palmitylsulfonyl fluoride; inhibits anandamide amidase; structure given in first source	4.88	6	0	acyl fluoride
hexachlorophene Hexachlorophene: A chlorinated bisphenol antiseptic with a bacteriostatic action against Gram-positive organisms, but much less effective against Gram-negative organisms. It is mainly used in soaps and creams and is an ingredient of various preparations used for skin disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p797). hexachlorophene : An organochlorine compound that is diphenylmethane in which each of the phenyl groups is substituted by chlorines at positions 2, 3, and 5, and by a hydroxy group at position 6. An antiseptic that is effective against Gram-positive organisms, it is used in soaps and creams for the treatment of various skin disorders. It is also used in agriculture as an acaricide and fungicide, but is not approved for such use within the European Union.	2.25	1	0	bridged diphenyl fungicide; polyphenol; trichlorobenzene	acaricide; antibacterial agent; antifungal agrochemical; antiseptic drug
hexamethonium Hexamethonium: A nicotinic cholinergic antagonist often referred to as the prototypical ganglionic blocker. It is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier. It has been used for a variety of therapeutic purposes including hypertension but, like the other ganglionic blockers, it has been replaced by more specific drugs for most purposes, although it is widely used a research tool.	2.71	3	0	quaternary ammonium salt
ibuprofen Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine	5.06	13	0	monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; radical scavenger; xenobiotic
lidocaine Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.. lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.	4.18	2	0	benzenes; monocarboxylic acid amide; tertiary amino compound	anti-arrhythmia drug; drug allergen; environmental contaminant; local anaesthetic; xenobiotic
imipramine Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.. imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom.	2.74	3	0	dibenzoazepine	adrenergic uptake inhibitor; antidepressant; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
indomethacin Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.	10.95	33	0	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic
iproniazid [no description available]	2.05	1	0	carbohydrazide; pyridines
isoflurane Isoflurane: A stable, non-explosive inhalation anesthetic, relatively free from significant side effects.	4.08	4	0	organofluorine compound	inhalation anaesthetic
isoproterenol Isoproterenol: Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant.. isoprenaline : A secondary amino compound that is noradrenaline in which one of the hydrogens attached to the nitrogen is replaced by an isopropyl group. A sympathomimetic acting almost exclusively on beta-adrenergic receptors, it is used (mainly as the hydrochloride salt) as a bronghodilator and heart stimulant for the management of a variety of cardiac disorders.	2.42	2	0	catechols; secondary alcohol; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; sympathomimetic agent
isradipine Isradipine: A potent antagonist of CALCIUM CHANNELS that is highly selective for VASCULAR SMOOTH MUSCLE. It is effective in the treatment of chronic stable angina pectoris, hypertension, and congestive cardiac failure.	2.69	3	0	benzoxadiazole; dihydropyridine; isopropyl ester; methyl ester
itraconazole [no description available]	2.03	1	0	piperazines
ketamine Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.. ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.	3.69	2	0	cyclohexanones; monochlorobenzenes; secondary amino compound	analgesic; environmental contaminant; intravenous anaesthetic; neurotoxin; NMDA receptor antagonist; xenobiotic
ketanserin Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.. ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.	3.56	1	1	aromatic ketone; organofluorine compound; piperidines; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; cardiovascular drug; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; serotonergic antagonist
ketoconazole 1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.	7.46	2	0	dichlorobenzene; dioxolane; ether; imidazoles; N-acylpiperazine; N-arylpiperazine
ketorolac Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed). ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure.. 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively.	7	1	0	amino acid; aromatic ketone; monocarboxylic acid; pyrrolizines; racemate	analgesic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
loratadine Loratadine: A second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Unlike most classical antihistamines (HISTAMINE H1 ANTAGONISTS) it lacks central nervous system depressing effects such as drowsiness.. loratadine : A benzocycloheptapyridine that is 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine substituted by a chloro group at position 8 and a 1-(ethoxycarbonyl)piperidin-4-ylidene group at position 11. It is a H1-receptor antagonist commonly employed in the treatment of allergic disorders.	3.31	1	0	benzocycloheptapyridine; ethyl ester; N-acylpiperidine; organochlorine compound; tertiary carboxamide	anti-allergic agent; cholinergic antagonist; geroprotector; H1-receptor antagonist
losartan Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.. losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position	2.07	1	0	biphenylyltetrazole; imidazoles	angiotensin receptor antagonist; anti-arrhythmia drug; antihypertensive agent; endothelin receptor antagonist
loxapine Loxapine: An antipsychotic agent used in SCHIZOPHRENIA.	3.23	1	0	dibenzooxazepine	antipsychotic agent; dopaminergic antagonist
ly 278584 LY 278584: structure given in first source; RN given refers to cpd without isomeric designation	2.01	1	0	aromatic amide; indazoles
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source	2.03	1	0	chromones; morpholines; organochlorine compound	autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector
mecamylamine Mecamylamine: A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool.	2.44	2	0	primary aliphatic amine
mefenamic acid Mefenamic Acid: A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.. mefenamic acid : An aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 2,3-dimethylphenyl group. Although classed as a non-steroidal anti-inflammatory drug, its anti-inflammatory properties are considered to be minor. It is used to relieve mild to moderate pain, including headaches, dental pain, osteoarthritis and rheumatoid arthritis.	3.23	1	0	aminobenzoic acid; secondary amino compound	analgesic; antipyretic; antirheumatic drug; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-steroidal anti-inflammatory drug; xenobiotic
mepivacaine Mepivacaine: A local anesthetic that is chemically related to BUPIVACAINE but pharmacologically related to LIDOCAINE. It is indicated for infiltration, nerve block, and epidural anesthesia. Mepivacaine is effective topically only in large doses and therefore should not be used by this route. (From AMA Drug Evaluations, 1994, p168). mepivacaine : A piperidinecarboxamide in which N-methylpipecolic acid and 2,6-dimethylaniline have combined to form the amide bond. It is used as a local amide-type anaesthetic.	3.31	1	0	piperidinecarboxamide	drug allergen; local anaesthetic
mesalamine Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed). mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position.	2.03	1	0	amino acid; aromatic amine; monocarboxylic acid; monohydroxybenzoic acid; phenols	non-steroidal anti-inflammatory drug
metformin Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289). metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.	7.15	1	0	guanidines	environmental contaminant; geroprotector; hypoglycemic agent; xenobiotic
methamidophos methamidophos: structure. methamidophos : An organic thiophosphate resulting from the N-deacylation of the proinsecticide acephate.	2	1	0	organic thiophosphate; organothiophosphate insecticide; phosphoramide	acaricide; agrochemical; avicide
metronidazole Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.. metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.	2.03	1	0	C-nitro compound; imidazoles; primary alcohol	antiamoebic agent; antibacterial drug; antimicrobial agent; antiparasitic agent; antitrichomonal drug; environmental contaminant; prodrug; radiosensitizing agent; xenobiotic
metyrapone Metyrapone: An inhibitor of the enzyme STEROID 11-BETA-MONOOXYGENASE. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of CUSHING SYNDROME.. metyrapone : An aromatic ketone that is 3,3-dimethylbutan-2-one in which the methyl groups at positions 1 and 4 are replaced by pyridin-3-yl groups. A steroid 11beta-monooxygenase (EC 1.14.15.4) inhibitor, it is used in the diagnosis of adrenal insufficiency.	2.59	2	0	aromatic ketone	antimetabolite; diagnostic agent; EC 1.14.15.4 (steroid 11beta-monooxygenase) inhibitor
mexiletine Mexiletine: Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties.. mexiletine : An aromatic ether which is 2,6-dimethylphenyl ether of 2-aminopropan-1-ol.	3.23	1	0	aromatic ether; primary amino compound	anti-arrhythmia drug
miconazole Miconazole: An imidazole antifungal agent that is used topically and by intravenous infusion.. 1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]imidazole : A member of the class of imidazoles that is 1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)ethanol in which the hydroxyl hydrogen is replaced by a 2,4-dichlorobenzyl group.. miconazole : A racemate composed of equimolar amounts of (R)- and (S)-miconazole. Used (as its nitrate salt) to treat skin infections such as athlete's foot, jock itch, ringworm and other fungal skin infections. It inhibits the synthesis of ergosterol, a critical component of fungal cell membranes.	2.42	2	0	dichlorobenzene; ether; imidazoles
midazolam Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.. midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.	2.05	1	0	imidazobenzodiazepine; monofluorobenzenes; organochlorine compound	anticonvulsant; antineoplastic agent; anxiolytic drug; apoptosis inducer; central nervous system depressant; GABAA receptor agonist; general anaesthetic; muscle relaxant; sedative
muscimol Muscimol: A neurotoxic isoxazole isolated from species of AMANITA. It is obtained by decarboxylation of IBOTENIC ACID. Muscimol is a potent agonist of GABA-A RECEPTORS and is used mainly as an experimental tool in animal and tissue studies.. muscimol : A member of the class of isoxazoles that is 1,2-oxazol-3(2H)-one substituted by an aminomethyl group at position 5. It has been isolated from mushrooms of the genus Amanita.	7.42	2	0	alkaloid; isoxazoles; primary amino compound	fungal metabolite; GABA agonist; oneirogen; psychotropic drug
ethylmaleimide Ethylmaleimide: A sulfhydryl reagent that is widely used in experimental biochemical studies.	3.25	1	0	maleimides	anticoronaviral agent; EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor; EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor; EC 2.7.1.1 (hexokinase) inhibitor
fg 7142 FG 7142: benzodiazepine receptor agonist	2.05	1	0	beta-carbolines
nifedipine Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.	4.76	3	0	C-nitro compound; dihydropyridine; methyl ester	calcium channel blocker; human metabolite; tocolytic agent; vasodilator agent
niflumic acid Niflumic Acid: An analgesic and anti-inflammatory agent used in the treatment of rheumatoid arthritis.	4.78	3	0	aromatic carboxylic acid; pyridines
nimesulide nimesulide: structure. nimesulide : An aromatic ether having phenyl and 2-methylsulfonamido-5-nitrophenyl as the two aryl groups.	3.16	5	0	aromatic ether; C-nitro compound; sulfonamide	cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
nitroglycerin Nitroglycerin: A volatile vasodilator which relieves ANGINA PECTORIS by stimulating GUANYLATE CYCLASE and lowering cytosolic calcium. It is also sometimes used for TOCOLYSIS and explosives.. nitroglycerol : A nitrate ester that is glycerol in which nitro group(s) replace the hydrogen(s) attached to one or more of the hydroxy groups.. nitroglycerin : A nitroglycerol that is glycerol in which the hydrogen atoms of all three hydroxy groups are replaced by nitro groups. It acts as a prodrug, releasing nitric oxide to open blood vessels and so alleviate heart pain.	3.34	6	0	nitroglycerol	explosive; muscle relaxant; nitric oxide donor; prodrug; tocolytic agent; vasodilator agent; xenobiotic
norfluoxetine norfluoxetine: metabolite of fluoxetine; RN given refers to parent cpd without isomeric designation	3.23	1	0	(trifluoromethyl)benzenes
ns 1619 NS 1619: structure given in first source. NS 1619 : A member of the class of benzimidazoles that is 1,3-dihydro-2H-benzimidazol-2-one in which the hydrogens at positions 1 and 5 are replaced are replaced by 2-hydroxy-5-(trifluoromethyl)phenyl and trifluoromethyl groups, respectively. It is an opener/activator of the large-conductance calcium-activated potassium channel (Bkca).	1.99	1	0	(trifluoromethyl)benzenes; benzimidazoles; phenols	potassium channel opener
n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide: structure given in first source. NS-398 : A C-nitro compound that is N-methylsulfonyl-4-nitroaniline bearing an additional cyclohexyloxy substituent at position 2.	2.43	2	0	aromatic ether; C-nitro compound; sulfonamide	antineoplastic agent; cyclooxygenase 2 inhibitor
ondansetron Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.	2.04	1	0	carbazoles
oxidopamine Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.. oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).	3.77	10	0	benzenetriol; catecholamine; primary amino compound	drug metabolite; human metabolite; neurotoxin
oxotremorine Oxotremorine: A non-hydrolyzed muscarinic agonist used as a research tool.	2.44	2	0	N-alkylpyrrolidine
fenclonine Fenclonine: A selective and irreversible inhibitor of tryptophan hydroxylase, a rate-limiting enzyme in the biosynthesis of serotonin (5-HYDROXYTRYPTAMINE). Fenclonine acts pharmacologically to deplete endogenous levels of serotonin.	2.07	1	0	phenylalanine derivative
palmidrol palmidrol: a cannabinoid receptor-inactive eCB-related molecule used as prophylactic in helping to prevent respiratory viral infection. palmitoyl ethanolamide : An N-(long-chain-acyl)ethanolamine that is the ethanolamide of palmitic (hexadecanoic) acid.	14.66	155	4	endocannabinoid; N-(long-chain-acyl)ethanolamine; N-(saturated fatty acyl)ethanolamine	anti-inflammatory drug; anticonvulsant; antihypertensive agent; neuroprotective agent
pd 98059 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one: inhibits MAP kinase kinase (MEK) activity, p42 MAPK and p44 MAPK; structure in first source. 2-(2-amino-3-methoxyphenyl)chromen-4-one : A member of the class of monomethoxyflavones that is 3'-methoxyflavone bearing an additional amino substituent at position 2'.	2.41	2	0	aromatic amine; monomethoxyflavone	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector
pentobarbital Pentobarbital: A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236). pentobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and sec-pentyl groups.	3.31	1	0	barbiturates	GABAA receptor agonist
phenolsulfonphthalein Phenolsulfonphthalein: Red dye, pH indicator, and diagnostic aid for determination of renal function. It is used also for studies of the gastrointestinal and other systems.. phenol red : 3H-2,1-Benzoxathiole 1,1-dioxide in which both of the hydrogens at position 3 have been substituted by 4-hydroxyphenyl groups. A pH indicator changing colour from yellow below pH 6.8 to bright pink above pH 8.2, it is commonly used as an indicator in cell cultures and in home swimming pool test kits. It is also used in the (now infrequently performed) phenolsulfonphthalein (PSP) test for estimation of overall blood flow through the kidney.	2.04	1	0	2,1-benzoxathiole; arenesulfonate ester; phenols; sultone	acid-base indicator; diagnostic agent; two-colour indicator
phenylmethylsulfonyl fluoride Phenylmethylsulfonyl Fluoride: An enzyme inhibitor that inactivates IRC-50 arvin, subtilisin, and the fatty acid synthetase complex.. phenylmethanesulfonyl fluoride : An acyl fluoride with phenylmethanesulfonyl as the acyl group.	6.48	34	0	acyl fluoride	serine proteinase inhibitor
phloretin [no description available]	1.99	1	0	dihydrochalcones	antineoplastic agent; plant metabolite
moxonidine moxonidine: structure given in first source	2	1	0	organohalogen compound; pyrimidines
pinacidil Pinacidil: A guanidine that opens POTASSIUM CHANNELS producing direct peripheral vasodilatation of the ARTERIOLES. It reduces BLOOD PRESSURE and peripheral resistance and produces fluid retention. (Martindale The Extra Pharmacopoeia, 31st ed)	2.42	2	0	pyridines
pioglitazone Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.. pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.	2.02	1	0	aromatic ether; pyridines; thiazolidinediones	antidepressant; cardioprotective agent; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; geroprotector; hypoglycemic agent; insulin-sensitizing drug; PPARgamma agonist; xenobiotic
piperazine [no description available]	2.05	1	0	azacycloalkane; piperazines; saturated organic heteromonocyclic parent	anthelminthic drug
potassium chloride Potassium Chloride: A white crystal or crystalline powder used in BUFFERS; FERTILIZERS; and EXPLOSIVES. It can be used to replenish ELECTROLYTES and restore WATER-ELECTROLYTE BALANCE in treating HYPOKALEMIA.. potassium chloride : A metal chloride salt with a K(+) counterion.	3.82	11	0	inorganic chloride; inorganic potassium salt; potassium salt	fertilizer
prazosin Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.. prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.	2.75	3	0	aromatic ether; furans; monocarboxylic acid amide; piperazines; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
proadifen Proadifen: An inhibitor of drug metabolism and CYTOCHROME P-450 ENZYME SYSTEM activity.	1.99	1	0	diarylmethane
probenecid Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.. probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.	2	1	0	benzoic acids; sulfonamide	uricosuric drug
propafenone Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.. propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.	3.57	2	0	aromatic ketone; secondary alcohol; secondary amino compound	anti-arrhythmia drug
propofol Propofol: An intravenous anesthetic agent which has the advantage of a very rapid onset after infusion or bolus injection plus a very short recovery period of a couple of minutes. (From Smith and Reynard, Textbook of Pharmacology, 1992, 1st ed, p206). Propofol has been used as ANTICONVULSANTS and ANTIEMETICS.. propofol : A phenol resulting from the formal substitution of the hydrogen at the 2 position of 1,3-diisopropylbenzene by a hydroxy group.	6.43	7	1	phenols	anticonvulsant; antiemetic; intravenous anaesthetic; radical scavenger; sedative
propranolol Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.. propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.	2.08	1	0	naphthalenes; propanolamine; secondary amine	anti-arrhythmia drug; antihypertensive agent; anxiolytic drug; beta-adrenergic antagonist; environmental contaminant; human blood serum metabolite; vasodilator agent; xenobiotic
pyrilamine Pyrilamine: A histamine H1 antagonist. It has mild hypnotic properties and some local anesthetic action and is used for allergies (including skin eruptions) both parenterally and locally. It is a common ingredient of cold remedies.. mepyramine : An ethylenediamine derivative that is ethylenediamine in which one of the amino nitrogens is substituted by two methyl groups and the remaining amino nitrogen is substituted by a 4-methoxybenzyl and a pyridin-2-yl group.	2	1	0	aromatic ether; ethylenediamine derivative	H1-receptor antagonist
resorcinol resorcinol: RN given refers to parent cpd; structure in Merck Index, 9th ed, #7951. resorcinol : A benzenediol that is benzene dihydroxylated at positions 1 and 3.	7.05	1	0	benzenediol; phenolic donor; resorcinols	erythropoietin inhibitor; sensitiser
riluzole Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.	8.59	2	0	benzothiazoles
rofecoxib [no description available]	7.43	2	0	butenolide; sulfone	analgesic; cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
rolipram [no description available]	2.02	1	0	pyrrolidin-2-ones	antidepressant; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
saccharin Saccharin: Flavoring agent and non-nutritive sweetener.. saccharin : A 1,2-benzisothiazole having a keto-group at the 3-position and two oxo substituents at the 1-position. It is used as an artificial sweetening agent.	2.78	3	0	1,2-benzisothiazole; N-sulfonylcarboxamide	environmental contaminant; sweetening agent; xenobiotic
sevoflurane Sevoflurane: A non-explosive inhalation anesthetic used in the induction and maintenance of general anesthesia. It does not cause respiratory irritation and may also prevent PLATELET AGGREGATION.. sevoflurane : An ether compound having fluoromethyl and 1,1,1,3,3,3-hexafluoroisopropyl as the two alkyl groups.	3.84	2	1	ether; organofluorine compound	central nervous system depressant; inhalation anaesthetic; platelet aggregation inhibitor
sibutramine sibutramine: serotonin and norepinephrine transporter inhibitor; Meridia is tradename for sibutramine hydrochloride	3.43	1	1	organochlorine compound; tertiary amino compound	anti-obesity agent; serotonin uptake inhibitor
iodoacetic acid Iodoacetic Acid: A derivative of ACETIC ACID that contains one IODINE atom attached to its methyl group.. iodoacetic acid : A haloacetic acid that is acetic acid in which one of the hydrogens of the methyl group is replaced by an iodine atom.	2.25	1	0	haloacetic acid; organoiodine compound	alkylating agent
sulfaphenazole Sulfaphenazole: A sulfonilamide anti-infective agent.. sulfaphenazole : A sulfonamide that is sulfanilamide in which the sulfonamide nitrogen is substituted by a 1-phenyl-1H-pyrazol-5-yl group. It is a selective inhibitor of cytochrome P450 (CYP) 2C9 isozyme, and antibacterial agent.	2.03	1	0	primary amino compound; pyrazoles; substituted aniline; sulfonamide antibiotic; sulfonamide	antibacterial drug; EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor; EC 1.14.13.67 (quinine 3-monooxygenase) inhibitor; P450 inhibitor
sulfinpyrazone Sulfinpyrazone: A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.	2.03	1	0	pyrazolidines; sulfoxide	uricosuric drug
sulpiride Sulpiride: A dopamine D2-receptor antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid. (From Merck Index, 11th ed). sulpiride : A member of the class of benzamides obtained from formal condensation between the carboxy group of 2-methoxy-5-sulfamoylbenzoic acid and the primary amino group of (1-ethylpyrrolidin-2-yl)methylamine.	3.46	1	1	benzamides; N-alkylpyrrolidine; sulfonamide	antidepressant; antiemetic; antipsychotic agent; dopaminergic antagonist
tetracaine Tetracaine: A potent local anesthetic of the ester type used for surface and spinal anesthesia.. tetracaine : A benzoate ester in which 4-N-butylbenzoic acid and 2-(dimethylamino)ethanol have combined to form the ester bond; a local ester anaesthetic (ester caine) used for surface and spinal anaesthesia.	3.31	1	0	benzoate ester; tertiary amino compound	local anaesthetic
tetraethylammonium Tetraethylammonium: A potassium-selective ion channel blocker. (From J Gen Phys 1994;104(1):173-90)	5.43	7	0	quaternary ammonium ion
thalidomide Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.. thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.. 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.	2.05	1	0	phthalimides; piperidones
tolbutamide Tolbutamide: A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290). tolbutamide : An N-sulfonylurea that consists of 1-butylurea having a tosyl group attached at the 3-position.	2.03	1	0	N-sulfonylurea	human metabolite; hypoglycemic agent; insulin secretagogue; potassium channel blocker
tolmetin Tolmetin: A non-steroidal anti-inflammatory agent (ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL) similar in mode of action to INDOMETHACIN.. tolmetin : A monocarboxylic acid that is (1-methylpyrrol-2-yl)acetic acid substituted at position 5 on the pyrrole ring by a 4-methylbenzoyl group. Used in the form of its sodium salt dihydrate as a nonselective nonsteroidal anti-inflammatory drug.	2	1	0	aromatic ketone; monocarboxylic acid; pyrroles	EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-steroidal anti-inflammatory drug
tolnaftate [no description available]	2.03	1	0	monothiocarbamic ester	antifungal drug
troglitazone Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.	2.02	1	0	chromanes; thiazolidinone	anticoagulant; anticonvulsant; antineoplastic agent; antioxidant; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; hypoglycemic agent; platelet aggregation inhibitor; vasodilator agent
tropicamide Tropicamide: One of the MUSCARINIC ANTAGONISTS with pharmacologic action similar to ATROPINE and used mainly as an ophthalmic parasympatholytic or mydriatic.	2.41	1	0	acetamides
tyramine [no description available]	2.08	1	0	monoamine molecular messenger; primary amino compound; tyramines	EC 3.1.1.8 (cholinesterase) inhibitor; Escherichia coli metabolite; human metabolite; mouse metabolite; neurotransmitter
urethane [no description available]	2.94	4	0	carbamate ester	fungal metabolite; mutagen
vesamicol vesamicol: RN given refers to parent cpd; structure	1.99	1	0	piperidines
(3r)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone [no description available]	2.02	1	0
xylazine Xylazine: An adrenergic alpha-2 agonist used as a sedative, analgesic and centrally acting muscle relaxant in VETERINARY MEDICINE.. xylazine : A methyl benzene that is 1,3-dimethylbenzene which is substituted by a 5,6-dihydro-4H-1,3-thiazin-2-ylnitrilo group at position 2. It is an alpha2 adrenergic receptor agonist and frequently used in veterinary medicine as an emetic and sedative with analgesic and muscle relaxant properties.	2.25	1	0	1,3-thiazine; methylbenzene; secondary amino compound	alpha-adrenergic agonist; analgesic; emetic; muscle relaxant; sedative
corticosterone [no description available]	9.45	21	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone	human metabolite; mouse metabolite
lysergic acid diethylamide Lysergic Acid Diethylamide: Semisynthetic derivative of ergot (Claviceps purpurea). It has complex effects on serotonergic systems including antagonism at some peripheral serotonin receptors, both agonist and antagonist actions at central nervous system serotonin receptors, and possibly effects on serotonin turnover. It is a potent hallucinogen, but the mechanisms of that effect are not well understood.. lysergic acid diethylamide : An ergoline alkaloid arising from formal condensation of lysergic acid with diethylamine.	2.6	1	0	ergoline alkaloid; monocarboxylic acid amide; organic heterotetracyclic compound	dopamine agonist; hallucinogen; serotonergic agonist
reserpine Reserpine: An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.. reserpine : An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria.	2	1	0	alkaloid ester; methyl ester; yohimban alkaloid	adrenergic uptake inhibitor; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; first generation antipsychotic; plant metabolite; xenobiotic
thymidine [no description available]	2.02	1	0	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; metabolite; mouse metabolite
benzimidazole 1H-benzimidazole : The 1H-tautomer of benzimidazole.	2.03	1	0	benzimidazole; polycyclic heteroarene
thyroxine Thyroxine: The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.. thyroxine : An iodothyronine compound having iodo substituents at the 3-, 3'-, 5- and 5'-positions.	2.46	2	0	2-halophenol; iodophenol; L-phenylalanine derivative; non-proteinogenic L-alpha-amino acid; thyroxine zwitterion; thyroxine	antithyroid drug; human metabolite; mouse metabolite; thyroid hormone
carbachol Carbachol: A slowly hydrolyzed CHOLINERGIC AGONIST that acts at both MUSCARINIC RECEPTORS and NICOTINIC RECEPTORS.	8.89	12	0	ammonium salt; carbamate ester	cardiotonic drug; miotic; muscarinic agonist; nicotinic acetylcholine receptor agonist; non-narcotic analgesic
aldosterone [no description available]	2.05	1	0	11beta-hydroxy steroid; 18-oxo steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid hormone; mineralocorticoid; primary alpha-hydroxy ketone; steroid aldehyde	human metabolite; mouse metabolite
penicillamine Penicillamine: 3-Mercapto-D-valine. The most characteristic degradation product of the penicillin antibiotics. It is used as an antirheumatic and as a chelating agent in Wilson's disease.. penicillamine : An alpha-amino acid having the structure of valine substituted at the beta position with a sulfanyl group.	2.4	2	0	non-proteinogenic alpha-amino acid; penicillamine	antirheumatic drug; chelator; copper chelator; drug allergen
dehydroepiandrosterone Dehydroepiandrosterone: A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.. dehydroepiandrosterone : An androstanoid that is androst-5-ene substituted by a beta-hydroxy group at position 3 and an oxo group at position 17. It is a naturally occurring steroid hormone produced by the adrenal glands.	3.76	2	0	17-oxo steroid; 3beta-hydroxy-Delta(5)-steroid; androstanoid	androgen; human metabolite; mouse metabolite
penicillin g Penicillin G: A penicillin derivative commonly used in the form of its sodium or potassium salts in the treatment of a variety of infections. It is effective against most gram-positive bacteria and against gram-negative cocci. It has also been used as an experimental convulsant because of its actions on GAMMA-AMINOBUTYRIC ACID mediated synaptic transmission.. benzylpenicillin : A penicillin in which the substituent at position 6 of the penam ring is a phenylacetamido group.	2	1	0	penicillin allergen; penicillin	antibacterial drug; drug allergen; epitope
pilocarpine Pilocarpine: A slowly hydrolyzed muscarinic agonist with no nicotinic effects. Pilocarpine is used as a miotic and in the treatment of glaucoma.. (+)-pilocarpine : The (+)-enantiomer of pilocarpine.	2.74	3	0	pilocarpine	antiglaucoma drug
pentylenetetrazole Pentylenetetrazole: A pharmaceutical agent that displays activity as a central nervous system and respiratory stimulant. It is considered a non-competitive GAMMA-AMINOBUTYRIC ACID antagonist. Pentylenetetrazole has been used experimentally to study seizure phenomenon and to identify pharmaceuticals that may control seizure susceptibility.. pentetrazol : An organic heterobicyclic compound that is 1H-tetrazole in which the hydrogens at positions 1 and 5 are replaced by a pentane-1,5-diyl group. A central and respiratory stimulant, it was formerly used for the treatment of cough and other respiratory tract disorders, cardiovascular disorders including hypotension, and pruritis.	2.85	3	0	organic heterobicyclic compound; organonitrogen heterocyclic compound
triiodothyronine Triiodothyronine: A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.. 3,3',5-triiodo-L-thyronine : An iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism.	2.46	2	0	2-halophenol; amino acid zwitterion; iodophenol; iodothyronine	human metabolite; mouse metabolite; thyroid hormone
biguanides Biguanides: Derivatives of biguanide (the structure formula HN(C(NH)NH2)2) that are primarily used as oral HYPOGLYCEMIC AGENTS for the treatment of DIABETES MELLITUS, TYPE 2 and PREDIABETES.. biguanides : A class of oral hypoglycemic drugs used for diabetes mellitus or prediabetes treatment. They have a structure based on the 2-carbamimidoylguanidine skeleton.	2.01	1	0	guanidines
alanine Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.. alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.	2.43	2	0	alanine zwitterion; alanine; L-alpha-amino acid; proteinogenic amino acid; pyruvate family amino acid	EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor; fundamental metabolite
serine Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.. serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.	3.07	4	0	L-alpha-amino acid; proteinogenic amino acid; serine family amino acid; serine zwitterion; serine	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
desoxycorticosterone acetate Desoxycorticosterone Acetate: The 21-acetate derivative of desoxycorticosterone.	2.17	1	0	corticosteroid hormone
aspartic acid Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.. aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent. L-aspartic acid : The L-enantiomer of aspartic acid.	2.71	3	0	aspartate family amino acid; aspartic acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; mouse metabolite; neurotransmitter
glutamine Glutamine: A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from GLUTAMIC ACID and AMMONIA. It is the principal carrier of NITROGEN in the body and is an important energy source for many cells.. L-glutamine : An optically active form of glutamine having L-configuration.. glutamine : An alpha-amino acid that consists of butyric acid bearing an amino substituent at position 2 and a carbamoyl substituent at position 4.	4.58	2	0	amino acid zwitterion; glutamine family amino acid; glutamine; L-alpha-amino acid; polar amino acid zwitterion; proteinogenic amino acid	EC 1.14.13.39 (nitric oxide synthase) inhibitor; Escherichia coli metabolite; human metabolite; metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
lysine Lysine: An essential amino acid. It is often added to animal feed.. lysine : A diamino acid that is caproic (hexanoic) acid bearing two amino substituents at positions 2 and 6.. L-lysine : An L-alpha-amino acid; the L-isomer of lysine.	2.05	1	0	aspartate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; lysine; organic molecular entity; proteinogenic amino acid	algal metabolite; anticonvulsant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
allyl isothiocyanate allyl isothiocyanate: used in the manufacture of flavors, war gases; medical use as a counterirritant; structure. allyl isothiocyanate : An isothiocyanate with the formula CH2=CHCH2N=C=S. A colorless oil with boiling point 152degreeC, it is responsible for the pungent taste of mustard, horseradish, and wasabi.	3.12	1	0	alkenyl isothiocyanate; isothiocyanate	antimicrobial agent; antineoplastic agent; apoptosis inducer; lachrymator; metabolite
sucrose Saccharum: A plant genus of the family POACEAE widely cultivated in the tropics for the sweet cane that is processed into sugar.	8.17	5	0	glycosyl glycoside	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; osmolyte; Saccharomyces cerevisiae metabolite; sweetening agent
ethinyl estradiol Ethinyl Estradiol: A semisynthetic alkylated ESTRADIOL with a 17-alpha-ethinyl substitution. It has high estrogenic potency when administered orally, and is often used as the estrogenic component in ORAL CONTRACEPTIVES.. 17alpha-ethynylestradiol : A 3-hydroxy steroid that is estradiol substituted by a ethynyl group at position 17. It is a xenoestrogen synthesized from estradiol and has been shown to exhibit high estrogenic potency on oral administration.	2.15	1	0	17-hydroxy steroid; 3-hydroxy steroid; terminal acetylenic compound	xenoestrogen
apomorphine Apomorphine: A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use.	2.52	2	0	aporphine alkaloid	alpha-adrenergic drug; antidyskinesia agent; antiparkinson drug; dopamine agonist; emetic; serotonergic drug
adenosine diphosphate Adenosine Diphosphate: Adenosine 5'-(trihydrogen diphosphate). An adenine nucleotide containing two phosphate groups esterified to the sugar moiety at the 5'-position.	2.71	3	0	adenosine 5'-phosphate; purine ribonucleoside 5'-diphosphate	fundamental metabolite; human metabolite
bromodeoxyuridine Bromodeoxyuridine: A nucleoside that substitutes for thymidine in DNA and thus acts as an antimetabolite. It causes breaks in chromosomes and has been proposed as an antiviral and antineoplastic agent. It has been given orphan drug status for use in the treatment of primary brain tumors.	2.01	1	0	pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent
carbostyril Quinolones: A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID.. quinolin-2(1H)-one : A quinolone that is 1,2-dihydroquinoline substituted by an oxo group at position 2.	2.08	1	0	monohydroxyquinoline; quinolone	bacterial xenobiotic metabolite
phenylephrine Phenylephrine: An alpha-1 adrenergic agonist used as a mydriatic, nasal decongestant, and cardiotonic agent.. phenylephrine : A member of the class of the class of phenylethanolamines that is (1R)-2-(methylamino)-1-phenylethan-1-ol carrying an additional hydroxy substituent at position 3 on the phenyl ring.	3.12	5	0	phenols; phenylethanolamines; secondary amino compound	alpha-adrenergic agonist; cardiotonic drug; mydriatic agent; nasal decongestant; protective agent; sympathomimetic agent; vasoconstrictor agent
levodopa Levodopa: The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.. L-dopa : An optically active form of dopa having L-configuration. Used to treat the stiffness, tremors, spasms, and poor muscle control of Parkinson's disease	3.31	6	0	amino acid zwitterion; dopa; L-tyrosine derivative; non-proteinogenic L-alpha-amino acid	allelochemical; antidyskinesia agent; antiparkinson drug; dopaminergic agent; hapten; human metabolite; mouse metabolite; neurotoxin; plant growth retardant; plant metabolite; prodrug
edetic acid Edetic Acid: A chelating agent that sequesters a variety of polyvalent cations such as CALCIUM. It is used in pharmaceutical manufacturing and as a food additive.	4.15	3	1	ethylenediamine derivative; polyamino carboxylic acid; tetracarboxylic acid	anticoagulant; antidote; chelator; copper chelator; geroprotector
tyrosine Tyrosine: A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.. tyrosine : An alpha-amino acid that is phenylalanine bearing a hydroxy substituent at position 4 on the phenyl ring.	8.47	7	0	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; proteinogenic amino acid; tyrosine	EC 1.3.1.43 (arogenate dehydrogenase) inhibitor; fundamental metabolite; micronutrient; nutraceutical
methoxamine Methoxamine: An alpha-1 adrenergic agonist that causes prolonged peripheral VASOCONSTRICTION.. methoxamine : An amphetamine in which the parent 1-phenylpropan-2-amine skeleton is substituted at position 1 with an hydroxy group and the phenyl ring is 2- and 5-substituted with methoxy groups. It is an antihypotensive agent (pressor), an agonist acting directly at alpha-adrenoceptors with selectivity for the alpha-1 adrenoceptor subtype similar to phenylephrine .	1.99	1	0	amphetamines	alpha-adrenergic agonist; antihypotensive agent
methacholine chloride Methacholine Chloride: A quaternary ammonium parasympathomimetic agent with the muscarinic actions of ACETYLCHOLINE. It is hydrolyzed by ACETYLCHOLINESTERASE at a considerably slower rate than ACETYLCHOLINE and is more resistant to hydrolysis by nonspecific CHOLINESTERASES so that its actions are more prolonged. It is used as a parasympathomimetic bronchoconstrictor agent and as a diagnostic aid for bronchial asthma. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1116)	3.63	3	0	quaternary ammonium salt
carbaryl Carbaryl: A carbamate insecticide and parasiticide. It is a potent anticholinesterase agent belonging to the carbamate group of reversible cholinesterase inhibitors. It has a particularly low toxicity from dermal absorption and is used for control of head lice in some countries.. carbaryl : A carbamate ester obtained by the formal condensation of 1-naphthol with methylcarbamic acid.	3.14	1	0	carbamate ester; naphthalenes	acaricide; agrochemical; carbamate insecticide; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; plant growth retardant
cytidine diphosphate Cytidine Diphosphate: Cytidine 5'-(trihydrogen diphosphate). A cytosine nucleotide containing two phosphate groups esterified to the sugar moiety. Synonyms: CRPP; cytidine pyrophosphate.	3.18	1	0	cytidine 5'-phosphate; pyrimidine ribonucleoside 5'-diphosphate	Escherichia coli metabolite; mouse metabolite
uridine triphosphate Uridine Triphosphate: Uridine 5'-(tetrahydrogen triphosphate). A uracil nucleotide containing three phosphate groups esterified to the sugar moiety.	2.02	1	0	pyrimidine ribonucleoside 5'-triphosphate; uridine 5'-phosphate	Escherichia coli metabolite; mouse metabolite
methionine Methionine: A sulfur-containing essential L-amino acid that is important in many body functions.. methionine : A sulfur-containing amino acid that is butyric acid bearing an amino substituent at position 2 and a methylthio substituent at position 4.	2.01	1	0	aspartate family amino acid; L-alpha-amino acid; methionine zwitterion; methionine; proteinogenic amino acid	antidote to paracetamol poisoning; human metabolite; micronutrient; mouse metabolite; nutraceutical
1,2-dipalmitoylphosphatidylcholine 1,2-Dipalmitoylphosphatidylcholine: Synthetic phospholipid used in liposomes and lipid bilayers to study biological membranes. It is also a major constituent of PULMONARY SURFACTANTS.	2.43	2	0
cycloheximide Cycloheximide: Antibiotic substance isolated from streptomycin-producing strains of Streptomyces griseus. It acts by inhibiting elongation during protein synthesis.. cycloheximide : A dicarboximide that is 4-(2-hydroxyethyl)piperidine-2,6-dione in which one of the hydrogens attached to the carbon bearing the hydroxy group is replaced by a 3,5-dimethyl-2-oxocyclohexyl group. It is an antibiotic produced by the bacterium Streptomyces griseus.	2.02	1	0	antibiotic fungicide; cyclic ketone; dicarboximide; piperidine antibiotic; piperidones; secondary alcohol	anticoronaviral agent; bacterial metabolite; ferroptosis inhibitor; neuroprotective agent; protein synthesis inhibitor
egtazic acid Egtazic Acid: A chelating agent relatively more specific for calcium and less toxic than EDETIC ACID.. ethylene glycol bis(2-aminoethyl)tetraacetic acid : A diether that is ethylene glycol in which the hydrogens of the hydroxy groups have been replaced by 2-[bis(carboxymethyl)amino]ethyl group respectively.	3.52	8	0	diether; tertiary amino compound; tetracarboxylic acid	chelator
chloroform Chloroform: A commonly used laboratory solvent. It was previously used as an anesthetic, but was banned from use in the U.S. due to its suspected carcinogenicity.. chloroform : A one-carbon compound that is methane in which three of the hydrogens are replaced by chlorines.	2.7	3	0	chloromethanes; one-carbon compound	carcinogenic agent; central nervous system drug; inhalation anaesthetic; non-polar solvent; refrigerant
gliotoxin Gliotoxin: A fungal toxin produced by various species of Trichoderma, Gladiocladium fimbriatum, Aspergillus fumigatus, and Penicillium. It is used as an immunosuppressive agent.. gliotoxin : A pyrazinoindole with a disulfide bridge spanning a dioxo-substituted pyrazine ring; mycotoxin produced by several species of fungi.	3.12	1	0	dipeptide; organic disulfide; organic heterotetracyclic compound; pyrazinoindole	antifungal agent; EC 2.5.1.58 (protein farnesyltransferase) inhibitor; immunosuppressive agent; mycotoxin; proteasome inhibitor
ampicillin Ampicillin: Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.. ampicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-phenylacetamido group.	2.25	1	0	beta-lactam antibiotic; penicillin allergen; penicillin	antibacterial drug
dithionitrobenzoic acid Dithionitrobenzoic Acid: A standard reagent for the determination of reactive sulfhydryl groups by absorbance measurements. It is used primarily for the determination of sulfhydryl and disulfide groups in proteins. The color produced is due to the formation of a thio anion, 3-carboxyl-4-nitrothiophenolate.. dithionitrobenzoic acid : An organic disulfide that results from the formal oxidative dimerisation of 2-nitro-5-thiobenzoic acid. An indicator used to quantify the number or concentration of thiol groups.	2	1	0	nitrobenzoic acid; organic disulfide	indicator
ornithine Ornithine: An amino acid produced in the urea cycle by the splitting off of urea from arginine.. ornithine : An alpha-amino acid that is pentanoic acid bearing two amino substituents at positions 2 and 5.	2.1	1	0	non-proteinogenic L-alpha-amino acid; ornithine	algal metabolite; hepatoprotective agent; mouse metabolite
dinitrofluorobenzene Dinitrofluorobenzene: Irritants and reagents for labeling terminal amino acid groups.. 1-fluoro-2,4-dinitrobenzene : The organofluorine compound that is benzene with a fluoro substituent at the 1-position and two nitro substituents in the 2- and 4-positions.	2.03	1	0	C-nitro compound; organofluorine compound	agrochemical; allergen; chromatographic reagent; EC 2.7.3.2 (creatine kinase) inhibitor; protein-sequencing agent; spectrophotometric reagent
asparagine Asparagine: A non-essential amino acid that is involved in the metabolic control of cell functions in nerve and brain tissue. It is biosynthesized from ASPARTIC ACID and AMMONIA by asparagine synthetase. (From Concise Encyclopedia Biochemistry and Molecular Biology, 3rd ed). asparagine : An alpha-amino acid in which one of the hydrogens attached to the alpha-carbon of glycine is substituted by a 2-amino-2-oxoethyl group.	2	1	0	amino acid zwitterion; asparagine; aspartate family amino acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
valine Valine: A branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.. valine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isopropyl group.. L-valine : The L-enantiomer of valine.	2.06	1	0	L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid; pyruvate family amino acid; valine	algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
arginine Arginine: An essential amino acid that is physiologically active in the L-form.. arginine : An alpha-amino acid that is glycine in which the alpha-is substituted by a 3-guanidinopropyl group.	2.98	4	0	arginine; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	biomarker; Escherichia coli metabolite; micronutrient; mouse metabolite; nutraceutical
acetonitrile acetonitrile: RN given refers to unlabeled cpd. acetonitrile : A nitrile that is hydrogen cyanide in which the hydrogen has been replaced by a methyl group.	7.11	1	0	aliphatic nitrile; volatile organic compound	EC 3.5.1.4 (amidase) inhibitor; NMR chemical shift reference compound; polar aprotic solvent
bromcresol green Bromcresol Green: An indicator and reagent. It has been used in serum albumin determinations and as a pH indicator.	1.99	1	0	benzofurans
phencyclidine Phencyclidine: A hallucinogen formerly used as a veterinary anesthetic, and briefly as a general anesthetic for humans. Phencyclidine is similar to KETAMINE in structure and in many of its effects. Like ketamine, it can produce a dissociative state. It exerts its pharmacological action through inhibition of NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE). As a drug of abuse, it is known as PCP and Angel Dust.. phencyclidine : A member of the class of piperidines that is piperidine in which the nitrogen is substituted with a 1-phenylcyclohexyl group. Formerly used as an anaesthetic agent, it exhibits both hallucinogenic and neurotoxic effects.	2.98	4	0	benzenes; piperidines	anaesthetic; neurotoxin; NMDA receptor antagonist; psychotropic drug
bisphenol a 4,4'-isopropylidene diphenol: stimulates proliferative responses and cytokine productions of murine spleen cells and thymus cells in vitro. bisphenol : By usage, the methylenediphenols, HOC6H4CH2C6H4OH, commonly p,p-methylenediphenol, and their substitution products (generally derived from condensation of two equivalent amounts of a phenol with an aldehyde or ketone). The term also includes analogues in the the methylene (or substituted methylene) group has been replaced by a heteroatom.. bisphenol A : A bisphenol that is 4,4'-methanediyldiphenol in which the methylene hydrogens are replaced by two methyl groups.	2.13	1	0	bisphenol	endocrine disruptor; environmental contaminant; xenobiotic; xenoestrogen
taurocholic acid Taurocholic Acid: The product of conjugation of cholic acid with taurine. Its sodium salt is the chief ingredient of the bile of carnivorous animals. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is used as a cholagogue and cholerectic.. taurocholate : An organosulfonate oxoanion that is the conjugate base of taurocholic acid.. taurocholic acid : A bile acid taurine conjugate of cholic acid that usually occurs as the sodium salt of bile in mammals.	2.02	1	0	amino sulfonic acid; bile acid taurine conjugate	human metabolite
penicillin v Penicillin V: A broad-spectrum penicillin antibiotic used orally in the treatment of mild to moderate infections by susceptible gram-positive organisms.. phenoxymethylpenicillin : A penicillin compound having a 6beta-(phenoxyacetyl)amino side-chain.	2.03	1	0	penicillin allergen; penicillin
2,4-dinitrobenzenesulfonic acid 2,4-dinitrobenzenesulfonic acid: RN given refers to parent cpd; structure. 2,4-dinitrobenzenesulfonic acid : The arenesulfonic acid that is benzenesulfonic acid with two nitro substituents in the 2- and 4-positions.	2.03	1	0	arenesulfonic acid; C-nitro compound
quinoxalines quinoxaline : A naphthyridine in which the nitrogens are at positions 1 and 4.	3.12	5	0	mancude organic heterobicyclic parent; naphthyridine; ortho-fused heteroarene
xanthenes Xanthenes: Compounds with three aromatic rings in linear arrangement with an OXYGEN in the center ring.	2.71	3	0	xanthene
propylparaben Parabens: Methyl, propyl, butyl, and ethyl esters of p-hydroxybenzoic acid. They have been approved by the FDA as antimicrobial agents for foods and pharmaceuticals. (From Hawley's Condensed Chemical Dictionary, 11th ed, p872)	2.13	1	0	benzoate ester; paraben; phenols	antifungal agent; antimicrobial agent
quinuclidines Quinuclidines: A class of organic compounds which contain two rings that share a pair of bridgehead carbon atoms and contains an amine group.	2.03	1	0	quinuclidines; saturated organic heterobicyclic parent
acrolein [no description available]	4.12	3	1	enal	herbicide; human xenobiotic metabolite; toxin
cyclohexanol Cyclohexanols: Monohydroxy derivatives of cyclohexanes that contain the general formula R-C6H11O. They have a camphorlike odor and are used in making soaps, insecticides, germicides, dry cleaning, and plasticizers.. cyclohexanols : An alcohol in which one or more hydroxy groups are attached to a cyclohexane skeleton.	8.5	109	0	cyclohexanols; secondary alcohol	solvent
tetraethyleneglycol dimethacrylate tetraethyleneglycol dimethacrylate: structure in first source	2.04	1	0
pyrroles 1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.	2.44	2	0	pyrrole; secondary amine
piperidine [no description available]	2.05	1	0	azacycloalkane; piperidines; saturated organic heteromonocyclic parent; secondary amine	base; catalyst; human metabolite; non-polar solvent; plant metabolite; protic solvent; reagent
heptanol Heptanol: A colorless liquid with a fragrant odor. It is used as an intermediate, solvent and in cosmetics.. heptanol : A fatty alcohol consisting of a hydroxy function at any position of an unbranched saturated chain of seven carbon atoms.. heptan-1-ol : A primary alcohol that is heptane substituted by a hydroxy group at position 1. It has been isolated from Capillipedium parviflorum.	2.42	2	0	heptanol; primary alcohol	flavouring agent; fragrance; gap junctional intercellular communication inhibitor; plant metabolite
diethylhexyl phthalate Diethylhexyl Phthalate: An ester of phthalic acid. It appears as a light-colored, odorless liquid and is used as a plasticizer for many resins and elastomers.. bis(2-ethylhexyl) phthalate : A phthalate ester that is the bis(2-ethylhexyl) ester of benzene-1,2-dicarboxylic acid.	7.52	2	0	diester; phthalate ester	androstane receptor agonist; apoptosis inhibitor; plasticiser
framycetin Framycetin: A component of NEOMYCIN that is produced by Streptomyces fradiae. On hydrolysis it yields neamine and neobiosamine B. (From Merck Index, 11th ed). framycetin : A tetracyclic antibacterial agent derived from neomycin, being a glycoside ester of neamine and neobiosamine B.	2.04	1	0	aminoglycoside	allergen; antibacterial drug; Escherichia coli metabolite
pregnenolone [no description available]	3.41	2	0	20-oxo steroid; 3beta-hydroxy-Delta(5)-steroid; C21-steroid	human metabolite; mouse metabolite
yohimbine Yohimbine: A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of ERECTILE DYSFUNCTION.. yohimbine : An indole alkaloid with alpha2-adrenoceptor antagonist activity. It is produced by Corynanthe johimbe and Rauwolfia serpentina.	3.15	5	0	methyl 17-hydroxy-20xi-yohimban-16-carboxylate	alpha-adrenergic antagonist; dopamine receptor D2 antagonist; serotonergic antagonist
diphenhydramine hydrochloride Antitussive Agents: Agents that suppress cough. They act centrally on the medullary cough center. EXPECTORANTS, also used in the treatment of cough, act locally.. diphenhydramine hydrochloride : The hydrochloride salt of diphenhydramine.	3.14	1	0	hydrochloride; organoammonium salt	anti-allergic agent; antiemetic; antiparkinson drug; antipruritic drug; H1-receptor antagonist; local anaesthetic; muscarinic antagonist; sedative
indazoles Indazoles: A group of heterocyclic aromatic organic compounds consisting of the fusion of BENZENE and PYRAZOLES.	2.45	2	0	indazole
cyclopentane Cyclopentanes: A group of alicyclic hydrocarbons with the general formula R-C5H9.. cyclopentanes : Cyclopentane and its derivatives formed by substitution.	7.08	1	0	cycloalkane; cyclopentanes; volatile organic compound	non-polar solvent
oxazoles Oxazoles: Five-membered heterocyclic ring structures containing an oxygen in the 1-position and a nitrogen in the 3-position, in distinction from ISOXAZOLES where they are at the 1,2 positions.. 1,3-oxazole : A five-membered monocyclic heteroarene that is an analogue of cyclopentadiene with O in place of CH2 at position 1 and N in place of CH at position 3.. oxazole : An azole based on a five-membered heterocyclic aromatic skeleton containing one N and one O atom.	3.16	5	0	1,3-oxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
thiazoles [no description available]	2.98	4	0	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
triphenyltetrazolium triphenyltetrazolium: RN given refers to parent cpd. 2,3,5-triphenyltetrazolium : An organic cation that is tetrazole carrying three phenyl substituents at positions 2, 3 and 5.	2.02	1	0	organic cation
muscarine Muscarine: A toxic alkaloid found in Amanita muscaria (fly fungus) and other fungi of the Inocybe species. It is the first parasympathomimetic substance ever studied and causes profound parasympathetic activation that may end in convulsions and death. The specific antidote is atropine.	2.03	1	0	monosaccharide
hydrazine diamine : Any polyamine that contains two amino groups.	2.42	2	0	azane; hydrazines	EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor
paraoxon [no description available]	2.48	2	0	aryl dialkyl phosphate; organophosphate insecticide	EC 3.1.1.7 (acetylcholinesterase) inhibitor; mouse metabolite
aminoimidazole carboxamide Aminoimidazole Carboxamide: An imidazole derivative which is a metabolite of the antineoplastic agents BIC and DIC. By itself, or as the ribonucleotide, it is used as a condensation agent in the preparation of nucleosides and nucleotides. Compounded with orotic acid, it is used to treat liver diseases.. 5-aminoimidazole-4-carboxamide : An aminoimidazole in which the amino group is at C-5 with a carboxamido group at C-4.	2.15	1	0	aminoimidazole; monocarboxylic acid amide	mouse metabolite
citrulline citrulline : The parent compound of the citrulline class consisting of ornithine having a carbamoyl group at the N(5)-position.	2.06	1	0	amino acid zwitterion; citrulline	Daphnia magna metabolite; EC 1.14.13.39 (nitric oxide synthase) inhibitor; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; protective agent; Saccharomyces cerevisiae metabolite
cyproterone acetate [no description available]	2.15	1	0	20-oxo steroid; 3-oxo-Delta(4) steroid; acetate ester; chlorinated steroid; steroid ester	androgen antagonist; geroprotector; progestin
4-toluenesulfonyl fluoride 4-toluenesulfonyl fluoride: inhibitor of peptide hydrolases; structure in second source	3.09	5	0
hydantoins Hydantoins: Compounds based on imidazolidine dione. Some derivatives are ANTICONVULSANTS.. imidazolidine-2,4-dione : An imidazolidinone with oxo groups at position 2 and 4.	2.41	2	0	imidazolidine-2,4-dione
bicuculline Bicuculline: An isoquinoline alkaloid obtained from Dicentra cucullaria and other plants. It is a competitive antagonist for GABA-A receptors.. bicuculline : A benzylisoquinoline alkaloid that is 6-methyl-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinoline which is substituted at the 5-pro-S position by a (6R)-8-oxo-6,8-dihydrofuro[3,4-e][1,3]benzodioxol-6-yl group. A light-sensitive competitive antagonist of GABAA receptors. It was originally identified in 1932 in plant alkaloid extracts and has been isolated from Dicentra cucullaria, Adlumia fungosa, Fumariaceae, and several Corydalis species.	3.85	11	0	benzylisoquinoline alkaloid; isoquinoline alkaloid; isoquinolines	agrochemical; central nervous system stimulant; GABA-gated chloride channel antagonist; GABAA receptor antagonist; neurotoxin
kainic acid Kainic Acid: (2S-(2 alpha,3 beta,4 beta))-2-Carboxy-4-(1-methylethenyl)-3-pyrrolidineacetic acid. Ascaricide obtained from the red alga Digenea simplex. It is a potent excitatory amino acid agonist at some types of excitatory amino acid receptors and has been used to discriminate among receptor types. Like many excitatory amino acid agonists it can cause neurotoxicity and has been used experimentally for that purpose.	4.57	9	0	dicarboxylic acid; L-proline derivative; non-proteinogenic L-alpha-amino acid; pyrrolidinecarboxylic acid	antinematodal drug; excitatory amino acid agonist
arachidic acid icosanoic acid : A C20 striaght-chain saturated fatty acid which forms a minor constituent of peanut (L. arachis) and corn oils. Used as an organic thin film in the production of liquid crystals for a wide variety of technical applications.	2.17	1	0	long-chain fatty acid; straight-chain saturated fatty acid	plant metabolite
oleanolic acid [no description available]	2.07	1	0	hydroxy monocarboxylic acid; pentacyclic triterpenoid	plant metabolite
methoxyhydroxyphenylglycol Methoxyhydroxyphenylglycol: Synthesized from endogenous epinephrine and norepinephrine in vivo. It is found in brain, blood, CSF, and urine, where its concentrations are used to measure catecholamine turnover.	2.45	2	0	methoxybenzenes; phenols
methamphetamine Methamphetamine: A central nervous system stimulant and sympathomimetic with actions and uses similar to DEXTROAMPHETAMINE. The smokable form is a drug of abuse and is referred to as crank, crystal, crystal meth, ice, and speed.. methamphetamine : A member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent.	2.74	3	0	amphetamines; secondary amine	central nervous system stimulant; environmental contaminant; neurotoxin; psychotropic drug; xenobiotic
malondialdehyde Malondialdehyde: The dialdehyde of malonic acid.. malonaldehyde : A dialdehyde that is propane substituted by two oxo groups at the terminal carbon atoms respectively. A biomarker of oxidative damage to lipids caused by smoking, it exists in vivo mainly in the enol form.	2.25	1	0	dialdehyde	biomarker
trinitrobenzenesulfonic acid Trinitrobenzenesulfonic Acid: A reagent that is used to neutralize peptide terminal amino groups.. 2,4,6-trinitrobenzenesulfonic acid : The arenesulfonic acid that is benzenesulfonic acid with three nitro substituents in the 2-, 4- and 6-positions.	2.44	2	0	arenesulfonic acid; C-nitro compound	epitope; explosive; reagent
dansyl chloride dansyl chloride: RN given refers to unlabeled cpd	2	1	0	aminonaphthalene; sulfonic acid derivative
acetylcysteine N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine.	3.3	6	0	acetylcysteine; L-cysteine derivative; N-acetyl-L-amino acid	antidote to paracetamol poisoning; antiinfective agent; antioxidant; antiviral drug; ferroptosis inhibitor; geroprotector; human metabolite; mucolytic; radical scavenger; vulnerary
erythromycin Erythromycin: A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.. erythromycin : Any of several wide-spectrum macrolide antibiotics obtained from actinomycete Saccharopolyspora erythraea (formerly known as Streptomyces erythraeus).. erythromycin A : An erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively.	2.03	1	0	cyclic ketone; erythromycin
diphenyl disulfide [no description available]	3.25	1	0	benzenes
aminoethyl-aminopropyl-trimethoxysilane aminoethyl-aminopropyl-trimethoxysilane: RN given refers to parent cpd; a silylating agent	2.05	1	0
tetrabutylammonium tetrabutylammonium: lipophilic probe; RN given refers to parent cpd	1.99	1	0	quaternary ammonium ion
dronabinol Dronabinol: A psychoactive compound extracted from the resin of Cannabis sativa (marihuana, hashish). The isomer delta-9-tetrahydrocannabinol (THC) is considered the most active form, producing characteristic mood and perceptual changes associated with this compound.. Delta(9)-tetrahydrocannabinol : A diterpenoid that is 6a,7,8,10a-tetrahydro-6H-benzo[c]chromene substituted at position 1 by a hydroxy group, positions 6, 6 and 9 by methyl groups and at position 3 by a pentyl group. The principal psychoactive constituent of the cannabis plant, it is used for treatment of anorexia associated with AIDS as well as nausea and vomiting associated with cancer chemotherapy.	15.62	229	2	benzochromene; diterpenoid; phytocannabinoid; polyketide	cannabinoid receptor agonist; epitope; hallucinogen; metabolite; non-narcotic analgesic
pimozide Pimozide: A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to HALOPERIDOL for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug Evaluations Annual, 1994, p403). pimozide : A member of the class of benzimidazoles that is 1,3-dihydro-2H-benzimidazol-2-one in which one of the nitrogens is substituted by a piperidin-4-yl group, which in turn is substituted on the nitrogen by a 4,4-bis(p-fluorophenyl)butyl group.	3.23	1	0	benzimidazoles; heteroarylpiperidine; organofluorine compound	antidyskinesia agent; dopaminergic antagonist; first generation antipsychotic; H1-receptor antagonist; serotonergic antagonist
dithiothreitol 1,4-dimercaptobutane-2,3-diol : A glycol that is butane-2,3-diol in which a hydrogen from each of the methyl groups is replaced by a thiol group.. 1,4-dithiothreitol : The threo-diastereomer of 1,4-dimercaptobutane-2,3-diol.	2.7	3	0	1,4-dimercaptobutane-2,3-diol; butanediols; dithiol; glycol; thiol	chelator; human metabolite; reducing agent
tranylcypromine Tranylcypromine: A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders. (From AMA Drug Evaluations Annual, 1994, p311). tranylcypromine : A racemate comprising equal amounts of (1R,2S)- and (1S,2R)-2-phenylcyclopropan-1-amine. An irreversible monoamine oxidase inhibitor that is used as an antidepressant (INN tranylcypromine).. (1R,2S)-tranylcypromine : A 2-phenylcyclopropan-1-amine that is the (1R,2S)-enantiomer of tranylcypromine.	2.04	1	0	2-phenylcyclopropan-1-amine
dideoxyadenosine Dideoxyadenosine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is an inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal side effect is nephrotoxicity. In vivo, dideoxyadenosine is rapidly metabolized to DIDANOSINE (ddI) by enzymatic deamination; ddI is then converted to dideoxyinosine monophosphate and ultimately to dideoxyadenosine triphosphate, the putative active metabolite.	2.11	1	0	adenosines; purine 2',3'-dideoxyribonucleoside	EC 3.5.4.4 (adenosine deaminase) inhibitor; EC 4.6.1.1 (adenylate cyclase) inhibitor
o,o-diethyl o-3,5,6-trichloro-2-pyridyl phosphate [no description available]	2.11	1	0
n-methylaspartate N-Methylaspartate: An amino acid that, as the D-isomer, is the defining agonist for the NMDA receptor subtype of glutamate receptors (RECEPTORS, NMDA).. N-methyl-D-aspartic acid : An aspartic acid derivative having an N-methyl substituent and D-configuration.	3.72	10	0	amino dicarboxylic acid; D-alpha-amino acid; D-aspartic acid derivative; secondary amino compound	neurotransmitter agent
lanthanum [no description available]	2.02	1	0	f-block element atom; lanthanoid atom; scandium group element atom
ruthenium Ruthenium: A hard, brittle, grayish-white rare earth metal with an atomic symbol Ru, atomic number 44, and atomic weight 101.07. It is used as a catalyst and hardener for PLATINUM and PALLADIUM.	2	1	0	iron group element atom; platinum group metal atom
gadolinium Gadolinium: An element of the rare earth family of metals. It has the atomic symbol Gd, atomic number 64, and atomic weight 157.25. Its oxide is used in the control rods of some nuclear reactors.	2.46	2	0	f-block element atom; lanthanoid atom
magnesium sulfate Magnesium Sulfate: A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions. (From AMA Drug Evaluations Annual, 1992, p1083). magnesium sulfate : A magnesium salt having sulfate as the counterion.	2.02	1	0	magnesium salt; metal sulfate; organic magnesium salt	anaesthetic; analgesic; anti-arrhythmia drug; anticonvulsant; calcium channel blocker; cardiovascular drug; fertilizer; tocolytic agent
galactosamine 2-amino-2-deoxy-D-galactopyranose : The pyranose form of D-galactosamine.. D-galactosamine : The D-stereoisomer of galactosamine.	2.05	1	0	D-galactosamine; primary amino compound	toxin
cesium chloride cesium chloride: RN given refers to unlabeled cpd. caesium chloride : The inorganic chloride salt of caesium; each caesium ion is coordinated by eight chlorine ions.	3.31	1	0	inorganic caesium salt; inorganic chloride	phase-transfer catalyst; vasoconstrictor agent
deuterium Deuterium: The stable isotope of hydrogen. It has one neutron and one proton in the nucleus.	2.39	2	0	dihydrogen
fluorine Fluorine: A nonmetallic, diatomic gas that is a trace element and member of the halogen family. It is used in dentistry as fluoride (FLUORIDES) to prevent dental caries.	2.08	1	0	diatomic fluorine; gas molecular entity	NMR chemical shift reference compound
chlorine Chlorine: An element with atomic symbol Cl, atomic number 17, and atomic weight 35, and member of the halogen family.	2.1	1	0	diatomic chlorine; gas molecular entity	bleaching agent
radon Radon: A naturally radioactive element with atomic symbol Rn, and atomic number 86. It is a member of the noble gas family found in soil, and is released during the decay of RADIUM.. radon(0) : A monoatomic radon that has an oxidation state of zero.	8.7	1	1	monoatomic radon; noble gas atom; p-block element atom
cadmium chloride Cadmium Chloride: A cadmium halide in the form of colorless crystals, soluble in water, methanol, and ethanol. It is used in photography, in dyeing, and calico printing, and as a solution to precipitate sulfides. (McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed). cadmium dichloride : A cadmium coordination entity in which cadmium(2+) and Cl(-) ions are present in the ratio 2:1. Although considered to be ionic, it has considerable covalent character to its bonding.	6.99	1	0	cadmium coordination entity
barium chloride barium chloride: RN given refers to parent cpd. barium chloride : The inorganic dichloride salt of barium.	2.44	2	0	barium salt; inorganic chloride	potassium channel blocker
diacerein diacerein: chelates with bivalent metals; a quinone which possesses redox properties; metabolized to active rhein; proposed mechanisms include inhibiting IL1 and metalloproteinases; called a slow acting symptomatic drug in osteoarthritis; no effect of cyclooxygenase;	3.25	1	0	anthraquinone
stearoylethanolamide N-(octadecanoyl)ethanolamine : An N-acylethanolamine 18:0 that is the ethanolamide of octadecanoic acid.	4.68	10	0	N-acylethanolamine 18:0
tetradecanoylphorbol acetate Tetradecanoylphorbol Acetate: A phorbol ester found in CROTON OIL with very effective tumor promoting activity. It stimulates the synthesis of both DNA and RNA.. phorbol ester : Esters of phorbol, originally found in croton oil (from Croton tiglium, of the family Euphorbiaceae). A number of phorbol esters possess activity as tumour promoters and activate the mechanisms associated with cell growth. Some of these are used in experiments as activators of protein kinase C.. phorbol 13-acetate 12-myristate : A phorbol ester that is phorbol in which the hydroxy groups at the cyclopropane ring juction (position 13) and the adjacent carbon (position 12) have been converted into the corresponding acetate and myristate esters. It is a major active constituent of the seed oil of Croton tiglium. It has been used as a tumour promoting agent for skin carcinogenesis in rodents and is associated with increased cell proliferation of malignant cells. However its function is controversial since a decrease in cell proliferation has also been observed in several cancer cell types.	3.41	7	0	acetate ester; diester; phorbol ester; tertiary alpha-hydroxy ketone; tetradecanoate ester	antineoplastic agent; apoptosis inducer; carcinogenic agent; mitogen; plant metabolite; protein kinase C agonist; reactive oxygen species generator
cannabichromene [no description available]	2.52	2	0	1-benzopyran
phosphotyrosine Phosphotyrosine: An amino acid that occurs in endogenous proteins. Tyrosine phosphorylation and dephosphorylation plays a role in cellular signal transduction and possibly in cell growth control and carcinogenesis.. O(4)-phospho-L-tyrosine : A non-proteinogenic L-alpha-amino acid that is L-tyrosine phosphorylated at the phenolic hydroxy group.	2.42	2	0	L-tyrosine derivative; non-proteinogenic L-alpha-amino acid; O(4)-phosphotyrosine	Escherichia coli metabolite; immunogen
dihydro-beta-erythroidine Dihydro-beta-Erythroidine: Dihydro analog of beta-erythroidine, which is isolated from the seeds and other plant parts of Erythrina sp. Leguminosae. It is an alkaloid with curarimimetic properties.. dihydro-beta-erythroidine : An organic heterotetracyclic compound resulting from the partial hydrogenation of the 1,3-diene moiety of beta-erythroidine to give the corresponding 2-ene.	2.03	1	0	delta-lactone; organic heterotetracyclic compound; tertiary amino compound	nicotinic antagonist
8-bromo cyclic adenosine monophosphate 8-Bromo Cyclic Adenosine Monophosphate: A long-acting derivative of cyclic AMP. It is an activator of cyclic AMP-dependent protein kinase, but resistant to degradation by cyclic AMP phosphodiesterase.. 8-Br-cAMP : A 3',5'-cyclic purine nucleotide that is 3',5'-cyclic AMP bearing an additional bromo substituent at position 8 on the adenine ring. An activator of cyclic AMP-dependent protein kinase, but resistant to degradation by cyclic AMP phosphodiesterase.	3.26	6	0	3',5'-cyclic purine nucleotide; adenyl ribonucleotide; organobromine compound	antidepressant; protein kinase agonist
alkenes [no description available]	2.8	3	0
glutamic acid Glutamic Acid: A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM.. glutamic acid : An alpha-amino acid that is glutaric acid bearing a single amino substituent at position 2.	7.57	40	0	glutamic acid; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; ferroptosis inducer; micronutrient; mouse metabolite; neurotransmitter; nutraceutical
2-n-octyl-4-isothiazolin-3-one octhilinone : A member of the class of 1,2-thiazole that is 1,2-thiazol-3-one substituted on the nitrogen (position 2) by an octyl group. A fungicide and antibacterial agent, it is used for treatment of canker and other fungal and bacterial diseases in fruit trees. It is no longer approved for use within the European Union.	3.25	1	0	1,2-thiazoles	antibacterial agent; antifungal agrochemical; environmental contaminant; xenobiotic
sodium azide Sodium Azide: A cytochrome oxidase inhibitor which is a nitridizing agent and an inhibitor of terminal oxidation. (From Merck Index, 12th ed). sodium azide : The sodium salt of hydrogen azide (hydrazoic acid).	7	1	0	inorganic sodium salt	antibacterial agent; explosive; mitochondrial respiratory-chain inhibitor; mutagen
azides Azides: Organic or inorganic compounds that contain the -N3 group.. azide : Any nitrogen molecular entity containing the group -N3.	2.44	2	0	pseudohalide anion	mitochondrial respiratory-chain inhibitor
timolol (S)-timolol (anhydrous) : The (S)-(-) (more active) enantiomer of timolol. A beta-adrenergic antagonist, both the hemihydrate and the maleate salt are used in the mangement of glaucoma, hypertension, angina pectoris and myocardial infarction, and for the prevention of migraine.	1.98	1	0	timolol	anti-arrhythmia drug; antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist
tetrahydrocannabivarin 9 tetrahydrocannabivarin 9: RN given refers to parent cpd; structure	2.02	1	0
nigericin Nigericin: A polyether antibiotic which affects ion transport and ATPase activity in mitochondria. It is produced by Streptomyces hygroscopicus. (From Merck Index, 11th ed). nigericin : A polyether antibiotic which affects ion transport and ATPase activity in mitochondria. It is produced by Streptomyces hygroscopicus.	1.98	1	0	polycyclic ether	antibacterial agent; antimicrobial agent; bacterial metabolite; potassium ionophore
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	2.05	1	0	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
substance p [no description available]	3.73	10	0	peptide	neurokinin-1 receptor agonist; neurotransmitter; vasodilator agent
etidocaine Etidocaine: A local anesthetic with rapid onset and long action, similar to BUPIVACAINE.. etidocaine : An amino acid amide in which 2-[ethyl(propyl)amino]butanoic acid and 2,6-dimethylaniline have combined to form the amide bond. Used as a local anaesthetic (amide caine), it has rapid onset and long action properties, similar to bupivacaine, and is given by injection during surgical procedures and during labour and delivery.	3.31	1	0	amino acid amide	local anaesthetic
phorbol 12,13-dibutyrate Phorbol 12,13-Dibutyrate: A phorbol ester found in CROTON OIL which, in addition to being a potent skin tumor promoter, is also an effective activator of calcium-activated, phospholipid-dependent protein kinase (protein kinase C). Due to its activation of this enzyme, phorbol 12,13-dibutyrate profoundly affects many different biological systems.	2.02	1	0	butyrate ester; phorbol ester; tertiary alpha-hydroxy ketone
ciclazindol ciclazindol: highly selective inhibitor of noradrenaline uptake; RN given refers to parent cpd; structure	1.99	1	0
isovelleral isovelleral: structure given in first source	2	1	0	aldehyde
profenofos [no description available]	2	1	0	monochlorobenzenes; organic thiophosphate; organochlorine insecticide; organophosphate insecticide	acaricide; agrochemical; EC 3.1.1.7 (acetylcholinesterase) inhibitor
diltiazem Diltiazem: A benzothiazepine derivative with vasodilating action due to its antagonism of the actions of CALCIUM ion on membrane functions.. diltiazem : A 5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate in which both stereocentres have S configuration. A calcium-channel blocker and vasodilator, it is used as the hydrochloride in the management of angina pectoris and hypertension.	6.99	1	0	5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate	antihypertensive agent; calcium channel blocker; vasodilator agent
ng-nitroarginine methyl ester NG-Nitroarginine Methyl Ester: A non-selective inhibitor of nitric oxide synthase. It has been used experimentally to induce hypertension.	4.91	35	0	alpha-amino acid ester; L-arginine derivative; methyl ester; N-nitro compound	EC 1.14.13.39 (nitric oxide synthase) inhibitor
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid [no description available]	2.13	1	0	chromanol; monocarboxylic acid; phenols	antioxidant; ferroptosis inhibitor; neuroprotective agent; radical scavenger; Wnt signalling inhibitor
sufentanil Sufentanil: An opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent.. sufentanil : An anilide resulting from the formal condensation of the aryl amino group of 4-(methoxymethyl)-N-phenyl-1-[2-(2-thienyl)ethyl]piperidin-4-amine with propanoic acid.	2.05	1	0	anilide; ether; piperidines; thiophenes	anaesthesia adjuvant; intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic
enkephalin, methionine Enkephalin, Methionine: One of the endogenous pentapeptides with morphine-like activity. It differs from LEU-ENKEPHALIN by the amino acid METHIONINE in position 5. Its first four amino acid sequence is identical to the tetrapeptide sequence at the N-terminal of BETA-ENDORPHIN.	2.7	3	0
azaconazole azaconazole: structure given in first source. azaconazole : A member of the class of dioxolanes that is 1,3-dioxolane substituted at position 2 by 2,4-dichlorophenyl and 1,2,4-triazol-1-ylmethyl groups. A fungicide used mainly in ornamental crops to control canker and other diseases. Azaconazole is moderately toxic to mammals but is not expected to bioaccumulate. It is moderately toxic to birds, fish and aquatic invertebrates.	2.03	1	0	conazole fungicide; cyclic ketal; dichlorobenzene; dioxolane; triazole fungicide; triazoles	antifungal agrochemical; EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor
captopril Captopril: A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin.. captopril : A L-proline derivative in which L-proline is substituted on nitrogen with a (2S)-2-methyl-3-sulfanylpropanoyl group. It is used as an anti-hypertensive ACE inhibitor drug.	1.99	1	0	alkanethiol; L-proline derivative; N-acylpyrrolidine; pyrrolidinemonocarboxylic acid	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
colforsin Colforsin: Potent activator of the adenylate cyclase system and the biosynthesis of cyclic AMP. From the plant COLEUS FORSKOHLII. Has antihypertensive, positive inotropic, platelet aggregation inhibitory, and smooth muscle relaxant activities; also lowers intraocular pressure and promotes release of hormones from the pituitary gland.	5.92	24	0	acetate ester; cyclic ketone; labdane diterpenoid; organic heterotricyclic compound; tertiary alpha-hydroxy ketone; triol	adenylate cyclase agonist; anti-HIV agent; antihypertensive agent; plant metabolite; platelet aggregation inhibitor; protein kinase A agonist
haloperidol decanoate [no description available]	2.1	1	0	organic molecular entity
lovastatin Lovastatin: A fungal metabolite isolated from cultures of Aspergillus terreus. The compound is a potent anticholesteremic agent. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It also stimulates the production of low-density lipoprotein receptors in the liver.. lovastatin : A fatty acid ester that is mevastatin carrying an additional methyl group on the carbobicyclic skeleton. It is used in as an anticholesteremic drug and has been found in fungal species such as Aspergillus terreus and Pleurotus ostreatus (oyster mushroom).	2.43	2	0	delta-lactone; fatty acid ester; hexahydronaphthalenes; polyketide; statin (naturally occurring)	anticholesteremic drug; antineoplastic agent; Aspergillus metabolite; prodrug
quinpirole Quinpirole: A dopamine D2/D3 receptor agonist.. quinpirole : A pyrazoloquinoline that is (4aR,8aR)-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrazolo[3,4-g]quinoline substituted by a propyl group at position 5. It acts as a dopamine agonist.	3.1	5	0	pyrazoloquinoline	dopamine agonist
mifepristone Mifepristone: A progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary CUSHING SYNDROME.	2.08	1	0	3-oxo-Delta(4) steroid; acetylenic compound; tertiary amino compound	abortifacient; contraceptive drug; hormone antagonist; synthetic oral contraceptive
pravadoline [no description available]	2.04	1	0
fura-2 Fura-2: A fluorescent calcium chelating agent which is used to study intracellular calcium in tissues.	3.41	7	0
mibefradil dihydrochloride [no description available]	3.31	1	0
mibefradil Mibefradil: A benzimidazoyl-substituted tetraline that selectively binds and inhibits CALCIUM CHANNELS, T-TYPE.	3.34	2	0	tetralins	T-type calcium channel blocker
sipatrigine sipatrigine: a glutamate release inhibitor which protects against focal cerebral ischemic damage	3.23	1	0	pyrimidines
adenosine quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit	5.03	7	0	adenosines; purines D-ribonucleoside	analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent
gadolinium chloride gadolinium chloride: a macrophage inhibitor; reduces pulmonary injury and inflammatory mediator production induced by inhaled ozone	2.11	1	0	gadolinium coordination entity	TRP channel blocker
tenocyclidine tenocyclidine : A tertiary amino compound that consists of cyclohexane having piperidin-1-yl and thiophen-2-yl groups attached at position 1. A dissociative anaesthetic drug with halluccinogenic and stimulant effects. Its effects are similar to those of phencyclidine (PCP, an analogue with the thienyl group replaced by phenyl), but it is rather more potent.	1.99	1	0	piperidines; tertiary amino compound; thiophenes	central nervous system stimulant; hallucinogen; neuroprotective agent; NMDA receptor antagonist
follicle stimulating hormone Urofollitropin: A protein extract of human menopausal urine in which LUTEINIZING HORMONE has been partially or completely removed. Urofollitropin represents FOLLICLE STIMULATING HORMONE from the urine.	2.25	1	0
glucose, (beta-d)-isomer beta-D-glucose : D-Glucopyranose with beta configuration at the anomeric centre.. (1->4)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->4) linkages.. (1->3)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->3) linkages.	2.04	1	0	D-glucopyranose	epitope; mouse metabolite
mevastatin mevastatin: antifungal metabolite from Penicillium brevicopactum; potent inhibitory activity to sterol synthesis; structure. mevastatin : A carboxylic ester that is pravastatin that is lacking the allylic hydroxy group. A hydroxymethylglutaryl-CoA reductase inhibitor (statin) isolated from Penicillium citrinum and from Penicillium brevicompactum, its clinical use as a lipid-regulating drug ceased following reports of toxicity in animals.	3.31	1	0	2-pyranones; carboxylic ester; hexahydronaphthalenes; polyketide; statin (naturally occurring)	antifungal agent; apoptosis inducer; EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor; fungal metabolite; Penicillium metabolite
thiazolyl blue thiazolyl blue: RN & II refers to bromide. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide : The bromide salt of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium.	2.48	2	0	organic bromide salt	colorimetric reagent; dye
allicin [no description available]	3.12	1	0	botanical anti-fungal agent; sulfoxide	antibacterial agent
fluorexon fluorexon: structure	2.03	1	0	xanthene dye	fluorochrome
aica ribonucleotide AICA ribonucleotide: purine precursor that has antineoplastic activity. AICA ribonucleotide : A 1-(phosphoribosyl)imidazolecarboxamide that is acadesine in which the hydroxy group at the 5' position has been converted to its monophosphate derivative.	2.15	1	0	1-(phosphoribosyl)imidazolecarboxamide; aminoimidazole	cardiovascular drug; Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
1,7-phenanthroline [no description available]	2	1	0	phenanthroline
triazoles Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.	2.58	2	0	1,2,3-triazole
medetomidine Medetomidine: An agonist of RECEPTORS, ADRENERGIC ALPHA-2 that is used in veterinary medicine for its analgesic and sedative properties. It is the racemate of DEXMEDETOMIDINE.	1.98	1	0	imidazoles
fluorodeoxyglucose f18 Fluorodeoxyglucose F18: The compound is given by intravenous injection to do POSITRON-EMISSION TOMOGRAPHY for the assessment of cerebral and myocardial glucose metabolism in various physiological or pathological states including stroke and myocardial ischemia. It is also employed for the detection of malignant tumors including those of the brain, liver, and thyroid gland. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1162)	2.15	1	0	2-deoxy-2-((18)F)fluoro-D-glucose; 2-deoxy-2-fluoro-aldehydo-D-glucose
rilmenidine Rilmenidine: Oxazole derivative that acts as an agonist for ALPHA-2 ADRENERGIC RECEPTORS and IMIDAZOLINE RECEPTORS. It is used in the treatment of HYPERTENSION.	2.04	1	0	isourea
selfotel selfotel: a N-methyl-D-aspartate (NMDA) antagonist; used to treat stroke-induced impairment	2.01	1	0	non-proteinogenic alpha-amino acid
tianeptine tianeptine: structure given in first source. tianeptine : A racemate comprising of equimolar amounts of (R)- and (S)-tianeptine. It is an atypical antidepressant used in Europe to treat patients who respond poorly to selective serotonin reuptake inhibitors (SSRIs).. 7-[(3-chloro-6-methyl-5,5-dioxido-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid : A member of the class of dibenzothiazepines that is 3-chloro-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide substituted by a (6-carboxyhexyl)amino group at position 11.. (S)-tianeptine : The S-enantiomer of tianeptine.	2.1	1	0	dibenzothiazepine; monocarboxylic acid; organochlorine compound
hexadecanamide hexadecanamide : A fatty amide that is the carboxamide derived from palmitic acid.	2.74	3	0	primary fatty amide	metabolite
n-methylscopolamine N-Methylscopolamine: A muscarinic antagonist used to study binding characteristics of muscarinic cholinergic receptors.	2	1	0
cromakalim Cromakalim: A potassium-channel opening vasodilator that has been investigated in the management of hypertension. It has also been tried in patients with asthma. (Martindale, The Extra Pharmacopoeia, 30th ed, p352)	7.44	2	0
masoprocol Masoprocol: A potent lipoxygenase inhibitor that interferes with arachidonic acid metabolism. The compound also inhibits formyltetrahydrofolate synthetase, carboxylesterase, and cyclooxygenase to a lesser extent. It also serves as an antioxidant in fats and oils.. masoprocol : The meso-form of nordihydroguaiaretic acid. An antioxidant found in the creosote bush, Larrea divaricata, it is a potent lipoxygenase inhibitor that interferes with arachidonic acid metabolism. It also inhibits (though to a lesser extent) formyltetrahydrofolate synthetase, carboxylesterase, and cyclooxygenase.	2.41	2	0	nordihydroguaiaretic acid	antineoplastic agent; hypoglycemic agent; lipoxygenase inhibitor; metabolite
trichlorosucrose trichlorosucrose: sweetness intensity roughly 600 times that of sucrose and is nonnutritive and noncaloric; largely unabsorbed in the gastrointestinal tract. sucralose : A disaccharide derivative consisting of 4-chloro-4-deoxy-alpha-D-galactopyranose and 1,6-dichloro-1,6-dideoxy-beta-D-fructofuranose units linked by a glycosidic bond.	2.25	1	0	disaccharide derivative; organochlorine compound	environmental contaminant; sweetening agent; xenobiotic
4-o-methyl-12-o-tetradecanoylphorbol 13-acetate [no description available]	2.01	1	0
beta-amyrin beta-amyrin: alpha-amyrin is also available; a 5 ring triterpene derived from oleanane that differs from alpha-amyrin in having the 29-carbon at the 20 position; RN given refers to (3 beta)-isomer. beta-amyrin : A pentacyclic triterpenoid that is oleanane substituted at the 3beta-position by a hydroxy group and containing a double bond between positions 12 and 13. It is one of the most commonly occurring triterpenoids in higher plants.	2.07	1	0	pentacyclic triterpenoid; secondary alcohol	Aspergillus metabolite; plant metabolite
gliclazide 18alpha-glycyrrhetinic acid: a gap junction inhibitor	2.71	3	0
biocytin biocytin : A monocarboxylic acid amide that results from the formal condensation of the carboxylic acid group of biotin with the N(6)-amino group of L-lysine.	2.05	1	0	azabicycloalkane; L-alpha-amino acid zwitterion; L-lysine derivative; monocarboxylic acid amide; non-proteinogenic L-alpha-amino acid; thiabicycloalkane; ureas	mouse metabolite
ferroin ferroin: RN given refers to parent cpd	2	1	0
coenzyme a [no description available]	1.98	1	0	adenosine 3',5'-bisphosphate	coenzyme; Escherichia coli metabolite; mouse metabolite
nicotine (S)-nicotine : A 3-(1-methylpyrrolidin-2-yl)pyridine in which the chiral centre has S-configuration. The naturally occurring and most active enantiomer of nicotine, isolated from Nicotiana tabacum.	5.23	15	0	3-(1-methylpyrrolidin-2-yl)pyridine	anxiolytic drug; biomarker; immunomodulator; mitogen; neurotoxin; nicotinic acetylcholine receptor agonist; peripheral nervous system drug; phytogenic insecticide; plant metabolite; psychotropic drug; teratogenic agent; xenobiotic
abnormal cannabidiol [no description available]	3.37	2	0	monoterpenoid
fibrinogen Fibrinogen: Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products.. D-iditol : The D-enantiomer of iditol.	2.1	1	0	iditol	fungal metabolite
3,4-dihydroxyphenylglycol 3,4-dihydroxyphenylglycol: noradrenaline metabolite in mouse brain; RN given refers to cpd without isomeric designation. 3,4-dihydroxyphenylethyleneglycol : A tetrol composed of ethyleneglycol having a 3,4-dihydroxyphenyl group at the 1-position.	2.45	2	0	catechols; tetrol	metabolite; mouse metabolite
homocysteine Homocysteine: A thiol-containing amino acid formed by a demethylation of METHIONINE.. homocysteine : A sulfur-containing amino acid consisting of a glycine core with a 2-mercaptoethyl side-chain.. L-homocysteine : A homocysteine that has L configuration.	7.49	2	0	amino acid zwitterion; homocysteine; serine family amino acid	fundamental metabolite; mouse metabolite
alpha,beta-methyleneadenosine 5'-triphosphate alpha,beta-methyleneadenosine 5'-triphosphate: do not confuse with beta,gamma-methylene ATP; RN given refers to parent cpd	2.03	1	0	nucleoside triphosphate analogue
1-methylhistidine 1-methylhistidine: found in muscle proteins; RN given refers to (L)-isomer. 1-methylhistidine : A methylhistidine in which the methyl group is located at N-1.. N(tele)-methyl-L-histidine : A L-histidine derivative in which the methyl group is at N(tele)-position.	2.07	1	0	L-histidine derivative; non-proteinogenic L-alpha-amino acid; zwitterion	human metabolite
enkephalinamide-met, ala(2)- enkephalinamide-Met, Ala(2)-: synthetic enkephalin analog;	1.99	1	0
cobalt Cobalt: A trace element that is a component of vitamin B12. It has the atomic symbol Co, atomic number 27, and atomic weight 58.93. It is used in nuclear weapons, alloys, and pigments. Deficiency in animals leads to anemia; its excess in humans can lead to erythrocytosis.. cobalt(1+) : A monovalent inorganic cation obtained from cobalt.. cobalt atom : A cobalt group element atom that has atomic number 27.	2.73	3	0	cobalt group element atom; metal allergen	micronutrient
p-methoxy-n-methylphenethylamine p-Methoxy-N-methylphenethylamine: A potent mast cell degranulator. It is involved in histamine release.. N,O-dimethyltyramine : A secondary amino compound that is tyramine in which the hydrogen of the phenolic hydroxy group has been replaced by a methyl group.	2	1	0	aromatic ether; secondary amino compound	metabolite
1,2-bis(2-aminophenoxy)ethane-n,n,n',n'-tetraacetic acid 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid: structure in first source	2.71	3	0	polyamino carboxylic acid; tetracarboxylic acid	chelator
enkephalin, d-penicillamine (2,5)- Enkephalin, D-Penicillamine (2,5)-: A disulfide opioid pentapeptide that selectively binds to the DELTA OPIOID RECEPTOR. It possesses antinociceptive activity.. DPDPE : A heterodetic cyclic peptide that is a cyclic enkephalin analogue, having D-penicillaminyl residues located at positions 2 and 5, which form the heterocycle via a disulfide bond.	2.07	1	0	heterodetic cyclic peptide	delta-opioid receptor agonist
u 73122 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione: structure given in first source. U-73122 : An aza-steroid that is 3-O-methyl-17beta-estradiol in which the 17beta-hydroxy group is replaced by a 6-(maleimid-1-yl)hexylamino group. An inibitor of phospholipase C.	2.95	4	0	aromatic ether; aza-steroid; maleimides	EC 3.1.4.11 (phosphoinositide phospholipase C) inhibitor
1,4-dihydropyridine [no description available]	3.8	3	0
alphaxalone alphaxalone: RN given refers to (3alpha,5alpha)-isomer; structure	3.31	1	0	corticosteroid hormone
sr141716 [no description available]	11.64	256	0	amidopiperidine; carbohydrazide; dichlorobenzene; monochlorobenzenes; pyrazoles	anti-obesity agent; appetite depressant; CB1 receptor antagonist
cp-55,940 [no description available]	6.76	17	0
1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1h-imidazole 1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1H-imidazole: inhibits platelet aggregation & Ca2+ entry into platelets. SKF-96365 free base : An ether that is 2-(1H-imidazol-1-yl)-1-(4-methoxyphenyl)ethanol in which the hydrogen of the hydroxy group has been substituted by a 3-(4-methoxyphenyl)propyl group.	2.94	1	0	ether; imidazoles; monomethoxybenzene	TRP channel blocker
fluo-3 Fluo-3: fluorescent Ca(2+) indicator; permits continuous monitoring of Ca without interference with use of UV-sensitive caged compounds	2	1	0	xanthene dye	fluorochrome
methyllycaconitine methyllycaconitine: natural toxin from seeds of Delphinium brownii; parasympathomimetic and mild nicotine antagonist; antagonist of alpha-conotoxin-MII sensitive presynaptic nicotinic receptors; potent insecticide; RN refers to (1alpha,4(S),6beta,14alpha,16beta)-isomer	2.03	1	0
cyproterone acetate, ethinyl estradiol drug combination [no description available]	2.15	1	0
1,1-dimethylheptyl-11-hydroxytetrahydrocannabinol HU 211: structure given in first source; HU 211 is active & HU 210 is inactive as canibinoids; functional N-methyl-D-aspartate receptor blocker; RN given is for (6aS-trans)-isomer	8.08	42	0
fr 139317 FR 139317: endothelin receptor A antagonist; structure given in first source	2.02	1	0
nantradol nantradol: cannabinoid-related analgetic with greater potency than morphine in some tests; 4 stereoisomers are mentioned in the literature: (+)-2'(S),6(R),6a(S),9(S)10a(S) [CP-53,870-1]; (-)-2'(R),6(S),6a(R),9(R)10a(R) [CP-50,556-1]; (+)-2'(R),6(R),6a(S),9(S),10a(S); (-)-2'(S),6(S),6a(R),9(R)10a(R); RN given is from CA 1977-79 Index Guide; structure in first source; use STEREOISOMERS if levonantradol is used	1.99	1	0
1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane 1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane: structure in first source	3.06	1	0
sr 95531 [no description available]	2.06	1	0	methoxybenzenes
4-desmethoxyverapamil [no description available]	1.99	1	0
parinaric acid parinaric acid: long-chain polyenoic fatty acid; RN given refers to cpd without isomeric designation. parinaric acid : An octadecatetraenoic acid containing a conjugated system of double bonds at positions 9, 11, 13 and 15.	2.03	1	0	octadecatetraenoic acid
1-hexadecyl-2-acetyl-glycero-3-phosphocholine Platelet Activating Factor: A phospholipid derivative formed by PLATELETS; BASOPHILS; NEUTROPHILS; MONOCYTES; and MACROPHAGES. It is a potent platelet aggregating agent and inducer of systemic anaphylactic symptoms, including HYPOTENSION; THROMBOCYTOPENIA; NEUTROPENIA; and BRONCHOCONSTRICTION.. 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine : A 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine betaine which has hexadecyl as the alkyl group. PAF is a potent phospholipid activator and mediator of many leukocyte functions, including platelet aggregation, inflammation, and anaphylaxis.	4.36	6	0	2-acetyl-1-alkyl-sn-glycero-3-phosphocholine	antihypertensive agent; beta-adrenergic antagonist; bronchoconstrictor agent; hematologic agent; vasodilator agent
sr 140333 SR 140333: SR-140603 is the (R)-antipode of SR-140333; a neurokinin-1 receptor antagonist	2.03	1	0
deoxyglucose Deoxyglucose: 2-Deoxy-D-arabino-hexose. An antimetabolite of glucose with antiviral activity.. deoxyglucose : A deoxyhexose comprising glucose having at least one hydroxy group replaced by hydrogen.	2.04	1	0
thromboxanes thromboxane : A class of oxygenated oxane derivatives, originally derived from prostaglandin precursors in platelets, that stimulate aggregation of platelets and constriction of blood vessels.	2.01	1	0
way 100135 WAY 100135: a selective antagonist at presynaptic & postsynaptic 5-HT(1A) receptors; structure given in first source	2.02	1	0	piperazines
egta acetoxymethyl ester EGTA acetoxymethyl ester: membrane-permeable form of EGTA	2.43	2	0
bw a868c BW A868C: a selective DP receptor antagonist; structure given in first source	2	1	0	imidazolidine-2,4-dione
2-palmitoylglycerol 2-palmitoylglycerol: increases 2-arachidonoyl-glycerol cannabinoid activity. 2-palmitoylglycerol : A 2-monoglyceride where the acyl group is hexadecanoyl (palmitoyl).	2.59	2	0	2-acylglycerol 16:0	algal metabolite
cdp ethanolamine [no description available]	3.18	1	0	nucleotide-(amino alcohol)s; phosphoethanolamine	mouse metabolite
deltorphin ii, ala(2)- deltorphin II, Ala(2)-: isolated from skin extracts of frogs belonging to the genus Phyllomedusa; has affinity to opioid receptors	2.04	1	0
n,n-dimethylarginine N,N-dimethylarginine: asymmetric dimethylarginine; do not confuse with N,N'-dimethylarginine. N(omega),N(omega)-dimethyl-L-arginine : A L-arginine derivative having two methyl groups both attached to the primary amino moiety of the guanidino group.	2.05	1	0	dimethylarginine; guanidines; L-arginine derivative; non-proteinogenic L-alpha-amino acid	EC 1.14.13.39 (nitric oxide synthase) inhibitor
glycerophosphoethanolamine glycerol 3-phosphoethanolamine: a membrane lipid degradation product	2.04	1	0	phosphoethanolamine; sn-glycerol 3-phosphates
rmi 12330a RMI 12330A: adenyl cyclase inhibitor in rat liver; RN given refers to (cis)-isomer; NM refers to HCl, (cis)-isomer; structure	2	1	0
glycerophosphoinositol 4,5-bisphosphate glycerophosphoinositol 4,5-bisphosphate: do not confuse with phosphatidylinositols which have fatty acids esterified at the C-1 and C-2 hydroxyl groups of glycerol	2.42	2	0
desacetylnantradol desacetylnantradol: active metabolite of nantradol; use STEREOISOMERS if levo cpd is discussed	1.99	1	0
methotrexate [no description available]	2.42	2	0	dicarboxylic acid; monocarboxylic acid amide; pteridines	abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent
reboxetine Reboxetine: A morpholine derivative that is a selective and potent noradrenaline reuptake inhibitor; it is used in the treatment of DEPRESSIVE DISORDER.	2.08	1	0	aromatic ether
acea 1011 ACEA 1011: a glycine site NMDA receptor antagonist; produces analgesia during the late phase of subcutaneous formalin injection in mice	2.07	1	0
agatoxin-489 agatoxin-489: structure given in first source; anhydrous MW 489 Da; isolated from Agelenopsis aperta	2.05	1	0
sc 51089 SC 51089: structure in first source; dinoprostone antagonist	2	1	0
l 368899 L 368899: a selective oxytocin receptor antagonist; structure in first source	2.11	1	0
n-palmitoylglycine N-hexadecanoylglycine : An N-acylglycine in which the acyl group is specified as hexadecanoyl (palmitoyl).	2.04	1	0	fatty amide; N-acylglycine 16:0	human metabolite; marine metabolite
phorbols Phorbols: The parent alcohol of the tumor promoting compounds from CROTON OIL (Croton tiglium).	2.03	1	0	diterpene; terpenoid fundamental parent
hydroxyl radical Hydroxyl Radical: The univalent radical OH. Hydroxyl radical is a potent oxidizing agent.	2.06	1	0	oxygen hydride; oxygen radical; reactive oxygen species
camphora camphora: a component of Guanxingao, a kind of traditional Chinese rubber electuary medicine which is able to either cure or guard against coronary heart disease and angina pectoris. (R)-camphor : The (R)- enantiomer of camphor.	3.12	1	0	camphor
ag 3-5 icilin: a cooling compound that activates TRPM8	3.53	2	0	C-nitro compound
delta(9-11)-tetrahydrocannabinol delta(9-11)-tetrahydrocannabinol: RN given refers to (trans)-isomer; structure given in first source	2.02	1	0
nordihydrocapsaicin [no description available]	2.11	1	0	methoxybenzenes; phenols
biotin vitamin B7 : Any member of a group of vitamers that belong to the chemical structural class called biotins that exhibit biological activity against vitamin B7 deficiency. Vitamin B7 deficiency is very rare in individuals who take a normal balanced diet. Foods rich in biotin are egg yolk, liver, cereals, vegetables (spinach, mushrooms) and rice. Symptoms associated with vitamin B7 deficiency include thinning hair, scaly skin rashes around eyes, nose and mouth, and brittle nails. The vitamers include biotin and its ionized and salt forms.	8.86	4	0	biotins; vitamin B7	coenzyme; cofactor; Escherichia coli metabolite; fundamental metabolite; human metabolite; mouse metabolite; nutraceutical; prosthetic group; Saccharomyces cerevisiae metabolite
angiotensin ii Giapreza: injectable form of angiotensin II used to increase blood pressure in adult patients with septic or other distributive shock. Ile(5)-angiotensin II : An angiotensin II that acts on the central nervous system (PDB entry: 1N9V).	7.97	4	0	amino acid zwitterion; angiotensin II	human metabolite
atropine tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate : A tropane alkaloid that is (1R,5)-8-methyl-8-azabicyclo[3.2.1]octane substituted by a (3-hydroxy-2-phenylpropanoyl)oxy group at position 3.	2.96	4	0
ropivacaine Ropivacaine: An anilide used as a long-acting local anesthetic. It has a differential blocking effect on sensory and motor neurons.. ropivacaine : The piperidinecarboxamide obtained by the formal condensation of N-propylpipecolic acid and 2,6-dimethylaniline.. (S)-ropivacaine : A piperidinecarboxamide-based amide-type local anaesthetic (amide caine) in which (S)-N-propylpipecolic acid and 2,6-dimethylaniline are combined to form the amide bond.	3.31	1	0	piperidinecarboxamide; ropivacaine	local anaesthetic
homocysteic acid homocysteic acid: promotes growth in hypophysectomized rats; RN given refers to parent cpd. homocysteic acid : A non-proteinogenic alpha-amino acid that is homocysteine in which the thiol group has benn oxidised to the corresponding sulfonic acid.. L-homocysteic acid : A homocysteic acid with L-configuration.	2.06	1	0	homocysteic acid	NMDA receptor agonist
organophosphonates hydrogenphosphite : A divalent inorganic anion resulting from the removal of a proton from two of the hydroxy groups of phosphorous acid.	5.19	15	0	divalent inorganic anion; phosphite ion
estradiol 3-benzoate 17beta-estradiol 3-benzoate : A benzoate ester resulting from the formal condensation of benzoic acid with the phenolic hydroxy group of 17beta-estradiol.	2.02	1	0	17beta-hydroxy steroid; benzoate ester	estrogen receptor agonist; xenoestrogen
cortisone [no description available]	2.51	2	0	11-oxo steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	human metabolite; mouse metabolite
lanosterol [no description available]	2.03	1	0	14alpha-methyl steroid; 3beta-sterol; tetracyclic triterpenoid	bacterial metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
benzofurans Benzofurans: Compounds that contain a BENZENE ring fused to a furan ring.	3.11	5	0
wortmannin [no description available]	2	1	0	acetate ester; cyclic ketone; delta-lactone; organic heteropentacyclic compound	anticoronaviral agent; antineoplastic agent; autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector; Penicillium metabolite; radiosensitizing agent
tris(2-pyridylmethyl)amine tris(2-pyridylmethyl)amine: structure in first source	2.03	1	0
dihydropyridines Dihydropyridines: Pyridine moieties which are partially saturated by the addition of two hydrogen atoms in any position.	3.8	3	0
lithium chloride Lithium Chloride: A salt of lithium that has been used experimentally as an immunomodulator.. lithium chloride : A metal chloride salt with a Li(+) counterion.	3.18	5	0	inorganic chloride; lithium salt	antimanic drug; geroprotector
bradykinin [no description available]	10.68	10	0	oligopeptide	human blood serum metabolite; vasodilator agent
oxytocin Oxytocin: A nonapeptide hormone released from the neurohypophysis (PITUITARY GLAND, POSTERIOR). It differs from VASOPRESSIN by two amino acids at residues 3 and 8. Oxytocin acts on SMOOTH MUSCLE CELLS, such as causing UTERINE CONTRACTIONS and MILK EJECTION.. oxytocin : A cyclic nonapeptide hormone with amino acid sequence CYIQNCPLG that also acts as a neurotransmitter in the brain; the principal uterine-contracting and milk-ejecting hormone of the posterior pituitary. Together with the neuropeptide vasopressin, it is believed to influence social cognition and behaviour.	3.2	5	0	heterodetic cyclic peptide; peptide hormone	oxytocic; vasodilator agent
inositol 1,4,5-trisphosphate Inositol 1,4,5-Trisphosphate: Intracellular messenger formed by the action of phospholipase C on phosphatidylinositol 4,5-bisphosphate, which is one of the phospholipids that make up the cell membrane. Inositol 1,4,5-trisphosphate is released into the cytoplasm where it releases calcium ions from internal stores within the cell's endoplasmic reticulum. These calcium ions stimulate the activity of B kinase or calmodulin.	3.13	5	0	myo-inositol trisphosphate	mouse metabolite
ouabain Ouabain: A cardioactive glycoside consisting of rhamnose and ouabagenin, obtained from the seeds of Strophanthus gratus and other plants of the Apocynaceae; used like DIGITALIS. It is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-EXCHANGING ATPASE.. cardiac glycoside : Steroid lactones containing sugar residues that act on the contractile force of the cardiac muscles.. ouabain : A steroid hormone that is a multi-hydroxylated alpha-L-rhamnosyl cardenoloide. It binds to and inhibits the plasma membrane Na(+)/K(+)-ATPase (sodium pump). It has been isolated naturally from Strophanthus gratus.	3.12	5	0	11alpha-hydroxy steroid; 14beta-hydroxy steroid; 5beta-hydroxy steroid; alpha-L-rhamnoside; cardenolide glycoside; steroid hormone	anti-arrhythmia drug; cardiotonic drug; EC 2.3.3.1 [citrate (Si)-synthase] inhibitor; EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; ion transport inhibitor; plant metabolite
nitroarginine Nitroarginine: An inhibitor of nitric oxide synthetase which has been shown to prevent glutamate toxicity. Nitroarginine has been experimentally tested for its ability to prevent ammonia toxicity and ammonia-induced alterations in brain energy and ammonia metabolites. (Neurochem Res 1995:200(4):451-6). N(gamma)-nitro-L-arginine : An L-arginine derivative that is L-arginine in which the terminal nitrogen of the guanidyl group is replaced by a nitro group.	2.43	2	0	guanidines; L-arginine derivative; N-nitro compound; non-proteinogenic L-alpha-amino acid
quinidine Quinidine: An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.. quinidine : A cinchona alkaloid consisting of cinchonine with the hydrogen at the 6-position of the quinoline ring substituted by methoxy.	3.31	1	0	cinchona alkaloid	alpha-adrenergic antagonist; anti-arrhythmia drug; antimalarial; drug allergen; EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor; EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor; muscarinic antagonist; P450 inhibitor; potassium channel blocker; sodium channel blocker
griseofulvin Griseofulvin: An antifungal agent used in the treatment of TINEA infections.. griseofulvin : An oxaspiro compound produced by Penicillium griseofulvum. It is used by mouth as an antifungal drug for infections involving the scalp, hair, nails and skin that do not respond to topical treatment.	2.03	1	0	1-benzofurans; antibiotic antifungal drug; benzofuran antifungal drug; organochlorine compound; oxaspiro compound	antibacterial agent; Penicillium metabolite
terconazole terconazole: structure & RN for (cis)-isomer from first source. terconazole : A racemate consisting of equimolar amounts of (2R,4S)- and (2S,4R)-terconazole. It has broad-spectrum antifungal activitiy and is used for the treatment of vaginal yeast infections (Candida).. (2R,4S)-terconazole : A 1-(4-{[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)-4-isopropylpiperazine in which positions 2 and 4 of the 1,3-dioxolane moiety have R and S configuration, respectively.	2.03	1	0	1-(4-{[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)-4-isopropylpiperazine
phorbol phorbol: RN given refers to (1aR-(1a alpha,1b beta,4a beta,7a alpha,7b alpha,8 alpha,9 beta,9b beta))-isomer; synonym isophorbol refers to (4a alpha)-isomer; structure in Merck Index, 9th ed, #7143. phorbol : A diterpenoid with the structure of tigliane hydroxylated at C-4, -9, -12(beta), -13 and -20, with an oxo group at C-3 and unsaturation at the 1- and 6-positions.	2.03	1	0	cyclic ketone; enone; tertiary alcohol; tertiary alpha-hydroxy ketone; tetracyclic diterpenoid
n-formylmethionine leucyl-phenylalanine N-Formylmethionine Leucyl-Phenylalanine: A formylated tripeptide originally isolated from bacterial filtrates that is positively chemotactic to polymorphonuclear leucocytes, and causes them to release lysosomal enzymes and become metabolically activated.. N-formyl-L-methionyl-L-leucyl-L-phenylalanine : A tripeptide composed of L-Met, L-Leu and L-Phe in a linear sequence with a formyl group at the amino terminus. It acts as a potent inducer of leucocyte chemotaxis and macrophage activator as well as a ligand for the FPR receptor.	2.02	1	0	tripeptide
betadex beta-Cyclodextrins: Cyclic GLUCANS consisting of seven (7) glucopyranose units linked by 1,4-glycosidic bonds.	3.82	11	0	cyclodextrin
cp 320626 CP 320626: structure in first source	2.03	1	0
arachidonic acid icosa-5,8,11,14-tetraenoic acid : Any icosatetraenoic acid with the double bonds at positions 5, 8, 11 and 14.. arachidonate : A long-chain fatty acid anion resulting from the removal of a proton from the carboxy group of arachidonic acid.	9.17	110	0	icosa-5,8,11,14-tetraenoic acid; long-chain fatty acid; omega-6 fatty acid	Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; human metabolite; mouse metabolite
phosphoramidon phosphoramidon: a membrane metallo-endopeptidase & endothelin-converting enzyme inhibitor; thermolysin inhibitor from culture filtrate of Streptomyces tanashiensis; structure. phosphoramidon : A dipeptide isolated from the cultures of Streptomyces tanashiensis.	2	1	0	deoxyaldohexose phosphate; dipeptide	bacterial metabolite; EC 3.4.24.11 (neprilysin) inhibitor; EC 3.4.24.71 (endothelin-converting enzyme 1) inhibitor
docosahexaenoate efalex: a mixture of fish oil and primrose oil; used as a high-docosahexaenoic acid fatty acid supplement. docosahexaenoic acid : Any C22 polyunsaturated fatty acid containing six double bonds.. docosahexaenoate : A polyunsaturated fatty acid anion that is the conjugate base of docosahexaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.. all-cis-docosa-4,7,10,13,16,19-hexaenoic acid : A docosahexaenoic acid having six cis-double bonds at positions 4, 7, 10, 13, 16 and 19.	2.59	2	0	docosahexaenoic acid; omega-3 fatty acid	algal metabolite; antineoplastic agent; Daphnia tenebrosa metabolite; human metabolite; mouse metabolite; nutraceutical
oleic acid Oleic Acid: An unsaturated fatty acid that is the most widely distributed and abundant fatty acid in nature. It is used commercially in the preparation of oleates and lotions, and as a pharmaceutical solvent. (Stedman, 26th ed). oleic acid : An octadec-9-enoic acid in which the double bond at C-9 has Z (cis) stereochemistry.	4.73	9	0	octadec-9-enoic acid	antioxidant; Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; Escherichia coli metabolite; mouse metabolite; plant metabolite; solvent
cocaine Cocaine: An alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse. Cocaine, like amphetamines, acts by multiple mechanisms on brain catecholaminergic neurons; the mechanism of its reinforcing effects is thought to involve inhibition of dopamine uptake.. cocaine : A tropane alkaloid obtained from leaves of the South American shrub Erythroxylon coca.	9.25	17	0	benzoate ester; methyl ester; tertiary amino compound; tropane alkaloid	adrenergic uptake inhibitor; central nervous system stimulant; dopamine uptake inhibitor; environmental contaminant; local anaesthetic; mouse metabolite; plant metabolite; serotonin uptake inhibitor; sodium channel blocker; sympathomimetic agent; vasoconstrictor agent; xenobiotic
eicosapentaenoic acid icosapentaenoic acid : Any straight-chain, C20 polyunsaturated fatty acid having five C=C double bonds.. all-cis-5,8,11,14,17-icosapentaenoic acid : An icosapentaenoic acid having five cis-double bonds at positions 5, 8, 11, 14 and 17.	4.87	7	1	icosapentaenoic acid; omega-3 fatty acid	anticholesteremic drug; antidepressant; antineoplastic agent; Daphnia galeata metabolite; fungal metabolite; micronutrient; mouse metabolite; nutraceutical
thapsigargin Thapsigargin: A sesquiterpene lactone found in roots of THAPSIA. It inhibits SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES.. thapsigargin : An organic heterotricyclic compound that is a hexa-oxygenated 6,7-guaianolide isolated fron the roots of Thapsia garganica L., Apiaceae. A potent skin irritant, it is used in traditional medicine as a counter-irritant. Thapsigargin inhibits Ca(2+)-transporting ATPase mediated uptake of calcium ions into sarcoplasmic reticulum and is used in experimentation examining the impacts of increasing cytosolic calcium concentrations.	4.33	7	0	butyrate ester; organic heterotricyclic compound; sesquiterpene lactone	calcium channel blocker; EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor
gw 6471 GW 6471: a PPARalpha antagonist; structure in first source	2.48	2	0
prostaglandin d2 Prostaglandin D2: The principal cyclooxygenase metabolite of arachidonic acid. It is released upon activation of mast cells and is also synthesized by alveolar macrophages. Among its many biological actions, the most important are its bronchoconstrictor, platelet-activating-factor-inhibitory, and cytotoxic effects.. prostaglandin D2 : A member of the class of prostaglandins D that is prosta-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9 and 15 and an oxo group at position 11 (the 5Z,9alpha,13E,15S- stereoisomer).	2.02	1	0	prostaglandins D	human metabolite; mouse metabolite
h 89 N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide: structure given in first source. N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide : A member of the class of isoquinolines that is the sulfonamide obtained by formal condensation of the sulfo group of isoquinoline-5-sulfonic acid with the primary amino group of N(1)-[3-(4-bromophenyl)prop-2-en-1-yl]ethane-1,2-diamine. It is a protein kinase A inhibitor.. (E)-N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide : A N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide in which the double bond adopts a trans-configuration.	3.36	2	0	N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide
imidazolidines [no description available]	2.01	1	0	azacycloalkane; imidazolidines; saturated organic heteromonocyclic parent
texas red Texas red: hydrophilic Texas red; structure given in first source	2.02	1	0	organic heteroheptacyclic compound	fluorochrome
kt 5720 KT 5720: indolocarbazole; synthetic derivative of K 252a. KT 5720 : An organic heterooctacyclic compound that is 1H,1'H-2,2'-biindole in which the nitrogens have undergone formal oxidative coupling to positions 2 and 5 of hexyl (3S)-3-hydroxy-2-methyltetrahydrofuran-3-carboxylate (the 2R,3S,5S product), and in which the 3 and 3' positions of the biindole moiety have also undergone formal oxidative coupling to positions 3 and 4 of 1,5-dihydro-2H-pyrrol-2-one.	2.03	1	0	carboxylic ester; gamma-lactam; hemiaminal; indolocarbazole; organic heterooctacyclic compound; semisynthetic derivative; tertiary alcohol	EC 2.7.11.11 (cAMP-dependent protein kinase) inhibitor
dactinomycin Dactinomycin: A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)	2	1	0	actinomycin	mutagen
enkephalin, leucine Enkephalin, Leucine: One of the endogenous pentapeptides with morphine-like activity. It differs from MET-ENKEPHALIN in the LEUCINE at position 5. Its first four amino acid sequence is identical to the tetrapeptide sequence at the N-terminal of BETA-ENDORPHIN.. Leu-enkephalin : A pentapeptide comprising L-tyrosine, glycine, glycine, L-phenylalanine and L-leucine residues joined in sequence by peptide linkages. It is an endogenous opioid peptide produced in vertebrate species, including rodents, primates and humans that results from decomposition of proenkephalin or dynorphin and exhibits antinociceptive properties.	2.69	3	0	pentapeptide; peptide zwitterion	analgesic; delta-opioid receptor agonist; human metabolite; mu-opioid receptor agonist; neurotransmitter; rat metabolite
diisononyl phthalate diisononyl phthalate: dielectric (electric insulating) fluid. diisononyl phthalate : The diisononyl ester of benzene-1,2-dicarboxylic acid.	2.57	2	0	diester; phthalate ester	plasticiser
carbenoxolone sodium Carbenoxolone: An agent derived from licorice root. It is used for the treatment of digestive tract ulcers, especially in the stomach. Antidiuretic side effects are frequent, but otherwise the drug is low in toxicity.	2.21	1	0	triterpenoid
cinnamaldehyde 3-phenylprop-2-enal : A member of the class of cinnamaldehydes that is prop-2-enal in which a hydrogen at position 3 has been replaced by a phenyl group. The configuration of the double bond is not specified; the name "cinnamaldehyde" is widely used to refer to the E (trans) isomer.. (E)-cinnamaldehyde : The E (trans) stereoisomer of cinnamaldehyde, the parent of the class of cinnamaldehydes.	5.22	3	1	3-phenylprop-2-enal; cinnamaldehydes	antifungal agent; EC 4.3.1.24 (phenylalanine ammonia-lyase) inhibitor; flavouring agent; hypoglycemic agent; plant metabolite; sensitiser; vasodilator agent
piperine piperine : A N-acylpiperidine that is piperidine substituted by a (1E,3E)-1-(1,3-benzodioxol-5-yl)-5-oxopenta-1,3-dien-5-yl group at the nitrogen atom. It is an alkaloid isolated from the plant Piper nigrum.	3.52	2	0	benzodioxoles; N-acylpiperidine; piperidine alkaloid; tertiary carboxamide	food component; human blood serum metabolite; NF-kappaB inhibitor; plant metabolite
delta-8-tetrahydrocannabinol [no description available]	3.55	2	0	1-benzopyran
stilbenes Stilbenes: Organic compounds that contain 1,2-diphenylethylene as a functional group.. trans-stilbene : The trans-isomer of stilbene.	2.07	1	0	stilbene
cannabidiol Cannabidiol: Compound isolated from Cannabis sativa extract.. cannabidiol : An cannabinoid that is cyclohexene which is substituted by a methyl group at position 1, a 2,6-dihydroxy-4-pentylphenyl group at position 3, and a prop-1-en-2-yl group at position 4.	12.78	47	4	olefinic compound; phytocannabinoid; resorcinols	antimicrobial agent; plant metabolite
sea 0400 SEA 0400: structure in first source	2.08	1	0
gw9662 2-chloro-5-nitrobenzanilide: pretreatment of peroxisome proliferator activated receptors with GW9662 results in the irreversible loss of ligand binding	2.02	1	0	benzamides
(2'-(benzyloxycarbonylaminomethyl)biphenyl-2-carboxylic acid 2-(2-pyridyl)ethylamide) [no description available]	3.31	1	0	biphenyls
tram 34 TRAM 34: inhibits IKCa1; structure in first source	2.03	1	0	organochlorine compound
sesquiterpenes [no description available]	2	1	0
etomidate Etomidate: Imidazole derivative anesthetic and hypnotic with little effect on blood gases, ventilation, or the cardiovascular system. It has been proposed as an induction anesthetic.. etomidate : The ethyl ester of 1-[(1R)-1-phenylethyl]-1H-imidazole-5-carboxylic acid. It is an intravenous general anaesthetic with no analgesic activity.	3.41	1	1	ethyl ester; imidazoles	intravenous anaesthetic; sedative
sb 366791 N-(3-methoxyphenyl)-4-chlorocinnamanilide: a TRPV1 antagonist; structure in first source	3.54	8	0
(e)-3-(4-t-butylphenyl)-n-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide 3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide: a vanilloid receptor 1 antagonist and antihyperalgesic agent; structure in first source	2.03	1	0
urb 754 URB 754: structure in first source	2.03	1	0
cotinine Cotinine: The N-glucuronide conjugate of cotinine is a major urinary metabolite of NICOTINE. It thus serves as a biomarker of exposure to tobacco SMOKING. It has CNS stimulating properties.. (-)-cotinine : An N-alkylpyrrolidine that consists of N-methylpyrrolidinone bearing a pyridin-3-yl substituent at position C-5 (the 5S-enantiomer). It is an alkaloid commonly found in Nicotiana tabacum.	2.06	1	0	N-alkylpyrrolidine; pyridines; pyrrolidin-2-ones; pyrrolidine alkaloid	antidepressant; biomarker; human xenobiotic metabolite; plant metabolite
flunarizine Flunarizine: Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity. It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy.	3.23	1	0	diarylmethane
curcumin Curcumin: A yellow-orange dye obtained from tumeric, the powdered root of CURCUMA longa. It is used in the preparation of curcuma paper and the detection of boron. Curcumin appears to possess a spectrum of pharmacological properties, due primarily to its inhibitory effects on metabolic enzymes.. curcumin : A beta-diketone that is methane in which two of the hydrogens are substituted by feruloyl groups. A natural dyestuff found in the root of Curcuma longa.	2.41	1	0	aromatic ether; beta-diketone; diarylheptanoid; enone; polyphenol	anti-inflammatory agent; antifungal agent; antineoplastic agent; biological pigment; contraceptive drug; dye; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor; EC 1.8.1.9 (thioredoxin reductase) inhibitor; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; flavouring agent; food colouring; geroprotector; hepatoprotective agent; immunomodulator; iron chelator; ligand; lipoxygenase inhibitor; metabolite; neuroprotective agent; nutraceutical; radical scavenger
methimazole Methimazole: A thioureylene antithyroid agent that inhibits the formation of thyroid hormones by interfering with the incorporation of iodine into tyrosyl residues of thyroglobulin. This is done by interfering with the oxidation of iodide ion and iodotyrosyl groups through inhibition of the peroxidase enzyme.. methimazole : A member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen which is attached to a nitrogen.	2.03	1	0	1,3-dihydroimidazole-2-thiones	antithyroid drug
urb 597 cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester: a fatty acid amide hydrolase inhibitor; structure in first source	14.48	144	0	biphenyls
sulindac Sulindac: A sulfinylindene derivative prodrug whose sulfinyl moiety is converted in vivo to an active NSAID analgesic. Specifically, the prodrug is converted by liver enzymes to a sulfide which is excreted in the bile and then reabsorbed from the intestine. This helps to maintain constant blood levels with reduced gastrointestinal side effects.. sulindac : A monocarboxylic acid that is 1-benzylidene-1H-indene which is substituted at positions 2, 3, and 5 by methyl, carboxymethyl, and fluorine respectively, and in which the phenyl group of the benzylidene moiety is substituted at the para position by a methylsulfinyl group. It is a prodrug for the corresponding sulfide, a non-steroidal anti-inflammatory drug, used particularly in the treatment of acute and chronic inflammatory conditions.	1.99	1	0	monocarboxylic acid; organofluorine compound; sulfoxide	analgesic; antineoplastic agent; antipyretic; apoptosis inducer; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug; tocolytic agent
capsaicin ALGRX-4975: an injectable capsaicin (TRPV1 receptor agonist) formulation for longlasting pain relief. capsaicinoid : A family of aromatic fatty amides produced as secondary metabolites by chilli peppers.	13.01	199	1	capsaicinoid	non-narcotic analgesic; TRPV1 agonist; voltage-gated sodium channel blocker
terbinafine [no description available]	3.31	1	0	acetylenic compound; allylamine antifungal drug; enyne; naphthalenes; tertiary amine	EC 1.14.13.132 (squalene monooxygenase) inhibitor; P450 inhibitor; sterol biosynthesis inhibitor
thiourea Thiourea: A photographic fixative used also in the manufacture of resins. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance may reasonably be anticipated to be a carcinogen (Merck Index, 9th ed). Many of its derivatives are ANTITHYROID AGENTS and/or FREE RADICAL SCAVENGERS.. thiourea : The simplest member of the thiourea class, consisting of urea with the oxygen atom substituted by sulfur.	3.65	3	0	one-carbon compound; thioureas; ureas	antioxidant; chromophore
D-fructopyranose [no description available]	2.08	1	0	cyclic hemiketal; D-fructose; fructopyranose	sweetening agent
digoxin Digoxin: A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666). digoxin : A cardenolide glycoside that is digitoxin beta-hydroxylated at C-12. A cardiac glycoside extracted from the foxglove plant, Digitalis lanata, it is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation, but the margin between toxic and therapeutic doses is small.	2.21	1	0	cardenolide glycoside; steroid saponin	anti-arrhythmia drug; cardiotonic drug; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; epitope
capsazepine capsazepine: modified capsaicin molecule; a capsaicin receptor antagonist. capsazepine : A benzazepine that is 2,3,4,5-tetrahydro-1H-2-benzazepine which is substituted by hydroxy groups at positions 7 and 8 and on the nitrogen atom by a 2-(p-chlorophenyl)ethylaminothiocarbonyl group. A synthetic analogue of capsaicin, it was the first reported capsaicin receptor antagonist.	7.08	77	0	benzazepine; catechols; monochlorobenzenes; thioureas	capsaicin receptor antagonist
2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide 2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide: partial structure given in first source; endothelium-derived relaxing factor antagonist	2.48	2	0
1,1-diphenyl-2-picrylhydrazyl 1,1-diphenyl-2-picrylhydrazyl: A diphenyl picrate; the ability to decolorize this stable radical indicates reactivity of tested compounds (Banda, Anal Chem 46:1772-7 1974)	2.03	1	0
t 0070907 T 0070907: a PPARgamma antagonist; structure in first source	2.02	1	0	carbonyl compound; organohalogen compound
valinomycin Valinomycin: A cyclododecadepsipeptide ionophore antibiotic produced by Streptomyces fulvissimus and related to the enniatins. It is composed of 3 moles each of L-valine, D-alpha-hydroxyisovaleric acid, D-valine, and L-lactic acid linked alternately to form a 36-membered ring. (From Merck Index, 11th ed) Valinomycin is a potassium selective ionophore and is commonly used as a tool in biochemical studies.. valinomycin : A twelve-membered cyclodepsipeptide composed of three repeating D-alpha-hydroxyisovaleryl-D-valyl-L-lactoyl-L-valyl units joined in sequence. An antibiotic found in several Streptomyces strains.	2.43	2	0	cyclodepsipeptide; macrocycle	antimicrobial agent; antiviral agent; bacterial metabolite; potassium ionophore
thiopental Thiopental: A barbiturate that is administered intravenously for the induction of general anesthesia or for the production of complete anesthesia of short duration.. thiopental : A barbiturate, the structure of which is that of 2-thiobarbituric acid substituted at C-5 by ethyl and sec-pentyl groups.	3.56	2	0	barbiturates	anticonvulsant; drug allergen; environmental contaminant; intravenous anaesthetic; sedative; xenobiotic
lithium Lithium: An element in the alkali metals family. It has the atomic symbol Li, atomic number 3, and atomic weight [6.938; 6.997]. Salts of lithium are used in treating BIPOLAR DISORDER.	2.01	1	0	alkali metal atom
raclopride Raclopride: A substituted benzamide that has antipsychotic properties. It is a dopamine D2 receptor (see RECEPTORS, DOPAMINE D2) antagonist.	2	1	0	salicylamides
orlistat Orlistat: A lactone derivative of LEUCINE that acts as a pancreatic lipase inhibitor to limit the absorption of dietary fat; it is used in the management of obesity.. orlistat : A carboxylic ester resulting from the formal condensation of the carboxy group of N-formyl-L-leucine with the hydroxy group of (3S,4S)-3-hexyl-4-[(2S)-2-hydroxytridecyl]oxetan-2-one. A pancreatic lipase inhibitor, it is used as an anti-obesity drug.	3.12	1	0	beta-lactone; carboxylic ester; formamides; L-leucine derivative	anti-obesity agent; bacterial metabolite; EC 2.3.1.85 (fatty acid synthase) inhibitor; EC 3.1.1.3 (triacylglycerol lipase) inhibitor
quinine [no description available]	3.87	3	0	cinchona alkaloid	antimalarial; muscle relaxant; non-narcotic analgesic
1,2-bis(2-aminophenoxy)ethane n,n,n',n'-tetraacetic acid acetoxymethyl ester [no description available]	2.45	2	0
glyceryl nonivamide N-(4-O-glycerol-3-methoxybenzyl)nonivamide: structure given in first source	2.01	1	0
phorbol 12-phenylacetate 13-acetate 20-homovanillate phorbol 12-phenylacetate 13-acetate 20-homovanillate: behavior contrasts with resiniferatoxin and capsaicin in the lack of cooperativity in binding vanilloid (capsaicin) receptor	2.01	1	0
4-(3-3,4-p-menthadien-(1,8)-yl)olivetol 4-(3-3,4-p-menthadien-(1,8)-yl)olivetol: has vasodilating activity	3.14	5	0
2-octyl-gamma-bromoacetoacetate 2-octyl-gamma-bromoacetoacetate: RN given refers to (D)-isomer; structure	3.14	1	0
sr 144528 SR 144528: a CB2 cannabinoid receptor antagonist; structure in first source. SR 144528 : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-(4-chloro-3-methylphenyl)-1-(4-methylbenzyl)-1H-pyrazole-3-carboxylic acid with the amino group of (1S,2S,4R)-1,3,3-trimethylbicyclo[2.2.1]heptan-2-amine. A potent and selective cannabinoid receptor type 2 (CB2 receptor) inverse agonist (Ki = 0.6 nM).	7.53	40	0	bridged compound; monochlorobenzenes; pyrazoles; secondary carboxamide	CB2 receptor antagonist; EC 2.3.1.26 (sterol O-acyltransferase) inhibitor
lenabasum lenabasum: a CB2 cannabinoid receptor agonist; structure in first source	3.56	2	0
2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline 2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline: structure given in first source; neuroprotectant for cerebral ischemia; AMPA receptor antagonist	1.99	1	0	naphthalenes; sulfonic acid derivative
ovalbumin Ovalbumin: An albumin obtained from the white of eggs. It is a member of the serpin superfamily.	2.98	4	0
gw 7647 GW 7647: a PPAR-alpha agonist; structure in first source. GW 7647 : A monocarboxylic acid that is 2-(phenylsulfanyl)isobutyric acid in which the phenyl group is substituted at the para- position by a 3-aza-7-cyclohexylhept-1-yl group in which the nitrogen is acylated by a (cyclohexylamino)carbonyl group.	2.03	1	0	aryl sulfide; monocarboxylic acid; ureas	PPARalpha agonist
sodium dodecyl sulfate Sodium Dodecyl Sulfate: An anionic surfactant, usually a mixture of sodium alkyl sulfates, mainly the lauryl; lowers surface tension of aqueous solutions; used as fat emulsifier, wetting agent, detergent in cosmetics, pharmaceuticals and toothpastes; also as research tool in protein biochemistry.. sodium dodecyl sulfate : An organic sodium salt that is the sodium salt of dodecyl hydrogen sulfate.	2.13	1	0	organic sodium salt	detergent; protein denaturant
2-chloro-5-hydroxyphenylglycine 2-chloro-5-hydroxyphenylglycine: activates mGlu(5) receptors; structure in first source	2.07	1	0
l 663536 MK-886: orally active leukotriene biosynthesis inhibitor. 3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(propan-2-yl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid : A member of the class of indoles that is 1H-indole substituted by a isopropyl group at position 5, a tert-butylsulfanediyl group at position 3, a 4-chlorobenzyl group at position 1 and a 2-carboxy-2-methylpropyl group at position 2. It acts as an inhibitor of arachidonate 5-lipoxygenase.	2.73	3	0	aryl sulfide; indoles; monocarboxylic acid; monochlorobenzenes	antineoplastic agent; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; leukotriene antagonist
6-cyano-7-nitroquinoxaline-2,3-dione 6-Cyano-7-nitroquinoxaline-2,3-dione: A potent excitatory amino acid antagonist with a preference for non-NMDA iontropic receptors. It is used primarily as a research tool.	2.94	4	0	quinoxaline derivative
jhw 015 [no description available]	5.76	10	0	indolecarboxamide
am 281 AM 281: radioligand for cannabinoid CB1 receptors; structure in first source	5.32	20	0	pyrazoles; ring assembly
am 630 iodopravadoline: an aminoalkylindole; a competitive cannabinoid receptor antagonist; structure given in first source	6.25	52	0	N-acylindole
sc 560 SC560 : A member of the class of pyrazoles that is 1H-pyrazole which is substituted at positions 1, 3 and 5 by 4-methoxyphenyl, trifluoromethyl and 4-chlorophenyl groups, respectively. Unlike many members of the diaryl heterocycle class of cyclooxygenase (COX) inhibitors, SC-560 is selective for COX-1.	2.03	1	0	aromatic ether; monochlorobenzenes; organofluorine compound; pyrazoles	angiogenesis modulating agent; antineoplastic agent; apoptosis inducer; cyclooxygenase 1 inhibitor; non-steroidal anti-inflammatory drug
2-(2-(5-bromo-1h-indol-3-yl)ethyl)-3-(1-methylethoxyphenyl)-4-(3h)-quinazolinone 2-(2-(5-bromo-1H-indol-3-yl)ethyl)-3-(1-methylethoxyphenyl)-4-(3H)-quinazolinone: CCK2 receptor antagonist	2.08	1	0	quinazolines
3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol: (-)-CP-55,940 and (+)-CP-56,667 are enantiomers; RN refers to CP-55,940	8.51	110	0	alkylbenzene; ring assembly
sphingosine sphing-4-enine : A sphingenine in which the C=C double bond is located at the 4-position.. sphingenine : A 2-aminooctadecene-1,3-diol having (2S,3R)-configuration.. sphingoid : Sphinganine, its homologs and stereoisomers, and the hydroxy and unsaturated derivatives of these compounds.. 2-aminooctadec-4-ene-1,3-diol : A 2-aminooctadecene-1,3-diol having its double bond at position 4.	3.3	6	0	sphing-4-enine	human metabolite; mouse metabolite
bilirubin [no description available]	2.05	1	0	biladienes; dicarboxylic acid	antioxidant; human metabolite; mouse metabolite
dinoprostone prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.	6.03	35	0	prostaglandins E	human metabolite; mouse metabolite; oxytocic
dinoprost Dinoprost: A naturally occurring prostaglandin that has oxytocic, luteolytic, and abortifacient activities. Due to its vasocontractile properties, the compound has a variety of other biological actions.. prostaglandin F2alpha : A prostaglandins Falpha that is prosta-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15. It is a naturally occurring prostaglandin used to induce labor.	3.67	9	0	monocarboxylic acid; prostaglandins Falpha	human metabolite; mouse metabolite
biochanin a [no description available]	2.05	1	0	4'-methoxyisoflavones; 7-hydroxyisoflavones	antineoplastic agent; EC 3.5.1.99 (fatty acid amide hydrolase) inhibitor; phytoestrogen; plant metabolite; tyrosine kinase inhibitor
arachidonyltrifluoromethane arachidonyltrifluoromethane: structure given in first source; inhibits 85-kDa phospholipase A2. AACOCF3 : A fatty acid derivative that is arachidonic acid in which the OH part of the carboxy group has been replaced by a trifluoromethyl group	4.71	5	0	fatty acid derivative; ketone; olefinic compound; organofluorine compound	EC 3.1.1.4 (phospholipase A2) inhibitor
linoleic acid Linoleic Acid: A doubly unsaturated fatty acid, occurring widely in plant glycosides. It is an essential fatty acid in mammalian nutrition and is used in the biosynthesis of prostaglandins and cell membranes. (From Stedman, 26th ed). linoleic acid : An octadecadienoic acid in which the two double bonds are at positions 9 and 12 and have Z (cis) stereochemistry.	3.39	6	0	octadecadienoic acid; omega-6 fatty acid	algal metabolite; Daphnia galeata metabolite; plant metabolite
calcitriol dihydroxy-vitamin D3: as a major in vitro metabolite of 1alpha,25-dihydroxyvitamin D3, produced in primary cultures of neonatal human keratinocytes	2.02	1	0	D3 vitamins; hydroxycalciol; triol	antineoplastic agent; antipsoriatic; bone density conservation agent; calcium channel agonist; calcium channel modulator; hormone; human metabolite; immunomodulator; metabolite; mouse metabolite; nutraceutical
11-cis-retinal Rhodopsin: A purplish-red, light-sensitive pigment found in RETINAL ROD CELLS of most vertebrates. It is a complex consisting of a molecule of ROD OPSIN and a molecule of 11-cis retinal (RETINALDEHYDE). Rhodopsin exhibits peak absorption wavelength at about 500 nm.. 11-cis-retinal : A retinal having 2E,4Z,6E,8E-double bond geometry.	2.43	2	0	retinal	chromophore; human metabolite; mouse metabolite
thromboxane a2 Thromboxane A2: An unstable intermediate between the prostaglandin endoperoxides and thromboxane B2. The compound has a bicyclic oxaneoxetane structure. It is a potent inducer of platelet aggregation and causes vasoconstriction. It is the principal component of rabbit aorta contracting substance (RCS).. thromboxane A2 : A thromboxane which is produced by activated platelets and has prothrombotic properties: it stimulates activation of new platelets as well as increases platelet aggregation.	2.03	1	0	epoxy monocarboxylic acid; thromboxanes A	mouse metabolite
prostaglandin f2beta prostaglandin F2beta: RN given refers to (5Z,9 beta,11 alpha,13E,15S)-isomer. prostaglandin F2beta : A prostaglandins Falpha that is prosta-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15. It is the 9beta-hydroxy epimer of prostaglandin F2alpha.	2	1	0	prostaglandins Fbeta	human metabolite
8,11,14-eicosatrienoic acid 8,11,14-Eicosatrienoic Acid: A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5.. all-cis-icosa-8,11,14-trienoic acid : An icosatrienoic acid having three cis double bonds at positions 8, 11 and 14.	3.54	8	0	fatty acid 20:3; long-chain fatty acid	fungal metabolite; human metabolite; nutraceutical
rutin Hydroxyethylrutoside: Monohydroxyethyl derivative of rutin. Peripheral circulation stimulant used in treatment of venous disorders.	2.13	1	0	disaccharide derivative; quercetin O-glucoside; rutinoside; tetrahydroxyflavone	antioxidant; metabolite
kaempferol [no description available]	2.04	1	0	7-hydroxyflavonol; flavonols; tetrahydroxyflavone	antibacterial agent; geroprotector; human blood serum metabolite; human urinary metabolite; human xenobiotic metabolite; plant metabolite
leukotriene d4 Leukotriene D4: One of the biologically active principles of SRS-A. It is generated from LEUKOTRIENE C4 after partial hydrolysis of the peptide chain, i.e., cleavage of the gamma-glutamyl portion. Its biological actions include stimulation of vascular and nonvascular smooth muscle, and increases in vascular permeability. (From Dictionary of Prostaglandins and Related Compounds, 1990). leukotriene D4 : A leukotriene that is (7E,9E,11Z,14Z)-icosa-7,9,11,14-tetraenoic acid substituted by a hydroxy group at position 5 (5S) and a L-cysteinylglycinyl group at position 6 (6R).	8.82	3	0	dipeptide; leukotriene; organic sulfide	bronchoconstrictor agent; human metabolite; mouse metabolite
6-ketoprostaglandin f1 alpha 6-Ketoprostaglandin F1 alpha: The physiologically active and stable hydrolysis product of EPOPROSTENOL. Found in nearly all mammalian tissue.. 6-oxoprostaglandin F1alpha : A prostaglandin Falpha that is prostaglandin F1alpha bearing a keto substituent at the 6-position.	2.72	3	0	prostaglandins Falpha	human metabolite; mouse metabolite
lipoxin a4 lipoxin A4: an antifibrolytic agent; structure given in first source; a role in ASPIRIN antiinflammatory activity. lipoxin A4 : A C20 hydroxy fatty acid having (5S)-, (6R)- and (15S)-hydroxy groups as well as (7E)- (9E)-, (11Z)- and (13E)-double bonds.	2.48	2	0	hydroxy polyunsaturated fatty acid; lipoxin; long-chain fatty acid	human metabolite; metabolite
alpha-linolenic acid linolenic acid : A two-membered subclass of octadecatrienoic acid comprising the (9Z,12Z,15Z)- and (6Z,9Z,12Z)-isomers. Linolenic acids are nutrients essential to the formation of prostaglandins and are also used in making paints and synthetic resins.. linolenate : A polyunsaturated fatty acid anion obtained by deprotonation of the carboxy group of either alpha- or gamma-linolenic acid.	2.47	2	0	linolenic acid; omega-3 fatty acid	micronutrient; mouse metabolite; nutraceutical
prostaglandin f3alpha prostaglandin F3alpha : A prostaglandin Falpha that is prosta-5,13,17-trien-1-oic acid carrying three hydroxy substituents at positions 9alpha, 11alpha and 15.	2	1	0	prostaglandins Falpha
genistein [no description available]	3.14	5	0	7-hydroxyisoflavones	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; human urinary metabolite; phytoestrogen; plant metabolite; tyrosine kinase inhibitor
erucic acid [no description available]	2.59	2	0	docosenoic acid
11-octadecenoic acid 11-octadecenoic acid: vaccenic acid is the (E)-isomer. trans-vaccenic acid : The trans- isomer of vaccenic acid.	3.04	1	0	vaccenic acid
baicalein [no description available]	2.48	2	0	trihydroxyflavone	angiogenesis inhibitor; anti-inflammatory agent; antibacterial agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antioxidant; apoptosis inducer; EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; EC 4.1.1.17 (ornithine decarboxylase) inhibitor; ferroptosis inhibitor; geroprotector; hormone antagonist; plant metabolite; prostaglandin antagonist; radical scavenger
daidzein [no description available]	7.03	1	0	7-hydroxyisoflavones	antineoplastic agent; EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor; EC 3.2.1.20 (alpha-glucosidase) inhibitor; phytoestrogen; plant metabolite
caffeic acid phenethyl ester phenethyl caffeate : An alkyl caffeate ester in which 2-phenylethyl is the alkyl component.	3.23	1	0	alkyl caffeate ester	anti-inflammatory agent; antibacterial agent; antineoplastic agent; antioxidant; antiviral agent; immunomodulator; metabolite; neuroprotective agent
flupenthixol cis-flupenthixol : A flupenthixol in which the double bond adopts a cis-configuration.	3.23	1	0	flupenthixol	dopaminergic antagonist
arachidonyl dopamine arachidonyl dopamine: a ligand for the vanilloid receptor VR1	6.38	21	0	catechols; fatty amide; N-(fatty acyl)-dopamine; secondary carboxamide
n-oleoyldopamine N-oleoyldopamine: putative capsaicin receptor ligand; produces hyperalgesia; isolated from the brain. N-oleoyldopamine : A fatty amide resulting from the formal condensation of the carboxy group of oleic acid with the amino group of dopamine. Synthesised in catecholaminergic neurons, it crosses the blood-brain barrier and might be considered as a carrier of dopamine into the brain. It is a transient receptor potential vanilloid type 1 (TRPV1) receptor agonist.	2.43	2	0	catechols; fatty amide; N-(fatty acyl)-dopamine; secondary carboxamide	TRPV1 agonist
lafutidine lafutidine: structure given in first source	2.03	1	0	organic molecular entity
travoprost Travoprost: A cloprostenol derivative that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.. travoprost : The isopropyl ester of prostaglandin F2alpha in which the pentyl group is replaced by a 3-(trifluoromethyl)phenoxymethyl group. A synthetic analogue of prostaglandin F2alpha, ophthalmic solutions of travoprost are used as a topical medication for controlling the progression of open-angle glaucoma and ocular hypertension, by reducing intraocular pressure. It is a pro-drug; the isopropyl ester group is hydrolysed by esterases in the cornea to the biologically active free acid, fluprostenol.	2.03	1	0	(trifluoromethyl)benzenes; isopropyl ester; prostaglandins Falpha	antiglaucoma drug; antihypertensive agent; ophthalmology drug; prodrug; prostaglandin receptor agonist
4-acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic acid 4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic Acid: A non-penetrating amino reagent (commonly called SITS) which acts as an inhibitor of anion transport in erythrocytes and other cells.	2.07	1	0	stilbenoid
homo-gamma-linolenylethanolamide homo-gamma-linolenylethanolamide: found in brain; binds to the cannabinoid receptor; RN given for (Z,Z,Z)-isomer; structure given in first source	4.37	6	0	N-acylethanolamine 20:3
7,10,13,16-docosatetraenylethanolamide 7,10,13,16-docosatetraenylethanolamide: found in brain; binds to the cannabinoid receptor; structure given in first source; RN given refers to (ALL-Z)-isomer	4.2	5	0	N-acylethanolamine 22:4
glyceryl 2-arachidonate glyceryl 2-arachidonate: binds to cannabinoid receptors; structure in first source. 2-arachidonoylglycerol : An endocannabinoid and an endogenous agonist of the cannabinoid receptors (CB1 and CB2). It is an ester formed from omega-6-arachidonic acid and glycerol.	19.7	556	8	2-acylglycerol 20:4; endocannabinoid	human metabolite
1-arachidonyl monoglyceride 1-arachidonyl monoglyceride: causes platelet aggregation	2.72	3	0	1-acylglycerol 20:4
n,n-dimethylsphingenine N,N-dimethylsphingosine: a sphingosine kinase inhibitor. N,N-dimethylsphingosine : A sphingoid that is sphingosine in which the two amino hydrogens are replaced by methyl groups.	2	1	0	aminodiol; sphingoid; tertiary amino compound	EC 2.7.1.91 (sphingosine kinase) inhibitor; metabolite
9-hydroxy-10,12-octadecadienoic acid 9-hydroxy-10,12-octadecadienoic acid: RN given refers to unspecified stereoisomer. 9-HODE : A HODE that consists of (10E,12Z)-octadecadienoic acid with the hydroxy substituent located at position 9.	2.07	1	0	HODE; octadecadienoic acid	human metabolite; metabolite; mouse metabolite; plant metabolite
15-keto-13,14-dihydroprostaglandin f2alpha 15-keto-13,14-dihydroprostaglandin F2alpha: main metabolite of PGF2alpha in plasma after allergen provoked asthma; RN given refers to (5Z,9alpha,11alpha)-isomer; structure. 13,14-dihydro-15-keto-PGF2alpha : A prostaglandin Falpha obtained by formal oxidation of the 15-hydroxy group and hydrogenation of the 13,14-double bond of prostaglandin F2alpha.	2.25	1	0	ketone; prostaglandins Falpha	metabolite
prostaglandin e2 ethanolamide prostaglandin E2 ethanolamide: structure in first source	3.74	10	0	prostanoid
thromboxane b2 Thromboxane B2: A stable, physiologically active compound formed in vivo from the prostaglandin endoperoxides. It is important in the platelet-release reaction (release of ADP and serotonin).. thromboxane B2 : A member of the class of thromboxanes B that is (5Z,13E)-thromboxa-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15.	2.03	1	0	thromboxanes B	human metabolite; mouse metabolite
20-hydroxy-5,8,11,14-eicosatetraenoic acid 20-hydroxy-5,8,11,14-eicosatetraenoic acid: stimulator of renal sodium, potassium atpase; RN given is for the (all-Z) isomer. 20-HETE : A HETE that consists of arachidonic acid bearing a hydroxy substituent at position 20.	2.45	2	0	HETE; hydroxy monocarboxylic acid	human metabolite; mouse metabolite
arachidonic acid 5-hydroperoxide arachidonic acid 5-hydroperoxide: 5-HPETE is used inconsistently in literature as syn for cpds with various tetraene locants; RN given refers to (6,8,11,14)-isomer; RN in CA Vol 91 Form Index for (E,Z,Z,Z)-isomer: 70968-82-0; RN for (5,8,11,13)-isomer: 71133-12-5; in Merck, arachidonic acid is the (5,8,11,14)-isomer. 5-HPETE : A HPETE that consists of (6E,8Z,11Z,14Z)-icosatetraenoic acid in which the hydroperoxy group is located at position 5.	1.99	1	0	HPETE	human xenobiotic metabolite
5,6-epoxy-8,11,14-eicosatrienoic acid 5,6-epoxy-8,11,14-eicosatrienoic acid: RN given refers to cpd without isomeric designation. 5,6-EET : An EET obtained by formal epoxidation of the 5,6-double bond of arachidonic acid.	2.44	2	0	EET	mouse metabolite
8-isoprostaglandin e2 8-isoprostaglandin E2: RN given refers to (5Z,8 beta,11 alpha,13E,15S)-isomer; see also 8,12-epi-prostaglandin E2 & prostaglandin E2. 8-epi-prostaglandin E2 : A prostanoid that is prostaglandin E2 having inverted stereochemistry at the 8-position.	2.42	2	0	cyclic ketone; diol; prostanoid; secondary alcohol	bronchoconstrictor agent; human metabolite; rat metabolite; vasoconstrictor agent
oleylamide oleylamide: plastic additive; can cause contact urticaria; RN given refers to (Z)-isomer; a sleep inducing factor. aliphatic amide : A carboxamide in which the amide linkage is bonded directly to an aliphatic system.. oleamide : A fatty amide derived from oleic acid.	7.44	29	0	primary fatty amide	human metabolite; plant metabolite
n-arachidonylglycine N-arachidonylglycine: structure in first source. N-arachidonoylglycine : Biologically active derivative of anandamide	10.53	12	0	fatty amide; N-acylglycine
arachidonoyl amine arachidonoyl amine : A primary fatty amide resulting from the formal condensation of the carboxy group of arachidonic acid with ammonia.	2.92	4	0	primary fatty amide	cannabinoid receptor agonist
linoleoyl ethanolamide linoleoyl ethanolamide: RN given for (Z,Z)-isomer. linoleoyl ethanolamide : An N-acylethanolamine 18:2 that is the ethanolamide of linoleic acid.	6.54	14	1	N-acylethanolamine 18:2	EC 3.5.1.99 (fatty acid amide hydrolase) inhibitor
N-(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoylethanolamine synaptamide: structurally similar to the endocannabinoid N-arachidonoylethanolamine (anandamide). N-(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoylethanolamine : An N-acylethanolamine 22:6 that is the ethanolamide of (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoic acid.	4.43	5	0	endocannabinoid; N-acylethanolamine 22:6
n-oleoylethanolamine N-oleoylethanolamine: ceramidase inhibitor. oleoyl ethanolamide : An N-(long-chain-acyl)ethanolamine that is the ethanolamide of oleic acid. The monounsaturated analogue of the endocannabinoid anandamide.	18.56	118	4	endocannabinoid; N-(long-chain-acyl)ethanolamine; N-acylethanolamine 18:1	EC 3.5.1.23 (ceramidase) inhibitor; geroprotector; PPARalpha agonist
sphingosine 1-phosphate sphingosine 1-phosphate: RN given refers to (R-(R,S-(E)))-isomer; RN for cpd without isomeric designation not available 8/89. sphingosine 1-phosphate : A phosphosphingolipid that consists of sphingosine having a phospho group attached at position 1	8.01	4	0	sphingoid 1-phosphate	mouse metabolite; signalling molecule; sphingosine-1-phosphate receptor agonist; T-cell proliferation inhibitor; vasodilator agent
nabilone nabilone: cannabinol deriv; RN given refers to cpd without isomeric designation; structure	3.58	2	0
naloxone Naloxone: A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors.. naloxone : A synthetic morphinane alkaloid that is morphinone in which the enone double bond has been reduced to a single bond, the hydrogen at position 14 has been replaced by a hydroxy group, and the methyl group attached to the nitrogen has been replaced by an allyl group. A specific opioid antagonist, it is used (commonly as its hydrochloride salt) to reverse the effects of opioids, both following their use of opioids during surgery and in cases of known or suspected opioid overdose.	8.9	12	0	morphinane alkaloid; organic heteropentacyclic compound; tertiary alcohol	antidote to opioid poisoning; central nervous system depressant; mu-opioid receptor antagonist
morphine Meconium: The thick green-to-black mucilaginous material found in the intestines of a full-term fetus. It consists of secretions of the INTESTINAL GLANDS; BILE PIGMENTS; FATTY ACIDS; AMNIOTIC FLUID; and intrauterine debris. It constitutes the first stools passed by a newborn.	7.9	25	0	morphinane alkaloid; organic heteropentacyclic compound; tertiary amino compound	anaesthetic; drug allergen; environmental contaminant; geroprotector; mu-opioid receptor agonist; opioid analgesic; plant metabolite; vasodilator agent; xenobiotic
arachidonyl-2-chloroethylamide arachidonyl-2-chloroethylamide: a potent and selective agonist of the neuronal cannabinoid receptor; structure in first source. arachidonyl-2'-chloroethylamide : A fatty amide obtained by the formal condensation of arachidonic acid with 2-chloroethanamine. It is a potent agonist of the CB1 receptor (Ki = 1.4 nM) and also has a low affinity for the CB2 receptor (Ki = 3100 nM).	10.91	18	0	fatty amide; organochlorine compound; secondary carboxamide; synthetic cannabinoid	CB1 receptor agonist; CB2 receptor agonist; neuroprotective agent
arachidonylcyclopropylamide arachidonylcyclopropylamide: a potent and selective agonist of neuronal cannabinoid receptor; structure in first source	4.39	6	0
bimatoprost Bimatoprost: A cloprostenol-derived amide that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.	2.46	2	0	monocarboxylic acid amide	antiglaucoma drug; antihypertensive agent
cloprostenol Cloprostenol: A synthetic prostaglandin F2alpha analog. The compound has luteolytic effects and is used for the synchronization of estrus in cattle.	2.46	2	0	prostanoid
cp 99994 3-(2-methoxybenzylamino)-2-phenylpiperidine: selective NK(1) receptor antagonist; CP-100263 is the inactive enantiomer	2	1	0
endomorphin 1 endomorphin 1: isolated from bovine brain	2.45	2	0	oligopeptide
endomorphin 2 endomorphin 2: isolated from bovine brain	2.04	1	0
olvanil [no description available]	7.32	19	1	methoxybenzenes; phenols
hu 243 HU 243: RN refers to tritium-labeled compound	4.69	3	0
l 759633 L 759633: structure in first source	3.18	1	0	1-benzopyran
latanoprost Latanoprost: A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.. latanoprost : A prostaglandin Falpha that is the isopropyl ester prodrug of latanoprost free acid. Used in the treatment of open-angle glaucoma and ocular hypertension.	2.03	1	0	isopropyl ester; prostaglandins Falpha; triol	antiglaucoma drug; antihypertensive agent; EC 4.2.1.1 (carbonic anhydrase) inhibitor; prodrug
al 8810 AL 8810: a prostaglandin F(2alpha) receptor antagonist; structure in first source	2.48	2	0	long-chain fatty acid
ly 320135 LY 320135: cannabinoid receptor antagonist; structure in first source	3.11	5	0	benzofurans
lysophosphatidic acid lysophosphatidic acid: RN given refers to parent cpd. 1-oleoyl-sn-glycerol 3-phosphate : A 1-acyl-sn-glycerol 3-phosphate having oleoyl as the 1-O-acyl group.. lysophosphatidic acid : A member of the class of lysophosphatidic acids obtained by hydrolytic removal of one of the two acyl groups of any phosphatidic acid. A 'closed' class.	2.6	1	0	1-acyl-sn-glycerol 3-phosphate
lysophosphatidylcholines lysophosphatidylcholine : An acylglycerophosphocholine resulting from partial hydrolysis of a phosphatidylcholine, which removes one of the fatty acyl groups. The structure is depicted in the image where R1 = acyl, R2 = H or where R1 = H, R2 = acyl.	2.25	1	0	1-O-acyl-sn-glycero-3-phosphocholine
mdl 100907 Serotonin 5-HT2 Receptor Antagonists: Drugs that bind to but do not activate SEROTONIN 5-HT2 RECEPTORS, thereby blocking the actions of SEROTONIN or SEROTONIN 5-HT2 RECEPTOR AGONISTS. Included under this heading are antagonists for one or more specific 5-HT2 receptor subtypes.	3.56	1	1
neurokinin a Neurokinin A: A mammalian neuropeptide of 10 amino acids that belongs to the tachykinin family. It is similar in structure and action to SUBSTANCE P and NEUROKININ B with the ability to excite neurons, dilate blood vessels, and contract smooth muscles, such as those in the BRONCHI.	2.08	1	0
(3r)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone WIN 55212-2 : A organic heterotricyclic compound that is 5-methyl-3-(morpholin-4-ylmethyl)-2,3-dihydro[1,4]oxazino[2,3,4-hi]indole substituted at position 6 by a 1-naphthylcarbonyl group.	5.89	18	0	morpholines; naphthyl ketone; organic heterotricyclic compound; synthetic cannabinoid	analgesic; apoptosis inhibitor; neuroprotective agent
1,2-oleoylphosphatidylcholine 1,2-oleoylphosphatidylcholine: RN given refers to (Z,Z)-isomer. dioleoyl phosphatidylcholine : A phosphatidylcholine in which the phosphatidyl acyl groups are both oleoyl.	2.47	2	0	phosphatidylcholine(1+)
cannabigerol cannabigerol: RN given refers to (E)-isomer; structure given in first source. cannabigerol : A member of the class of resorcinols that is resorcinol which is substituted by a (2E)-3,7-dimethylocta-2,6-dien-1-yl group at position 2 and by a pentyl group at position 5. It is a natural product found in Cannabis sativa and Helichrysum species.	2.17	1	0	phytocannabinoid; resorcinols	anti-inflammatory agent; antibacterial agent; antioxidant; appetite enhancer; cannabinoid receptor agonist; neuroprotective agent; plant metabolite
2-oleoylglycerol 2-oleoylglycerol : A 2-monoglyceride where the acyl group is (9Z)-octadecenoyl.	8.6	8	0	2-acylglycerol 18:1; monooleoylglycerol
ag-490 [no description available]	3.23	1	0	catechols; enamide; monocarboxylic acid amide; nitrile; secondary carboxamide	anti-inflammatory agent; antioxidant; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; geroprotector; STAT3 inhibitor
15-hydroxy-5,8,11,13-eicosatetraenoic acid 15-hydroxy-5,8,11,13-eicosatetraenoic acid: potent & selective inhibitor of platelet lipoxygenase; RN given refers to cpd without isomeric designation	2.42	2	0
15-hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic acid 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid: A stable prostaglandin endoperoxide analog which serves as a thromboxane mimetic. Its actions include mimicking the hydro-osmotic effect of VASOPRESSIN and activation of TYPE C PHOSPHOLIPASES. (From J Pharmacol Exp Ther 1983;224(1): 108-117; Biochem J 1984;222(1):103-110)	3.42	7	0
oleoylanilide oleoylanilide: alters lipid metabolism of lung & adipose tissue; do not confuse with oleoanilide; RN given refers to (Z)-isomer. oleylanilide : The fatty amide resulting from the formal condensation of oleic acid and aniline.	2	1	0	anilide; fatty amide
barium Barium: An element of the alkaline earth group of metals. It has an atomic symbol Ba, atomic number 56, and atomic weight 138. All of its acid-soluble salts are poisonous.	2.69	3	0	alkaline earth metal atom; elemental barium
naltrexone Naltrexone: Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.. naltrexone : An organic heteropentacyclic compound that is naloxone substituted in which the allyl group attached to the nitrogen is replaced by a cyclopropylmethyl group. A mu-opioid receptor antagonist, it is used to treat alcohol dependence.	8.27	6	0	cyclopropanes; morphinane-like compound; organic heteropentacyclic compound	antidote to opioid poisoning; central nervous system depressant; environmental contaminant; mu-opioid receptor antagonist; xenobiotic
methylazoxymethanol acetate Methylazoxymethanol Acetate: The aglycone of CYCASIN. It acts as a potent carcinogen and neurotoxin and inhibits hepatic DNA, RNA, and protein synthesis.	2.21	1	0	azoxy compound
erucyl amide erucyl amide: RN given refers to (Z)-isomer. erucamide : A primary fatty amide resulting from the formal condensation of the carboxy group of erucic acid with ammonia. It is commonly used as a slip additive in the plastic manufacturing industry.	2.17	1	0	13-docosenamide	EC 3.1.1.7 (acetylcholinesterase) inhibitor; human metabolite; mammalian metabolite; plant metabolite; rat metabolite
2-linoleoylglycerol 2-linoleoylglycerol: increases 2-arachidonoyl-glycerol cannabinoid activity. 2-linoleoylglycerol : A 2-monoglyceride where linoleoyl forms the 2-acyl group.	2.03	1	0	2-acylglycerol 18:2
cysteine Cysteine: A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.. L-cysteinium : The L-enantiomer of cysteinium.. cysteine : A sulfur-containing amino acid that is propanoic acid with an amino group at position 2 and a sulfanyl group at position 3.	2.03	1	0	cysteinium	fundamental metabolite
heroin Heroin: A narcotic analgesic that may be habit-forming. It is a controlled substance (opium derivative) listed in the U.S. Code of Federal Regulations, Title 21 Parts 329.1, 1308.11 (1987). Sale is forbidden in the United States by Federal statute. (Merck Index, 11th ed). heroin : A morphinane alkaloid that is morphine bearing two acetyl substituents on the O-3 and O-6 positions. As with other opioids, heroin is used as both an analgesic and a recreational drug. Frequent and regular administration is associated with tolerance and physical dependence, which may develop into addiction. Its use includes treatment for acute pain, such as in severe physical trauma, myocardial infarction, post-surgical pain, and chronic pain, including end-stage cancer and other terminal illnesses.	2.42	2	0	morphinane alkaloid	mu-opioid receptor agonist; opioid analgesic; prodrug
norbinaltorphimine norbinaltorphimine: kappa opiate receptor antagonist; structure given in first source	2.39	2	0	isoquinolines
binaltorphimine binaltorphimine: kappa opiate receptor antagonist; structure given in first source	2.31	1	0
ici 118551 ICI 118551: RN given refers to (R,R)-(+-)-isomer; structure in first source; ICI 111581 is hydrochloride of ICI 118551. ICI 118551 : An indane substituted at position 7 by a methyl group and at position 4 by a 3-(isopropylamino)-2-hydroxybutoxy group (the 2R,3S-diastereomer).	2.42	2	0	aromatic ether; indanes; secondary alcohol; secondary amino compound	beta-adrenergic antagonist
enkephalin, ala(2)-mephe(4)-gly(5)- Enkephalin, Ala(2)-MePhe(4)-Gly(5)-: An enkephalin analog that selectively binds to the MU OPIOID RECEPTOR. It is used as a model for drug permeability experiments.	2.42	2	0
arachidonyl-coenzyme a arachidonoyl-CoA : An unsaturated fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of arachidononic acid.	2.05	1	0	arachidonoyl bioconjugate; unsaturated fatty acyl-CoA
naltrindole naltrindole: delta opioid receptor antagonist	2.04	1	0	isoquinolines
resiniferatoxin resiniferatoxin: phorbol related diterpene ester; potent agonist of vanilloid TRPV1 receptors. resiniferatoxin : A heteropentacyclic compound found in Euphorbia poissonii with molecular formula C37H40O9. It is an agonist of the transient receptor potential cation channel subfamily V member 1 (TrpV1).	7.57	22	0	carboxylic ester; diterpenoid; enone; monomethoxybenzene; organic heteropentacyclic compound; ortho ester; phenols; tertiary alpha-hydroxy ketone	analgesic; neurotoxin; plant metabolite; TRPV1 agonist
virodhamine virodhamine: arachidonic acid and ethanolamine joined by an ester linkage, like anandamide with oxygen and nitrogen reversed; an endocannabinoid from rat; structure in first source	11.59	14	0	fatty acid ester
salubrinal salubrinal: prevents dephosphorylation of eIF2alpha; structure in first source. salubrinal : A member of the class of quinolines that is a mixed aminal resulting from the formal condensation oftrichloroacetaldehyde with the amide nitrogen of trans-cinnamamide and the primary amino group of 1-quinolin-8-ylthiourea. It is a selective inhibitor of cellular complexes that dephosphorylate eukaryotic translation initiation factor 2 subunit alpha (eIF2alpha).	2.03	1	0	aminal; organochlorine compound; quinolines; secondary carboxamide; thioureas
6-(bromomethylene)tetrahydro-3-(1-naphthaleneyl)-2h-pyran-2-one 6-(bromomethylene)tetrahydro-3-(1-naphthaleneyl)-2H-pyran-2-one: structure given in first source; potent irreversible, mechanism-based inhibitor of myocardial calcium-independent phospholipase A2	4.32	3	0	naphthalenes
4,4'-diisothiocyanostilbene-2,2'-disulfonic acid 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid: An inhibitor of anion conductance including band 3-mediated anion transport.	2.07	1	0
am-356 methanandamide: structure given in first source; RN given refers to (all-Z)-(+-)-isomer	7.41	87	0	fatty amide
iodoresiniferatoxin iodoresiniferatoxin: a vanilloid receptor 1 antagonist	3.53	8	0
mastoparan [no description available]	2.01	1	0	mastoparans; peptidyl amide	antimicrobial agent
tetrodotoxin Tetrodotoxin: An aminoperhydroquinazoline poison found mainly in the liver and ovaries of fishes in the order TETRAODONTIFORMES, which are eaten. The toxin causes paresthesia and paralysis through interference with neuromuscular conduction.. tetrodotoxin : A quinazoline alkaloid that is a marine toxin isolated from fish such as puffer fish. It has been shown to exhibit potential neutotoxicity due to its ability to block voltage-gated sodium channels.	5.38	18	0	azatetracycloalkane; oxatetracycloalkane; quinazoline alkaloid	animal metabolite; bacterial metabolite; marine metabolite; neurotoxin; voltage-gated sodium channel blocker
dizocilpine maleate Dizocilpine Maleate: A potent noncompetitive antagonist of the NMDA receptor (RECEPTORS, N-METHYL-D-ASPARTATE) used mainly as a research tool. The drug has been considered for the wide variety of neurodegenerative conditions or disorders in which NMDA receptors may play an important role. Its use has been primarily limited to animal and tissue experiments because of its psychotropic effects.. dizocilpine maleate : A maleate salt obtained by reaction of dizocilpine with one equivalent of maleic acid.	3.72	10	0	maleate salt; tetracyclic antidepressant	anaesthetic; anticonvulsant; neuroprotective agent; nicotinic antagonist; NMDA receptor antagonist
linoleamide linoleamide: C18-H33-N-O. linoleamide : A fatty amide obtained from linoleic acid.	2.17	1	0	primary fatty amide	human metabolite
1-palmitoyl-2-oleoylphosphatidylcholine 1-palmitoyl-2-oleoylphosphatidylcholine: RN given refers to (Z)-isomer	2.06	1	0
n-hydroxy-9-octadecenamide N-hydroxy-9-octadecenamide: RN given refers to (9Z)-isomer; OA-Hy is the (cis)-isomer; a matrix metalloproteinase-2 inhibitor	2	1	0
involucrin involucrin: soluble precursor protein of cross-linked envelope characteristic of epidermal s. corneum synthesized by keratinocytes in natural & cultured human epithelia; see also related records for prekeratin & stratum corneum basic protein precursor	2.04	1	0
diarachidonyl diglyceride diradylglycerol : Any lipid that is glycerol bearing two substituent groups - either acyl, alkyl, or alk-1-enyl - at any two of the three possible positions.	2.02	1	0
2-(4-amylcinnamoyl)amino-4-chlorobenzoic acid 2-(4-amylcinnamoyl)amino-4-chlorobenzoic acid: phospholipase A2 inhibitor	3.23	1	0
3-hydroxy-5,8,11,14-eicosatetraenoic acid 3-hydroxy-5,8,11,14-eicosatetraenoic acid: from yeast Dipodascopsis uninucleata UOFs-Y128; structure given in first source; RN given is for all-Z isomer	3.54	2	0
guineensine guineensine: an Acyl-CoA: cholesterol acyltransferase inhibitor, from the fruits of Piper longum; structure in first sourc	2.54	2	0	benzodioxoles
4,7,10,13,16,19-docosahexaenoic acid dopamine conjugate NMI 8739: structure given in first source; RN given refers to all-cis isomer	2.46	2	0
oleoylimidazolide [no description available]	2.08	1	0
arvanil arvanil: structure in first source	5.31	17	0	methoxybenzenes; phenols
noladin ether noladin ether: a cannabinoid CB1 receptor agonist; structure in first source. 2-arachidonyl glyceryl ether : A monoalkylglycerol that is glycerol which is substituted by a (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraen-1-yl group at position 2.	11.57	14	0	2-alkylglycerol; endocannabinoid; monoalkylglycerol
fm1 43 FM1 43: labels motor nerve terminals in an activity-dependent fashion that involves dye uptake by synaptic vesicles that are recycling; structure given in second source	2	1	0	organic bromide salt; pyridinium salt; quaternary ammonium salt; tertiary amine	fluorochrome
clocinnamox clocinnamox: structure given in first source; an opioid mu receptor agonist	2.76	2	0
gw2974 GW2974: quinazoline derivative, which is able to block the activation of both the EGFR and erbB2	3.31	1	0	pyridopyrimidine
am 404 [no description available]	12.82	93	0	anilide
omdm-2 cpd OMDM-2 cpd: structure in first source	5.07	13	0
n-stearoyltyrosine [no description available]	7.53	2	0	tyrosine derivative
adenosine-3',5'-cyclic phosphorothioate adenosine-3',5'-cyclic phosphorothioate: RP-cAMP-S is a protein kinase A inhibitor; SP-cAMP-S is a protein kinase A agonist. (Sp)-cAMPS : A nucleoside 3',5'-cyclic phosphorothioate having adenine as the nucleobase (the Sp-stereoisomer).. (Rp)-cAMPS : A nucleoside 3',5'-cyclic phosphorothioate having adenine as the nucleobase (the Rp-stereoisomer).	2.7	3	0	nucleoside 3',5'-cyclic phosphorothioate
sq-23377 Ionomycin: A divalent calcium ionophore that is widely used as a tool to investigate the role of intracellular calcium in cellular processes.. ionomycin : A very long-chain fatty acid that is docosa-10,16-dienoic acid which is substituted by methyl groups at positions 4, 6, 8, 12, 14, 18 and 20, by hydroxy groups at positions 11, 19 and 21, and by a (2',5-dimethyloctahydro-2,2'-bifuran-5-yl)ethanol group at position 21. An ionophore produced by Streptomyces conglobatus, it is used in research to raise the intracellular level of Ca(2+) and as a research tool to understand Ca(2+) transport across biological membranes.	4.81	10	0	cyclic ether; enol; polyunsaturated fatty acid; very long-chain fatty acid	calcium ionophore; metabolite
jwh-133 1,1-dimethylbutyl-1-deoxy-Delta(9)-THC: a CB2 receptor agonists; no further information available on 8/2001. JWH-133 : A dibenzopyran that is Delta(9)-tetrahydrocannabinol which is lacking the hydroxy group and in which the pentyl group at position 3 has been replaced by a 1,1-dimethylbutyl group. A potent and highly selective CB2 receptor agonist.	5.47	19	0	benzochromene; dibenzopyran; organic heterotricyclic compound	analgesic; anti-inflammatory agent; antineoplastic agent; apoptosis inhibitor; CB2 receptor agonist; opioid analgesic; vasodilator agent
staurosporine staurosporinium : Conjugate acid of staurosporine.	2.7	3	0	ammonium ion derivative
azimilide azimilide: structure given in first source; RN given refers to dihydrochloride	2.01	1	0	imidazolidine-2,4-dione
triacsin c triacsin C: from Streptomyces No. 1228; structure given in first source; an acyl-CoA synthetase antagonist. triacsin C : A nitroso compound that is N-undecylnitrous hydrazide carrying double bonds at positions 1,2,4, and 7. It is a long-chain fatty acyl CoA synthetase inhibitor and interferes with lipid metabolism by inhibiting the de novo synthesis of glycerolipids and cholesterol esters.	2	1	0	hydrazone; nitroso compound; olefinic compound	antimalarial; apoptosis inhibitor; bacterial metabolite; EC 3.1.1.64 (retinoid isomerohydrolase) inhibitor; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; vasodilator agent
lassbio 294 [no description available]	2.03	1	0
CB-13 naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: has antihyperalgesic activity; structure in first source	2.1	1	0	benzophenones
ave 0118 [no description available]	3.31	1	0
hu 210 [no description available]	5.75	10	0	1-benzopyran
kb r7943 2-(2-(4-(4-nitrobenzyloxy)phenyl)ethyl)isothiourea methanesulfonate: inhibits the reverse mode of Na+/Ca++ exchange in cells expressing NCX1; structure in first source	3.37	2	0
a 1899 A 1899: a TASK-1 potassium channel blocker; structure in first source	3.31	1	0
sincalide Sincalide: An octapeptide hormone present in the intestine and brain. When secreted from the gastric mucosa, it stimulates the release of bile from the gallbladder and digestive enzymes from the pancreas.	2.05	1	0	oligopeptide
cp 55244 CP 55244: RN given refers to the (2alpha,4abeta,6alpha,8alpha,8aalpha)-(+-)-isomer; RN for cpd without isomeric designation not avail 9/90; structure given in first source	1.99	1	0
delta9-tetrahydrocannabinol hemisuccinate [no description available]	2.41	2	0
sr 147778 surinabant: structure in first source	3.12	1	0	pyrazoles; ring assembly
mocetinostat mocetinostat: undergoing phase II clinical trials for treatment of cancer. mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11).	2.44	2	0	aminopyrimidine; benzamides; pyridines; secondary amino compound; secondary carboxamide; substituted aniline	antineoplastic agent; apoptosis inducer; autophagy inducer; cardioprotective agent; EC 3.5.1.98 (histone deacetylase) inhibitor; hepatotoxic agent
jte 907 JTE 907: a cannabinoid CB2 receptor ligand; structure in first source	2.08	1	0	aromatic amide; quinolines
capsinolol capsinolol: structure given in first source	2.01	1	0
1-(2,3-dichlorobenzoyl)-5-methoxy-2-methyl-(2-(mopholin-4-yl)ethyl)-1h-indole [no description available]	3.56	2	0	N-acylindole
cay 10499 [no description available]	3.25	1	0	carbamate ester
gw0742 GW 610742: structure in first source	2.1	1	0	monocarboxylic acid
CAY10435 [no description available]	3.25	1	0	oxazolopyridine
cgp 20712a CGP 20712A: structure given in first source; CGP 26505, a beta1-selective beta-adrenoceptor antagonist, is the (S)-isomer of CGP 20712A	2.03	1	0
n-stearoyl-dopamine N-stearoyl-dopamine: a dopamine derivative	2.02	1	0	carboxamide
arachidonoylserotonin arachidonoylserotonin: an NSAID with antinociceptive activity; fatty acid amide hydrolase inhibitor; structure in first source. N-arachidonoylserotonin : An N-acylserotonin obtained by formal condensation of the carboxy group of arachidonic acid with the primary amino group of serotonin.	10.01	12	0	N-acylserotonin; phenols	anti-inflammatory agent; anticonvulsant; antioxidant; capsaicin receptor antagonist; EC 3.5.1.99 (fatty acid amide hydrolase) inhibitor; human metabolite; signalling molecule
4-[(2-butyl-6,7-dichloro-2-cyclopentyl-1-oxo-3H-inden-5-yl)oxy]butanoic acid [no description available]	3.23	1	0	indanones
urb 524 [no description available]	4.09	2	0
am 1241 AM 1241: a CB(2) receptor-selective agonist; no further information available 11/2001	3.18	1	0
1-(2,4-dichlorophenyl)-6-methyl-N-(1-piperidinyl)-4H-indeno[1,2-c]pyrazole-3-carboxamide [no description available]	3.18	1	0	pyrazoles; ring assembly
jwh 018 1-pentyl-3-(1-naphthoyl)indole: structure in first source	3.61	2	0	indolecarboxamide
omdm-1 cpd OMDM-1 cpd: structure in first source	4.92	11	0
ol-135 [no description available]	4.37	3	0
methyl arachidonylfluorophosphonate [no description available]	4.55	4	0	phosphonic ester
oxadiazoles Oxadiazoles: Compounds containing five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom which exist in various regioisomeric forms.	2.71	3	0
n-arachidonoyl l-serine N-arachidonoyl L-serine: an endocannabinoid-like brain constituent with vasodilatory properties; structure in first source. N-arachidonoyl-L-serine : An N-acyl-amino acid resulting from the formal condensation of the carboxy group of arachidonic acid with the amino group of L-serine. It is an endocannabinoid-like lipid isolated from bovine brains.	2.25	1	0	N-(fatty acyl)-L-alpha-amino acid	cannabinoid receptor agonist; mammalian metabolite; neuroprotective agent; pro-angiogenic agent; vasodilator agent
sch 442416 SCH 442416: an adenosine A2A receptor ligand	2.05	1	0	triazolopyrimidines
ly 341495 LY 341495: structure in first source	2.05	1	0
ucn 1028 c calphostin C: structure given in first source; isolated from Cladosporium cladosporioides	1.99	1	0
urb602 URB602: inhibitor of 2-arachidonoylglycerol (2-AG)-deactivating enzyme, monoacylglycerol lipase, structure in first source	9.77	9	0
nystatin a1 Nystatin: Macrolide antifungal antibiotic complex produced by Streptomyces noursei, S. aureus, and other Streptomyces species. The biologically active components of the complex are nystatin A1, A2, and A3.. nystatin : A heterogeneous mixture of polyene compounds produced by cultures of Streptomyces noursei. It mainly consists of three biologically active components designated nystatin A1, nystatin A2, and nystatin A3. It is used to treat oral and dermal fungal infections.. nystatin A1 : A polyene macrolide antibiotic; part of the nystatin complex produced by several Streptomyces species. It is an antifungal antibiotic used for the treatment of topical fungal infections caused by a broad spectrum of fungal pathogens comprising yeast-like and filamentous species.	2.73	3	0	nystatins
ly2183240 LY2183240: structure in first source	4.37	3	0	biphenyls
methylphenidate N-phenyl-4-(quinolin-2-ylmethyl)piperazine-1-carboxamide: a fatty acid amide hydrolase inhibitor; structure in first source	3.25	1	0
hu 308 HU 308: a specific agonist for CB(2), a peripheral cannabinoid receptor; structure in first source. HU-308 : A carbobicyclic compound that is bicyclo[3.1.1]hept-2-ene which is substituted by a hydroxymethyl group at position 2, a 2,6-dimethoxy-4-(2-methyloctan-2-yl)phenyl group at position 4, and two methyl groups at position 6 (the 1S,4S,5S stereoisomer). A highly selective and effective cannabinoid type-2 agonist and the enantiomer of HU-433.	3.86	3	0	aromatic ether; bridged compound; carbobicyclic compound; primary allylic alcohol; synthetic cannabinoid	anti-inflammatory agent; antihypertensive agent; apoptosis inhibitor; bone density conservation agent; CB2 receptor agonist
veratridine Veratridine: A benzoate-cevane found in VERATRUM and Schoenocaulon. It activates SODIUM CHANNELS to stay open longer than normal.	4.71	5	0
losartan potassium Erythropoietin: Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.	2.4	2	0
calcimycin Calcimycin: An ionophorous, polyether antibiotic from Streptomyces chartreusensis. It binds and transports CALCIUM and other divalent cations across membranes and uncouples oxidative phosphorylation while inhibiting ATPase of rat liver mitochondria. The substance is used mostly as a biochemical tool to study the role of divalent cations in various biological systems.	3.51	8	0	benzoxazole
octoclothepine maleate [no description available]	3.31	1	0
scopolamine hydrobromide [no description available]	2.45	2	0
pituitrin Pituitrin: A substance or extract from the neurohypophysis (PITUITARY GLAND, POSTERIOR).	2.75	3	0
4-cyano-1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-n-(piperidin-1-yl)-1h-pyrazole-3-carboxamide 4-cyano-1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide: a CB1 cannabinoid receptor radioligand for PET imaging	2.08	1	0
acid phosphatase Acid Phosphatase: An enzyme that catalyzes the conversion of an orthophosphoric monoester and water to an alcohol and orthophosphate. EC 3.1.3.2.	2.05	1	0
mefloquine Mefloquine: A phospholipid-interacting antimalarial drug (ANTIMALARIALS). It is very effective against PLASMODIUM FALCIPARUM with very few side effects.. mefloquine : A racemate composed of (+)-(11R,2'S)- and (-)-(11S,2'R)-enantiomers of mefloquine. An antimalarial agent which acts as a blood schizonticide; its mechanism of action is unknown.	2.21	1	0
omdm 169 OMDM 169: has antinociceptive activity; structure in first source	2.1	1	0
cytochrome c-t Cytochromes c: Cytochromes of the c type that are found in eukaryotic MITOCHONDRIA. They serve as redox intermediates that accept electrons from MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX III and transfer them to MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX IV.	3.14	5	0
mead ethanolamide mead ethanolamide: an eicosanoid; an agonist for the central and peripheral cannabinoid receptors	1.98	1	0	N-acylethanolamine 20:3
bms 309403 [no description available]	2.13	1	0
cholecystokinin Cholecystokinin: A peptide, of about 33 amino acids, secreted by the upper INTESTINAL MUCOSA and also found in the central nervous system. It causes gallbladder contraction, release of pancreatic exocrine (or digestive) enzymes, and affects other gastrointestinal functions. Cholecystokinin may be the mediator of satiety.	2.45	2	0
ceruletide Ceruletide: A specific decapeptide obtained from the skin of Hila caerulea, an Australian amphibian. Caerulein is similar in action and composition to CHOLECYSTOKININ. It stimulates gastric, biliary, and pancreatic secretion; and certain smooth muscle. It is used in paralytic ileus and as diagnostic aid in pancreatic malfunction.. ceruletide : A decapeptide comprising 5-oxoprolyl, glutamyl, aspartyl, O-sulfotyrosyl, threonyl, glycyl, tryptopyl, methionyl, aspartyl and phenylalaninamide residues in sequence. Found in the skins of certain Australian amphibians, it is an analogue of the gastrointestinal peptide hormone cholecystokinin and stimulates gastric, biliary, and pancreatic secretion. It is used in cases of paralysis of the intestine (paralytic ileus) and as a diagnostic aid in pancreatic malfunction.	2.44	2	0	oligopeptide	diagnostic agent; gastrointestinal drug
dynorphins Dynorphins: A class of opioid peptides including dynorphin A, dynorphin B, and smaller fragments of these peptides. Dynorphins prefer kappa-opioid receptors (RECEPTORS, OPIOID, KAPPA) and have been shown to play a role as central nervous system transmitters.	4.01	4	0
lhrh, his(5)-trp(7)-tyr(8)- LHRH, His(5)-Trp(7)-Tyr(8)-: isolated from chicken hypothalamus; also ostrich; RN given refers to all-(L)-isomer	2.06	1	0
gramicidin a Gramicidin: A group of peptide antibiotics from BACILLUS brevis. Gramicidin C or S is a cyclic, ten-amino acid polypeptide and gramicidins A, B, D are linear. Gramicidin is one of the two principal components of TYROTHRICIN.	2.15	1	0
glucagon Glucagon: A 29-amino acid pancreatic peptide derived from proglucagon which is also the precursor of intestinal GLUCAGON-LIKE PEPTIDES. Glucagon is secreted by PANCREATIC ALPHA CELLS and plays an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1511). glucagon : A 29-amino acid peptide hormone consisting of His, Ser, Gln, Gly, Thr, Phe, Thr, Ser, Asp, Tyr, Ser, Lys, Tyr, Leu, Asp, Ser, Arg, Arg, Ala, Gln, Asp, Phe, Val, Gln, Trp, Leu, Met, Asn and Thr residues joined in sequence.	3.14	1	0	peptide hormone
beta-endorphin beta-Endorphin: A 31-amino acid peptide that is the C-terminal fragment of BETA-LIPOTROPIN. It acts on OPIOID RECEPTORS and is an analgesic. Its first four amino acids at the N-terminal are identical to the tetrapeptide sequence of METHIONINE ENKEPHALIN and LEUCINE ENKEPHALIN.. beta-endorphin : A polypeptide consisting of 31 amino acid residues in the sequence Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr-Leu-Phe-Lys-Asn-Ala-Ile-Ile-Lys-Asn-Ala-Tyr-Lys-Lys-Gly-Glu. It is an endogenous opioid peptide neurotransmitter found in the neurons of both the central and peripheral nervous system and results from processing of the precursor protein proopiomelanocortin (POMC).	6.8	7	2
neuropeptide y Neuropeptide Y: A 36-amino acid peptide present in many organs and in many sympathetic noradrenergic neurons. It has vasoconstrictor and natriuretic activity and regulates local blood flow, glandular secretion, and smooth muscle activity. The peptide also stimulates feeding and drinking behavior and influences secretion of pituitary hormones.	3.16	5	0
iberiotoxin [no description available]	3.12	5	0
glucagon-like peptide 1 Glucagon-Like Peptide 1: A peptide of 36 or 37 amino acids that is derived from PROGLUCAGON and mainly produced by the INTESTINAL L CELLS. GLP-1(1-37 or 1-36) is further N-terminally truncated resulting in GLP-1(7-37) or GLP-1-(7-36) which can be amidated. These GLP-1 peptides are known to enhance glucose-dependent INSULIN release, suppress GLUCAGON release and gastric emptying, lower BLOOD GLUCOSE, and reduce food intake.	2.17	1	0
incretins Incretins: Peptides which stimulate INSULIN release from the PANCREATIC BETA CELLS following oral nutrient ingestion, or postprandially.	2.17	1	0
endothelin-1 Endothelin-1: A 21-amino acid peptide produced in a variety of tissues including endothelial and vascular smooth-muscle cells, neurons and astrocytes in the central nervous system, and endometrial cells. It acts as a modulator of vasomotor tone, cell proliferation, and hormone production. (N Eng J Med 1995;333(6):356-63)	3.15	5	0
phosphatidylcholines Phosphatidylcholines: Derivatives of PHOSPHATIDIC ACIDS in which the phosphoric acid is bound in ester linkage to a CHOLINE moiety.	4.91	11	0	1,2-diacyl-sn-glycero-3-phosphocholine
sphingosine kinase [no description available]	2.6	1	0
a-836339 A-836339: structure in first source	3.18	1	0
palmitoyl trifluoromethyl ketone palmitoyl trifluoromethyl ketone: phospholipase A2 inhibitor	2.01	1	0
calpain Calpain: Cysteine proteinase found in many tissues. Hydrolyzes a variety of endogenous proteins including NEUROPEPTIDES; CYTOSKELETAL PROTEINS; proteins from SMOOTH MUSCLE; CARDIAC MUSCLE; liver; platelets; and erythrocytes. Two subclasses having high and low calcium sensitivity are known. Removes Z-discs and M-lines from myofibrils. Activates phosphorylase kinase and cyclic nucleotide-independent protein kinase. This enzyme was formerly listed as EC 3.4.22.4.	7.42	2	0
lucifer yellow lucifer yellow: RN given refers to di-Li salt	2.4	2	0	organic lithium salt	fluorochrome
ethyl octylphosphonofluoridate ethyl octylphosphonofluoridate: a neuropathy target esterase inhibitor; structure given in first source	2.6	1	0
menotropins Menotropins: Extracts of urine from menopausal women that contain high concentrations of pituitary gonadotropins, FOLLICLE STIMULATING HORMONE and LUTEINIZING HORMONE. Menotropins are used to treat infertility. The FSH:LH ratio and degree of purity vary in different preparations.	2.25	1	0
9-(tetrahydro-2-furyl)-adenine [no description available]	2	1	0
s-nitro-n-acetylpenicillamine S-nitro-N-acetylpenicillamine: a NO donor	2.4	2	0
stearates Stearates: Salts and esters of the 18-carbon saturated, monocarboxylic acid--stearic acid.	2.02	1	0
am 6701 [no description available]	3.25	1	0
picrotoxin Picrotoxin: A noncompetitive antagonist at GABA-A receptors and thus a convulsant. Picrotoxin blocks the GAMMA-AMINOBUTYRIC ACID-activated chloride ionophore. Although it is most often used as a research tool, it has been used as a CNS stimulant and an antidote in poisoning by CNS depressants, especially the barbiturates.. picrotoxin : A mixture consisting of equimolar amounts of picrotoxinin and picrotin found in the climbing plant Anamirta cocculus.	2.7	3	0
jzl 184 JZL 184: inhibits monoacylglycerol lipase; structure in first source	5.37	20	0	benzodioxoles
quetiapine fumarate Quetiapine Fumarate: A dibenzothiazepine and ANTIPSYCHOTIC AGENT that targets the SEROTONIN 5-HT2 RECEPTOR; HISTAMINE H1 RECEPTOR, adrenergic alpha1 and alpha2 receptors, as well as the DOPAMINE D1 RECEPTOR and DOPAMINE D2 RECEPTOR. It is used in the treatment of SCHIZOPHRENIA; BIPOLAR DISORDER and DEPRESSIVE DISORDER.	2.04	1	0	fumarate salt
cardiovascular agents Cardiovascular Agents: Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume.	4.33	3	0
rimorphin rimorphin: tridecapeptide NH2-Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe-Lys-Val-Val-Thr-COOH from bovine posterior pituitary gland; major leucine enkephalin containing peptide in tissue that contains dynorphin & alpha-neo-endorphin	2	1	0
pf 3845 PF 3845: inhibits fatty acid amide hydrolase	5.85	10	0	piperidines
pf 750 N-phenyl-4-(quinolin-3-ylmethyl)piperidine-1-carboxamide: a fatty acid amide hydrolase inhibitor; structure in first source	3.6	2	0	quinolines
11,12-epoxy-5,8,14-eicosatrienoic acid 11,12-epoxy-5,8,14-eicosatrienoic acid: RN given refers to cpd without isomeric designation. (11S,12R)-EET : An 11,12-EET in which the epoxy moiety has 11S,12R-configuration.. 11,12-EET : An EET obtained by formal epoxidation of the 11,12-double bond of arachidonic acid.	2.03	1	0	11,12-EET	human xenobiotic metabolite
n-arachidonoylalanine N-arachidonoylalanine: inhibits fatty acid amide hydrolase; structure in first source. N-arachidonoyl-L-alanine : An N-acyl-L-alanine resulting from the formal condensation of the amino group of L-alanine with the carboxy group of arachidonic acid.	2.04	1	0	N-(fatty acyl)-L-alpha-amino acid; N-acyl-L-alanine	mammalian metabolite
eoxin c4 eoxin C4: structure in first source. eoxin C4 : A leukotriene that is the 14R-(S-glutathionyl),15S-hydroxy derivative of (5Z,8Z,10E,12E)-icosa-7,9,11,14-tetraenoic acid.	2.07	1	0	eoxin; leukotriene	metabolite
gw 1000 nabiximols: a combination of the above cpds for treatment of multiple sclerosis pain	4.92	2	1
glycolipids [no description available]	3.09	1	0
piperidines Piperidines: A family of hexahydropyridines.	12.44	418	0
interleukin-8 Interleukin-8: A member of the CXC chemokine family that plays a role in the regulation of the acute inflammatory response. It is secreted by variety of cell types and induces CHEMOTAXIS of NEUTROPHILS and other inflammatory cells.	2.74	3	0
hemopressin hemopressin: hemoglobin alpha-chain fragment	2.07	1	0
gardiquimod [no description available]	2.06	1	0
malhamensilipin a malhamensilipin A: a chlorosulfolipid; from the cultured chrysophyte Poterioochromonas malhamensis	1.99	1	0
jzl195 JZL195: inhibits both fatty-acid amide hydrolase 1 and monoglyceride lipase; structure in first source	3	4	0
am6545 AM6545: structure in first source	2.11	1	0
vasoactive intestinal peptide Vasoactive Intestinal Peptide: A highly basic, 28 amino acid neuropeptide released from intestinal mucosa. It has a wide range of biological actions affecting the cardiovascular, gastrointestinal, and respiratory systems and is neuroprotective. It binds special receptors (RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE).	3.81	3	0
urb937 URB937: a peripherally restricted inhibitor of fatty acid amide hydrolase	4.3	5	0
propenylphosphonic acid 6-(2-propargyloxyphenyl)hexanoic acid: inhibits rat renal microsomal arachidonic acid epoxidation	2.07	1	0	aromatic ether
minocycline Minocycline: A TETRACYCLINE analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant STAPHYLOCOCCUS infections.. minocycline : A tetracycline analogue having a dimethylamino group at position 7 and lacking the methyl and hydroxy groups at position 5.	2.05	1	0
piroxicam [no description available]	2.02	1	0	benzothiazine; monocarboxylic acid amide; pyridines	analgesic; antirheumatic drug; cyclooxygenase 1 inhibitor; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-steroidal anti-inflammatory drug
mobic Meloxicam: A benzothiazine and thiazole derivative that acts as a NSAID and cyclooxygenase-2 (COX-2) inhibitor. It is used in the treatment of RHEUMATOID ARTHRITIS; OSTEOARTHRITIS; and ANKYLOSING SPONDYLITIS.. meloxicam : A benzothiazine that is piroxicam in which the pyridin-2-yl group is replaced by a 5-methyl-1,3-thiazol-2-yl group. A non-steroidal anti-inflammatory drug and selective inhibitor of COX-2, it is used particularly for the management of rheumatoid arthritis.	2.02	1	0	1,3-thiazoles; benzothiazine; monocarboxylic acid amide	analgesic; antirheumatic drug; cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
warfarin Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.	2.6	1	0	benzenes; hydroxycoumarin; methyl ketone
sar127303 SAR127303: inhibits monoacylglycerol lipase; structure in first source	3.25	1	0
toxin ii (anemonia sulcata) toxin II (Anemonia sulcata): toxic polypeptide closely related to anthopleurin A with potent cardiac stimulant activity from Anemonia sulcata; do not confuse with altertoxin II which is also abbreviated ATX II	2.1	1	0
epidermal growth factor Epidermal Growth Factor: A 6-kDa polypeptide growth factor initially discovered in mouse submaxillary glands. Human epidermal growth factor was originally isolated from urine based on its ability to inhibit gastric secretion and called urogastrone. Epidermal growth factor exerts a wide variety of biological effects including the promotion of proliferation and differentiation of mesenchymal and EPITHELIAL CELLS. It is synthesized as a transmembrane protein which can be cleaved to release a soluble active form.	2.1	1	0
charybdotoxin [no description available]	3.4	7	0
transforming growth factor beta Transforming Growth Factor beta: A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins.	2.03	1	0
s-777469 S-777469: an orally available cannabinoid receptor CB2 agonist as an antipruritic agent; structure in first source	3.18	1	0
am4113 AM4113: a cannabinoid CB1 receptor neutral antagonist	2.31	1	0
n-palmitoyl-vanillamide N-palmitoyl-vanillamide: structure in first source	2.06	1	0
kiss1 protein, human Kisspeptins: Intercellular signaling peptides that were originally characterized by their ability to suppress NEOPLASM METASTASIS. Kisspeptins have since been found to play an important role in the neuroendocrine regulation of REPRODUCTION.	2.13	1	0
mjn110 MJN110: structure in first source	3.97	3	0
cyclin d1 Cyclin D1: Protein encoded by the bcl-1 gene which plays a critical role in regulating the cell cycle. Overexpression of cyclin D1 is the result of bcl-1 rearrangement, a t(11;14) translocation, and is implicated in various neoplasms.	2.03	1	0
lysophosphatidylinositol [no description available]	7.77	3	0
neuropeptide y, leu(31)-pro(34)- neuropeptide Y, Leu(31)-Pro(34)-: specific Y1 receptor agonist	2.25	1	0
aconitine Aconitine: A C19 norditerpenoid alkaloid (DITERPENES) from the root of ACONITUM; DELPHINIUM and larkspurs. It activates VOLTAGE-GATED SODIUM CHANNELS. It has been used to induce ARRHYTHMIAS in experimental animals and it has anti-inflammatory and anti-neuralgic properties.. aconitine : A diterpenoid that is 20-ethyl-3alpha,13,15alpha-trihydroxy-1alpha,6alpha,16beta-trimethoxy-4-(methoxymethyl)aconitane-8,14alpha-diol having acetate and benzoate groups at the 8- and 14-positions respectively.	2.03	1	0
cyclosporine Cyclosporine: A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).	2.03	1	0
silybin Silybin: The major active component of silymarin flavonoids extracted from seeds of the MILK THISTLE, Silybum marianum; it is used in the treatment of HEPATITIS; LIVER CIRRHOSIS; and CHEMICAL AND DRUG INDUCED LIVER INJURY, and has antineoplastic activity; silybins A and B are diastereomers.	2.6	1	0
peptide yy Peptide YY: A 36-amino acid peptide produced by the L cells of the distal small intestine and colon. Peptide YY inhibits gastric and pancreatic secretion.. peptide YY : A 36-membered human gut polypeptide consisting of Tyr, Pro, Ile, Lys, Pro, Glu, Ala, Pro, Gly, Glu, Asp, Ala, Ser, Pro, Glu, Glu, Leu, Asn, Arg, Tyr, Tyr, Ala, Ser, Leu, Arg, His, Tyr, Leu, Asn, Leu, Val, Thr, Arg, Gln, Arg and Tyr-NH2 residues joined in sequence.	7.07	1	0
apyrase Apyrase: A calcium-activated enzyme that catalyzes the hydrolysis of ATP to yield AMP and orthophosphate. It can also act on ADP and other nucleoside triphosphates and diphosphates. EC 3.6.1.5.	2.11	1	0
amyloid beta-peptides amyloid beta-protein (1-40): although acutely neurotoxic in both rat & monkey cerebral cortex, neuronal degeneration in primates resembles more closely to that found in Alzheimer's disease; amino acid sequence has been determined	2.74	3	0
cyclic gmp Cyclic GMP: Guanosine cyclic 3',5'-(hydrogen phosphate). A guanine nucleotide containing one phosphate group which is esterified to the sugar moiety in both the 3'- and 5'-positions. It is a cellular regulatory agent and has been described as a second messenger. Its levels increase in response to a variety of hormones, including acetylcholine, insulin, and oxytocin and it has been found to activate specific protein kinases. (From Merck Index, 11th ed). 3',5'-cyclic GMP : A 3',5'-cyclic purine nucleotide in which the purine nucleobase is specified as guanidine.	3.14	5	0	3',5'-cyclic purine nucleotide; guanyl ribonucleotide	Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
sapropterin sapropterin: RN given refers to parent cpd; co-factor required for catalytic activity of nitric oxide synthases. (6R)-5,6,7,8-tetrahydrobiopterin : A 5,6,7,8-tetrahydrobiopterin in which the stereocentre at position 6 has R-configuration.. sapropterin : A tetrahydropterin that is 2-amino-5,6,7,8-tetrahydropteridin-4(3H)-one in which a hydrogen at position 6 is substituted by a 1,2-dihydroxypropyl group (6R,1'R,2'S-enantiomer).	2.04	1	0	5,6,7,8-tetrahydrobiopterin	coenzyme; cofactor; diagnostic agent; human metabolite
folic acid folcysteine: used to promote fertility in chickens. vitamin B9 : Any B-vitamin that exhibits biological activity against vitamin B9 deficiency. Vitamin B9 refers to the many forms of folic acid and its derivatives, including tetrahydrofolic acid (the active form), methyltetrahydrofolate (the primary form found in blood), methenyltetrahydrofolate, folinic acid amongst others. They are present in abundance in green leafy vegetables, citrus fruits, and animal products. Lack of vitamin B9 leads to anemia, a condition in which the body cannot produce sufficient number of red blood cells. Symptoms of vitamin B9 deficiency include fatigue, muscle weakness, and pale skin.	2.46	2	0	folic acids; N-acyl-amino acid	human metabolite; mouse metabolite; nutrient
3-methyladenine N3-methyladenine: structure in first source	2.25	1	0
guanosine 5'-o-(3-thiotriphosphate) Guanosine 5'-O-(3-Thiotriphosphate): Guanosine 5'-(trihydrogen diphosphate), monoanhydride with phosphorothioic acid. A stable GTP analog which enjoys a variety of physiological actions such as stimulation of guanine nucleotide-binding proteins, phosphoinositide hydrolysis, cyclic AMP accumulation, and activation of specific proto-oncogenes.	6.55	24	0	nucleoside triphosphate analogue
rifampin Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)	2.03	1	0	cyclic ketal; hydrazone; N-iminopiperazine; N-methylpiperazine; rifamycins; semisynthetic derivative; zwitterion	angiogenesis inhibitor; antiamoebic agent; antineoplastic agent; antitubercular agent; DNA synthesis inhibitor; EC 2.7.7.6 (RNA polymerase) inhibitor; Escherichia coli metabolite; geroprotector; leprostatic drug; neuroprotective agent; pregnane X receptor agonist; protein synthesis inhibitor
clozapine Clozapine: A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.. clozapine : A benzodiazepine that is 5H-dibenzo[b,e][1,4]diazepine substituted by a chloro group at position 8 and a 4-methylpiperazin-1-yl group at position 11. It is a second generation antipsychotic used in the treatment of psychiatric disorders like schizophrenia.	2.11	1	0	benzodiazepine; N-arylpiperazine; N-methylpiperazine; organochlorine compound	adrenergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; GABA antagonist; histamine antagonist; muscarinic antagonist; second generation antipsychotic; serotonergic antagonist; xenobiotic
ganciclovir [no description available]	2.07	1	0	2-aminopurines; oxopurine	antiinfective agent; antiviral drug
olanzapine Olanzapine: A benzodiazepine derivative that binds SEROTONIN RECEPTORS; MUSCARINIC RECEPTORS; HISTAMINE H1 RECEPTORS; ADRENERGIC ALPHA-1 RECEPTORS; and DOPAMINE RECEPTORS. It is an antipsychotic agent used in the treatment of SCHIZOPHRENIA; BIPOLAR DISORDER; and MAJOR DEPRESSIVE DISORDER; it may also reduce nausea and vomiting in patients undergoing chemotherapy.. olanzapine : A benzodiazepine that is 10H-thieno[2,3-b][1,5]benzodiazepine substituted by a methyl group at position 2 and a 4-methylpiperazin-1-yl group at position 4.	7.11	1	0	benzodiazepine; N-arylpiperazine; N-methylpiperazine	antiemetic; dopaminergic antagonist; histamine antagonist; muscarinic antagonist; second generation antipsychotic; serotonergic antagonist; serotonin uptake inhibitor
clozapine n-oxide clozapine N-oxide: structure given in first source	2.11	1	0	dibenzodiazepine
batrachotoxinin a 20-alpha-benzoate [no description available]	2.01	1	0
concanavalin a Concanavalin A: A MANNOSE/GLUCOSE binding lectin isolated from the jack bean (Canavalia ensiformis). It is a potent mitogen used to stimulate cell proliferation in lymphocytes, primarily T-lymphocyte, cultures.	2.04	1	0
leptin Leptin: A 16-kDa peptide hormone secreted from WHITE ADIPOCYTES. Leptin serves as a feedback signal from fat cells to the CENTRAL NERVOUS SYSTEM in regulation of food intake, energy balance, and fat storage.	10.4	13	1
pyrimidinones Pyrimidinones: Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O.	2.03	1	0
filipin Filipin: A complex of polyene antibiotics obtained from Streptomyces filipinensis. Filipin III alters membrane function by interfering with membrane sterols, inhibits mitochondrial respiration, and is proposed as an antifungal agent. Filipins I, II, and IV are less important.	2.03	1	0

Condition	Relationship Strength	Studies	Trials
Muscle Contraction A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.	7	28	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	10.89	167	0
Anasarca [description not available]	3.29	6	0
Ache [description not available]	13.29	98	3
Edema Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.	3.29	6	0
Pain An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.	13.29	98	3
Encephalitis, Polio [description not available]	2.42	2	0
Poliomyelitis An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)	2.42	2	0
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	11.93	25	1
Arrhythmia [description not available]	3.87	4	0
Aura [description not available]	6.16	11	0
Innate Inflammatory Response [description not available]	11.99	78	1
Arrhythmias, Cardiac Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.	3.87	4	0
Depression Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.	15.3	27	1
Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)	6.16	11	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	11.99	78	1
MS (Multiple Sclerosis) [description not available]	7.97	21	1
Multiple Sclerosis An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)	7.97	21	1
Carcinogenesis The origin, production or development of cancer through genotypic and phenotypic changes which upset the normal balance between cell proliferation and cell death. Carcinogenesis generally requires a constellation of steps, which may occur quickly or over a period of many years.	2.55	2	0
Metastase [description not available]	3.41	2	0
Osteogenic Sarcoma [description not available]	2.48	2	0
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	3.41	2	0
Osteosarcoma A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)	7.48	2	0
Allodynia [description not available]	6.67	49	0
Angiogenesis, Pathologic [description not available]	4.36	4	0
Chronic Illness [description not available]	8.46	13	1
Airway Hyper-Responsiveness [description not available]	3.8	3	0
Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	8.46	13	1
Cough A sudden, audible expulsion of air from the lungs through a partially closed glottis, preceded by inhalation. It is a protective response that serves to clear the trachea, bronchi, and/or lungs of irritants and secretions, or to prevent aspiration of foreign materials into the lungs.	9.84	5	0
Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.	6.16	9	0
Idiopathic Parkinson Disease [description not available]	4.91	7	0
Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)	4.91	7	0
Disbacteriosis [description not available]	2.31	1	0
Experimental Lung Inflammation Inflammation of any part, segment or lobe, of the lung parenchyma.	2.98	4	0
Acute Respiratory Distress Syndrome [description not available]	7.31	1	0
Pneumonia Infection of the lung often accompanied by inflammation.	2.98	4	0
Respiratory Distress Syndrome A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.	7.31	1	0
Polycystic Ovarian Syndrome [description not available]	2.88	3	0
Polycystic Ovary Syndrome A complex disorder characterized by infertility, HIRSUTISM; OBESITY; and various menstrual disturbances such as OLIGOMENORRHEA; AMENORRHEA; ANOVULATION. Polycystic ovary syndrome is usually associated with bilateral enlarged ovaries studded with atretic follicles, not with cysts. The term, polycystic ovary, is misleading.	2.88	3	0
Anxiety Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.	11.19	51	2
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	12.17	87	2
Infections, Staphylococcal [description not available]	3.04	4	0
Staphylococcal Infections Infections with bacteria of the genus STAPHYLOCOCCUS.	3.04	4	0
Breast Cancer [description not available]	5.02	15	0
Breast Neoplasms Tumors or cancer of the human BREAST.	5.02	15	0
Absence Seizure [description not available]	4.14	15	0
Seizures Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.	4.14	15	0
Autism Spectrum Disorder Wide continuum of associated cognitive and neurobehavioral disorders, including, but not limited to, three core-defining features: impairments in socialization, impairments in verbal and nonverbal communication, and restricted and repetitive patterns of behaviors. (from DSM-V)	4.21	5	0
Autism [description not available]	9.15	5	0
Autistic Disorder A disorder beginning in childhood. It is marked by the presence of markedly abnormal or impaired development in social interaction and communication and a markedly restricted repertoire of activity and interest. Manifestations of the disorder vary greatly depending on the developmental level and chronological age of the individual. (DSM-V)	4.15	5	0
Depression, Involutional Form of depression in those MIDDLE AGE with feelings of ANXIETY.	4.26	6	0
Depressive Disorder, Major Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5)	4.26	6	0
Pain, Chronic [description not available]	4.8	4	0
Arthritis, Degenerative [description not available]	5.2	6	0
Osteoarthritis A progressive, degenerative joint disease, the most common form of arthritis, especially in older persons. The disease is thought to result not from the aging process but from biochemical changes and biomechanical stresses affecting articular cartilage. In the foreign literature it is often called osteoarthrosis deformans.	10.2	6	0
Chronic Pain Aching sensation that persists for more than a few months. It may or may not be associated with trauma or disease, and may persist after the initial injury has healed. Its localization, character, and timing are more vague than with acute pain.	4.8	4	0
Colorectal Cancer [description not available]	8.21	5	0
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	3.21	5	0
Psychoses [description not available]	5.42	8	0
Psychotic Disorders Disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations. (From DSM-IV, 1994)	5.42	8	0
Injury, Ischemia-Reperfusion [description not available]	3.93	12	0
Reperfusion Injury Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.	3.93	12	0
Cancer of Stomach [description not available]	2.81	3	0
Stomach Neoplasms Tumors or cancer of the STOMACH.	2.81	3	0
Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).	13.1	65	5
Cannabis Abuse [description not available]	12.99	18	1
Marijuana Abuse Use of marijuana associated with abnormal psychological, social, and or occupational functioning.	7.99	18	1
Brain Atrophy, Circumscribed Lobar [description not available]	2.6	1	0
DDPAC [description not available]	2.6	1	0
Pick Disease of the Brain A rare form of DEMENTIA that is sometimes familial. Clinical features include APHASIA; APRAXIA; CONFUSION; ANOMIA; memory loss; and personality deterioration. This pattern is consistent with the pathologic findings of circumscribed atrophy of the poles of the FRONTAL LOBE and TEMPORAL LOBE. Neuronal loss is maximal in the HIPPOCAMPUS, entorhinal cortex, and AMYGDALA. Some ballooned cortical neurons contain argentophylic (Pick) bodies. (From Brain Pathol 1998 Apr;8(2):339-54; Adams et al., Principles of Neurology, 6th ed, pp1057-9)	2.6	1	0
Frontotemporal Dementia The most common clinical form of FRONTOTEMPORAL LOBAR DEGENERATION, this dementia presents with personality and behavioral changes often associated with disinhibition, apathy, and lack of insight.	2.6	1	0
Adenocarcinoma Of Kidney [description not available]	2.6	1	0
Cancer of Kidney [description not available]	2.6	1	0
Anorexia The lack or loss of APPETITE accompanied by an aversion to food and the inability to eat. It is the defining characteristic of the disorder ANOREXIA NERVOSA.	9.2	3	1
Cachexia General ill health, malnutrition, and weight loss, usually associated with chronic disease.	3.44	2	0
Carcinoma, Renal Cell A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.	2.6	1	0
Kidney Neoplasms Tumors or cancers of the KIDNEY.	2.6	1	0
Nerve Pain [description not available]	6.4	20	0
Neuralgia Intense or aching pain that occurs along the course or distribution of a peripheral or cranial nerve.	6.4	20	0
Appetite Disorders [description not available]	2.6	1	0
Feeding and Eating Disorders A group of disorders characterized by physiological and psychological disturbances in appetite or food intake.	2.6	1	0
Inadequate Sleep [description not available]	2.99	4	0
Graft-Versus-Host Disease [description not available]	7.6	1	0
Graft vs Host Disease The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.	2.6	1	0
Bladder Pain Syndrome [description not available]	7.6	1	0
Bladder, Overactive [description not available]	2.6	1	0
Pelvic Pain Pain in the pelvic region of genital and non-genital origin.	2.6	1	0
Cystitis, Interstitial A condition with recurring discomfort or pain in the URINARY BLADDER and the surrounding pelvic region without an identifiable disease. Severity of pain in interstitial cystitis varies greatly and often is accompanied by increased urination frequency and urgency.	2.6	1	0
Urinary Bladder, Overactive Symptom of overactive detrusor muscle of the URINARY BLADDER that contracts with abnormally high frequency and urgency. Overactive bladder is characterized by the frequent feeling of needing to urinate during the day, during the night, or both. URINARY INCONTINENCE may or may not be present.	2.6	1	0
Lupus Erythematosus, Cutaneous, Subacute [description not available]	2.6	1	0
Libman-Sacks Disease [description not available]	2.6	1	0
Lupus Erythematosus, Cutaneous A form of lupus erythematosus in which the skin may be the only organ involved or in which skin involvement precedes the spread into other body systems. It has been classified into three forms - acute (= LUPUS ERYTHEMATOSUS, SYSTEMIC with skin lesions), subacute, and chronic (= LUPUS ERYTHEMATOSUS, DISCOID).	2.6	1	0
Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.	2.6	1	0
Alcohol Drinking Behaviors associated with the ingesting of ALCOHOLIC BEVERAGES, including social drinking.	3.61	8	0
Delayed Effects, Prenatal Exposure [description not available]	4.36	7	0
Prodromal Characteristics [description not available]	3.76	3	0
Encephalopathy, Toxic [description not available]	3.33	6	0
Marijuana Use Medicinal or recreational utilization of MARIJUANA.	2.21	1	0
Cystitis Inflammation of the URINARY BLADDER, either from bacterial or non-bacterial causes. Cystitis is usually associated with painful urination (dysuria), increased frequency, urgency, and suprapubic pain.	9.97	5	0
Clerambault Syndrome [description not available]	3.12	1	0
Acquired-Immune Deficiency Syndrome Dementia Complex [description not available]	3.36	2	0
HIV Coinfection [description not available]	3.63	3	0
AIDS Dementia Complex A neurologic condition associated with the ACQUIRED IMMUNODEFICIENCY SYNDROME and characterized by impaired concentration and memory, slowness of hand movements, ATAXIA, incontinence, apathy, and gait difficulties associated with HIV-1 viral infection of the central nervous system. Pathologic examination of the brain reveals white matter rarefaction, perivascular infiltrates of lymphocytes, foamy macrophages, and multinucleated giant cells. (From Adams et al., Principles of Neurology, 6th ed, pp760-1; N Engl J Med, 1995 Apr 6;332(14):934-40)	3.36	2	0
HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).	3.63	3	0
Preterm Birth [description not available]	2.57	2	0
Labor, Premature [description not available]	2.55	2	0
Premature Birth CHILDBIRTH before 37 weeks of PREGNANCY (259 days from the first day of the mother's last menstrual period, or 245 days after FERTILIZATION).	2.57	2	0
Acute Post-Traumatic Stress Disorder [description not available]	5.13	9	0
Stress Disorders, Post-Traumatic A class of traumatic stress disorders with symptoms that last more than one month.	5.13	9	0
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	5.76	20	1
Encephalopathy, Traumatic [description not available]	2.66	2	0
Brain Injuries, Traumatic A form of acquired brain injury which occurs when a sudden trauma causes damage to the brain.	2.66	2	0
Chronic Kidney Failure [description not available]	2.25	1	0
Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.	2.25	1	0
Abortion, Tubal [description not available]	4.94	8	1
Abortion, Spontaneous Expulsion of the product of FERTILIZATION before completing the term of GESTATION and without deliberate interference.	4.94	8	1
Blood Pressure, High [description not available]	5.33	20	0
Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.	5.33	20	0
Gelineau Syndrome [description not available]	2.25	1	0
Narcolepsy A condition characterized by recurrent episodes of daytime somnolence and lapses in consciousness (microsomnias) that may be associated with automatic behaviors and AMNESIA. CATAPLEXY; SLEEP PARALYSIS, and hypnagogic HALLUCINATIONS frequently accompany narcolepsy. The pathophysiology of this disorder includes sleep-onset rapid eye movement (REM) sleep, which normally follows stage III or IV sleep. (From Neurology 1998 Feb;50(2 Suppl 1):S2-S7)	7.25	1	0
Dementia Praecox [description not available]	8.81	19	1
Schizophrenia A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.	8.81	19	1
Lassitude [description not available]	3.17	1	0
Diffuse Myofascial Pain Syndrome [description not available]	3.42	2	0
Fatigue The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli.	3.17	1	0
Fibromyalgia A common nonarticular rheumatic syndrome characterized by myalgia and multiple points of focal muscle tenderness to palpation (trigger points). Muscle pain is typically aggravated by inactivity or exposure to cold. This condition is often associated with general symptoms, such as sleep disturbances, fatigue, stiffness, HEADACHES, and occasionally DEPRESSION. There is significant overlap between fibromyalgia and the chronic fatigue syndrome (FATIGUE SYNDROME, CHRONIC). Fibromyalgia may arise as a primary or secondary disease process. It is most frequent in females aged 20 to 50 years. (From Adams et al., Principles of Neurology, 6th ed, p1494-95)	3.42	2	0
Cancer of Prostate [description not available]	4.47	8	0
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	4.47	8	0
Weight Reduction [description not available]	8.31	9	3
Weight Loss Decrease in existing BODY WEIGHT.	8.31	9	3
Overweight A status with BODY WEIGHT that is above certain standards. In the scale of BODY MASS INDEX, overweight is defined as having a BMI of 25.0-29.9 kg/m2. Overweight may or may not be due to increases in body fat (ADIPOSE TISSUE), hence overweight does not equal over fat.	3.27	5	0
Cicatrix, Hypertrophic An elevated scar, resembling a KELOID, but which does not spread into surrounding tissues. It is formed by enlargement and overgrowth of cicatricial tissue and regresses spontaneously.	2.25	1	0
Surgical Incision [description not available]	2.25	1	0
Cicatrization The formation of fibrous tissue in the place of normal tissue during the process of WOUND HEALING. It includes scar tissue formation occurring in healing internal organs as well as in the skin after surface injuries.	2.25	1	0
Cicatrix The fibrous tissue that replaces normal tissue during the process of WOUND HEALING.	2.25	1	0
Anxiety Neuroses [description not available]	5.98	6	0
Anxiety Disorders Persistent and disabling ANXIETY.	5.98	6	0
Gastric Stasis [description not available]	2.31	1	0
Complications of Diabetes Mellitus [description not available]	2.31	1	0
Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.	2.31	1	0
Gastroparesis Chronic delayed gastric emptying. Gastroparesis may be caused by motor dysfunction or paralysis of STOMACH muscles or may be associated with other systemic diseases such as DIABETES MELLITUS.	2.31	1	0
Candida Infection [description not available]	2.25	1	0
Candidiasis Infection with a fungus of the genus CANDIDA. It is usually a superficial infection of the moist areas of the body and is generally caused by CANDIDA ALBICANS. (Dorland, 27th ed)	2.25	1	0
Disease Exacerbation [description not available]	3.32	6	0
Allergic Encephalomyelitis [description not available]	3.65	9	0
Cognitive Decline [description not available]	3.17	1	0
Acute Confusional Senile Dementia [description not available]	5.46	9	0
Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)	5.46	9	0
Cognitive Dysfunction Diminished or impaired mental and/or intellectual function.	3.17	1	0
Binge-Eating Disorder A disorder associated with three or more of the following: eating until feeling uncomfortably full; eating large amounts of food when not physically hungry; eating much more rapidly than normal; eating alone due to embarrassment; feeling of disgust, DEPRESSION, or guilt after overeating. Criteria includes occurrence on average, at least 2 days a week for 6 months. The binge eating is not associated with the regular use of inappropriate compensatory behavior (i.e. purging, excessive exercise, etc.) and does not co-occur exclusively with BULIMIA NERVOSA or ANOREXIA NERVOSA. (From DSM-IV, 1994)	2.25	1	0
ALS - Amyotrophic Lateral Sclerosis [description not available]	3.73	3	0
Amyotrophic Lateral Sclerosis A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)	3.73	3	0
Metabolically Benign Obesity [description not available]	3.7	1	1
Endometrioma An enlarged area of ENDOMETRIOSIS that resembles a tumor. It is usually found in the OVARY. When it is filled with old blood, it is known as a chocolate cyst.	4.66	3	0
Sterility, Female [description not available]	3.74	3	0
Endometriosis A condition in which functional endometrial tissue is present outside the UTERUS. It is often confined to the PELVIS involving the OVARY, the ligaments, cul-de-sac, and the uterovesical peritoneum.	4.66	3	0
Infertility, Female Diminished or absent ability of a female to achieve conception.	3.74	3	0
Jaundice, Cholestatic [description not available]	2.31	1	0
Jaundice, Obstructive Jaundice, the condition with yellowish staining of the skin and mucous membranes, that is due to impaired BILE flow in the BILIARY TRACT, such as INTRAHEPATIC CHOLESTASIS, or EXTRAHEPATIC CHOLESTASIS.	2.31	1	0
Osteoarthritis of Knee [description not available]	4.22	3	1
Osteoarthritis, Knee Noninflammatory degenerative disease of the knee joint consisting of three large categories: conditions that block normal synchronous movement, conditions that produce abnormal pathways of motion, and conditions that cause stress concentration resulting in changes to articular cartilage. (Crenshaw, Campbell's Operative Orthopaedics, 8th ed, p2019)	4.22	3	1
Fatty Liver, Nonalcoholic [description not available]	3.97	4	0
Non-alcoholic Fatty Liver Disease Fatty liver finding without excessive ALCOHOL CONSUMPTION.	8.97	4	0
Carcinoma, Squamous Cell of Head and Neck [description not available]	2.41	1	0
Cancer of Head [description not available]	2.59	2	0
Squamous Cell Carcinoma of Head and Neck The most common type of head and neck carcinoma that originates from cells on the surface of the NASAL CAVITY; MOUTH; PARANASAL SINUSES, SALIVARY GLANDS, and LARYNX. Mutations in TNFRSF10B, PTEN, and ING1 genes are associated with this cancer.	2.41	1	0
Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)	2.59	2	0
Muscle Pain [description not available]	2.31	1	0
Myalgia Painful sensation in the muscles.	2.31	1	0
Degenerative Diseases, Central Nervous System [description not available]	5.82	9	0
Behavior Disorders [description not available]	4.5	3	0
Depression, Endogenous [description not available]	4.82	4	0
Mental Disorders Psychiatric illness or diseases manifested by breakdowns in the adaptational process expressed primarily as abnormalities of thought, feeling, and behavior producing either distress or impairment of function.	4.5	3	0
Depressive Disorder An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent.	4.82	4	0
Neurodegenerative Diseases Hereditary and sporadic conditions which are characterized by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral nervous system structures.	5.82	9	0
Affective Disorders [description not available]	3.91	2	0
Chemical Dependence [description not available]	6.69	11	0
Diseases, Metabolic [description not available]	3.91	2	0
Nervous System Disorders [description not available]	4.84	5	0
Metabolic Diseases Generic term for diseases caused by an abnormal metabolic process. It can be congenital due to inherited enzyme abnormality (METABOLISM, INBORN ERRORS) or acquired due to disease of an endocrine organ or failure of a metabolically important organ such as the liver. (Stedman, 26th ed)	3.91	2	0
Nervous System Diseases Diseases of the central and peripheral nervous system. This includes disorders of the brain, spinal cord, cranial nerves, peripheral nerves, nerve roots, autonomic nervous system, neuromuscular junction, and muscle.	4.84	5	0
Mood Disorders Those disorders that have a disturbance in mood as their predominant feature.	3.91	2	0
Substance-Related Disorders Disorders related to substance use or abuse.	6.69	11	0
Cancer of Pituitary [description not available]	2.48	2	0
Craniopharyngioma, Adamantinous [description not available]	2.31	1	0
Craniopharyngioma A benign pituitary-region neoplasm that originates from Rathke's pouch. The two major histologic and clinical subtypes are adamantinous (or classical) craniopharyngioma and papillary craniopharyngioma. The adamantinous form presents in children and adolescents as an expanding cystic lesion in the pituitary region. The cystic cavity is filled with a black viscous substance and histologically the tumor is composed of adamantinomatous epithelium and areas of calcification and necrosis. Papillary craniopharyngiomas occur in adults, and histologically feature a squamous epithelium with papillations. (From Joynt, Clinical Neurology, 1998, Ch14, p50)	2.31	1	0
Pituitary Neoplasms Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA.	2.48	2	0
Hypertension, Essential [description not available]	2.31	1	0
Essential Hypertension Hypertension that occurs without known cause, or preexisting renal disease. Associated polymorphisms for a number of genes have been identified, including AGT, GNB3, and ECE1. OMIM: 145500	2.31	1	0
Acute Kidney Failure [description not available]	2.66	2	0
Acute Kidney Injury Abrupt reduction in kidney function. Acute kidney injury encompasses the entire spectrum of the syndrome including acute kidney failure; ACUTE KIDNEY TUBULAR NECROSIS; and other less severe conditions.	2.66	2	0
Peripheral Nerve Diseases [description not available]	3.58	8	0
Peripheral Nervous System Diseases Diseases of the peripheral nerves external to the brain and spinal cord, which includes diseases of the nerve roots, ganglia, plexi, autonomic nerves, sensory nerves, and motor nerves.	3.58	8	0
Nerve Degeneration Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways.	4.58	9	0
Absence Status [description not available]	2.52	2	0
Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.	8.55	8	0
Status Epilepticus A prolonged seizure or seizures repeated frequently enough to prevent recovery between episodes occurring over a period of 20-30 minutes. The most common subtype is generalized tonic-clonic status epilepticus, a potentially fatal condition associated with neuronal injury and respiratory and metabolic dysfunction. Nonconvulsive forms include petit mal status and complex partial status, which may manifest as behavioral disturbances. Simple partial status epilepticus consists of persistent motor, sensory, or autonomic seizures that do not impair cognition (see also EPILEPSIA PARTIALIS CONTINUA). Subclinical status epilepticus generally refers to seizures occurring in an unresponsive or comatose individual in the absence of overt signs of seizure activity. (From N Engl J Med 1998 Apr 2;338(14):970-6; Neurologia 1997 Dec;12 Suppl 6:25-30)	2.52	2	0
Alveolitis, Fibrosing [description not available]	2.31	1	0
Hermanski-Pudlak Syndrome Syndrome characterized by the triad of oculocutaneous albinism (ALBINISM, OCULOCUTANEOUS); PLATELET STORAGE POOL DEFICIENCY; and lysosomal accumulation of ceroid lipofuscin.	2.31	1	0
Pulmonary Fibrosis A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.	2.31	1	0
Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)	4.71	29	0
Abdominal Migraine [description not available]	6.9	11	0
Migraine Disorders A class of disabling primary headache disorders, characterized by recurrent unilateral pulsatile headaches. The two major subtypes are common migraine (without aura) and classic migraine (with aura or neurological symptoms). (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)	6.9	11	0
HbS Disease [description not available]	2.15	1	0
Anemia, Sickle Cell A disease characterized by chronic hemolytic anemia, episodic painful crises, and pathologic involvement of many organs. It is the clinical expression of homozygosity for hemoglobin S.	2.15	1	0
Chronic Pancreatitis [description not available]	2.15	1	0
Cancer-Associated Pain [description not available]	2.15	1	0
Cancer of Pancreas [description not available]	2.15	1	0
Colicky Pain [description not available]	2.15	1	0
Carcinoma, Ductal, Pancreatic [description not available]	2.15	1	0
Cancer Pain Pain that may be caused by or related to cellular, tissue, and systemic changes that occur during NEOPLASM growth, tissue invasion, and METASTASIS.	2.15	1	0
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	2.15	1	0
Abdominal Pain Sensation of discomfort, distress, or agony in the abdominal region.	2.15	1	0
Carcinoma, Pancreatic Ductal Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.	2.15	1	0
Pancreatitis, Chronic INFLAMMATION of the PANCREAS that is characterized by recurring or persistent ABDOMINAL PAIN with or without STEATORRHEA or DIABETES MELLITUS. It is characterized by the irregular destruction of the pancreatic parenchyma which may be focal, segmental, or diffuse.	2.15	1	0
Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.	9.44	21	0
Liver Steatosis [description not available]	3.32	6	0
Fatty Liver Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.	3.32	6	0
Canine Diseases [description not available]	2.52	2	0
Age-Related Memory Disorders [description not available]	4.34	4	1
Memory Disorders Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with DEMENTIA; CRANIOCEREBRAL TRAUMA; ENCEPHALITIS; ALCOHOLISM (see also ALCOHOL AMNESTIC DISORDER); SCHIZOPHRENIA; and other conditions.	4.34	4	1
Endotoxemia A condition characterized by the presence of ENDOTOXINS in the blood. On lysis, the outer cell wall of gram-negative bacteria enters the systemic circulation and initiates a pathophysiologic cascade of pro-inflammatory mediators.	10.26	4	1
Akinetic-Rigid Variant of Huntington Disease [description not available]	2.98	4	0
Huntington Disease A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)	2.98	4	0
Cancer of Colon [description not available]	3.47	7	0
Colonic Neoplasms Tumors or cancer of the COLON.	3.47	7	0
Arteriosclerosis, Coronary [description not available]	2.17	1	0
Diabetes Mellitus, Adult-Onset [description not available]	6.08	12	0
Coronary Artery Disease Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.	2.17	1	0
Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.	6.08	12	0
Acute Disease Disease having a short and relatively severe course.	5.3	12	1
Leanness [description not available]	5.78	4	1
Fra(X) Syndrome [description not available]	3.47	2	0
Bone Diseases Diseases of BONES.	3.12	1	0
Fragile X Syndrome A condition characterized genotypically by mutation of the distal end of the long arm of the X chromosome (at gene loci FRAXA or FRAXE) and phenotypically by cognitive impairment, hyperactivity, SEIZURES, language delay, and enlargement of the ears, head, and testes. INTELLECTUAL DISABILITY occurs in nearly all males and roughly 50% of females with the full mutation of FRAXA. (From Menkes, Textbook of Child Neurology, 5th ed, p226)	3.47	2	0
Genetic Predisposition [description not available]	3.18	5	0
Affective Psychosis, Bipolar [description not available]	3.39	2	0
Bipolar Disorder A major affective disorder marked by severe mood swings (manic or major depressive episodes) and a tendency to remission and recurrence.	3.39	2	0
Disorder, Borderline Personality [description not available]	2.53	2	0
Borderline Personality Disorder A personality disorder marked by a pattern of instability of interpersonal relationships, self-image, and affects, and marked impulsivity beginning by early adulthood and present in a variety of contexts. (DSM-IV)	2.53	2	0
Autosomal Dominant Juvenile Parkinson Disease [description not available]	3.43	7	0
Dyskinesia, Medication-Induced [description not available]	3.17	5	0
Dyskinesia, Drug-Induced Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199)	3.17	5	0
Parkinsonian Disorders A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.	3.43	7	0
Allergic Contact Dermatitis [description not available]	2.48	2	0
Dermatitis, Allergic Contact A contact dermatitis due to allergic sensitization to various substances. These substances subsequently produce inflammatory reactions in the skin of those who have acquired hypersensitivity to them as a result of prior exposure.	2.48	2	0
Anorexia Nervosa An eating disorder that is characterized by the lack or loss of APPETITE, known as ANOREXIA. Other features include excess fear of becoming OVERWEIGHT; BODY IMAGE disturbance; significant WEIGHT LOSS; refusal to maintain minimal normal weight; and AMENORRHEA. This disorder occurs most frequently in adolescent females. (APA, Thesaurus of Psychological Index Terms, 1994)	4.83	4	0
Cocaine Abuse [description not available]	2.53	2	0
Cocaine-Related Disorders Disorders related or resulting from use of cocaine.	2.53	2	0
Ataxia Impairment of the ability to perform smoothly coordinated voluntary movements. This condition may affect the limbs, trunk, eyes, pharynx, larynx, and other structures. Ataxia may result from impaired sensory or motor function. Sensory ataxia may result from posterior column injury or PERIPHERAL NERVE DISEASES. Motor ataxia may be associated with CEREBELLAR DISEASES; CEREBRAL CORTEX diseases; THALAMIC DISEASES; BASAL GANGLIA DISEASES; injury to the RED NUCLEUS; and other conditions.	3.36	2	0
Cataract, Membranous [description not available]	3.12	1	0
Polyneuropathy, Acquired [description not available]	3.12	1	0
Pigmentary Retinopathy [description not available]	3.12	1	0
Cataract Partial or complete opacity on or in the lens or capsule of one or both eyes, impairing vision or causing blindness. The many kinds of cataract are classified by their morphology (size, shape, location) or etiology (cause and time of occurrence). (Dorland, 27th ed)	3.12	1	0
Polyneuropathies Diseases of multiple peripheral nerves simultaneously. Polyneuropathies usually are characterized by symmetrical, bilateral distal motor and sensory impairment with a graded increase in severity distally. The pathological processes affecting peripheral nerves include degeneration of the axon, myelin or both. The various forms of polyneuropathy are categorized by the type of nerve affected (e.g., sensory, motor, or autonomic), by the distribution of nerve injury (e.g., distal vs. proximal), by nerve component primarily affected (e.g., demyelinating vs. axonal), by etiology, or by pattern of inheritance.	3.12	1	0
Retinitis Pigmentosa Hereditary, progressive degeneration of the retina due to death of ROD PHOTORECEPTORS initially and subsequent death of CONE PHOTORECEPTORS. It is characterized by deposition of pigment in the retina.	3.12	1	0
Pyrexia [description not available]	4.09	5	0
Fever An abnormal elevation of body temperature, usually as a result of a pathologic process.	4.09	5	0
Colitis Gravis [description not available]	2.76	3	0
Colitis, Granulomatous [description not available]	2.21	1	0
Bowel Diseases, Inflammatory [description not available]	4.6	3	0
Colitis, Ulcerative Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.	2.76	3	0
Crohn Disease A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.	2.21	1	0
Inflammatory Bowel Diseases Chronic, non-specific inflammation of the GASTROINTESTINAL TRACT. Etiology may be genetic or environmental. This term includes CROHN DISEASE and ULCERATIVE COLITIS.	4.6	3	0
Analgesia, Congenital [description not available]	2.21	1	0
Cardiac Remodeling, Ventricular [description not available]	2.54	2	0
Mast Cell Activation Disease [description not available]	2.21	1	0
Mastocytosis A rare neoplastic disorder characterized by a clonal proliferation of MAST CELLS, associated with KIT-D816 mutations, and accompanied by aberrant mast cell activation. The abnormal increase of MAST CELLS may occur in only the skin (MASTOCYTOSIS, CUTANEOUS), in extracutaneous tissues involving multiple organs (MASTOCYTOSIS, SYSTEMIC), or in solid tumors (MASTOCYTOMA).	2.21	1	0
Combat Disorders Neurotic reactions to unusual, severe, or overwhelming military stress.	2.25	1	0
Suicidal Ideation A risk factor for suicide attempts and completions, it is the most common of all suicidal behavior, but only a minority of ideators engage in overt self-harm.	2.25	1	0
Airway Obstruction Any hindrance to the passage of air into and out of the lungs.	7.72	3	0
Cardiometabolic Syndrome A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components not only include metabolic dysfunctions of METABOLIC SYNDROME but also HYPERTENSION, and ABDOMINAL OBESITY.	5.29	4	0
Metabolic Syndrome A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.	5.29	4	0
Glial Cell Tumors [description not available]	4.27	18	0
Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)	4.27	18	0
Anoxemia [description not available]	3	4	0
Hypoxia Sub-optimal OXYGEN levels in the ambient air of living organisms.	3	4	0
Ischemia A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION.	2.46	2	0
Compensatory Hyperinsulinemia A GLUCOSE-induced HYPERINSULINEMIA, a marker of insulin-resistant state. It is a mechanism to compensate for reduced sensitivity to insulin.	2.49	2	0
Insulin Sensitivity [description not available]	5.2	17	0
Hyperinsulinism A syndrome with excessively high INSULIN levels in the BLOOD. It may cause HYPOGLYCEMIA. Etiology of hyperinsulinism varies, including hypersecretion of a beta cell tumor (INSULINOMA); autoantibodies against insulin (INSULIN ANTIBODIES); defective insulin receptor (INSULIN RESISTANCE); or overuse of exogenous insulin or HYPOGLYCEMIC AGENTS.	2.49	2	0
Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.	10.2	17	0
Clasp-Knife Spasticity [description not available]	4.13	3	1
Muscle Spasticity A form of muscle hypertonia associated with upper MOTOR NEURON DISEASE. Resistance to passive stretch of a spastic muscle results in minimal initial resistance (a free interval) followed by an incremental increase in muscle tone. Tone increases in proportion to the velocity of stretch. Spasticity is usually accompanied by HYPERREFLEXIA and variable degrees of MUSCLE WEAKNESS. (From Adams et al., Principles of Neurology, 6th ed, p54)	4.13	3	1
Benign Neoplasms, Brain [description not available]	3.81	11	0
Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.	3.81	11	0
Fibrosarcoma A sarcoma derived from deep fibrous tissue, characterized by bundles of immature proliferating fibroblasts with variable collagen formation, which tends to invade locally and metastasize by the bloodstream. (Stedman, 25th ed)	2.48	2	0
Heart Disease, Ischemic [description not available]	2.74	3	0
Myocardial Ischemia A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).	2.74	3	0
Sterility, Male [description not available]	3.89	4	0
Infertility, Male The inability of the male to effect FERTILIZATION of an OVUM after a specified period of unprotected intercourse. Male sterility is permanent infertility.	3.89	4	0
Colitis Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.	2.75	3	0
Ventricular Fibrillation A potentially lethal cardiac arrhythmia that is characterized by uncoordinated extremely rapid firing of electrical impulses (400-600/min) in HEART VENTRICLES. Such asynchronous ventricular quivering or fibrillation prevents any effective cardiac output and results in unconsciousness (SYNCOPE). It is one of the major electrocardiographic patterns seen with CARDIAC ARREST.	2.08	1	0
Absence Seizure Disorder [description not available]	2.49	2	0
Epilepsy, Absence A seizure disorder usually occurring in childhood characterized by rhythmic electrical brain discharges of generalized onset. Clinical features include a sudden cessation of ongoing activity usually without loss of postural tone. Rhythmic blinking of the eyelids or lip smacking frequently accompanies the SEIZURES. The usual duration is 5-10 seconds, and multiple episodes may occur daily. Juvenile absence epilepsy is characterized by the juvenile onset of absence seizures and an increased incidence of myoclonus and tonic-clonic seizures. (Menkes, Textbook of Child Neurology, 5th ed, p736)	2.49	2	0
Drug Withdrawal Symptoms [description not available]	4.95	14	0
Substance Withdrawal Syndrome Physiological and psychological symptoms associated with withdrawal from the use of a drug after prolonged administration or habituation. The concept includes withdrawal from smoking or drinking, as well as withdrawal from an administered drug.	4.95	14	0
Hyperglycemia, Postprandial Abnormally high BLOOD GLUCOSE level after a meal.	3	4	0
Hyperglycemia Abnormally high BLOOD GLUCOSE level.	3	4	0
Emesis [description not available]	8.14	5	0
Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.	4.24	6	0
Vomiting The forcible expulsion of the contents of the STOMACH through the MOUTH.	8.14	5	0
Complications, Pregnancy [description not available]	2.97	4	0
Alcohol Abuse [description not available]	8.9	4	0
Alcoholism A primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic. (Morse & Flavin for the Joint Commission of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism: in JAMA 1992;268:1012-4)	3.9	4	0
Malignant Melanoma [description not available]	2.48	2	0
Cancer of Skin [description not available]	3.02	4	0
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	7.48	2	0
Skin Neoplasms Tumors or cancer of the SKIN.	3.02	4	0
Weight Gain Increase in BODY WEIGHT over existing weight.	8.47	7	0
Pernicious Vomiting of Pregnancy [description not available]	2.1	1	0
Hyperemesis Gravidarum Intractable VOMITING that develops in early PREGNANCY and persists. This can lead to DEHYDRATION and WEIGHT LOSS.	7.1	1	0
Pulmonary Hypertension [description not available]	2.46	2	0
Hypertension, Pulmonary Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.	2.46	2	0
Atheroma [description not available]	2.49	2	0
Acute Brain Injuries [description not available]	3.42	7	0
Bleeding [description not available]	2.5	2	0
Brain Injuries Acute and chronic (see also BRAIN INJURIES, CHRONIC) injuries to the brain, including the cerebral hemispheres, CEREBELLUM, and BRAIN STEM. Clinical manifestations depend on the nature of injury. Diffuse trauma to the brain is frequently associated with DIFFUSE AXONAL INJURY or COMA, POST-TRAUMATIC. Localized injuries may be associated with NEUROBEHAVIORAL MANIFESTATIONS; HEMIPARESIS, or other focal neurologic deficits.	3.42	7	0
Hemorrhage Bleeding or escape of blood from a vessel.	2.5	2	0
Cirrhosis, Liver [description not available]	4.74	11	0
Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.	4.74	11	0
Recrudescence [description not available]	2.76	3	0
Anochlesia [description not available]	3.53	8	0
Hypothermia, Accidental [description not available]	3.63	9	0
Hypothermia Lower than normal body temperature, especially in warm-blooded animals.	8.63	9	0
Air Sickness [description not available]	2.1	1	0
Motion Sickness Disorder caused by motion. It includes sea sickness, train sickness, roller coaster rides, rocking chair, hammock swing, car sickness, air sickness, or SPACE MOTION SICKNESS. Symptoms include nausea, vomiting and/or dizziness.	2.1	1	0
Delayed Hypersensitivity [description not available]	2.48	2	0
Chronic Hepatitis C [description not available]	2.51	2	0
Glucose Metabolic Disorder [description not available]	2.1	1	0
Hepatitis C, Chronic INFLAMMATION of the LIVER in humans that is caused by HEPATITIS C VIRUS lasting six months or more. Chronic hepatitis C can lead to LIVER CIRRHOSIS.	2.51	2	0
Injuries, Spinal Cord [description not available]	3.91	4	0
Spinal Cord Injuries Penetrating and non-penetrating injuries to the spinal cord resulting from traumatic external forces (e.g., WOUNDS, GUNSHOT; WHIPLASH INJURIES; etc.).	3.91	4	0
Carcinoma, Epidermoid [description not available]	2.48	2	0
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	2.48	2	0
Adenocarcinoma, Basal Cell [description not available]	2.51	2	0
Carcinoma, Non-Small Cell Lung [description not available]	2.46	2	0
Cancer of Lung [description not available]	2.97	4	0
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	2.51	2	0
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	2.46	2	0
Lung Neoplasms Tumors or cancer of the LUNG.	2.97	4	0
Colitis, Mucous [description not available]	2.52	2	0
Visceral Pain Pain originating from internal organs (VISCERA) associated with autonomic phenomena (PALLOR; SWEATING; NAUSEA; and VOMITING). It often becomes a REFERRED PAIN.	4.63	3	0
Irritable Bowel Syndrome A disorder with chronic or recurrent colonic symptoms without a clearcut etiology. This condition is characterized by chronic or recurrent ABDOMINAL PAIN, bloating, MUCUS in FECES, and an erratic disturbance of DEFECATION.	2.52	2	0
Anhedonia Inability to experience pleasure due to impairment or dysfunction of normal psychological and neurobiological mechanisms. It is a symptom of many PSYCHOTIC DISORDERS (e.g., DEPRESSIVE DISORDER, MAJOR; and SCHIZOPHRENIA).	3.01	1	0
Gestational Hypertension [description not available]	2.1	1	0
Hypertension, Pregnancy-Induced A condition in pregnant women with elevated systolic (	2.1	1	0
Cardiac Hypertrophy Enlargement of the HEART due to chamber HYPERTROPHY, an increase in wall thickness without an increase in the number of cells (MYOCYTES, CARDIAC). It is the result of increase in myocyte size, mitochondrial and myofibrillar mass, as well as changes in extracellular matrix.	2.52	2	0
Cardiomegaly Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES.	2.52	2	0
Left Ventricular Dysfunction [description not available]	2.74	3	0
Cardiomyopathies, Primary [description not available]	2.46	2	0
Cardiovascular Stroke [description not available]	3.13	5	0
Injury, Myocardial Reperfusion [description not available]	2.96	4	0
Cardiomyopathies A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).	2.46	2	0
Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).	8.13	5	0
Ventricular Dysfunction, Left A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall.	2.74	3	0
Astheno Teratozoospermia [description not available]	2.1	1	0
Pericementitis [description not available]	2.75	3	0
Periodontitis Inflammation and loss of connective tissues supporting or surrounding the teeth. This may involve any part of the PERIODONTIUM. Periodontitis is currently classified by disease progression (CHRONIC PERIODONTITIS; AGGRESSIVE PERIODONTITIS) instead of age of onset. (From 1999 International Workshop for a Classification of Periodontal Diseases and Conditions, American Academy of Periodontology)	7.75	3	0
Blood Clot [description not available]	2.52	2	0
Thrombosis Formation and development of a thrombus or blood clot in the blood vessel.	2.52	2	0
Constriction, Pathological [description not available]	2.46	2	0
Constriction, Pathologic The condition of an anatomical structure's being constricted beyond normal dimensions.	2.46	2	0
Lung Injury, Acute [description not available]	2.1	1	0
Acid Aspiration Syndrome [description not available]	2.1	1	0
Respiratory Aspiration of Gastric Contents Inhaling refluxed gastric or duodenal contents.	2.1	1	0
Pneumonia, Aspiration A type of lung inflammation resulting from the aspiration of food, liquid, or gastric contents into the upper RESPIRATORY TRACT.	2.1	1	0
Acute Lung Injury A condition of lung damage that is characterized by bilateral pulmonary infiltrates (PULMONARY EDEMA) rich in NEUTROPHILS, and in the absence of clinical HEART FAILURE. This can represent a spectrum of pulmonary lesions, endothelial and epithelial, due to numerous factors (physical, chemical, or biological).	2.1	1	0
Panic Attacks [description not available]	2.81	3	0
Panic Disorder A type of anxiety disorder characterized by unexpected panic attacks that last minutes or, rarely, hours. Panic attacks begin with intense apprehension, fear or terror and, often, a feeling of impending doom. Symptoms experienced during a panic attack include dyspnea or sensations of being smothered; dizziness, loss of balance or faintness; choking sensations; palpitations or accelerated heart rate; shakiness; sweating; nausea or other form of abdominal distress; depersonalization or derealization; paresthesias; hot flashes or chills; chest discomfort or pain; fear of dying and fear of not being in control of oneself or going crazy. Agoraphobia may also develop. Similar to other anxiety disorders, it may be inherited as an autosomal dominant trait.	2.81	3	0
Aggression Behavior which may be manifested by destructive and attacking action which is verbal or physical, by covert attitudes of hostility or by obstructionism.	2.44	2	0
Adverse Drug Event [description not available]	4.41	1	1
Addiction, Opioid [description not available]	4.41	1	1
Opioid-Related Disorders Disorders related to or resulting from abuse or misuse of OPIOIDS.	4.41	1	1
Drug-Related Side Effects and Adverse Reactions Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.	4.41	1	1
Adenoma, Prostatic [description not available]	2.11	1	0
Prostatic Hyperplasia Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both.	2.11	1	0
Edema-Proteinuria-Hypertension Gestosis [description not available]	2.5	2	0
Pre-Eclampsia A complication of PREGNANCY, characterized by a complex of symptoms including maternal HYPERTENSION and PROTEINURIA with or without pathological EDEMA. Symptoms may range between mild and severe. Pre-eclampsia usually occurs after the 20th week of gestation, but may develop before this time in the presence of trophoblastic disease.	7.5	2	0
Benign Neoplasms [description not available]	5.95	9	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	5.95	9	0
Asthma, Bronchial [description not available]	3	4	0
Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).	8	4	0
Morbid Obesity [description not available]	2.11	1	0
Obesity, Morbid The condition of weighing two, three, or more times the ideal weight, so called because it is associated with many serious and life-threatening disorders. In the BODY MASS INDEX, morbid obesity is defined as having a BMI greater than 40.0 kg/m2.	2.11	1	0
Liver Dysfunction [description not available]	3.38	2	0
Liver Diseases Pathological processes of the LIVER.	3.38	2	0
Hyperphagia Ingestion of a greater than optimal quantity of food.	2.72	3	0
Anesthesia A state characterized by loss of feeling or sensation. This depression of nerve function is usually the result of pharmacologic action and is induced to allow performance of surgery or other painful procedures.	3.73	10	0
Brain Inflammation [description not available]	2.46	2	0
Encephalitis Inflammation of the BRAIN due to infection, autoimmune processes, toxins, and other conditions. Viral infections (see ENCEPHALITIS, VIRAL) are a relatively frequent cause of this condition.	2.46	2	0
Central Nervous System Disease [description not available]	3.03	1	0
Central Nervous System Diseases Diseases of any component of the brain (including the cerebral hemispheres, diencephalon, brain stem, and cerebellum) or the spinal cord.	3.03	1	0
Invasiveness, Neoplasm [description not available]	4.13	3	0
Nicotine Addiction [description not available]	3.88	4	0
Tobacco Use Disorder Tobacco used to the detriment of a person's health or social functioning. Tobacco dependence is included.	3.88	4	0
Apnea, Obstructive Sleep [description not available]	2.5	2	0
Sleep Apnea, Obstructive A disorder characterized by recurrent apneas during sleep despite persistent respiratory efforts. It is due to upper airway obstruction. The respiratory pauses may induce HYPERCAPNIA or HYPOXIA. Cardiac arrhythmias and elevation of systemic and pulmonary arterial pressures may occur. Frequent partial arousals occur throughout sleep, resulting in relative SLEEP DEPRIVATION and daytime tiredness. Associated conditions include OBESITY; ACROMEGALY; MYXEDEMA; micrognathia; MYOTONIC DYSTROPHY; adenotonsilar dystrophy; and NEUROMUSCULAR DISEASES. (From Adams et al., Principles of Neurology, 6th ed, p395)	2.5	2	0
Dermatitis, Irritant A non-allergic contact dermatitis caused by prolonged exposure to irritants and not explained by delayed hypersensitivity mechanisms.	2.13	1	0
Actinic Reticuloid Syndrome [description not available]	2.13	1	0
Chronic Motor and Vocal Tic Disorder [description not available]	2.13	1	0
Tourette Syndrome A neuropsychological disorder related to alterations in DOPAMINE metabolism and neurotransmission involving frontal-subcortical neuronal circuits. Both multiple motor and one or more vocal tics need to be present with TICS occurring many times a day, nearly daily, over a period of more than one year. The onset is before age 18 and the disturbance is not due to direct physiological effects of a substance or another medical condition. The disturbance causes marked distress or significant impairment in social, occupational, or other important areas of functioning. (From DSM-IV, 1994; Neurol Clin 1997 May;15(2):357-79)	2.13	1	0
Nociceptive Pain Dull or sharp aching pain caused by stimulated NOCICEPTORS due to tissue injury, inflammation or diseases. It can be divided into somatic or tissue pain and VISCERAL PAIN.	2.54	2	0
Alloxan Diabetes [description not available]	3	4	0
Asymmetric Diabetic Proximal Motor Neuropathy [description not available]	2.5	2	0
Diabetic Neuropathies Peripheral, autonomic, and cranial nerve disorders that are associated with DIABETES MELLITUS. These conditions usually result from diabetic microvascular injury involving small blood vessels that supply nerves (VASA NERVORUM). Relatively common conditions which may be associated with diabetic neuropathy include third nerve palsy (see OCULOMOTOR NERVE DISEASES); MONONEUROPATHY; mononeuropathy multiplex; diabetic amyotrophy; a painful POLYNEUROPATHY; autonomic neuropathy; and thoracoabdominal neuropathy. (From Adams et al., Principles of Neurology, 6th ed, p1325)	2.5	2	0
Anticipatory Vomiting [description not available]	2.13	1	0
Amyloidosis A group of sporadic, familial and/or inherited, degenerative, and infectious disease processes, linked by the common theme of abnormal protein folding and deposition of AMYLOID. As the amyloid deposits enlarge they displace normal tissue structures, causing disruption of function. Various signs and symptoms depend on the location and size of the deposits.	2.13	1	0
Hyperhomocysteinemia Condition in which the plasma levels of homocysteine and related metabolites are elevated (	2.13	1	0
Autokinetic Effect [description not available]	2.15	1	0
Fetal Malnutrition [description not available]	2.13	1	0
Symptom Cluster [description not available]	3.85	2	1
Syndrome A characteristic symptom complex.	3.85	2	1
Cerebral Ischemia [description not available]	4.91	8	0
Brain Vascular Disorders [description not available]	2.15	1	0
Brain Ischemia Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.	4.91	8	0
Cerebrovascular Disorders A spectrum of pathological conditions of impaired blood flow in the brain. They can involve vessels (ARTERIES or VEINS) in the CEREBRUM, the CEREBELLUM, and the BRAIN STEM. Major categories include INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; and others.	2.15	1	0
Amentia [description not available]	2.15	1	0
Dementia An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness.	2.15	1	0
Burns Injuries to tissues caused by contact with heat, steam, chemicals (BURNS, CHEMICAL), electricity (BURNS, ELECTRIC), or the like.	2.04	1	0
Acute Edematous Pancreatitis [description not available]	2.44	2	0
Pancreatitis INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.	7.44	2	0
Glaucoma An ocular disease, occurring in many forms, having as its primary characteristics an unstable or a sustained increase in the intraocular pressure which the eye cannot withstand without damage to its structure or impairment of its function. The consequences of the increased pressure may be manifested in a variety of symptoms, depending upon type and severity, such as excavation of the optic disk, hardness of the eyeball, corneal anesthesia, reduced visual acuity, seeing of colored halos around lights, disturbed dark adaptation, visual field defects, and headaches. (Dictionary of Visual Science, 4th ed)	4.65	4	0
Hyperthyroid [description not available]	2.04	1	0
Central Hypothyroidism [description not available]	2.46	2	0
Hyperthyroidism Hypersecretion of THYROID HORMONES from the THYROID GLAND. Elevated levels of thyroid hormones increase BASAL METABOLIC RATE.	2.04	1	0
Hypothyroidism A syndrome that results from abnormally low secretion of THYROID HORMONES from the THYROID GLAND, leading to a decrease in BASAL METABOLIC RATE. In its most severe form, there is accumulation of MUCOPOLYSACCHARIDES in the SKIN and EDEMA, known as MYXEDEMA. It may be primary or secondary due to other pituitary disease, or hypothalamic dysfunction.	2.46	2	0
Cholangiocellular Carcinoma [description not available]	2.96	4	0
Cholangiocarcinoma A malignant tumor arising from the epithelium of the BILE DUCTS.	2.96	4	0
Cerebral Infarction, Middle Cerebral Artery [description not available]	2.95	4	0
Apoplexy [description not available]	4.2	6	0
Metabolic Acidosis [description not available]	2.43	2	0
Anoxia, Brain [description not available]	2.05	1	0
Acidosis A pathologic condition of acid accumulation or depletion of base in the body. The two main types are RESPIRATORY ACIDOSIS and metabolic acidosis, due to metabolic acid build up.	2.43	2	0
Infarction, Middle Cerebral Artery NECROSIS occurring in the MIDDLE CEREBRAL ARTERY distribution system which brings blood to the entire lateral aspects of each CEREBRAL HEMISPHERE. Clinical signs include impaired cognition; APHASIA; AGRAPHIA; weak and numbness in the face and arms, contralaterally or bilaterally depending on the infarction.	2.95	4	0
Stroke A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)	9.2	6	0
Endotoxin Shock [description not available]	4.73	11	0
Shock, Septic Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.	4.73	11	0
Gastric Ulcer [description not available]	3.14	5	0
Stomach Ulcer Ulceration of the GASTRIC MUCOSA due to contact with GASTRIC JUICE. It is often associated with HELICOBACTER PYLORI infection or consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).	3.14	5	0
Bone Cancer [description not available]	7.46	2	0
Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES.	2.46	2	0
Fungal Diseases [description not available]	2.05	1	0
Mycoses Diseases caused by FUNGI.	2.05	1	0
Bone Loss, Osteoclastic [description not available]	2.05	1	0
Cardiac Diseases [description not available]	5.6	3	2
Heart Diseases Pathological conditions involving the HEART including its structural and functional abnormalities.	5.6	3	2
Apnea A transient absence of spontaneous respiration.	2.73	3	0
Muscle Relaxation That phase of a muscle twitch during which a muscle returns to a resting position.	3.8	11	0
Cancer of the Thyroid [description not available]	3.64	3	0
Thyroid Neoplasms Tumors or cancer of the THYROID GLAND.	3.64	3	0
Menopause The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age.	2.05	1	0
Hay Fever [description not available]	2.05	1	0
Itching [description not available]	2.05	1	0
Rhinitis, Allergic, Seasonal Allergic rhinitis that occurs at the same time every year. It is characterized by acute CONJUNCTIVITIS with lacrimation and ITCHING, and regarded as an allergic condition triggered by specific ALLERGENS.	2.05	1	0
Pruritus An intense itching sensation that produces the urge to rub or scratch the skin to obtain relief.	2.05	1	0
Blood Pressure, Low [description not available]	6.33	14	1
Hypotension Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients.	11.33	14	1
ADDH [description not available]	2.44	2	0
Attention Deficit Disorder with Hyperactivity A behavior disorder originating in childhood in which the essential features are signs of developmentally inappropriate inattention, impulsivity, and hyperactivity. Although most individuals have symptoms of both inattention and hyperactivity-impulsivity, one or the other pattern may be predominant. The disorder is more frequent in males than females. Onset is in childhood. Symptoms often attenuate during late adolescence although a minority experience the full complement of symptoms into mid-adulthood. (From DSM-V)	2.44	2	0
Schistosoma japonicum Infection [description not available]	2.05	1	0
Biliary Cirrhosis [description not available]	7.95	4	0
Liver Cirrhosis, Biliary FIBROSIS of the hepatic parenchyma due to obstruction of BILE flow (CHOLESTASIS) in the intrahepatic or extrahepatic bile ducts (BILE DUCTS, INTRAHEPATIC; BILE DUCTS, EXTRAHEPATIC). Primary biliary cholangitis involves the destruction of small intra-hepatic bile ducts and decreased bile secretion. Secondary biliary cholangitis is produced by prolonged obstruction of large intrahepatic or extrahepatic bile ducts from a variety of causes.	2.95	4	0
Abortion, Septic Any type of abortion, induced or spontaneous, that is associated with infection of the UTERUS and its appendages. It is characterized by FEVER, uterine tenderness, and foul discharge.	2.05	1	0
Goldblatt Syndrome [description not available]	2.05	1	0
Hypertension, Renovascular Hypertension due to RENAL ARTERY OBSTRUCTION or compression.	2.05	1	0
Abnormal Movements [description not available]	2.05	1	0
Angor Pectoris [description not available]	2.05	1	0
Rupture, Spontaneous Tear or break of an organ, vessel or other soft part of the body, occurring in the absence of external force.	2.05	1	0
Angina Pectoris The symptom of paroxysmal pain consequent to MYOCARDIAL ISCHEMIA usually of distinctive character, location and radiation. It is thought to be provoked by a transient stressful situation during which the oxygen requirements of the MYOCARDIUM exceed that supplied by the CORONARY CIRCULATION.	2.05	1	0
Aberrant Tissue [description not available]	2.05	1	0
Algodystrophic Syndrome [description not available]	2.05	1	0
Injuries Used with anatomic headings, animals, and sports for wounds and injuries. Excludes cell damage, for which pathology is used.	2.05	1	0
Reflex Sympathetic Dystrophy A syndrome characterized by severe burning pain in an extremity accompanied by sudomotor, vasomotor, and trophic changes in bone without an associated specific nerve injury. This condition is most often precipitated by trauma to soft tissue or nerve complexes. The skin over the affected region is usually erythematous and demonstrates hypersensitivity to tactile stimuli and erythema. (Adams et al., Principles of Neurology, 6th ed, p1360; Pain 1995 Oct;63(1):127-33)	2.05	1	0
Wounds and Injuries Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.	2.05	1	0
Dizzyness [description not available]	2.05	1	0
Drop Attack [description not available]	2.05	1	0
Dizziness An imprecise term which may refer to a sense of spatial disorientation, motion of the environment, or lightheadedness.	2.05	1	0
Syncope A transient loss of consciousness and postural tone caused by diminished blood flow to the brain (i.e., BRAIN ISCHEMIA). Presyncope refers to the sensation of lightheadedness and loss of strength that precedes a syncopal event or accompanies an incomplete syncope. (From Adams et al., Principles of Neurology, 6th ed, pp367-9)	2.05	1	0
Orthostatic Intolerance Symptoms of cerebral hypoperfusion or autonomic overaction which develop while the subject is standing, but are relieved on recumbency. Types of this include NEUROCARDIOGENIC SYNCOPE; POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME; and neurogenic ORTHOSTATIC HYPOTENSION. (From Noseworthy, JH., Neurological Therapeutics Principles and Practice, 2007, p2575-2576)	2.05	1	0
Benign Psychomotor Epilepsy, Childhood [description not available]	2.75	3	0
Epilepsy, Temporal Lobe A localization-related (focal) form of epilepsy characterized by recurrent seizures that arise from foci within the TEMPORAL LOBE, most commonly from its mesial aspect. A wide variety of psychic phenomena may be associated, including illusions, hallucinations, dyscognitive states, and affective experiences. The majority of complex partial seizures (see EPILEPSY, COMPLEX PARTIAL) originate from the temporal lobes. Temporal lobe seizures may be classified by etiology as cryptogenic, familial, or symptomatic. (From Adams et al., Principles of Neurology, 6th ed, p321).	2.75	3	0
Cardiac Failure [description not available]	2.05	1	0
Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.	2.05	1	0
Cholera Infantum [description not available]	4.73	2	0
Carcinoma, Anaplastic [description not available]	2.73	3	0
Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.	7.73	3	0
Bile Duct Cancer [description not available]	2.46	2	0
Bile Duct Neoplasms Tumors or cancer of the BILE DUCTS.	2.46	2	0
Apnea, Sleep [description not available]	2.05	1	0
Sleep Apnea Syndromes Disorders characterized by multiple cessations of respirations during sleep that induce partial arousals and interfere with the maintenance of sleep. Sleep apnea syndromes are divided into central (see SLEEP APNEA, CENTRAL), obstructive (see SLEEP APNEA, OBSTRUCTIVE), and mixed central-obstructive types.	2.05	1	0
Nephritis Inflammation of any part of the KIDNEY.	2.05	1	0
Parasitemia The presence of parasites (especially malarial parasites) in the blood. (Dorland, 27th ed)	2.05	1	0
Infections, Plasmodium [description not available]	2.05	1	0
Malaria A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.	2.05	1	0
Neuralgia, Sciatic [description not available]	2.05	1	0
Sciatica A condition characterized by pain radiating from the back into the buttock and posterior/lateral aspects of the leg. Sciatica may be a manifestation of SCIATIC NEUROPATHY; RADICULOPATHY (involving the SPINAL NERVE ROOTS; L4, L5, S1, or S2, often associated with INTERVERTEBRAL DISK DISPLACEMENT); or lesions of the CAUDA EQUINA.	2.05	1	0
Anankastic Personality [description not available]	2.45	2	0
Obsessive-Compulsive Disorder An anxiety disorder characterized by recurrent, persistent obsessions or compulsions. Obsessions are the intrusive ideas, thoughts, or images that are experienced as senseless or repugnant. Compulsions are repetitive and seemingly purposeful behavior which the individual generally recognizes as senseless and from which the individual does not derive pleasure although it may provide a release from tension.	2.45	2	0
Hyperactivity, Motor [description not available]	2.93	4	0
Coronary Heart Disease [description not available]	2.06	1	0
Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.	2.06	1	0
Autoimmune Disease Models, Nervous System [description not available]	2.06	1	0
Cardiovirus Infections Infections caused by viruses of the genus CARDIOVIRUS, family PICORNAVIRIDAE.	2.44	2	0
Intraocular Pressure The pressure of the fluids in the eye.	4.63	10	0
Cadaver A dead body, usually a human body.	2.07	1	0
Cognition Disorders Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.	6.66	4	1
Erythermalgia [description not available]	2.06	1	0
Erythromelalgia A peripheral arterial disease that is characterized by the triad of ERYTHEMA, burning PAIN, and increased SKIN TEMPERATURE of the extremities (or red, painful extremities). Erythromelalgia may be classified as primary or idiopathic, familial or non-familial. Secondary erythromelalgia is associated with other diseases, the most common being MYELOPROLIFERATIVE DISORDERS.	2.06	1	0
Uveitis Inflammation of part or all of the uvea, the middle (vascular) tunic of the eye, and commonly involving the other tunics (sclera and cornea, and the retina). (Dorland, 27th ed)	7.06	1	0
Alcoholic Liver Diseases [description not available]	2.06	1	0
Liver Diseases, Alcoholic Liver diseases associated with ALCOHOLISM. It usually refers to the coexistence of two or more subentities, i.e., ALCOHOLIC FATTY LIVER; ALCOHOLIC HEPATITIS; and ALCOHOLIC CIRRHOSIS.	2.06	1	0
Vascular Injuries [description not available]	2.06	1	0
Celiac Sprue [description not available]	2.46	2	0
Celiac Disease A malabsorption syndrome that is precipitated by the ingestion of foods containing GLUTEN, such as wheat, rye, and barley. It is characterized by INFLAMMATION of the SMALL INTESTINE, loss of MICROVILLI structure, failed INTESTINAL ABSORPTION, and MALNUTRITION.	7.46	2	0
Ileitis Inflammation of any segment of the ILEUM and the ILEOCECAL VALVE.	2.44	2	0
Impaired Glucose Tolerance [description not available]	2.45	2	0
Glucose Intolerance A pathological state in which BLOOD GLUCOSE level is less than approximately 140 mg/100 ml of PLASMA at fasting, and above approximately 200 mg/100 ml plasma at 30-, 60-, or 90-minute during a GLUCOSE TOLERANCE TEST. This condition is seen frequently in DIABETES MELLITUS, but also occurs with other diseases and MALNUTRITION.	2.45	2	0
Cirrhosis [description not available]	2.07	1	0
Fibrosis Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.	2.07	1	0
Diabetic Cardiomyopathies Diabetes complications in which VENTRICULAR REMODELING in the absence of CORONARY ATHEROSCLEROSIS and hypertension results in cardiac dysfunctions, typically LEFT VENTRICULAR DYSFUNCTION. The changes also result in myocardial hypertrophy, myocardial necrosis and fibrosis, and collagen deposition due to impaired glucose tolerance.	2.07	1	0
B16 Melanoma [description not available]	2.07	1	0
Potassium Deficiency A condition due to decreased dietary intake of potassium, as in starvation or failure to administer in intravenous solutions, or to gastrointestinal loss in diarrhea, chronic laxative abuse, vomiting, gastric suction, or bowel diversion. Severe potassium deficiency may produce muscular weakness and lead to paralysis and respiratory failure. Muscular malfunction may result in hypoventilation, paralytic ileus, hypotension, muscle twitches, tetany, and rhabomyolysis. Nephropathy from potassium deficit impairs the concentrating mechanism, producing POLYURIA and decreased maximal urinary concentrating ability with secondary POLYDIPSIA. (Merck Manual, 16th ed)	2.06	1	0
Cancer of Liver [description not available]	2.07	1	0
Liver Neoplasms Tumors or cancer of the LIVER.	2.07	1	0
Joint Pain [description not available]	2.07	1	0
Adjuvant Arthritis [description not available]	3.62	3	0
Arthralgia Pain in the joint.	2.07	1	0
Acute Pain Intensely discomforting, distressful, or agonizing sensation associated with trauma or disease, with well-defined location, character, and timing.	2.07	1	0
Granuloma, Hodgkin [description not available]	2.07	1	0
Hodgkin Disease A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.	2.07	1	0
Ectopic Pregnancy [description not available]	2.48	2	0
Pregnancy, Ectopic A potentially life-threatening condition in which EMBRYO IMPLANTATION occurs outside the cavity of the UTERUS. Most ectopic pregnancies (	2.48	2	0
Psychoses, Drug [description not available]	2.99	1	0
Alveolar Bone Atrophy [description not available]	2.07	1	0
Astrocytoma, Grade IV [description not available]	2.44	2	0
Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.	2.44	2	0
Anoxia-Ischemia, Brain [description not available]	2.07	1	0
Hypoxia-Ischemia, Brain A disorder characterized by a reduction of oxygen in the blood combined with reduced blood flow (ISCHEMIA) to the brain from a localized obstruction of a cerebral artery or from systemic hypoperfusion. Prolonged hypoxia-ischemia is associated with ISCHEMIC ATTACK, TRANSIENT; BRAIN INFARCTION; BRAIN EDEMA; COMA; and other conditions.	2.07	1	0
Rheumatoid Arthritis [description not available]	3.38	2	0
Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.	3.38	2	0
Complication, Postoperative [description not available]	4.37	1	1
Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.	4.37	1	1
Academic Disorder, Developmental [description not available]	2.08	1	0
Learning Disabilities Conditions characterized by a significant discrepancy between an individual's perceived level of intellect and their ability to acquire new language and other cognitive skills. These may result from organic or psychological conditions. Relatively common subtypes include DYSLEXIA, DYSCALCULIA, and DYSGRAPHIA.	2.08	1	0
Anterior Cerebral Circulation Infarction [description not available]	2.44	2	0
Dyskinesia Syndromes [description not available]	3.86	4	0
Movement Disorders Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions.	3.86	4	0
Brain Infarction Tissue NECROSIS in any area of the brain, including the CEREBRAL HEMISPHERES, the CEREBELLUM, and the BRAIN STEM. Brain infarction is the result of a cascade of events initiated by inadequate blood flow through the brain that is followed by HYPOXIA and HYPOGLYCEMIA in brain tissue. Damage may be temporary, permanent, selective or pan-necrosis.	2.44	2	0
Peripheral Nerve Injury [description not available]	3.36	2	0
Peripheral Nerve Injuries Injuries to the PERIPHERAL NERVES.	3.36	2	0
Polyarthritis [description not available]	2.99	1	0
Arthritis Acute or chronic inflammation of JOINTS.	2.99	1	0
Atherogenesis [description not available]	2.08	1	0
Aortic Diseases Pathological processes involving any part of the AORTA.	2.08	1	0
Atherosclerosis A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.	2.08	1	0
Disease A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.	2.92	1	0
Hemiplegia, Crossed [description not available]	2.01	1	0
Hemiplegia Severe or complete loss of motor function on one side of the body. This condition is usually caused by BRAIN DISEASES that are localized to the cerebral hemisphere opposite to the side of weakness. Less frequently, BRAIN STEM lesions; cervical SPINAL CORD DISEASES; PERIPHERAL NERVOUS SYSTEM DISEASES; and other conditions may manifest as hemiplegia. The term hemiparesis (see PARESIS) refers to mild to moderate weakness involving one side of the body.	2.01	1	0
Chronic Idiopathic Intestinal Pseudo-Obstruction [description not available]	2.01	1	0
Intestinal Pseudo-Obstruction A type of ILEUS, a functional not mechanical obstruction of the INTESTINES. This syndrome is caused by a large number of disorders involving the smooth muscles (MUSCLE, SMOOTH) or the NERVOUS SYSTEM.	2.01	1	0
Morphine Abuse [description not available]	3.61	3	0
Morphine Dependence Strong dependence, both physiological and emotional, upon morphine.	3.61	3	0
Pheochromocytoma, Extra-Adrenal [description not available]	2.41	2	0
Pheochromocytoma A usually benign, well-encapsulated, lobular, vascular tumor of chromaffin tissue of the ADRENAL MEDULLA or sympathetic paraganglia. The cardinal symptom, reflecting the increased secretion of EPINEPHRINE and NOREPINEPHRINE, is HYPERTENSION, which may be persistent or intermittent. During severe attacks, there may be HEADACHE; SWEATING, palpitation, apprehension, TREMOR; PALLOR or FLUSHING of the face, NAUSEA and VOMITING, pain in the CHEST and ABDOMEN, and paresthesias of the extremities. The incidence of malignancy is as low as 5% but the pathologic distinction between benign and malignant pheochromocytomas is not clear. (Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1298)	2.41	2	0
Anaplastic Astrocytoma [description not available]	3.1	5	0
Astrocytoma Neoplasms of the brain and spinal cord derived from glial cells which vary from histologically benign forms to highly anaplastic and malignant tumors. Fibrillary astrocytomas are the most common type and may be classified in order of increasing malignancy (grades I through IV). In the first two decades of life, astrocytomas tend to originate in the cerebellar hemispheres; in adults, they most frequently arise in the cerebrum and frequently undergo malignant transformation. (From Devita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2013-7; Holland et al., Cancer Medicine, 3d ed, p1082)	3.1	5	0
Angiospasm, Intracranial [description not available]	2.01	1	0
Vasospasm, Intracranial Constriction of arteries in the SKULL due to sudden, sharp, and often persistent smooth muscle contraction in blood vessels. Intracranial vasospasm results in reduced vessel lumen caliber, restricted blood flow to the brain, and BRAIN ISCHEMIA that may lead to hypoxic-ischemic brain injury (HYPOXIA-ISCHEMIA, BRAIN).	2.01	1	0
Lesion of Sciatic Nerve [description not available]	2.72	3	0
Brain Disorders [description not available]	2.01	1	0
Brain Diseases Pathologic conditions affecting the BRAIN, which is composed of the intracranial components of the CENTRAL NERVOUS SYSTEM. This includes (but is not limited to) the CEREBRAL CORTEX; intracranial white matter; BASAL GANGLIA; THALAMUS; HYPOTHALAMUS; BRAIN STEM; and CEREBELLUM.	2.01	1	0
Hepatitis INFLAMMATION of the LIVER.	2.01	1	0
Circulatory Collapse [description not available]	3.4	1	1
Prosthesis Durability [description not available]	3.4	1	1
Shock A pathological condition manifested by failure to perfuse or oxygenate vital organs.	3.4	1	1
Chronic Insomnia [description not available]	2.01	1	0
Sleep Initiation and Maintenance Disorders Disorders characterized by impairment of the ability to initiate or maintain sleep. This may occur as a primary disorder or in association with another medical or psychiatric condition.	2.01	1	0
Basophilic Leukemia, Acute [description not available]	3.1	5	0
Leukemia, Basophilic, Acute A rare acute myeloid leukemia in which the primary differentiation is to BASOPHILS. It is characterized by an extreme increase of immature basophilic granulated cells in the bone marrow and blood. Mature basophils are usually sparse.	3.1	5	0
Urinary Incontinence Involuntary loss of URINE, such as leaking of urine. It is a symptom of various underlying pathological processes. Major types of incontinence include URINARY URGE INCONTINENCE and URINARY STRESS INCONTINENCE.	4.1	3	0
Cancer of Cervix [description not available]	2.02	1	0
Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX.	2.02	1	0
Hyperventilation A pulmonary ventilation rate faster than is metabolically necessary for the exchange of gases. It is the result of an increased frequency of breathing, an increased tidal volume, or a combination of both. It causes an excess intake of oxygen and the blowing off of carbon dioxide.	2.02	1	0
Impairment, Light Touch Sensation [description not available]	2.02	1	0
Amnesia, Anterograde Loss of the ability to form new memories beyond a certain point in time. This condition may be organic or psychogenic in origin. Organically induced anterograde amnesia may follow CRANIOCEREBRAL TRAUMA; SEIZURES; ANOXIA; and other conditions which adversely affect neural structures associated with memory formation (e.g., the HIPPOCAMPUS; FORNIX (BRAIN); MAMMILLARY BODIES; and ANTERIOR THALAMIC NUCLEI). (From Memory 1997 Jan-Mar;5(1-2):49-71)	2.02	1	0
Allergic Reaction [description not available]	2.02	1	0
Endocarditis, Loeffler [description not available]	2.02	1	0
Hypersensitivity Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen.	2.02	1	0
Hypereosinophilic Syndrome A heterogeneous group of disorders with the common feature of prolonged eosinophilia of unknown cause and associated organ system dysfunction, including the heart, central nervous system, kidneys, lungs, gastrointestinal tract, and skin. There is a massive increase in the number of EOSINOPHILS in the blood, mimicking leukemia, and extensive eosinophilic infiltration of the various organs.	2.02	1	0
Cruveilhier-Baumgarten Syndrome Liver cirrhosis with intrahepatic portal obstruction, HYPERTENSION, and patent UMBILICAL VEINS.	2.42	2	0
Hypertension, Portal Abnormal increase of resistance to blood flow within the hepatic PORTAL SYSTEM, frequently seen in LIVER CIRRHOSIS and conditions with obstruction of the PORTAL VEIN.	2.42	2	0
Anterior Circulation Transient Ischemic Attack [description not available]	2.02	1	0
Ischemic Attack, Transient Brief reversible episodes of focal, nonconvulsive ischemic dysfunction of the brain having a duration of less than 24 hours, and usually less than one hour, caused by transient thrombotic or embolic blood vessel occlusion or stenosis. Events may be classified by arterial distribution, temporal pattern, or etiology (e.g., embolic vs. thrombotic). (From Adams et al., Principles of Neurology, 6th ed, pp814-6)	2.02	1	0
Adipocere [description not available]	2.92	4	0
Abnormal Deep Tendon Reflex [description not available]	2.7	3	0
Reflex, Abnormal An abnormal response to a stimulus applied to the sensory components of the nervous system. This may take the form of increased, decreased, or absent reflexes.	2.7	3	0
Cirrhoses, Experimental Liver [description not available]	3.12	5	0
Smoking Cessation Discontinuing the habit of SMOKING.	3.35	2	0
Decerebrate Posturing [description not available]	2.43	2	0
Binge Eating [description not available]	3.41	1	1
Bulimia Eating an excess amount of food in a short period of time, as seen in the disorder of BULIMIA NERVOSA. It is caused by an abnormal craving for food, or insatiable hunger also known as ox hunger.	8.41	1	1
Anterior Choroidal Artery Infarction [description not available]	2.02	1	0
Cerebral Infarction The formation of an area of NECROSIS in the CEREBRUM caused by an insufficiency of arterial or venous blood flow. Infarcts of the cerebrum are generally classified by hemisphere (i.e., left vs. right), lobe (e.g., frontal lobe infarction), arterial distribution (e.g., INFARCTION, ANTERIOR CEREBRAL ARTERY), and etiology (e.g., embolic infarction).	2.02	1	0
MPTP Neurotoxicity Syndrome [description not available]	2.43	2	0
Disease, Pulmonary [description not available]	2.94	1	0
Lung Diseases Pathological processes involving any part of the LUNG.	2.94	1	0
Borna Disease An encephalomyelitis of horses, sheep and cattle caused by BORNA DISEASE VIRUS.	2.02	1	0
Inflammatory Response Syndrome, Systemic [description not available]	2.94	1	0
MODS [description not available]	3.35	2	0
Multiple Organ Failure A progressive condition usually characterized by combined failure of several organs such as the lungs, liver, kidney, along with some clotting mechanisms, usually postinjury or postoperative.	3.35	2	0
Systemic Inflammatory Response Syndrome A systemic inflammatory response to a variety of clinical insults, characterized by two or more of the following conditions: (1) fever	2.94	1	0
Neurogenic Inflammation Inflammation caused by an injurious stimulus of peripheral neurons and resulting in release of neuropeptides which affect vascular permeability and help initiate proinflammatory and immune reactions at the site of injury.	2.02	1	0
Acute Necrotizing Pancreatitis [description not available]	2.02	1	0
Blood Poisoning [description not available]	2.02	1	0
Sepsis Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.	2.02	1	0
Diffuse Lymphocytic Lymphoma, Poorly-Differentiated [description not available]	2.02	1	0
Leukemia, Plasmacytic [description not available]	2.02	1	0
Cell Transformation, Viral An inheritable change in cells manifested by changes in cell division and growth and alterations in cell surface properties. It is induced by infection with a transforming virus.	2.02	1	0
Leukemia, Plasma Cell A rare, aggressive variant of MULTIPLE MYELOMA characterized by the circulation of excessive PLASMA CELLS in the peripheral blood. It can be a primary manifestation of multiple myeloma or develop as a terminal complication during the disease.	2.02	1	0
Lymphoma, Mantle-Cell A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1).	2.02	1	0
Experimental Mammary Neoplasms [description not available]	2.03	1	0
Alcoholic Cirrhosis [description not available]	2.94	1	0
Liver Cirrhosis, Alcoholic FIBROSIS of the hepatic parenchyma due to chronic excess ALCOHOL DRINKING.	2.94	1	0
Gingivitis Inflammation of gum tissue (GINGIVA) without loss of connective tissue.	2.03	1	0
Diverticula [description not available]	2.03	1	0
Age-Related Osteoporosis [description not available]	2.03	1	0
Osteoporosis Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.	2.03	1	0
Separation Anxiety Disorder [description not available]	2.03	1	0
Anxiety, Separation Anxiety experienced by an individual upon separation from a person or object of particular significance to the individual.	2.03	1	0
Brain Damage, Chronic A condition characterized by long-standing brain dysfunction or damage, usually of three months duration or longer. Potential etiologies include BRAIN INFARCTION; certain NEURODEGENERATIVE DISORDERS; CRANIOCEREBRAL TRAUMA; ANOXIA, BRAIN; ENCEPHALITIS; certain NEUROTOXICITY SYNDROMES; metabolic disorders (see BRAIN DISEASES, METABOLIC); and other conditions.	2.03	1	0
Astrocytosis [description not available]	2.44	2	0
Age-Related Macular Degeneration [description not available]	2.03	1	0
Diabetic Retinopathy Disease of the RETINA as a complication of DIABETES MELLITUS. It is characterized by the progressive microvascular complications, such as ANEURYSM, interretinal EDEMA, and intraocular PATHOLOGIC NEOVASCULARIZATION.	2.03	1	0
Macular Degeneration Degenerative changes in the RETINA usually of older adults which results in a loss of vision in the center of the visual field (the MACULA LUTEA) because of damage to the retina. It occurs in dry and wet forms.	2.03	1	0
Active Hyperemia [description not available]	2.03	1	0
Hyperemia The presence of an increased amount of blood in a body part or an organ leading to congestion or engorgement of blood vessels. Hyperemia can be due to increase of blood flow into the area (active or arterial), or due to obstruction of outflow of blood from the area (passive or venous).	2.03	1	0
Analgesic Overuse Headache [description not available]	5.08	5	0
Respiratory Tract Diseases Diseases involving the RESPIRATORY SYSTEM.	2.95	1	0
Atrophy Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.	2.03	1	0
Hypersomnia, Post-Traumatic [description not available]	2.95	1	0
Glaucoma, Suspect [description not available]	2.03	1	0
Ocular Hypertension A condition in which the intraocular pressure is elevated above normal and which may lead to glaucoma.	2.03	1	0
Retinal Diseases Diseases involving the RETINA.	2.03	1	0
Impotence, Arteriogenic [description not available]	2.03	1	0
Atherosclerotic Parkinsonism [description not available]	2.03	1	0
Parkinson Disease, Secondary Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)	2.03	1	0
Low Back Ache [description not available]	7.46	4	4
Low Back Pain Acute or chronic pain in the lumbar or sacral regions, which may be associated with musculo-ligamentous SPRAINS AND STRAINS; INTERVERTEBRAL DISK DISPLACEMENT; and other conditions.	7.46	4	4
Autoimmune Diabetes [description not available]	2.95	1	0
Diabetes Mellitus, Type 1 A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.	2.95	1	0
Common Migraine [description not available]	2.04	1	0
Migraine without Aura Recurrent unilateral pulsatile headaches, not preceded or accompanied by an aura, in attacks lasting 4-72 hours. It is characterized by PAIN of moderate to severe intensity; aggravated by physical activity; and associated with NAUSEA and / or PHOTOPHOBIA and PHONOPHOBIA. (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)	2.04	1	0
Cardiomyopathy, Congestive [description not available]	2.04	1	0
Cardiomyopathy, Dilated A form of CARDIAC MUSCLE disease that is characterized by ventricular dilation, VENTRICULAR DYSFUNCTION, and HEART FAILURE. Risk factors include SMOKING; ALCOHOL DRINKING; HYPERTENSION; INFECTION; PREGNANCY; and mutations in the LMNA gene encoding LAMIN TYPE A, a NUCLEAR LAMINA protein.	2.04	1	0
Hyperplasia An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.	2.04	1	0
Autoimmune Chronic Hepatitis [description not available]	2.04	1	0
Hepatitis, Autoimmune A chronic self-perpetuating hepatocellular INFLAMMATION of unknown cause, usually with HYPERGAMMAGLOBULINEMIA and serum AUTOANTIBODIES.	2.04	1	0
Ocular Hypotension Abnormally low intraocular pressure often related to chronic inflammation (uveitis).	2.39	2	0
Acute-Phase Reaction An early local inflammatory reaction to insult or injury that consists of fever, an increase in inflammatory humoral factors, and an increased synthesis by hepatocytes of a number of proteins or glycoproteins usually found in the plasma.	1.99	1	0
Infections, Picornaviridae [description not available]	1.99	1	0
Hemorrhagic Shock [description not available]	1.99	1	0
Acquired Immune Deficiency Syndrome [description not available]	1.99	1	0
Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993.	1.99	1	0
Orchitis Inflammation of a TESTIS. It has many features of EPIDIDYMITIS, such as swollen SCROTUM; PAIN; PYURIA; and FEVER. It is usually related to infections in the URINARY TRACT, which likely spread to the EPIDIDYMIS and then the TESTIS through either the VAS DEFERENS or the lymphatics of the SPERMATIC CORD.	1.99	1	0
Diathesis [description not available]	1.99	1	0
Benign Meningeal Neoplasms [description not available]	1.99	1	0
Angioblastic Meningioma [description not available]	2.4	2	0
Meningeal Neoplasms Benign and malignant neoplastic processes that arise from or secondarily involve the meningeal coverings of the brain and spinal cord.	1.99	1	0
Meningioma A relatively common neoplasm of the CENTRAL NERVOUS SYSTEM that arises from arachnoidal cells. The majority are well differentiated vascular tumors which grow slowly and have a low potential to be invasive, although malignant subtypes occur. Meningiomas have a predilection to arise from the parasagittal region, cerebral convexity, sphenoidal ridge, olfactory groove, and SPINAL CANAL. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2056-7)	2.4	2	0
Hormone-Dependent Neoplasms [description not available]	2	1	0
Abortion, Recurrent [description not available]	2.41	2	0
Abnormalities, Autosome [description not available]	2	1	0
Abortion, Habitual Three or more consecutive spontaneous abortions.	2.41	2	0
Bradyarrhythmia [description not available]	2.92	1	0
Bradycardia Cardiac arrhythmias that are characterized by excessively slow HEART RATE, usually below 50 beats per minute in human adults. They can be classified broadly into SINOATRIAL NODE dysfunction and ATRIOVENTRICULAR BLOCK.	2.92	1	0
Bronchospasm [description not available]	2	1	0
Bronchial Spasm Spasmodic contraction of the smooth muscle of the bronchi.	2	1	0
Blunt Injuries [description not available]	2	1	0
Muscle Spasm [description not available]	2	1	0
Spasm An involuntary contraction of a muscle or group of muscles. Spasms may involve SKELETAL MUSCLE or SMOOTH MUSCLE.	2	1	0
Germinoblastoma [description not available]	2	1	0
Lymphoma A general term for various neoplastic diseases of the lymphoid tissue.	2	1	0
Bladder Diseases [description not available]	2	1	0
Leucocythaemia [description not available]	2	1	0
Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)	2	1	0
Cerebral Concussion [description not available]	2	1	0
Craniocerebral Injuries [description not available]	2	1	0
Brain Concussion A nonspecific term used to describe transient alterations or loss of consciousness following closed head injuries. The duration of UNCONSCIOUSNESS generally lasts a few seconds, but may persist for several hours. Concussions may be classified as mild, intermediate, and severe. Prolonged periods of unconsciousness (often defined as greater than 6 hours in duration) may be referred to as post-traumatic coma (COMA, POST-HEAD INJURY). (From Rowland, Merritt's Textbook of Neurology, 9th ed, p418)	2	1	0
Craniocerebral Trauma Traumatic injuries involving the cranium and intracranial structures (i.e., BRAIN; CRANIAL NERVES; MENINGES; and other structures). Injuries may be classified by whether or not the skull is penetrated (i.e., penetrating vs. nonpenetrating) or whether there is an associated hemorrhage.	2	1	0
Experimental Neoplasms [description not available]	2	1	0
Brain Swelling [description not available]	2	1	0
Brain Edema Increased intracellular or extracellular fluid in brain tissue. Cytotoxic brain edema (swelling due to increased intracellular fluid) is indicative of a disturbance in cell metabolism, and is commonly associated with hypoxic or ischemic injuries (see HYPOXIA, BRAIN). An increase in extracellular fluid may be caused by increased brain capillary permeability (vasogenic edema), an osmotic gradient, local blockages in interstitial fluid pathways, or by obstruction of CSF flow (e.g., obstructive HYDROCEPHALUS). (From Childs Nerv Syst 1992 Sep; 8(6):301-6)	2	1	0
Shock, Cardiogenic Shock resulting from diminution of cardiac output in heart disease.	2	1	0
Gastroduodenal Ulcer [description not available]	2.92	1	0
Peptic Ulcer Ulcer that occurs in the regions of the GASTROINTESTINAL TRACT which come into contact with GASTRIC JUICE containing PEPSIN and GASTRIC ACID. It occurs when there are defects in the MUCOSA barrier. The common forms of peptic ulcers are associated with HELICOBACTER PYLORI and the consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).	2.92	1	0

anandamide

Description

Cross-References

Synonyms (70)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (3)

Drug Classes (2)

Pathways (8)

Protein Targets (30)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (117)

Molecular Functions (42)

Ceullar Components (28)

Bioassays (233)

Research

Studies (2,515)

Market Indicators

Research Demand Index: 62.60

Study Types